Glandula Thyreoidea et Senescens by Chaker, L. (Layal)
G
LA
N
D
U
LA
 T
H
Y
R
EO
ID
EA
 ET
 SEN
ESC
EN
S
  T
H
Y
R
O
ID
 A
N
D
 AG
IN
G
  
LAYA
L C
H
A
K
ER
GLANDULA THYREOIDEA
ET SENESCENS
THYROID AND AGING
Uitnodiging
voor het bijwonen van de 
openbare verdediging van het 
proefschrift
GLANDULA THYREOIDEA ET 
SENESCENS
THYROID AND AGING
door 
Layal Chaker
dinsdag 3 oktober 2017
om 15.30
Locatie
professor Andries Queridozaal
Onderwijscentrum
Erasmus MC
Dr. Molewaterplein 50
Rotterdam
Na aﬂ oop van de promotie bent 
u van harte uitgenodigd voor 
de receptie.
Paranimfen
Sanaz Sedaghat
Tim I.M. Korevaar
Voor vragen en opmerkingen:
layalpromotie@gmail.com
Layal Chaker
Carelreinierszkade 59
2593 HL te ’s Gravenhage
l.chaker@erasmusmc.nl
Layal Chaker

 
 
 
GLANDULA THYREOIDEA ET SENESCENS 
 
THYROID AND AGING  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Layal Chaker 
 
 
 
  
  
ACKNOWLEDGEMENTS 
 
The work presented in this thesis was conducted at the Rotterdam Thyroid Center, 
Department of Internal Medicine and the Cardiovascular Group of the Department of 
Epidemiology, Erasmus Medical Center, The Netherlands. The studies in this thesis were 
largely conducted within the context of the Rotterdam Study. The contribution of the study 
participants, the staff from the Rotterdam Study, and participating general practitioners and 
pharmacists is gratefully acknowledged. The Rotterdam Study in general is supported by the 
Erasmus MC and Erasmus University Rotterdam; the Netherlands Organization for Scientific 
Research (NWO); the Netherlands Organization for Health Research and Development 
(ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands 
Genomics Initiative (NGI); the Ministry of Education, Culture and Science; the Ministry of 
Health Welfare and Sports; the European Commission (DG XII); and the Municipality of 
Rotterdam. The funders had no role in design or conduct of the studies; collection, 
management, analysis, or interpretation of the data; or preparation, review or approval of the 
manuscripts described in this thesis.  
 
Publication of this thesis was kindly supported by the Department of Epidemiology of 
Erasmus Medical Center and by the Erasmus University Rotterdam, The Netherlands. 
Additional financial support by the Dutch Heart Foundation for the publication of this thesis is 
gratefully acknowledged. Further financial support for the publication of this thesis was 
kindly provided by Goodlife B.V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN:   978-94-6299-699-1 
Printing: Ridderprint BV 
Cover: The Madonna of the Carnation (1478-1480) by Leonardo da Vinci. 
Leonardo Da Vinci is credited as the first to recognize and draw the 
thyroid gland as an anatomical organ. 
 
Copyright © 2017 Layal Chaker. All rights reserved.  
No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any 
form or by any means without prior permission from the author of this thesis or, when 
appropriate, from the publishers of the publications in this thesis.  
 
 
Glandula Thyreoidea et Senescens 
Thyroid and Aging 
De Schildklier en Veroudering 
 
Proefschrift 
 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de  
rector magnificus 
 
Prof.dr. H.A.P. Pols 
 
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op 
dinsdag 3 oktober 2017 om 15.30 uur 
 
door 
Layal Chaker 
geboren te al-Lādhiqīyah, Syrië 
 
  
PROMOTIECOMMISSIE 
 
Promotoren:  Prof.dr. R.P. Peeters 
Prof.dr. O.H. Franco 
 
Overige leden:  Prof.dr. M.A. Ikram 
Prof.dr. H. Völzke 
Prof.dr. O.M. Dekkers  
 
Copromotor:   Dr. A. Dehghan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paranimfen:  Dr. S. Sedaghat 
   Dr. T.I.M. Korevaar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my mom, who is no longer with me 
To Wouter, who is always beside me
  
TABLE OF CONTENTS 
 
Chapter 1  Introduction           15 
1.1 General introduction and outline          17 
1.2 Hypothyroidism            27 
 
Chapter 2  The heart           61 
2.1  Thyroid function and sudden cardiac death        63 
2.2  The association of normal thyroid function with atrial fibrillation      83 
2.3 Thyroid function and QT variability         101 
2.4 Thyroid function and the risk of atherosclerotic cardiovascular       123 
morbidity and mortality  
2.5 Defining optimal health range for thyroid function based        145 
on the risk of cardiovascular disease 
 
Chapter 3  The brain           165 
3.1  Subclinical thyroid disease and the risk of stroke:        167 
systemic review and meta-analysis 
3.2  Subclinical hypothyroidism and the risk of stroke and mortality:      187 
a meta-analysis of individual patient data  
3.3  Variations within euthyroidism and the risk of stroke events       209 
and fatal stroke: a meta-analysis of individual participant data 
3.4  The association between thyroid function and dementia       235 
3.5  Age-dependent association of thyroid function with       253 
brain morphology and microstructure  
 
Chapter 4 Metabolism           277 
4.1 Low-normal thyroid function is associated with increased risk of       279 
diabetes type II and progression from prediabetes to diabetes  
4.2 Thyroid Function and the risk of nonalcoholic fatty liver disease      297 
 
 
 
 
 
Chapter 5 Aging            317       
5.1 Thyroid Function and Cancer Risk          319 
5.2 The association between thyroid function and the risk of        337 
decline in kidney function and incident chronic kidney disease.  
5.3 Gait patterns associated with thyroid function        355 
5.4  The risk of AMD according to thyroid status        373 
5.5 Characteristics and determinants of thyroid function       393 
 
Chapter 6  General Discussion          413 
 
Chapter 7 Summary and Samenvatting         431 
 
Chapter 8 Appendices           439       
Author Affiliations           440 
PhD Portfolio            445 
List of Publications           447 
Word of Thanks            451 
About the Author           454 
 
 
  
  
 
 
MANUSCRIPTS THAT FORM THE BASIS OF THIS THESIS 
 
 
Chapter 1  Introduction 
Hypothyroidism. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Lancet, 
Epub 2017, Mar 20. pii: S0140-6736(17)30703-1 
 
Chapter 2  The heart  
Thyroid Function and Sudden Cardiac Death: A Prospective Population-
Based Cohort Study. Chaker L*, van den Berg ME*, Niemeijer MN, Franco 
OH, Dehghan A, Hofman A, Rijnbeek PR, Deckers JW, Eijgelsheim M, 
Stricker BH, Peeters RP. Circulation. 2016 Sep 6;134(10):713-22  
 
Response by Chaker et al to Letter Regarding Article, Thyroid Function 
and Sudden Cardiac Death: A Prospective Population-Based Cohort 
Study. Chaker L, van den Berg ME, Stricker BH, Peeters RP. Circulation. 
2017 Feb 21;135(8):e90-e91 
 
Normal Thyroid Function and the Risk of Atrial Fibrillation: the Rotterdam 
Study. Chaker L, Heeringa J, Dehghan A, Medici M, Visser WE, 
Baumgartner C, Hofman A, Rodondi N, Peeters RP, Franco OH. J Clin 
Endocrinol Metab. 2015 Oct;100(10):3718-24 
 
Does thyroid function affect QT variability? A population-based study.van 
den Berg ME*, Chaker L *, Niemeijer MN, Kors JA, Eijgelsheim M, 
Rijnbeek PR, Peeters RP, Stricker BH. Submitted 
 
Thyroid function and the risk of atherosclerotic cardiovascular morbidity 
and mortality: The Rotterdam Study. Bano A, Chaker L, Mattace-Raso 
FUS, van der Lugt A, Ikram MA, Franco OH, Peeters RP, Kavousi M. 
Submitted 
 
  
Defining optimal health range for thyroid function based on the risk of 
cardiovascular disease. Chaker L, Korevaar TIM, Rizopoulos D, Collet T-
H, Völzke H, Hofman A, Rodondi N, Cappola AR, Peeters RP, Franco OH. 
J Clin Endocrinol Metab. Epub 2017 May 17. doi: 10.1210/jc.2017-00410 
 
Chapter 3  The brain 
Subclinical thyroid dysfunction and the risk of stroke: a systematic review 
and meta-analysis. Chaker L, Baumgartner C, Ikram MA, Dehghan A, 
Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH. Eur 
J Epidemiol. 2014 Nov;29(11):791-800 
 
Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal 
Stroke: An Individual Participant Data Analysis. Chaker L, Baumgartner C, 
den Elzen WP, Ikram MA, Blum MR, Collet TH, Bakker SJ, Dehghan A, 
Drechsler C, Luben RN, Hofman A, Portegies ML, Medici M, Iervasi G, 
Stott DJ, Ford I, Bremner A, Wanner C, Ferrucci L, Newman AB, Dullaart 
RP, Sgarbi JA, Ceresini G, Maciel RM, Westendorp RG, Jukema JW, 
Imaizumi M, Franklyn JA, Bauer DC, Walsh JP, Razvi S, Khaw KT, 
Cappola AR, Völzke H, Franco OH, Gussekloo J, Rodondi N, Peeters RP; 
Thyroid Studies Collaboration. J Clin Endocrinol Metab. 2015 
Jun;100(6):2181-91 
 
Thyroid Function Within the Reference Range and the Risk of Stroke: An 
Individual Participant Data Analysis. Chaker L, Baumgartner C, den Elzen 
WP, Collet TH, Ikram MA, Blum MR, Dehghan A, Drechsler C, Luben RN, 
Portegies ML, Iervasi G, Medici M, Stott DJ, Dullaart RP, Ford I, Bremner 
A, Newman AB, Wanner C, Sgarbi JA, Dörr M, Longstreth WT Jr, Psaty 
BM, Ferrucci L, Maciel RM, Westendorp RG, Jukema JW, Ceresini G, 
Imaizumi M, Hofman A, Bakker SJ, Franklyn JA, Khaw KT, Bauer DC, 
Walsh JP, Razvi S, Gussekloo J, Völzke H, Franco OH, Cappola AR, 
Rodondi N, Peeters RP; Thyroid Studies Collaboration. J Clin Endocrinol 
Metab. 2016 Nov;101(11):4270-4282 
 
 
 
Thyroid function and the risk of dementia: The Rotterdam Study. Chaker 
L, Wolters FJ, Bos D, Korevaar TIM, Hofman A, van der Lugt A, Koudstaal 
PJ, Franco OH, Dehghan A, Vernooij MW, Peeters RP, Ikram MA. 
Neurology. 2016 Oct 18;87(16):1688-1695 
 
Age dependent association of thyroid function with brain morphology and 
microstructural organization: evidence from brain imaging. Chaker L*, 
Cremers GM*, Korevaar TIM, de Groot M, Dehghan A, Franco OH, 
Niessen WJ, Ikram MA, Peeters RP, Vernooij MW. Accepted Neurobiol 
Aging 
 
 
Chapter 4 Metabolism 
Thyroid function and risk of type 2 diabetes: a population-based 
prospective cohort study. Chaker L, Ligthart S, Korevaar TIM, Hofman A, 
Franco OH, Peeters RP, Dehghan A. BMC Med. 2016 Sep 30;14(1):150 
 
Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The 
Rotterdam Study. Bano A*, Chaker L*, Plompen EP, Hofman A, Dehghan 
A, Franco OH, Janssen HL, Darwish Murad S, Peeters RP. J Clin 
Endocrinol Metab. 2016 Aug;101(8):3204-11 
 
 
Chapter 5 Aging 
Thyroid Function and Cancer Risk: The Rotterdam Study. Khan SR*, 
Chaker L*, Ruiter R, Aerts JG, Hofman A, Dehghan A, Franco OH, 
Stricker BH, Peeters RP. J Clin Endocrinol Metab. 2016 
Dec;101(12):5030-5036 
 
Thyroid dysfunction and breast cancer risk - an unfinished story. Chaker L, 
Visser TJ. Nat Rev Endocrinol. 2016 Jun;12(6):313-4 
 
  
The association of thyroid function and the risk of kidney function decline: 
a population-based cohort study. Chaker L*, Sedaghat S*, Hoorn EJ, den 
Elzen WP, Gussekloo J, Hofman A, Ikram MA, Franco OH, Dehghan A, 
Peeters RP. Eur J Endocrinol. 2016 Dec;175(6):653-660 
 
Gait patterns associated with thyroid function: The Rotterdam Study. Bano 
A, Chaker L, Darweesh SK, Korevaar TIM, Mattace-Raso FU, Dehghan A, 
Franco OH, van der Geest JN, Ikram MA, Peeters RP. Sci Rep. 2016 Dec 
14;6:38912 
 
Thyroid function and age-related macular degeneration: a prospective 
population-based cohort study - the Rotterdam Study. Chaker L*, 
Buitendijk GH*, Dehghan A, Medici M, Hofman A, Vingerling JR, Franco 
OH, Klaver CC, Peeters RP. BMC Med. 2015 Apr 23;13:94 
 
Thyroid Function Characteristics and Determinants: The Rotterdam Study. 
Chaker L, Korevaar TIM, Medici M, Uitterlinden AG, Hofman A, Dehghan 
A, Franco OH, Peeters RP. Thyroid. 2016 Sep;26(9):1195-204 
 
 
Chapter 6  General Discussion 
“What is a normal thyroid function?” Chaker L, Peeters RP. Ned Tijdschr 
Geneeskd. 2017;161(0):D926 
 
Towards a new definition of ‘normal’ thyroid function? Chaker L, Peeters 
RP. Submitted 
 
 
*Denotes equal contribution  
 
 
 
 
  
 
 
 
 
 
CHAPTER 1   
INTRODUCTION 
 
  
  
 
  
 
 
 
 
 
CHAPTER 1.1 
GENERAL INTRODUCTION AND OUTLINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 1.1 
18  
GENERAL INTRODUCTION 
The thyroid gland is a butterfly-shaped organ in the base of neck and produces the 
thyroid hormones thyroxine (T4) and triiodothyronine (T3) in approximately a 14:1 
ratio.
1
 Circulating thyroid hormone levels are tightly regulated by the negative 
feedback mechanism of the hypothalamic-pituitary-thyroid axis (Figure 1); through 
thyrotropin-releasing hormone secreted from the hypothalamus and thyroid-
stimulating hormone (TSH) from the pituitary. The set-point for this axis is 
individually determined, meaning that the TSH level needed to achieve similar 
levels of circulating thyroid hormones is different between individuals.
2
 This is 
reflected in a smaller intra-individual variability than inter-individual variability. Main 
determinant of this set-point seems to be genetic variability
3,4
 but other existential 
and environmental factors have been proposed to contribute, such as older age.
5
 
Serum T4 is predominantly bound to protein and thus not available for use in the 
end-target organs and tissues.
6
 Therefore, free thyroxine (FT4) is used in both 
clinical and research settings as serum marker for thyroid function, next to TSH. 
 
Thyroid hormone action is crucial for the function of virtually all organs and tissues, 
but transport and metabolism of thyroid hormone is organ- and cell specific.
7,8
 The 
pleiotropic effects of thyroid hormone are also apparent in the signs and symptoms 
of overt thyroid disorders, hyperthyroidism (thyroid hormone excess) and 
hypothyroidism (thyroid hormone deficiency). For example; signs and complaints of 
hyperthyroidism include but are not restricted to palpitations, weight loss, diarrhea, 
heat intolerance, emotional liability, atrial fibrillation and low bone mineral density. 
However, due to the large variation in clinical presentation and general absence of 
symptom speciﬁcity
9,10
, the deﬁnition of thyroid dysfunction is predominantly 
biochemical. Overt or clinical hypothyroidism is defined by serum TSH 
concentrations above the reference range and serum FT4 concentrations below 
the reference range, whilst with subclinical hypothyroidism FT4 is still within the 
reference range.
11
 In the case of mild or subclinical hyperthyroidism TSH levels are 
below the reference range, and serum FT4 levels are above the reference range, 
whilst with subclinical hyperthyroidism FT4 is still within the reference range.
11
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Thyroid disorders have been long recognized disease entities. Seaweed, 
containing iodine, was described as a remedy for patients with goiter back in 2700 
BCE. The first injection with extract of sheep thyroid for treatment of 
hypothyroidism was administered in 1891 Nevertheless; many unresolved issues 
concerning thyroid function and dysfunction still exist to date. Thyroid dysfunction, 
especially subclinical thyroid disorders, is common in the general population. The 
prevalence of clinical and subclinical hypothyroidism is 0.2-5.3 % and 4-15% of the 
adult population, respectively.
12-15
 For overt and subclinical hyperthyroidism the 
prevalence is 0.8-1.3% and 0.6-9.8%, respectively.
16,17
 These numbers depend on 
the definitions and assays used and populations studied, amongst others. Because 
clinical thyroid disease is generally treated, long-term consequences of thyroid 
dysfunction have been mainly studied in the context of subclinical hyper- and 
hypothyroidism. The most studied target of thyroid hormone in scientific literature 
has been the cardiovascular system, where both subclinical hyperthyroidism and 
subclinical hypothyroidism have been associated with coronary heart disease and 
heart failure in large individual participant data meta-analyses.
18-20
 Some of these 
associations have also shown to extend within the currently defined reference 
ranges.
21
 Therefore a debate concerning the accuracy and usefulness in terms of 
clinical care and prevention of the reference ranges has emerged.  
 
The relation between TSH and FT4 has been described as log-linear, and TSH is 
therefore perceived as the most sensitive marker in subjects with thyroid disease.
22
 
Most studies to date investigating the association of thyroid function with clinical 
outcomes have incorporated FT4 serum concentrations only in the context of TSH 
(e.g. clinical versus subclinical hypothyroidism). However, in euthyroid subjects, 
TSH predominantly reflects the pituitary-thyroid axis set point
23
 while, independent 
of TSH, circulating FT4 (and subsequently T3 acting intracellular) represents the 
bioavailable thyroid hormone that can be taken up by cells and thereby could lead 
to clinical consequences of thyroid hormones peripherally. It is unclear to what 
extent FT4 solely could be a sufficient marker of thyroid function, dysfunction and 
thyroid-related diseases and whether TSH and FT4 could be indicating 
complementary perspectives into thyroid health. 
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Figure 1 The negative feedback mechanism 
 
 
 
T3 = Triiodothyronine; T4 = Thyroxine; TRH = Thyrotropin-releasing hormone; TSH = Thyroid-
stimulating hormone. 
 
AIM OF THIS THESIS 
The aim of this thesis was to study the association of thyroid function, both TSH 
and FT4, with cardiovascular, neurological and other diseases of older age, 
beyond the current categorization for thyroid function and dysfunction. We 
hypothesized that risk of disease is not restricted to statistically defined reference 
ranges of thyroid function but represent a continuum of risk and as such also 
extends within these reference ranges. 
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OUTLINE OF THIS THESIS 
In Chapter 2 we focus on the outcome that to date has proven most relevant for 
thyroid function and dysfunction: cardiovascular disease and mortality. Chapters 
2.1 and 2.2 describe the association of thyroid function variations with sudden 
cardiac death and atrial fibrillation, respectively. The focus of the chapters is 
quantifying the association of thyroid function within the currently applied reference 
range with the increased risk of disease. In Chapter 2.3 we examine the 
association of thyroid function with QT variability as a potential mediator of 
deleterious thyroid hormone effects on cardiac repolarization. Atherosclerosis is of 
specific interest due to the consistent finding in previous studies that the 
association of thyroid function with cardiovascular disease seems independent of 
cardiovascular risk factors and therefore perhaps not through atherosclerotic 
mediators. Chapter 2.4 is devoted to the link of thyroid function with not only 
clinical makers of atherosclerosis (e.g. myocardial infarction), but also subclinical 
markers (i.e. coronary artery calcification score). Chapter 2.5 aims to create a 
proof of concept for identifying the optimal health range for thyroid function based 
on the risk of cardiovascular disease i.e. a threshold for the laboratory markers of 
thyroid function based on the risk of cardiovascular mortality, coronary heart 
disease and stroke. 
Chapter 3 describes the important implications of thyroid hormone and thyroid 
function for brain health. In Chapters 3.1, 3.2 and 3.3 describes the association of 
subclinical thyroid dysfunction and variations of thyroid function within the normal 
range and the risk of stroke in a meta-analysis design. Chapter 3.1 summarizes 
evidence from literature, while Chapters 3.2 and 3.3 are conducted using an 
individual participant data meta-analysis method. Chapter 3.4 investigates the 
association of thyroid function with dementia and hypothesizes that the association 
could be through vascular pathways, including markers of vascular disease on 
MRI. In Chapter 3.5 we study potential age-dependent effects of thyroid function 
on measures of brain morphology and microstructure, as possible alternative 
mediators of the association between thyroid dysfunction and cognitive decline. 
Chapter 4 examines metabolism, one of the other major targets of thyroid 
hormone action. Type II diabetes, together with thyroid disease the most common 
Chapter 1.1 
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endocrine disorder, is a large contributor to morbidity and mortality and a strong 
risk factor of cardiovascular disease amongst others. Chapter 4.1 estimates the 
absolute risk of developing diabetes in the upcoming years in participants without 
diabetes at baseline in general and in persons with prediabetes specifically. Non-
alcoholic fatty liver disease (NAFLD), which is strongly correlated with metabolic 
syndrome, is the most common chronic liver condition worldwide. Hypothyroidism 
has been implicated with NAFLD in previous studies. In Chapter 4.2 we assess the 
association of thyroid function parameters and thyroid status with NAFLD cross-
sectionally and longitudinally. Additionally we assessed the risk of liver fibrosis in 
those with NAFLD according to thyroid function. 
In Chapter 5 we determine the association of thyroid function with cancer risk 
(Chapter 5.1), chronic kidney disease (Chapter 5.2), gait (Chapter 5.3), and AMD 
(Chapter 5.4), all outcomes in or markers of advancing age, and examine changes 
of thyroid function with aging (in Chapter 5.5). 
Finally, in Chapter 6, we summarize the main findings of this thesis, define the 
implications of the results and discuss future perspectives into thyroid research and 
care.  
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ABSTRACT 
Hypothyroidism is a common condition of thyroid hormone deficiency, which is 
readily diagnosed and treated but potentially fatal in untreated severe cases. The 
definition of hypothyroidism is based on the statistical reference ranges of the 
relevant biochemical parameters and is increasingly a matter of discussion. Clinical 
manifestations of hypothyroidism range from life threatening to no signs or 
symptoms. The most common symptoms of hypothyroidism in adults are fatigue, 
lethargy, cold intolerance, weight gain, constipation, change in voice and dry skin, 
but the clinical presentation can differ with age and gender, amongst other factors. 
Standard care of hypothyroidism is thyroid hormone replacement therapy with 
levothyroxine. However, a substantial proportion of patients reach biochemical 
treatment targets but remain unsatisfied due to persistent complaints. In this 
Seminar we discuss the epidemiology, etiology and symptomatology, summarize 
evidence on diagnosis, long-term risk, treatment modalities and management and 
highlight future directions for research into hypothyroidism.  
Hypothyroidism 
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INTRODUCTION 
Hypothyroidism refers to the common pathological condition of thyroid hormone 
deficiency. When untreated, it can lead to serious adverse health effects and 
ultimately death. Due to large variation in clinical presentation and a general lack of 
symptom specificity, the definition of hypothyroidism is predominantly biochemical. 
Overt or clinical primary hypothyroidism is defined as thyroid-stimulating hormone 
(TSH) levels above the reference range with free thyroxine (FT4) levels below the 
reference range. Mild or subclinical hypothyroidism is defined by TSH levels above 
the reference range while FT4 levels are within the normal range and is commonly 
regarded as a sign of early thyroidal failure. Subclinical hypothyroidism, reviewed in 
a previous Lancet Seminar, is not the focus of this seminar.
1
 
Whether the current reference ranges of TSH and FT4, defining thyroid 
dysfunction, are appropriate is a matter of debate. This is of clinical importance 
because these reference ranges are generally used as a threshold for treatment. 
Thyroid hormone replacement with levothyroxine (L-T4) is the standard of care in 
patients with hypothyroidism. However, a substantial proportion of L-T4-treated 
patients have persistent complaints despite reaching the biochemical therapy 
targets. This has prompted the question of whether L-T4 treatment is sufficient for 
all patients or whether alternative therapies (e.g. combination with liothyronine (L-
T3) preparations) could be adopted.  
 
EPIDEMIOLOGY 
Prevalence and risk factors 
The prevalence of overt hypothyroidism in the general population varies between 
0.3 and 3.7% in the US and between 0.2 to 5.3% in Europe
2-6
, depending on the 
definition used. A meta-analysis from studies across 9 European countries 
estimated the prevalence of undiagnosed hypothyroidism, including both overt and 
mild cases, around 5%.
5
 Differences in iodine status affect the prevalence of 
hypothyroidism, which occurs more frequently both in populations with a relatively 
high iodine intake and in severely iodine-deficient populations.
7,8
 Hypothyroidism 
occurs more frequently in women, at older age and in Caucasian populations, 
although data on ethnic differences are sparse.
3,9,10
 Hypothyroidism is more 
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common in patients with auto-immune diseases, such as diabetes type 1, 
autoimmune gastric atrophy and celiac disease and can occur as part of multiple 
autoimmune endocrinopathies. Individuals with Downs’ or Turners’ syndrome have 
a higher risk of hypothyroidism. In contrast, tobacco smoking and moderate alcohol 
are associated with a lower risk of hypothyroidism.
11,12
 
Genetic epidemiology 
The heritability of TSH and FT4 is estimated to be 65% and 23-65% 
respectively.
13,14
 Genome-wide association studies (GWAS), have so far only 
explained a small proportion of thyroid function variability
15
 To date, only three 
GWAS have focused on hypothyroidism specifically.
16-18
 The loci most consistently 
implicated in hypothyroidism include auto-immunity related genes and general and 
thyroid-specific regulatory genes (Table 1). Most of these are also related to serum 
TSH within the reference range.
15
 Monogenetic disorders leading to (congenital) 
hypothyroidism are rare and include TSH resistance (due to an inactivating 
mutation in TSHR), thyroid dysgenesis and thyroid dyshormonogenesis.
19
 
 
ETIOLOGY 
Hypothyroidism can be classified as primary (due to thyroid hormone deficiency), 
secondary (e.g. due to TSH deficiency), tertiary (e.g. due to thyrotropin-releasing 
hormone [TRH] deficiency) and peripheral (extra-thyroidal) (Table 1). Central 
hypothyroidism (including both secondary and tertiary) and perhipheral 
hypothyroidism are rare and include less than 1% of hypothyroid patients.
20
 
Primary hypothyroidism 
Chronic autoimmune thyroiditis 
In iodine sufficient areas, the most common etiology of hypothyroidism is chronic 
autoimmune (Hashimoto) thyroiditis. High antithyroid antibodies (predominantly 
thyroid peroxidase antibodies [TPOAb] and/or anti-thyroglobulin antibodies [TgAb]) 
are present in nearly all patients with auto-immune thyroiditis. High TPOAbs are 
also detected in approximately 11% of the general population.
6
 In patients with 
subclinical hypothyroidism, TPOAbs measurements help to predict progression to 
overt disease.
21,22
 The exact mechanisms underlying autoimmune thyroiditis are 
not known, but both genetic and environmental factors are involved. A higher 
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genetic risk score using 5 genetic variants identified by GWAS for TPOAb’s 
showed a graded association with higher TSH levels and clinical hypothyroidism. 
23
 
24
 Smokers have lower TPOAbs levels than non-smokers, and incidence of auto-
immune thyroiditis increases after smoking cessation.
25,26
 Other environmental 
factors implicated in autoimmune thyroiditis are vitamin D and selenium deficiency 
as well as moderate alcohol intake.
27
 
Iodine 
Iodine is an essential component of thyroid hormone. Iodine deficiency can result in 
goiter, thyroid nodules and hypothyroidism. The most severe consequence of 
iodine deficiency is cretinism (restricted mental and physical development in utero 
and childhood). Iodine fortification programs are one of the safest and cheapest 
public health interventions in the prevention of cognitive and physical 
impairment.
28,29
 Despite efforts, suboptimal iodine status still affects large parts of 
Africa and Asia, but also several high-income countries in specific subpopulations, 
most notably pregnant women ( e.g. some areas of Italy, US and UK).
29-31
 In 
populations that shift from severe to mild iodine deficiency the prevalence of 
hypothyroidism decreases. In populations shifting from mild deficiency to optimum 
or excessive intake of iodine, the prevalence of autoimmune hypothyroidism 
increases.
32,33
 
Drugs  
Iodine-containing drugs, most infamously amiodarone, can restrict thyroid hormone 
production through iodine overload, immediately blocking thyroid hormone 
synthesis (Wolff-Chaikoff effect). Approximately 14% of amiodarone-treated 
patients develops hypothyroidism.
34
 Lithium is also causes hypothyroidism via 
effects on thyroid hormone synthesis and release.
35
 In one study 6% of lithium-
treated patients needed L-T4 therapy within 18-months.
36
  
Tyrosine kinase inhibitors (TKI) are targeted therapy for several cancers. In a meta-
analysis of randomized controlled trials (RCT’s), 14% of patients receiving 
sunitinib, developed hypothyroidism. Other TKI (e.g. sorafenib) are also, although 
less frequently, associated with risk of developing hypothyroidism.
37
 Several other 
drugs, including interferon-alfa, thalidomide, certain monoclonal antibodies, anti-
epileptic drugs and drugs for second-line treatment of multidrug resistant 
tuberculosis can also cause primary hypothyroidism (Table 1). 
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Other etiologies of primary hypothyroidism 
Hypothyroidism is common after radioiodine treatment, after hemithyroidectomy or 
after neck radiation for cancer therapy.
38-42
 In the long-term, ~80% of radioiodine 
treated Graves patients will become hypothyroid, even when low doses are used. 
Hypothyroidism is reported to occur in 55% of patients treated for toxic nodular 
goiter 
38
 and approximately 8% of patients treated for solitary toxic nodules.
43
 In a 
meta-analysis of 32 studies, 20% of patients developed hypothyroidism after 
hemithyroidectomy.
41
 Other causes of primary hypothyroidism include transient 
thyroiditis and infiltrative disease (Table 1). 
Central hypothyroidism 
Central hypothyroidism is rare and affects both sexes equally. It is more often 
related to pituitary than hypothalamic disorders but frequently involves both.
20
 
Biochemically, central hypothyroidism is defined by a low or low-normal TSH with 
an inappropriately low FT4. Occasionally, TSH is mildly elevated, likely due to a 
decreased bioactivity.
44
 More than half of cases of central hypothyroidism are due 
to pituitary adenomas.
20
 Other causes of central hypothyroidism include pituitary or 
hypothalamic dysfunction due to head trauma, pituitary apoplexy, Sheehan’s 
syndrome, surgery, radiotherapy, genetic and, infiltrative disease. Several drugs 
are known to intervene on the hypothalamic-pituitary-thyroid axis (Table 1).
45,46
 
Peripheral hypothyroidism 
Consumptive hypothyroidism is caused by aberrant expression of the thyroid 
hormone inactivating deiodinase (Dio) 3 enzyme in tumor tissue. Although very 
rare, it can induce severe hypothyroidism. It was first described in a newborn with 
infantile hepatic hemangiomatosis but can also occur in patients with vascular and 
fibrotic tumors and gastrointestinal stromal tumors.
47
 Patients with rare genetic 
syndromes leading to a reduced sensitivity to thyroid hormone (Table 1) usually 
have normal TSH values, but can also present with tissue-specific 
hypothyroidism.
48  
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Table 1 Etiology of hypothyroidism 
Primary hypothyroidism 
Chronic autoimmune thyroiditis (Hashimoto) 
Iodine 
    Severe iodine deficiency 
    Mild and severe iodine excess 
Drugs such as amiodarone, lithium, TKI, interferon-alfa, thalidomide, monoclonal 
antibodies(e.g. ipilimumab and nivolumab), anti-epileptics(e.g. valproate) 
Iatrogenic 
    Post radio-iodine treatment (e.g. for Graves’ disease or toxic nodular disease) 
    Post (hemi)thyroidectomy 
    Post radiotherapy or surgery in neck/head region 
Transient thyroiditis  
    Viral (De Quervains’s) 
    Post-partum 
    Silent thyroiditis 
    Destructive thyroiditis 
Thyroid gland infiltration* 
    Infectious (e.g. Mycoplasma) 
    Malignant (e.g. Thyroid malignancy, lymphoma, metastasis of malignancy elsewhere) 
    Autoimmune (e.g. Sarcoidosis) 
    Inflammatory (e.g. Riedels’s) 
Genetic* 
    Auto-immunity related genes (e.g. HLA class I region, PTPN22, SH2B3, and VAV3) 
    General and thyroid-specfic (e.g. FOXE1, ATXN2 and PDE8B) 
 
Central hypothyroidism 
Pituitary tumors (secreting or non-secreting) 
Pituitary dysfunction (e.g. Sheehan’s) 
Hypothalamic dysfunction (e.g. posttraumatic) 
TSH or TRH resistance 
Drugs (e.g. dopamine, somatostatins, glucocorticosteroids, and RXR selective ligands). 
Increased TSH due to leptin stimulation** 
 
Peripheral (extra-thyroidal) hypothyroidism 
Consumptive Hypothyroidism 
Tissue-specific hypothyroidism due to decreased sensitivity to TH (e.g. mutations in MCT8, 
SECISBP2, TRalpha and TRbeta) 
* rare causes of primary hypothyroidism, ** evidence mainly from animal models. 
Abbreviations: TH thyroid hormone, TKI Tyrosine kinase inhibitors, TRH thyrotropin releasing hormone, 
TSH thyroid-stimulating hormone 
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CLINICAL PRESENTATION AND IMPLICATIONS 
Myxedema coma and severe hypothyroidism 
The clinical manifestations of hypothyroidism range from life threatening – in the 
case of myxedema coma – to no signs or symptoms. Myxedema coma, first 
described in the late 1900s when it was an inevitable outcome of longstanding 
untreated and severe hypothyroidism has become a rare condition. Nevertheless, 
due to its dramatic course with mortality rates of 40% despite treatment, early 
recognition is vital.
49
 Myxedema coma leads to an altered mental status, 
hypothermia, progressive lethargy, and bradycardia and can eventually lead to 
multiple organ dysfunction syndrome and death. Early start of thyroid hormone 
therapy and other supportive measures is pivotal.
50
 
Although very rare, severe primary hypothyroidism can lead to pituitary hyperplasia 
with concomitant pituitary pathology (e.g. secondary adrenal insufficiency) and 
symptoms (e.g. amenorrhea).
51
 
Signs and symptoms  
The most common symptoms of hypothyroidism in adults are fatigue, lethargy, cold 
intolerance, weight gain, constipation, change in voice and dry skin, but the clinical 
presentation can include a wide variety of symptoms and differs with age, gender 
and time between onset and diagnosis (Table 2).
52,53
 Unfortunately, the specificity 
of these symptoms to diagnose hypothyroidism is low, especially in the elderly who 
present with fewer and less classical signs and symptoms.
53
 Change of symptoms 
may predict hypothyroidism, since change in 7 or more symptoms in the last year 
increases the likelihood of hypothyroidism (likelihood ratio 8.7).
54
 However, in a 
case-control study, none of 34 hypothyroidism-related symptoms could be used to 
identify patients with hypothyroidism.
55
 Furthermore, 15% of patients with auto-
immune hypothyroidism do not report any or only one hypothyroidism related 
symptom, while 70%of euthyroid controls have one or more thyroid-related 
complaints.
55
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Hypothyroidism has clinical implications related to virtually all end-organs (Table 2), 
but the cardiovascular system is the most robustly studied. Hypothyroidism results  
in an increased vascular resistance, decreased cardiac output, decreased left 
ventricular function and changes in several other markers of cardiovascular 
contractility. Patients with hypothyroidism more often exhibit myocardial injuries 
and pericardial effusions than matched euthyroid controls.56 Furthermore, they 
have a higher prevalence of cardiovascular risk factors and often exhibit features of 
the metabolic syndrome including hypertension, increased waist circumference and 
dyslipidemia. 57 Hypothyroidism also increases total cholesterol, low-density 
lipoprotein and homocysteine levels.  
Patients with acute hypothyroidism, in the context of thyroid cancer treatment, 
display a decline in mood and quality of life.
58
 Hypothyroidism is considered a 
cause of reversible dementia, although unclear how often this occurs and in what 
proportion truly reversible.
59
 Other manifestations include neurosensory, 
musculoskeletal and gastrointestinal signs and symptoms (Table 2). Due to the 
pleiotropic effects of thyroid hormone, hypothyroidism can also affect the course of 
other disorders. For example, statin intolerance is more prevalent in hypothyroid 
individuals than in controls.
60
  
Long-term outcomes 
Most long-term consequences of hypothyroidism have been studied in the context 
of subclinical hypothyroidism, as overt hypothyroidism is generally treated. Only 
few studies investigated the association of hypothyroidism with all-cause mortality 
and results are mainly available for subclinical hypothyroidism.
61-63
 A study in 599 
participants (all 85 years of age) suggested that (subclinical) hypothyroidism in the 
oldest old might be associated with better survival.
63
 This could however not be 
confirmed in a large individual participant based meta-analyses, which included 
over 2500 participants above 80.
61
 The same meta-analysis did show an increased 
risk of coronary heart disease (CHD) events and CHD mortality in those with higher 
TSH levels, particularly with TSH levels above 10 mIU/L. The relation between 
hypothyroidism and coronary artery disease however has been long recognized.
64
 
Subclinical hypothyroidism with TSH levels above 10 mIU/L have also been 
associated with an increased risk of heart failure.
61,65
 Patients with hypothyroidism 
undergoing percutaneous coronary intervention had more major adverse 
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cardiovascular and cerebral events compared to those with normal thyroid function 
and to those with adequately treated hypothyroidism.
66
 The association with stroke 
is less evident and might only be apparent in younger individuals.
67
 Interestingly, 
patients with hypothyroidism have less neurological deficits post-stroke than 
controls
68
; normally after a stroke there is localized hypothyroidism due to induction 
of Dio3 in the ischemic brain area.
69,70
 The risk of CHD in patients with subclinical 
hypothyroidism does not differ by TPOAb levels, suggesting that auto-immunity per 
se is not a contributing factor to the association.
71
 Hypothyroidism can present with 
cognitive impairments but the association of hypothyroidism with development of 
cognitive impairment and dementia is controversial, since a recent population-
based cohort study showed a protective effect of higher TSH levels on the risk of 
dementia.
72-75
 Studies have also shown an association of hypothyroidism with 
NAFLD, cancer mortality, arthritis, kidney dysfunction and diabetes and in most 
cases causality is suggested but not proven.
76-79
 
80
 
 
DIAGNOSIS 
As previously mentioned, primary hypothyroidism is defined as TSH levels above 
the reference range (most commonly used 0.4-4.0 mIU/L) with FT4 levels below 
the reference range (Figure 1). The U.S. Preventive Service Task Force has 
suggested reserving the term “overt hypothyroidism” for cases where patients 
experience symptoms.
81
 This will however be challenging to assess due to the 
large variability in presentation of even severe hypothyroidism. In addition, patients 
may only recognize prior symptoms after the initiation of L-T4 treatment. 
TSH shows circadian fluctuations, with higher concentrations towards the evening. 
Patients with severe hypothyroidism show irregularity of TSH secretion.
82
 Seasonal 
variations have also been described, with higher TSH levels in winter and spring.
83
 
There are no indications for routine measurement of total triiodothyronine (T3), total 
T4 or free T3. TPOAb measurement is not strictly necessary to diagnose 
hypothyroidism but is useful to affirm the diagnosis of autoimmune primary 
hypothyroidism. Hypothyroidism is often characterized by a hypo-echogenic pattern 
seen on thyroid sonography, even in the absence of raised TPOAb. However, in 
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absence of additional clinical indications, such as abnormal thyroid palpation, an 
ultrasound is not required.  
 
Figure 1 Diagnosis and treatment of primary hypothyroidism 
 
 
 
TSH; thryoid-stimulating hormone. 
 
Reference ranges of thyroid function tests 
Most commercially available TSH and FT4 assays are immunoassays and their 
reference ranges are statistically defined taking the 2.5th and 97.5th percentile in 
an apparently healthy population. The reference ranges therefore inherently do not 
consider symptomatology or risk of adverse events or disease. This is 
demonstrated by recent studies showing an increased risk of adverse events with 
thyroid function variations even within these reference ranges.
74,84-87
 Furthermore, 
the reference ranges differ with age, gender and ethnic background.
88
 The 
currently applied reference ranges for thyroid function have been a matter of 
debate in recent years, 
89,90
 Applying age-specific reference ranges, typically with a 
higher upper limit of TSH in older individuals, showed conflicting results concerning 
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younger individuals in studies from the UK and Australia.
91,92
 Nevertheless, both 
showed a reclassification from abnormal to normal thyroid function predominantly 
in older individuals.
91,92
 Due to lack of information on consequences of treatment, 
there are currently no convincing arguments to change the applied reference 
ranges.  
 
Figure 2 Interpretation of thyroid function tests associated with hypothyroidism 
 
 
 
NTI; non-thyroidal illness, TSH; thryoid-stimulating hormone.TRH; thyrotropin-releasing hormone.   
 
Conditions interfering with diagnosis  
There are several conditions that can interfere with the laboratory measurements of 
thyroid analytes. This should be suspected when thyroid function tests do not 
match the clinical presentation. Human anti-animal antibodies in patient’s serum 
can cause falsely high TSH and can interfere with FT4 equilibrium dialysis platform 
assays. Heparin, including low molecular weight heparin, can lead to falsely 
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elevated levels of FT4.
93
 High biotin intake, a popular over-the-counter supplement, 
can interfere with biotin-based hormone assays leading to false high or false low 
thyroid function tests. 
FT4 measurement is important to diagnose hypothyroidism (e.g. central 
hypothyroidism) and during follow-up and treatment. The accuracy of FT4 
immunoassays has been questioned in conditions that affect binding protein 
concentrations (i.e. albumin or thyroxine-binding globulin) such as pregnancy or 
acute illness. However, FT4 assays generally perform well in daily clinical practice. 
FT4 measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
seems to perform better in certain clinical conditions,
94
 but is not available in the 
vast majority of centers.  
Independent of measurement artifacts, severe illness is characterized by low 
thyroid hormone status, but the TSH is generally within the normal range, although 
it can be transiently increased during recovery of non-thyroidal illness (NTI).
95
 
Changes in thyroid hormone metabolism, thyroid hormone transporters, and thyroid 
hormone receptors all play a role in the pathofysiology. NTI occurs in different 
disease states, but is present in almost all critically ill patients.
95
 Thyroid function 
testing should therefore not be performed in these patients, unless there is a clear 
suspicion of thyroid disease or central hypothyroidism. To date, there is no 
evidence that thyroid hormone replacement therapy is beneficial in critically ill 
patients. 
Screening 
Despite the high prevalence of hypothyroidism, easy diagnostics and cheap 
treatment, there is no consensus about TSH screening in specific subgroups of the 
general population. Several organizations, including the American Thyroid 
Association (ATA), American Association of Clinical Endocrinologists and the Latin 
American Thyroid Society recommend screening above a particular age (ranging 
from >35 year old individuals every 5 years to those ≥ 60 years once), especially in 
women.
96,97
 The U.S. Preventive Services Task Force found no evidence for or 
against screening while the Royal College of Physicians London states that 
screening of the general population is unjustified.
81,98
 However, evidence does 
support case finding of hypothyroidism in patients with dementia, infertility, auto-
immune diseases, hypercholesterolemia, dysmenorrhea, family history of auto-
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immune hypothyroidism, patients taking amiodarone or lithium or when iatrogenic 
hypothyroidism could be suspected (e.g. after neck radiation). 
 
TREATMENT 
L-T4 monotherapy in solid formulation, taken on an empty stomach, is the 
treatment of choice for hypothyroidism. Presence of clinical features of 
hypothyroidism with biochemical confirmation of overt hypothyroidism is the 
indication for treatment initiation. There is no rationale for not prescribing generic 
preparations, but switches between L-T4 products in patients that are stable are 
not recommended.
99
 The optimal daily L-T4 dose in overt hypothyroidism is 
typically between 1.5–1.8 μg/actual body weight (kg) per day.
99-101
 In patients with 
coronary artery disease the starting dose is generally 12.5-25 μg per day and 
should be gradually increased based on symptoms and TSH levels.
99
 This regimen 
is often also preferred in the elderly, especially when many comorbidities exist.
99,100
 
In younger patients without comorbidities, the full dose can usually be given from 
the start with adequate monitoring to avoid overtreatment. After initial start of 
therapy, TSH measurement is repeated after 4-12 weeks, and subsequently every 
6 months and, once stabilized, annually. Adjustment according to laboratory 
findings should be made, keeping in mind that in some patients (i.e. low body 
weight, higher age) small changes in dose can have substantial effects on serum 
TSH concentrations. The clinical significance of low T3 levels in some patients 
despite reaching normal TSH levels is unknown. T3 should not routinely be 
measured to evaluate treatment.
102
 
Women of childbearing age 
It is of pivotal importance to inform women of childbearing age with L-T4-treated 
hypothyroidism to increase their levothyroxine dosage in case of pregnancy. Due to 
several physiologic changes during pregnancy an increase in L-T4 dose is required 
to maintain euthyroidism.
103
 Women with hypothyroidism should therefore increase 
the L-T4 dose by 30% once pregnant, and directly contact their physician for 
further guidance.
104
 Screening, definition of (subclinical) hypothyroidism and 
potential treatment during pregnancy are beyond the scope of this seminar.
105,106
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Treatment targets  
Treatment targets include normalization of TSH and resolution of physical and 
mental complaints, while avoiding under- or overtreatment.
99
 Nevertheless, there is 
a considerable proportion of treated hypothyroid patients that do not reach these 
goals. An estimated 35-60% of patients treated with L-T4 are not within the target 
range of TSH (either over- or undertreated).
107,108
 A study from the UK showed that 
after 5 years of L-T4 therapy almost 6% of patients have TSH levels below 
0.1mIU/L and over 10% have TSH levels above 10.0mIU/L.
107
 Overtreatment (i.e. 
iatrogenic subclinical or overt hyperthyroidism) bears the risk of deleterious health 
effects such as atrial fibrillation and osteoporosis and should always be avoided, 
especially in elderly and postmenopausal women. Under-treatment (i.e. persistent 
thyroid hormone deficiency) can result in increased risk of cardiovascular disease 
and persistent signs and symptoms. Treatment targets for central hypothyroidism 
are different from primary hypothyroidism because clinicians cannot rely on the 
“reflex TSH strategy”. Further information on treatment of central hypothyroidism 
can be found elsewhere.
20
  
Causes of not reaching treatment targets 
Causes of not reaching therapy targets include inadequate dosage prescription or 
intake, interaction with supplements or medication, concurrent medical conditions 
and non-adherence to therapy (Table 3). Lower LT4doses are needed to suppress 
TSH secretion in the elderly and higher doses are needed after thyroidectomy. LT4 
treatment and therapy targets in the context of thyroid malignancy are beyond the 
scope of this seminar.  
L-T4 is absorbed in the small intestine and intake is advised in the morning 30-60 
minutes before breakfast. Intake before bedtime (2 to 3 hours after last meal) may 
improve absorption, and can be considered to increase compliance.
109
 Multiple 
drugs can interfere with absorption, availability or metabolism of L-T4, although 
evidence for some of these preparations comes from N=1 trials. Gastrointestinal 
conditions that reduce L-T4 absorption include H. Pylori gastritis, celiac disease, 
and, autoimmune atrophic gastritis. Some studies suggest that liquid and soft gel 
formulations of L-T4 do not depend on gastric pH for their absorption, and could 
provide a solution for patients with difficulties ingesting L-T4 30-60 minutes prior to 
breakfast.
110,111
 A recent double-blind randomized cross-over trial of liquid 
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thyroxine in 77 treatment-naive hypothyroidism patients demonstrated no 
significant differences in thyroid function tests when the liquid preparation was 
ingested at or 30 minutes before breakfast.
112
 However, no studies to date have 
compared liquid gel formulations of L-T4 with solid formulations in relation to 
clinical outcomes. 
If high TSH persists and other etiologies have been excluded, the possibility of 
non-adherence, a common cause of therapy failure, should be considered and 
discussed with the patient. High TSH with normal or high-normal FT4 values can 
be a result of L-T4 tablets taken shortly before blood sampling. A supervised 
thyroxine absorption test to distinguish non-adherence from other reasons for 
undertreatment should be considered. A protocol that combines both acute and 
longer-term supervised administration has been suggested and is presented in 
Figure 3.
113,114
  
Persistent complaints despite biochemical normalization of TSH 
About 5-10% of biochemically well-controlled patients with L-T4 treated 
hypothyroidism experience persistent symptoms such as depression and impaired 
mental well-being.
115
 First of all, concurrent diseases or perimenopausal status 
may cause these complaints and should be excluded. Patients with hypothyroidism 
have a higher prevalence of autoimmune pathologies that could give rise to similar 
symptoms. Some studies suggest that auto-immunity per se could lead to 
persistent symptoms.
116
 Circulating thyroid hormone levels are regulated by the 
hypothalamic-pituitary-thyroid axis with an individually determined set-point, 
reflected in a smaller intra-individual variability than inter-individual variability.
117
 
This means that the TSH level needed to achieve similar levels of circulating 
thyroid hormones differs between individuals. Differences in individual set-point 
may explain why patients with similar TSH levels under treatment respond 
differently. However, the individual set-point prior to hypothyroidism is rarely 
known. Also, studies that targeted different TSH goals in hypothyroid patients 
generally do not show alterations in well-being or other clinical parameters.
118,119
 
An alternative explanation for persistent complaints in specific patients may be the 
imperfections of L-T4 monotherapy itself. It is generally accepted that L-T4 can 
ensure adequate concentrations of circuating T4 which can then be converted into 
T3 by deiodination (by Dio1 and Dio2). However, in euthyroid patients, about 20% 
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of circulating T3 is derived from direct thyroidal secretion, whereas in patients on L-
T4 monotherapy all T3 is derived from peripheral T4 to T3 conversion. As a 
consequence, patients on L-T4 monotherapy have higher FT4 to FT3 ratios than 
euthyroid individuals. Some patients with normalized TSH have serum T3 
concentrations below the reference range, while FT4 serum levels are high.
120-122
 
The clinical significance of this is unknown. However, L-T4 monotherapy cannot 
restore physiological T3 concentrations or thyroid hormone-dependent biological 
effects in all tissues of hypothyroid rats.
123,124
 Although a normal TSH reflects 
euthyroidism at the level of the pituitary, this may not necessarily reflect 
euthyroidism in all tissues. Tissue-specific differences in inactivation of Dio2 may 
play a role, resulting in normalization of T3 levels in the hypothalamus before T3 
levels have fully normalized in the rest of the body.
123
 
 
Figure 3 Thyroxine absorption test 
 
 
 
 
Protocol for supervised thyroxine absorption test, followed by weekly supervised thyroxine 
administration. Adapted from reference 115, by permission of Elsevier. TSH=thryoid-stimulating 
hormone. *Laboratory test values, especially an increase in free thyroxine, can be interpreted already at 
this stage. †Adequate free thyroxine rise is estimated to be roughly 50% from baseline at 120 min
116
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L-T4/LT-3 Combination Therapy 
This has prompted several trials in the past 15 years with combined L-T4 and L-
T3.
125
 Although some studies show some beneficial effect, such as patient 
preference for combination therapy or an improved metabolic profile, 
126-129
 all 
studies together do not demonstrate that patients on combination therapy fare 
better than those taking L-T4 monotherapy.
130
 Possible explanations why 
combination therapy has failed to show superiority include inadequate L-T4 and L-
T3 dosages or frequency of administration.
131
 L-T3 has a short half-life and none of 
the above mentioned studies used a slow-release T3. Most trials were also of 
relatively short duration, and the instruments used (questionnaires) may not have 
been sufficiently targeted or sensitive enough to detect the symptoms experienced 
by patients. 
Alternatively, trials so far may have failed to identify the appropriate subgroups that 
would benefit. Most trials did not specifically recruit patients who do not feel well on 
L-T4 or those with particularly low serum T3 levels. Individuals with genetic 
variations in thyroid hormone metabolism have not been specifically targeted.
131
 A 
particular subgroup concerns individuals with common genetic variations in the 
Dio2 enzyme, responsible for local conversion of T4 to T3 in several tissues, 
including the brain.
132
 A genetic variation in Dio2 (THr92Ala), with a longer-half life 
than wildtype and ectopic localization in the Golgi apparatus, has shown to alter 
expression profiles in the cerebral cortex in a similar pattern as seen in 
neurodegenerative disease, without evidence of changed thyroid hormone 
signaling.
133
 In a study of 552 people, the Thr92Ala polymorphism in the Dio2 gene 
was associated with lower baseline psychological well-being in patients on L-T4 
replacement and with better response to combination therapy.
134
 However, after 
appropriate multiple testing correction, the results failed to reach significance. Also, 
a recent population-based cohort study showed no effect of the Thr92Ala 
polymorphism quality of life or cognitive function measures.
135
 Sufficiently powered 
prospective RCT’s are therefore required before conclusions can be drawn. 
While both the ATA and ETA guidelines generally recommend against the routine 
use of combination therapy in hypothyroid patients, the recommendations 
concerning trials in patients with persistent symptoms slightly differ. The ETA 
states that a 3-months trial of L-T4 and L-T3 combination might be considered 
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experimentally in adherent biochemically well-controlled L-T4-treated hypothyroid 
patients with persistent complaints.
136
 and provides methods for calculating L-T4 
and L-T3 dosages.
136
 Treatment should however be initiated only by accredited 
internists/endocrinologists, closely monitored and discontinued if no improvement 
is experienced. The ATA however, recommends against any routine use of such 
trials outside of formal research and clinical trials, mainly due to uncertainty 
regarding benefit and long-term safety.
99
 Both the ETA and ATA do agree on the 
need for long-term RCT’s to assess risk-benefit ratios. Such trials would need to 
incorporate investigation of the ideal thyroid parameters to monitor during 
combination therapy, and whether T3 levels would be an important parameter. The 
timing of phlebotomy is also important, particularly if L-T3 is being administered 
more than once daily.  
There is lack of evidence to support other therapies for hypothyroidism. The use of 
thyroid extracts or L-T3 monotherapy is generally not recommended because of 
potential safety concerns related to the presence of supraphysiologic serum T3 
levels and a paucity of long-term safety outcome data. The use of compounded 
thyroid hormones, dietary supplements, and any over-the counter drug for 
treatment of hypothyroidism is discouraged. 
 
DIRECTIONS FOR FUTURE RESEARCH 
Although great advances have been made in the identification of etiology, 
knowledge of clinical implications, diagnosis and treatment of hypothyroidism, 
several unanswered questions remain, especially regarding diagnosis and 
treatment of hypothyroidism. 
Etiology of hypothyroidism 
Many risk factors have been identified for abnormal TSH levels, FT4 levels and 
thyroid disease, but only a small proportion of the variability is explained.
137
 
Therefore, identification of novel risk factors is important. There is increasing 
evidence for endocrine disrupting chemicals as possible etiological factors for 
endocrine diseases. Thyroid-disrupting chemical (TDC) exposure can come from 
different sources ranging from environmental (e.g. flame retardants,) to dietary 
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(e.g. food packaging material).
138
 A recent transatlantic call for action has been 
made to answer these questions in a collaborative effort.
139
 
Clinical implications 
The association of hypothyroidism with cardiovascular disease has been 
established and replicated in several studies.
61,65
 However, the mechanisms 
behind this association remain unclear. The link between hypothyroidism and 
several cardiovascular diseases seems independent of traditional cardiovascular 
risk factors.
61,65,67
 Further research focused on novel cardiovascular risk factors or 
other pathways could shed a light on the exact mechanisms. This is crucial to 
support treatment decisions and monitoring strategies in patients with (subclinical) 
hypothyroidism. 
Diagnosis 
The diagnosis of hypothyroidism is currently based on statistically defined 
reference ranges for TSH and FT4. As previously mentioned, these reference 
ranges do not consider whether patients are at risk to develop disease. Due to the 
arbitrary nature of the cut-offs defining mild and overt hypothyroidism, an 
alternative grading system has been proposed according to the thyroid function 
tests. The arbitrary nature of these cut-offs were also highlighted by the U.S. 
Preventive Service Task Force as one of the important factors hampering decision 
making on screening of thyroid dysfunction in asymptomatic patients.
81
 This also 
holds true for treatment decisions in asymptomatic patients with hypothyroidism. 
Further research is needed to identify which adverse health events occur after 
long-term thyroid dysfunction. Furthermore, it needs to be established which levels 
of TSH and FT4 are accompanied by increased risk of disease. This information 
can come from collaborative efforts of observational cohort studies with sufficiently 
long follow-up. Only after this information is available, RCT’s can assess if 
treatment of thyroid function beyond these thyroid function test levels reduces 
excess risk and assess the risk-benefit ratio of treatment. 
Treatment 
As mentioned, L-T4 monotherapy is the standard of care. However, there are 
several unresolved issues concerning patients that are biochemically well-
controlled but unsatisfied. Future studies should addresswhether alternative 
regimens could provide a solution for at least a proportion of patients with residual 
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symptoms. Concerning treatment of hypothyroidism, the research areas most 
urgently in need of progress include 1) unravelling the etiology of persistent 
symptoms in biochemically well-controlled hypothyroid patients 2) investigating if a 
more adequate dosage (e.g. tailored to patient serum T3 or to a patient’s own 
particular TSH set-point, if this could be identified) produces more satisfactory 
therapy, 3) investigation if new formulations (e.g. slow release L-T3) or more 
frequent administration of L-T4/L-T3 combination therapy (e.g. L-T3 thrice daily) 
can ameliorate patient symptoms 4) identification of subgroups that could benefit 
from therapies other than L-T4 monotherapy, for example by identifying additional 
genetic polymorphisms that could provide information on the individual thyroid set 
point. GWAS studies including larger number of individuals with more detailed 
genotyping could provide such information.   
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ABSTRACT 
BACKGROUND The association between thyroid function and cardiovascular 
disease is well established, but no study to date has assessed whether it is a risk 
factor for sudden cardiac death (SCD). 
Therefore, we studied the association of thyroid function with SCD in a prospective 
population-based cohort. 
 
METHODS Participants from the Rotterdam Study ≥45 years with thyroid-
stimulating hormone or free thyroxine (FT4) measurements and clinical follow-up 
were eligible. We assessed the association of thyroid-stimulating hormone and FT4 
with the risk of SCD by using an age- and sex-adjusted Cox proportional-hazards 
model, in all participants and also after restricting the analysis to euthyroid 
participants (defined by thyroid-stimulating hormone 0.4–4.0 mIU/L). Additional 
adjustment included cardiovascular risk factors, notably hypertension, serum 
cholesterol, and smoking. We stratified by age and sex and performed sensitivity 
analyses by excluding participants with abnormal FT4 values (reference range of 
0.85–1.95 ng/dL) and including only witnessed SCDs as outcome. Absolute risks 
were calculated in a competing risk model by taking death by other causes into 
account. 
 
RESULTS We included 10 318 participants with 261 incident SCDs (median follow-
up, 9.1 years). Higher levels of FT4 were associated with an increased SCD risk, 
even in the normal range of thyroid function (hazard ratio, 2.28 per 1 ng/dL FT4; 
95% confidence interval, 1.31–3.97). Stratification by age or sex and sensitivity 
analyses did not change the risk estimates substantially. The absolute 10-year risk 
of SCD increased in euthyroid participants from 1% to 4% with increasing FT4 
levels.  
 
CONCLUSIONS Higher FT4 levels are associated with an increased risk of SCD, 
even in euthyroid participants. 
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INTRODUCTION  
Thyroid hormone is critical for the development and function of nearly all organs 
and tissues, with the cardiovascular system being one of the major targets. Thyroid 
hormone is known to increase heart rate, increase cardiac contractility, alter 
systolic and diastolic function and decrease systematic vascular resistance
1
. 
Thyroid dysfunction, even in the subclinical range, is associated with an increased 
incidence of cardiovascular risk factors and disease
2-4
. Both overt and subclinical 
hypothyroidism are associated with hypertension, dyslipidemia and coronary heart 
disease (CHD)
4,5
, whereas excess of thyroid hormone, subclinical and overt 
hyperthyroidism, increases the risk of atrial fibrillation (AF), CHD and heart failure 
(HF)
2,6
. However, little is known about the association between thyroid 
(dys)function and the risk of sudden cardiac death (SCD).  
SCD is defined as unexpected natural death from a cardiac cause within a short 
time period, generally <1 hour from the onset of symptoms, in a person without any 
prior condition that would appear fatal
7
. SCD accounts for over 50% of 
cardiovascular deaths and 15% to 20% of total mortality
8
. As much as 75 percent 
of SCDs have been attributed to CHD (known or unknown) and the risk factors for 
CHD and SCD are therefore very similar and include older age, male sex, 
hypertension, HF, smoking and dyslipidemia
7,9,10
. Additional risk factors include 
non-ischemic cardiac disease (e.g. congenital heart disease) and non-cardiac 
disorders (e.g. drug-induced)
10
. However, the predictability of SCD in the general 
population remains poor, as almost half of the SCD cases are the first presentation 
of cardiac disease
11
. It is therefore of crucial importance to identify additional risk 
factors other than well-established cardiovascular risk factors. We hypothesized 
that thyroid function is associated with an increased risk of SCD and set to 
determine this association and possible subgroups at risk in a population-based 
cohort study. 
 
METHODS 
Setting 
All analyses were performed in the Rotterdam Study (RS), a prospective 
population-based cohort study that investigates determinants and occurrence of 
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cardiovascular, neurological, ophthalmologic, psychiatric, and endocrine diseases 
in the middle-aged and elderly population. The aims and design of the Rotterdam 
study have been described in detail elsewhere
12
. We included participants from 
three independent cohorts within the Rotterdam Study. The RS Cohort 1 (RSI) 
includes participants aged 55 years and older and baseline data were collected 
during 1990-1993. RS Cohort II (RSII) includes participants aged 55 years and 
older and baseline data were collected from 2000-2001. For the RS Cohort 3 
(RSIII), all residents of Ommoord aged 45 years and over who had not been invited 
before, were asked to participate and baseline data were collected from 2006 to 
2008. The Medical Ethics Committee of the Erasmus University approved the study 
protocols and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study)”. All included participants provided a written informed consent in 
accordance with the Declaration of Helsinki to participate in the study and to obtain 
information from their family physicians. 
Study population  
Participants were eligible for inclusion if they had thyroid-stimulating hormone 
(TSH) or free thyroxine (FT4) measurements made at baseline visit of the study 
cohorts RSI (RSI-1), RSII (RSII-1) and RSIII (RSIII-1). Since a number of 
participants from RSI did not have thyroid measurements at the first visit, they were 
included in the analyses using data from their third visit 3 (RSI-3) and were follow-
up since the date of their laboratory measurement. A total of 10,318 participants 
from the three cohorts were included in our analyses. All study participants were 
followed up from the day of baseline laboratory testing to date of SCD, to death 
from other causes, or to December 12th, 2010, whichever came first. 
Assessment of thyroid function 
For RSI-1, serum TSH (TSH Lumitest; Henning, Berlin, Germany) and F T4 levels 
(FT4; Vitros, ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, 
Amersham, UK) were determined in a random subset of the baseline serum 
samples (n=1855). For RSI-3, RSII-1 and RSIII-1, thyroid function assessment was 
also performed in baseline serum samples for TSH and FT4 (The 
electrochemiluminescence immunoassay for thyroxine and thyrotropine, “ECLIA”, 
Roche). The two tests’ TSH reference ranges did not differ substantially and had a 
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good Spearman correlation co-efficient (0.96 for TSH, p < 0.0001and 0.81 for FT4, 
p < 0.0001). We determined the cut-off values for normal range TSH as 0.4-4.0 
mIU/L according to national guidelines and our previous studies
13
. The reference 
range for FT4 was 0.85-1.95 ng/dL (=11-25 pmol/L)
14
. Euthyroidism was defined as 
a TSH value within the reference range. Hypothyroidism was defined by TSH 
mIU/L > 4.0 and FT4 <0.85 ng/dL whilst with subclinical hypothyroidism FT4 was 
still within the reference range. Hyperthyroidism was defined by TSH mIU/L < 0.4 
and FT4 > 1.95 ng/dL whilst with subclinical hyperthyroidism FT4 was still within 
the reference range. 
Sudden cardiac death definition and case ascertainment 
nformation on SCD was obtained from medical records and death certificates. 
Deaths were considered from study entry through December 12
th
 2010. SCD was 
defined in accordance with the Myerburg definition
15
, which is endorsed by the 
European Society of Cardiology
16
, as “a natural death due to cardiac causes, 
heralded by abrupt loss of consciousness within one hour from onset of acute 
symptoms. Pre-existing heart disease may have been known to be present, but the 
time and mode of death are unexpected. We included cases of unwitnessed death 
if the person was seen in a stable medical condition 24 hours preceding death and 
if there was no evidence of a non-cardiac cause of death. We considered both 
witnessed and unwitnessed SCD cases for the main outcome, and conducted a 
sensitivity analysis excluding participants with unwitnessed SCD. In addition, in 
case of sparse information, cases were labelled as SCD when treating physicians 
labelled death as sudden or unexpected 
17
. Case validation and definition of SCD 
has been described earlier in previous publications from the Rotterdam Study
17,18
. 
In short, SCD cases were adjudicated by two independent reviewers. SCD cases 
were coded as “possible” if there was insufficient information in the medical file 
regarding the period prior to and until death to code an SCD as “certain”. We 
conducted a sensitivity analysis excluding SCD cases coded as possible. If there 
was disagreement, this was resolved by consensus meetings. All cases were 
ultimately reviewed by a senior cardiologist. 
Baseline and other measurements 
Blood pressure was measured twice using a random-zero sphygmomanometer and 
averaged. Hypertension was defined as having a systolic blood pressure > 140 
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mmHg or a diastolic blood pressure > 90 mmHg or using antihypertensives at 
baseline (diuretics, anti-adrenergic agents, β blockers, calcium channel blockers 
and RAAS inhibitors). Smoking was categorized in current or non-current smokers. 
QT-interval was measured on a resting ECG. Heart-rate variability was 
automatically determined by MEANS. We assessed the standard deviation of the 
normal-to-normal RR intervals (SDNN)
19
: a time-domain HRV marker, based on all 
the RR intervals on the 10-second ECGs. For the analyses with heart-rate 
variability, we removed ECGs with excessive noise, excessive baseline wander, 
premature ventricular beats, and premature supraventricular beats. Outliers of 
heart-rate variability values were visually checked and discarded if related to poor 
signal quality. Pulse rate was measured twice with a pulse oximeter and averaged. 
Serum total cholesterol was measured using standard laboratory techniques. 
Diabetes was defined by an impaired fasting glucose ≥ 7 mmol/L, non-fasting 
glucose use ≥ 11.1 mmol/L or use of glucose lowering medication. Body-mass 
index (BMI) was calculated as weight in kilograms divided by height in meters 
squared. Ascertainment of AF in the Rotterdam Study has been described in detail 
previously 
20
. In short, it was ascertained using three methods 1) ECG’s at baseline 
and during follow-up, ascertained by a cardiologist, 2) medical information obtained 
from the General Practitioners, after ascertainment of ECG and 3) national registry 
of hospital discharge diagnosis. Cases of incident HF were obtained by continuous 
monitoring of participants during follow-up through automated linkage with files 
from general practitioners 
12,21
. All available data on HF, such as hospital discharge 
letters and notes from general practitioners, were copied from the medical records. 
HF was adjudicated in accordance with in accordance with the guidelines of the 
European Society of Cardiology 
22
 and included typical signs and symptoms of 
heart failure confirmed by objective evidence of cardiac dysfunction. 
Statistical analysis 
We assessed the association of TSH or FT4 at baseline, in separate models, with 
the risk of SCD both in the full and the euthyroid range of thyroid function (defined 
by TSH 0.4-4.0 mIU/L), using Cox-proportional hazards model. We also evaluated 
the risk of SCD according to thyroid state with euthyroidism as reference. All 
primary analyses were sex and age-adjusted. Multivariable models additionally 
adjusted for cohort, pulse rate, hypertension, serum cholesterol, diabetes mellitus, 
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BMI, smoking and QT-interval, after applying multiple imputation for missing data of 
these covariates (missingness < 3% for all covariates). Variables in the 
multivariable models represent the most common confounding or mediating factors 
of the association between thyroid function and SCD. Absolute 10 year risk-
probabilities were estimated, given the covariates used in the primary Cox-
proportional hazards model, according to the Fine and Gray model 
23
. This model 
takes the competing risks of death due to all other (non-SCD) causes into account. 
We also derived the subdistribution HRs (SHR) for included variables from this 
model.  
Pre-defined stratification by sex, age categories and cohort were performed. The 
cut-off of the age categories was 65 years, which is close to the median age of our 
population. Sensitivity analyses included 1) restricting to the analyses euthyroid 
individuals with witnessed SCDs as outcome 2) excluding possible SCD events 3) 
restricting the analyses to euthyroid subjects with normal FT4 values and excluding 
individuals using thyroid medication defined as hormone replacement therapy or 
anti-thyroid drugs (e.g. Methimazole), 4) additionally censoring participants at 
thyroid medication use during follow-up 5) excluding abnormal FT4 values and 
thyroid function altering medication (defined as thyroid medication, amiodarone or 
corticosteroids) and 6) additionally excluding participants with CHD and HF at 
baseline 7) adjusting the analyses additionally for HRV.  
We explored the possible role of incident AF or HF in the association between 
thyroid function and SCD by censoring the analyses at time of AF or HF. Follow-up 
data on HF incidence was available in 6893 participants. Furthermore, we 
compared the hazard ratios of SCD with those of total mortality, total 
cardiovascular mortality as well as non-sudden cardiovascular mortality. The 
proportional hazards assumption was assessed with plots and test of Schoenfeld 
residuals. The proportional hazards assumption was met for all analyses. We also 
performed a goodness-of-fit test for the Fine and Gray model for the absolute risk 
estimation, using the Zou Laird Fine test, and this revealed no linear, quadratic or 
log time varying effects of ft4 in the full or euthyroid range (p > 0.35 for all 
analyses). Non-linearity was tested using fractional polynomials and adding 
quadratic terms to the model. The best fit was determined to be linear. TSH was 
log transformed for all continuous analyses to approximate normality while FT4 
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levels were normally distributed. Fractional polynomials were performed using 
STATA (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP). Schoenfeld plot, Schoenfeld test and competing risk 
calculations were performed in R (survival and cmprsk packages R-project, 
Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, 
version 3.0.2). All other statistical analyses were performed using SPSS version 21 
(SPSS IBM, New York, U.S.A). Results of this study are reported according to the 
STROBE statement guidelines 
24
. 
 
RESULTS 
We included 10,318 participants with a maximum follow-up of 21.2 years and a 
median of 9.2 years (interquartile range 3.8-11.1). A total of 261 SCD events 
occurred during follow-up (incidence rate = 3.1 per 1000 person-years) and 
completeness of follow-up was 97.9% 
25
. When restricting to euthyroid subjects, 
there were 231 cases. Of the total number of participants, 10,314 had TSH 
measurements and 10,225 had FT4 measurements. Baseline characteristics are 
shown in Table 1.  
 
 
Table 1 Baseline characteristics of included participants 
Variable Mean (SD)* 
Number of individuals in the study 10,318 
Age, in years 64.7 (9.5) 
Age range, years 46-106 
Women N (%)  5886 (57.0) 
Diabetes mellitus N ( %) 1042 (10.1) 
BMI  27.2 (4.2) 
Cholesterol 5.89 (1.40) 
Smoking current N (%)  2372 (23.0) 
Hypertension N (%) 6142 (59.5) 
Pulse rate 71 (11) 
Median TSH (IQR) mIU/L 1.85 (1.23-2.72) 
FT4 ng/dL 1.23 (0.20) 
Thyroid hormone replacement therapy use N (%) 298 (2.9) 
*unless specified otherwise 
Abbreviations: BMI Body-Mass Index, IQR interquartile range, FT4 free thyroxine, SCD Sudden Cardiac 
Death, SD standard deviation, TSH Thyroid-Stimulating Hormone, N number, TSH is missing in 4 
participants, FT4 is missing in 93 participants 
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Thyroid function and SCD 
Higher levels of FT4 were associated with an increased risk of SCD with a hazard 
ratio (HR) of 1.87 per 1 ng/dL increase of FT4 (95% Confidence Interval [CI], 1.09-
2.86) (Table 2). The log relative hazard between FT4 and SCD as well as the 
distribution of FT4 in the population are plotted in Figure 1. When restricting to 
euthyroid subjects, there was an increased risk of SCD events with a HR of 2.26 
(95% CI, 1.30-3.94). In line with an increased risk for higher FT4 levels, higher TSH 
levels were associated with a concomitant decreased risk but failed to reach 
statistical significance (HR 0.92, 95% CI, 0.80-1.04, per one unit increase of natural 
log transformed TSH).  
The highest compared to the lowest tertile of FT4 had a higher risk of SCD in the 
full range (HR 1.35, 95% CI, 1.01-1.83, p for trend 0.022) (Table 3). Sensitivity 
analyses did not alter risk estimates substantially (Table 4).  
 
 
Table 2 Association between thyroid function and the risk of SCD 
Thyroid 
function  
SCD Events/ 
total N 
HR (95% CI), 
Model 1 
HR (95% CI), 
Model 2 
HR (95% CI),  
Model 3 
Full range of measurement    
TSH mIU/L 261/10,314 0.91 (0.80-1.04) 0.91 (0.80-1.03) 0.92 (0.80-1.04) 
FT4 ng/dL 249/10,225 1.87 (1.18-2.96) 1.76 (1.10-2.86) 1.77 (1.09-2.86) 
Euthyroid participants*    
TSH mIU/L 231/8953 0.81 (0.63-1.04) 0.80 (0.62-1.03) 0.80 (0.62-1.04) 
FT4 ng/dL 222/8881 2.54 (1.48-4.40) 2.24 (1.31-4.40) 2.26 (1.30-3.94) 
Model 1: adjusted for sex and age. Model 2: Model 1 + cohort, pulse rate, hypertension, cholesterol, 
diabetes, body-mass index and smoking. Model 3: Model 2 + and QT-interval. *Euthyroidism is defined 
by TSH 0.4-4.0 mIU/LResults for TSH are per one unit increase of the natural logarithm of TSH and 
results for FT4 per 1 ng/dL.Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, 
SCD sudden cardiac death, TSH thyroid-stimulating hormone. 
 
 
When restricting to euthyroid subjects with normal FT4 values, the absolute 10 
year risks increased from 1% to almost 4% with increasing FT4 values (Figure 2). 
There seemed to be a differential risk of SCD in different age groups 
(Supplemental Table 1). However, the number of cases in the younger age 
category (≤ 65 years) was small and the p for interaction (p >0.30) insignificant. 
Stratification analyses for age, sex and cohort did not show differential risks (p for 
interaction for all analyses > 0.40) (Supplemental Table 1). Participants with 
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subclinical or overt hypo- or hyperthyroidism did not have a higher risk of SCD 
compared to euthyroid participants (Supplemental Table 2), but the number of 
events per category was small. Censoring the analyses at time of incident AF or 
HF did not alter risk estimates meaningfully (Supplemental Table 3 and 4), neither 
did censoring the analyses for both AF and HF (data not shown). The SHRs 
obtained from the competing risk model were slightly more attenuated for all 
variables compared to the HRs obtained from the conventional Cox-proportional 
hazard model, but remained qualitatively similar for the FT4 analyses 
(Supplemental Table 5). As compared to the SCD analyses the risk estimates were 
slightly higher for non-sudden cardiovascular mortality and  
slightly lower for total mortality (Supplemental Table 6). 
 
 
Table 3 Associations of tertiles of TSH and FT4 with SCD 
 
SCD Events/ 
Total N 
HR (95% CI), 
Model 1 
HR (95% CI),  
Model 2 
HR (95% CI),  
Model 3 
TSH tertiles     
0.01-1.43 113/3436 REFERENCE REFERENCE REFERENCE 
1.44-2.36 81/3442 0.88 (0.66-1.17) 0.87 (0.65-1.15) 0.86 (0.65-1.15) 
2.37-80.64 67/3436 0.78 (0.57-1.05) 0.79 (0.58-1.07) 0.78 (0.58-1.06) 
P for trend  0.17 0.18 0.18 
     
FT4 tertiles     
0.12-1.14 72/3420 REFERENCE REFERENCE REFERENCE 
1.14-1.29 71/3404 1.03 (0.74-1.43) 1.03 (0.74-1.44) 1.03 (0.74-1.44) 
1.29-4.73 106/3401 1.39 (1.03-1.87) 1.35 (1.01-1.83) 1.35 (1.01-1.83) 
P for trend  0.008 0.026 0.022 
Model 1: adjusted for sex and age. Model 2: Model 1 + cohort, pulse rate, hypertension, 
cholesterol, diabetes mellitus, body-mass index and smoking. Model 3: Model 2 + QT-interval. 
*Euthyroidism is defined by TSH 0.4-4.0 mIU/L. FT4 is in ng/dL. 
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, SCD sudden cardiac 
death, TSH thyroid-stimulating hormone.  
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Figure 1 Relative risk of sudden cardiac death according to FT4 serum values 
 
Log relative hazard plotted against absolute FT4 ng/dL values with historgram of FT4 distribution in the 
population. Estimates for the relative hazard were derived using 3 restricted cubic splines with a p for 
non-linearity = 0.49 
 
DISCUSSION 
In the current study, higher FT4 levels were associated with an increased relative 
and absolute risk of SCD, even in the normal range of thyroid function. The relative 
risk estimates were similar in the analyses with only witnessed SCDs as outcome 
or when excluding prevalent cases of cardiac diseases and those using thyroid-
function altering medication. 
This is the first study addressing the association between thyroid function and SCD 
in the general population. Two earlier studies that evaluated the relation between 
thyroid function and SCD were conducted in specific patient populations (HF 
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patients and diabetic hemodialysis patients). These studies did not investigate the 
association of FT4 with SCD and had conflicting results
26,27
. The SCD-HeFT study, 
conducted in HF patients, found no difference in SCD risk between TSH 
categories
27
. The 4D study, investigating 1000 diabetic hemodialysis patients, 
reported a higher risk of SCD in subjects with subclinical hyperthyroidism
26
. In the 
current study, additional adjustment for diabetes mellitus at baseline and exclusion 
of participants with prevalent HF did not alter risk estimates substantially. In 
addition, stratification by age and sex showed no differential risk. This suggests 
that the association of higher FT4 levels with an increased risk of SCD is not driven 
by a certain subgroup.  
Thyroid hormone is an important overall regulator of the cardiovascular system
1
. 
The pathways through which thyroid hormone can interfere with the cardiovascular 
system are both direct as well as indirect (e.g. cardiovascular risk factors). Thyroid 
hormone directly influences the adrenergic system where it has a stimulatory effect 
on beta-adrenergic signaling leading to positive chronotopic, dromotropic and 
inotropic effects 
28
. This hyperdynamic state, which causes many of the symptoms 
in hyperthyroid patients, could be one of the mechanisms explaining the relation 
between thyroid hormone and SCD. Furthermore, thyroid hormones have been 
shown to lead to QT-interval prolongation 
29,30
, which in turn is related to 
cardiovascular disease in general 
31
 and SCD in particular 
18
. Another pathway 
could be through various cardiovascular risk factors related to thyroid dysfunction, 
and thus leading to ischemic heart disease, in turn a large contributor in SCD. 
Subclinical thyroid dysfunction has also been related to CHD and HF In large 
collaborative individual participant efforts
2-4
. In the current study we did not find 
evidence for either hypotheses as including pulse rate, reflecting a chronotropic 
effect of adrenergic system stimulation, and various cardiovascular risk factors, 
including QT-interval duration and HRV, did not change risk estimates in the 
multivariable analyses. The exact mechanism for the association between thyroid 
hormone and SCD therefore still needs to be determined. Alternative pathways 
could be via the effects of thyroid hormone on the activity and availability of several 
cation transporters such as cardiac Na-K-ATPase 
32,33
 or via the transcription and 
translation of several cardiac genes (e.g. α- and β-myosin heavy chain genes) 
34
. 
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Table 4 Sensitivity analyses for association between thyroid function and SCD risk in 
euthyroid subjects* 
Sensitivity analysis SCD Events/ 
Total N 
HR (95% CI),  
Model 1 
HR (95% CI), 
Model 2 
 
Restricting to witnessed SCD’s    
TSH mIU/L 133/8953 0.74 (0.53-1.04) 0.74 (0.53-1.03)  
FT4 ng/dL 126/8881 3.36 (1.69-6.66) 3.39 (1.68-6.81)  
     
Excluding possible SCD’s    
TSH mIU/L 195/8953 0.85 (0.65-1.21) 0.84 (0.64-1.11)  
FT4 ng/dL 186/8881 2.20 (1.17-4.15) 2.02 (1.07-3.82)  
 
Excluding abnormal FT4 values† & thyroid medication at baseline ‡  
TSH mIU/L 216/8642 0.83 (0.64-1.08) 0.83 (0.64-1.08)  
FT4 ng/dL 216/8642 3.00 (1.44-6.18) 2.79 (1.34-5.71)  
     
Excluding abnormal FT4 values† & thyroid medication at baseline and censoring 
participants with thyroid medication use at during follow-up‡ 
TSH mIU/L 216/8642 0.83 (0.64-1.08) 0.83 (0.64-1.08)  
FT4 ng/dL 216/8642 2.99 (1.45-6.17) 2.80 (1.34-5.82)  
 
Excluding abnormal FT4 values† and thyroid function altering medication at 
baseline§ 
 
TSH mIU/L 206/8519 0.81 (0.62-1.06) 0.81 (0.62-1.06)  
FT4 ng/dL 206/8519 2.42 (1.14-5.16) 2.25 (1.05-4.82)  
     
Excluding abnormal FT4 values†, thyroid function altering medication§ & prevalent HF and 
CHD 
TSH mIU/L 145/7746 0.80 (0.58-1.09) 0.80 (0.58-1.10)  
FT4 ng/dL 145/7746 2.48 (1.00-6.11) 2.22 (0.95-5.52)  
     
Additionally adjusting for HRV 
TSH mIU/L 135/7146 0.91 (0.65-1.28) 0.91 (0.65-1.28)  
FT4 ng/dL 133/7131 3.38 (1.41-8.14) 3.04 (1.27-7.03)  
Model 1: adjusted for sex and age. Model 2: Model 1+ cohort, pulse rate, hypertension, cholesterol, 
diabetes mellitus, body-mass index and smoking.* Euthyroidism is defined by TSH 0.4-4.0 mIU/L. 
†Normal range of FT4 0.85-1.95 ng/dL. ‡Thyroid medication is use of thyroid hormone replacement 
therapy or any anti-thyroid drug. §Thyroid function altering medication is defined as use of thyroid 
medication, amiodarone or corticosteroids. Results are per one unit increase of the natural logarithm of 
TSH, are per 1 unit increase for FT4. 
Abbreviations: CHD coronary heart disease, CI confidence interval, FT4 free thyroxine, HF heart failure, 
HR hazard ratio, HRV heart rate variability, SCD sudden cardiac death, TSH thyroid-stimulating 
hormone.  
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Figure 2 Absolute 10-year risk of SCD by FT4 values 
 
Absolute 10-years risks of SCD were calculated taking competing risk of death by other causes into 
account, and are plotted against FT4 values in all participants in the two upper figures and in euthyroid 
participants in the lower two. The normal range of FT4 is highlighted in the two right figures. FT4 free 
thyroxine, SCD Sudden Cardiac Death. 
 
 
We find an effect of FT4 on the risk of SCD, while the association with TSH is less 
evident. These findings seem to be in line with previous literature investigating the 
risk of thyroid function on several clinical endpoints
14,35-37
. Thyroid hormone levels 
are regulated by the hypothalamus-pituitary-thyroid axis, which has a unique set 
point for each individual
38
. There is a wide variety of factors that can modulate this 
set point, including illness and aging. A change in set point over time might be an 
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explanation why the association with FT4 is stronger than for TSH. We do not have 
repeated measures of thyroid function and can therefore not investigate if changes 
in TSH over time could explain the apparent discrepant findings between FT4 and 
TSH. 
We find roughly similar estimates for SCD, CVD mortality, and total mortality. This 
was not surprising, as the association between thyroid dysfunction and CVD 
mortality (mainly consisting of CHD mortality) has been described in several 
previous studies and is well established
4,39
. Guidelines recommend treatment of 
subclinical thyroid disease from a certain TSH value cut-off mainly based on data 
regarding CHD outcomes from large collaborative studies. Cardiovascular diseases 
are the leading cause of burden of disease and mortality in elderly worldwide
40
. In 
high-income countries, cancer mortality is the second leading cause. Although the 
underlying mechanisms are probably different to CVD mortality, the association of 
high thyroid dysfunction and cancer has been previously described and could 
therefore contribute to the association found with total mortality. The associations 
of thyroid function with CVD mortality and of thyroid function and SCD seem to 
both be independent of cardiovascular risk factors. However, bigger sample size 
and more detailed data are needed to determine whether these associations share 
the same or have distinct pathways.  
SCD develops within a short timeframe and there is limited time to start 
intervention and cardiopulmonary resuscitation. Therefore, identification of 
modifiable risk factors is crucial in the setting of identification of certain populations 
or subgroups at risk, as well as screening and prevention. In the current study, we 
were not able to demonstrate differential risks by age and sex, but the association 
between thyroid function and SCD was more pronounced within the normal range 
of thyroid function. This can likely be explained by the fact that participants with a 
thyroid function outside the reference range have a higher probability of being 
treated, which will alter their risk. In contrast, people with FT4 levels in the normal 
range have no indication for treatment and are usually stable with very little intra-
individual variation, reflecting the individual set point. When we exclude those using 
levothyroxine or anti-thyroid drugs at baseline or during follow-up, risk estimates 
only slightly shift towards the risk in euthyroid participants. However in our study, 
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no conclusions on the benefits or risks of thyroid medication can be drawn. Ideally, 
this should be investigated in a randomized controlled trial. 
Strengths and limitations 
Major strengths of our study are the number of participants and covariates included 
in the analyses. All data were collected irrespective of the current hypothesis. 
Furthermore,, we were able to phenotype SCD in detail and make a distinction 
between witnessed and unwitnessed types. The setting of a population-based 
cohort and the long follow-up allowed for estimation of long-term absolute risks. 
Limitations include possible residual confounding and the availability of one 
baseline measurement of thyroid function, not allowing for assessment of temporal 
changes of TSH and FT4. Furthermore, there were a limited number of participants 
with FT4 values outside the reference range (190 participants). The vast majority of 
participants in the study were of Caucasian descent and therefore our results might 
not be generalizable to other populations. 
Conclusions 
In summary, we describe an increased risk of SCD with increasing FT4 levels, 
even when restricting to euthyroid participants. 
 
Online supplemental material 
http://circ.ahajournals.org/content/134/10/713.long 
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ABSTRACT 
BACKGROUND Hyperthyroidism is an established risk factor for atrial fibrillation 
(AF), but information concerning the association with variations within the normal 
range of thyroid function and subgroups at risk is lacking. We therefore aimed to 
investigate the association between normal thyroid function and AF prospectively 
and explore potential differential risk patterns. 
 
METHODS From the Rotterdam Study we included 9166 participants ≥45 years 
with thyroid stimulating hormone (TSH) and/or free thyroxine (FT4) measurements 
and AF assessment (1997-2012, median follow-up 6.8 years), with 399 prevalent 
and 403 incident AF cases. Outcome measures were threefold 1) Hazard Ratio’s 
(HRs) for the risk of incident AF by Cox Proportional-Hazards models 2) Ten-year 
absolute risks taking competing risk of death into account. 3) Discrimination ability 
of adding FT4 to the CHARGE-AF Simple Model, an established prediction model 
for AF. 
 
RESULTS Higher FT4 levels were associated with higher risks of AF (HR 1.63, 
95% Confidence Interval 1.19-2.22), when comparing those in the highest quartile 
to those in lowest quartile. Absolute 10-year risks increased with higher FT4 in 
participants ≤65 years from 1% to 9% and from 6% to 12% in subjects ≥65 years. 
Discrimination of the prediction model improved when adding FT4 to the Simple 
Model (c-statistic 0.722 vs 0.729, p=0.039). TSH levels were not associated with 
AF. 
 
CONCLUSIONS There is an increased risk of AF with higher FT4 levels within the 
normal range, especially in younger subjects. Adding FT4 to the Simple Model 
slightly improved discrimination of risk prediction. 
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INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and a leading cause 
of cardiovascular disease, particularly stroke 
1
. Lifetime risks for developing AF in 
Europe are calculated to be up to 25% 
2
. Despite efforts improving management of 
major classical risk factors of AF (e.g. hypertension), prevalence and costs of AF 
are expected to increase in upcoming years
3,4
. This highlights the need to improve 
prevention of AF and identification of additional risk factors. Overt and subclinical 
hyperthyroidism are well-documented risk factors for AF, with a prevalence of AF of 
over 10% in patients with hyperthyroidism
5-7
. Furthermore, higher thyroid-
stimulating hormone (TSH) levels within the normal range have been associated 
with increased cardiovascular mortality and an unfavorable metabolic profile 
8
, 
while low-normal TSH levels are associated with increased risks of fractures and 
depressive disorders 
8,9
. Nevertheless, only two studies have specifically 
investigated the association between thyroid function in the normal range and 
AF
10,11
 with both specific limitations. Neither addressed possible differential risks in 
specific subgroups (e.g. gender) or possible clinical implications. Identification of 
specific populations at risk is a crucial requirement in a primary prevention setting 
or with a targeted screening approach. Therefore, we aimed to investigate the 
association between variations in normal thyroid function and AF in a longitudinal 
prospective cohort study, to explore possible subgroups at risk and calculate 
absolute 10-year risk of AF. Furthermore, we assessed the potential role of thyroid 
function in a risk prediction model for AF. 
 
METHODS 
Study population  
The Rotterdam Study is a prospective cohort study ongoing since 1990 in 
Ommoord, a suburb of the city of Rotterdam, The Netherlands. The study targets 
cardiovascular, endocrine, hepatic, neurologic, ophthalmic, psychiatric, 
dermatological, oncological and respiratory disease. Until now 14,926 subjects of 
45 years and older are included in the Rotterdam Study. The participants 
interviewed at home and extensively examined at the research center at baseline. 
These examinations focused on possible causes of diseases in the middle-aged 
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and elderly. Participants of the Rotterdam Study are followed for several older age 
related diseases. The aims and design of the Rotterdam Study have been 
described in detail elsewhere 
12
. For this study, we included participants from three 
independent cohorts within RS: RS Cohort 1 (RSI), including 7,983 participants 
aged ≥55 (baseline 1990-1993), RS Cohort II (RSII), including 3,011 participants 
aged ≥55 (baseline 2000-2001) and RS Cohort 3 (RSIII), including 3,932 
participants aged ≥45 (baseline 2006-2008). Participants from the three cohorts 
were eligible for the study if TSH or FT4 measurements were performed and if 
information on AF was available. All study participants were followed up from the 
day of baseline laboratory testing to date of onset of AF, to death, or to June 1, 
2012, whichever came first. The Medical Ethics Committee of the Erasmus 
University has approved study protocols, and written informed consent was 
obtained from all study participants. 
Assessment of thyroid function 
Thyroid function was measured using the same methods and assay in all samples, 
which were collected between 1997 and 2008, depending on the cohort. TSH, free 
thyroxine (FT4) and Thyroid Peroxidase Antibodies (TPOAb) measurements were 
performed in serum samples stored at -80°C (The electrochemiluminescence 
immunoassay for thyroxine, thyrotropin and thyroid perioxidase antibodies, 
“ECLIA”, Roche). Date and time of blood drawing was recorded and regarded as 
baseline. We determined cut-off values for normal range TSH as 0.4-4.0 mIU/L and 
FT4 as 11-25 pmol/L (0.86-1.94 ng/dL) according to guidelines and previous 
studies 
10
. TPOAb levels greater than 35 kU/mL were regarded as positive, 
according to manufacturer recommendation.  
Diagnosis of atrial fibrillation 
Ascertainment of AF cases within RS has been reported elsewhere 
2
. In short, 
cases of AF, including paroxysmal AF, were ascertained using 3 methods. ECG’s 
were recorded at baseline and during follow-up examinations, stored digitally, and 
analyzed by the Modular ECG Analysis System (MEANS)
13,14
. As verification, all 
ECGs with a diagnosis of AF, atrial flutter, or any other rhythm disorders by the 
MEANS program were recoded by 2 independent research physicians who were 
blinded to MEANS diagnosis. The judgment of a cardiologist was sought and taken 
as decisive in case disagreement persisted between the coding physicians. 
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Additionally, information on AF was obtained for all participants from general 
practitioners records, which included their own results as well as results from 
physicians practicing in hospitals and outpatient clinics. Finally, information was 
obtained from a national registry of all hospital discharge diagnoses. Those 
patients who developed AF during a serious disease, resulting in death shortly after 
the detection of AF, which was not the cause of the serious disease, were not 
considered as having AF and were censored on date of detection of AF. 
Furthermore, subjects with transitory atrial fibrillation during myocardial infarction or 
during cardiac operative procedures were not included among AF cases. We did 
not distinguish between AF and atrial flutter when identifying cases because both 
conditions are very similar with respect to risk factors and consequences
15,16
. 
Baseline measurements 
Information on smoking and history of thyroid disease was derived from baseline 
questionnaires. Systolic and diastolic blood pressure were calculated as the 
average of two consecutive measurements. Hypertension was defined as systolic 
blood pressure ≥140 mmHg or diastolic blood pressure ≥90mmHg or using anti-
hypertensive medication. Cholesterol was measured using standard laboratory 
techniques. History of diabetes was defined by a repeated impaired fasting glucose 
≥ 7 or use of anti-glycemic medication. Coronary heart disease (CHD) was defined 
as a history of myocardial infarction (MI), percutaneous coronary intervention or 
coronary artery bypass graft
17
. Assessment of heart failure was done using a 
validated score
18
, according to the definition of heart failure of the European 
Society of Cardiology
19
.This score was based on the presence of at least two signs 
or symptoms suggestive of heart failure (shortness of breath, ankle swelling and 
pulmonary crepitations) or use of medication for the indication of heart failure, in 
combination with objective evidence of cardiovascular disease including angina 
pectoris, myocardial infarction, and left ventricular hypertrophy. Furthermore, heart 
failure cases were identified through hospital and medical records.  
Statistical analysis 
Details of the statistical analyses performed are included in the Supplemental 
Material. In short we performed logistic regression to assess the association 
between thyroid function and prevalent AF and cox-proportional hazards models 
were used to assess the association between thyroid function and incident AF 
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prospectively. TSH and FT4 were examined as continuous measures and quartiles. 
Primary models adjusted for age and gender and multivariable models additionally 
adjusted for smoking, hypertension, cholesterol, diabetes and BMI. We performed 
pre-defined stratification by age categories - cutoff at 65 years of age-, gender, 
prevalent CHD and TPOAb positivity. Absolute 10 year risk-probabilities were 
estimated taking competing risk of death into account 
20
. To investigate the 
robustness of our findings, we conducted sensitivity analyses 1) including only 
those participants included in the previous report on thyroid function and AF from 
RS 
10
 2) including only subjects using thyroid hormone medication, 3) excluding 
participants with thyroid function altering medication, including thyroid hormone 
replacement therapy, anti-thyroid drugs, amiodarone and corticosteroids at 
baseline 4) excluding participants with thyroid function altering medication at 
baseline and follow-up and 5) excluding the first two and first four years of follow-
up to examine possible reverse causality. Furthermore, we compared 
discrimination of two prediction models by using C-statistic and Net Reclassification 
Index (NRI). The first model - proposed in 2013 by the CHARGE-AF Consortium 
and will be referred to as the Simple Model 
21
 (Supplemental Material). The second 
model additionally included FT4 in the full and normal range. For these analyses 
we excluded all non-white participants (n=357). The reclassification tables 
classified participants in AF risk categories of low (<2.5%), intermediate (2.5% to 
5%), and high (>5%)
21
. Statistical analyses were performed using SPSS version 21 
(SPSS IBM, New York, U.S.A), R statistical software (survival, cmprsk and nricens 
packages, R-project, Institute for Statistics and Mathematics, R Core Team (2013), 
Vienna, Austria, version 3.0.2) or Stata (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP). 
 
RESULTS 
In total, 9166 participants were included (mean age 65 years) in the cross-sectional 
and 8740 in the longitudinal analyses (399 participants with AF at baseline and 27 
with missing follow-up data were excluded) (Table 1). Among included participants, 
five missed TSH measurement and six FT4 measurement. Only participants with 
both TSH and FT4 measurements available were included in the analyses 
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evaluating the associations within normal ranges. During a median follow-up of 6.8 
years (interquartile range 3.9-10.9 years) a total of 403 AF events occurred, with an 
incidence rate of 6.2 per 1000 person-years. There were 256 participants using 
levothyroxine replacement therapy, which was prescribed by their own GP or 
specialist and within the context of regular treatment and blinded to measurements 
of the Rotterdam Study. Of these, 208 reported a history of hypothyroidism and 40 
reported a history another thyroid disease. 
 
 
Table 1 Baseline characteristics of included participants (n=9166)* 
Variable Number (%)
a 
Age, years, mean (SD) 65.0 (9.9) 
Gender, female 5200 (56.7) 
History of Diabetes 773 (8.4) 
BMI kg/m
2
, mean (SD) 27.1 (4.1) 
Cholesterol mmol/L, mean (SD) 5.7 (1.0) 
Smoking, 
    current 1857 (20.3) 
   past 4376 (47.7) 
   never 2855 (31.1) 
Hypertension 4743 (51.7) 
TSH mIU/L median (IQR) 1.91 (1.29-2.77) 
FT4 pmol/L 15.7 (2.3) 
TPOAb positive (>35 kU/L) 1200 (13.1) 
Use of thyroid medication 256 (2.8) 
History of CHD 638 (6.9) 
* For the survival analyses, 399 participants had prevalent atrial fibrillation and 27 participant did 
not have follow-up times or data on atrial fibrillation and were excluded, making the total number 
8740 participants. 
a
 Values are number of participants and percentage unless otherwise specified 
BMI, body-mass index; TSH, thyroid-stimulating hormone, FT4, free thyroxine; SD, Standard 
deviation; IQR, inter-quartile range; TPOAb, thyroid peroxidase antibodies; CHD, coronary heart 
disease, including myocardial infarction, coronary artery bypass graft or percutaneous coronary 
intervention 
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The cross-sectional analyses are shown in Table S1. Increased levels of FT4 were 
associated with an increased risk of AF for the continuous analysis (OR 1.21, 95% 
CI, 1.15-1.28) and for FT4 quartiles (OR 2.24, 95% CI, 1.59-3.16, lowest vs highest 
quartile; P for trend, <0.001). The longitudinal analyses were conducted after 
excluding subjects with prevalent AF, and comprised 8740 participants (Table 2). 
The risk of AF was significantly higher with higher levels of FT4, both outside (HR 
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1.07, 95% CI 1.03-1.12,) as within the normal range of thyroid function (HR 1.10, 
95% CI 1.04-1.15) (Table 2). After excluding subjects with TSH and/or FT4 values 
outside the reference range and thyroid hormone medication users (n=1333), 
participants in the highest quartile compared with the lowest quartile of FT4 had an 
increased risk of AF in the multivariable analysis (HR 1.63, 95% CI, 1.19-2.22, p for 
trend of 0.005) (Table 2). Additionally adjusting for time of blood drawing, fasting 
state at blood drawing, prevalent CHD at baseline or cohort did not alter risk 
estimates. There was no association between TSH and AF in the cross-sectional or 
survival analyses (Table S1, Table 2).  
 
 
Table 2 Association between thyroid function and incident atrial fibrillation (AF) *
 
 
Incident 
AF N / 
Total N 
Total N 
HR (95% CI) 
adjusted for age 
and gender 
HR (95% CI) 
multivariable 
adjustment 
a 
TSH mIU/L 402 8736 0.94 (0.84-1.06) 0.91 (0.81-1.03) 
FT4 pmol/L 403 8734 1.06 (1.02-1.10) 1.07 (1.03-1.12) 
     
Within normal function of TSH and FT4
b
, excluding thyroid medication users 
TSH mIU/L 334 7409 0.91 (0.73-1.13) 0.91 (0.73-1.09) 
FT4 pmol/L 334 7409 1.09 (1.03-1.15) 1.10 (1.04-1.15) 
   
 
 TSH quartiles  
0.41-1.28 94 1850 1 (REFERENCE) 1 (REFERENCE) 
1.29-1.80 88 1858 1.03 (0.77-1.38) 1.04 (0.81-1.39) 
1.81-2.48 76 1858 0.90 (0.66-1.22) 0.93 (0.69-1.26) 
2.49-3.99 76 1843 0.99 (0.73-1.33) 0.95 (0.70-1.29) 
p for trend 
  
0.71 0.60 
    
 
FT4 quartiles 
11.01-14.33 64 1862 1 (REFERENCE) 1 (REFERENCE) 
14.34-15.59 84 1861 1.22 (0.88-1.70) 1.28 (0.93-1.78) 
15.60-16.96 80 1861 1.18 (0.85-1.63) 1.20 (0.86-1.66) 
16.97-24.69 106 1825 1.56 (1.14-2.12) 1.63 (1.19-2.22) 
p for trend 
  
0.008 0.005 
* TSH was log transformed for the continuous analyses, results are per one increase of the natural 
logarithm of TSH. Five participants had missing TSH and six had missing FT4 values. No thyroid 
function measurements were missing in the normal range analyses. 
a
 adjusted for age, gender, body mass index, smoking, hypertension, diabetes and cholesterol 
b
 normal range of TSH 0.4-4.0 mIU/L and of FT4 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL) 
AF, atrial fibrillation; FT4, free thyroxine; TSH, thyroid-stimulating hormone; HR, hazard ratio; CI, 
confidence interval 
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Stratified and sensitivity analyses 
There was a differential risk by age (p for interaction 0.040) (Table 3). Comparing 
the highest quartile of FT4 to the reference quartile in participants below and above 
65 years of age there was an increased risk of AF, with HRs of 2.23 (95% CI, 1.18-
4.22) and 1.45 (95% CI, 1.01-2.08) respectively (Figure 1, Table S2). No 
differences were found when stratifying for gender, history of CHD and TPOAb 
positivity (Table S3). Including only the participants analyzed previously in RS 
10
, 
risk estimates are more comparable to our current results, with an association 
between FT4 (p for trend 0.001) and AF but not for TSH (p for trend 0.32). 
Including only thyroid hormone users with thyroid function in normal range (n=720, 
events=12), also yielded higher risks for FT4, but did not reach statistical 
significance (HR 1.07, 95% CI, 0.88-1.31).  
 
 
Table 3 Stratified analysis by  age for TSH and FT4 within normal range and incident 
atrial fibrillation * 
 Age AF N/ 
 Total N 
HR (95% CI) 
adjusted for 
age & gender  
P- 
value 
HR (95% CI) 
multivariable 
adjustment 
a 
P- 
value 
TSH  <65 82/4273 0.80 (0.51-1.26) 0.34 0.83 (0.53-1.31) 0.43 
  ≥65 252/3136 0.94 (0.73-1.20) 0.59 0.93 (0.72-1.19) 0.55 
P int   0.54  0.46  
FT4  < 65 82/4273 1.19 (1.08-1.32)  <0.001 1.19 (1.07-1.32) 0.001 
 ≥ 65 252/3136 1.06 (1.00-1.12) 0.071 1.06 (1.00-1.13) 0.046 
P int   0.059  0.040  
* normal range of TSH 0.4-4.0 mIU/L and of FT4 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL), 
excluding thyroid hormone users. TSH was log transformed for the continuous analyses, results are 
per one increase of the natural logarithm of TSH 
a
 adjusted for age, gender, body mass index, smoking, hypertension, diabetes and cholesterol. AF, 
atrial fibrillation; FT4, free thyroxine; TSH, thyroid-stimulating hormone; HR, hazard ratio; CI, 
confidence interval; p int, p for interaction. 
 
Absolute risk calculation and prediction models 
Absolute 10 year risks of AF were plotted against FT4 serum values within the 
normal range in Figure 2 for both age groups (<65 years and ≥65years). The 10 
year absolute risk for those older than 65 years gradually increased from 6% up to 
12%. For younger participants, risk increased from 1% to almost 9%. Adding FT4 
to the Simple Model slightly improved discrimination of the model (c-statistic 0.722 
vs 0.729, p=0.039, Table 4). Tables S5 and S6 summarize the NRI results when 
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adding FT4 to the Simple Model. There was no significant improvement in NRI for 
the full or normal range of FT4. Excluding participants with thyroid function altering 
medication and excluding the first two or four years of follow-up, did not alter risk 
estimates (Table S4).  
 
Table 4 Discriminative ability adding FT4 to CHARGE-AF Simple Model for 10 year risk 
prediction of incident atrial fibrillation* 
Participants C-Statistic Simple 
Model 
C-Statistic Simple Model 
including FT4 
p-value 
All participants 0.722 0.729 0.039 
Normal Range
a 
0.722  0.730  0.071 
Age <65 years 0.694  0.712  0.132 
Age ≥65years 0.677  0.683  0.299 
* CHARGE-AF Simple Model included age, race, height, weight, blood pressure, smoking, anti-
hypertensive medication, diabetes, history of heart failure and history of myocardial infarction. For these 
analyses we excluded all non-white participants. Age-stratified analyses included age as a predictor. 
a
 
normal range: TSH 0.4-4.0 mIU/L, FT4 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL), excluding 
thyroid hormone users.AF, atrial fibrillation; FT4, free thyroxine; TSH, thyroid-stimulating hormone. 
 
 
Figure 1 Stratified Analysis for the Association between FT4 Levels in Normal Range and 
Incident AF*
 
 
The normal range of TSH was defined as 0.4-4.0 mIU/L and of FT4 as 11-25 pmol/L (Conversion 1 
pmol/L = 0.0777 ng/dL), thyroid hormone medication users were excluded.  
The multivariable analyses were adjusted for age, gender, body mass index, smoking, hypertension, 
diabetes and cholesterol.Abbreviations AF = atrial fibrillation, TSH = thyroid-stimulating hormone, FT4 = 
free thyroxine, HR = hazard ratio, CI = confidence interval 
Normal thyroid function and atrial fibrillation 
93 
 
Figure 2 Atrial fibrillation absolute 10-year risk for euthyroid subjects below and above 65 
years of age plotted against FT4 within the normal range.* 
 
 
 
* The normal range of FT4 was defined as 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL) 
Absolute risk analyses were conducted taking competing risk of death into account using a Fine and 
Gray model and adjusted for age and gender within strata.  
FT4, free thyroxine.  
 
DISCUSSION 
Higher FT4 levels –within the normal range – are associated with an increased risk 
of AF, irrespective of age, gender and other potential confounders, with consistent 
results for both prevalent and incident AF. This effect was stronger among subjects 
younger than 65 years of age. We found higher 10 year absolute risks with 
increasing FT4 levels in participants older than 65 years of age with an increase in 
risk from 6% to 12%. In younger participants this was more marked, with an 
increase of risk from 1% to 9% with increasing FT4 levels within the normal range. 
Adding FT4 to the Simple Model for AF risk prediction improved discrimination of 
the model slightly. 
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Our overall results concerning relative risks are consistent with a previous study by 
Selmer et al. that reported a higher risk of AF towards hyperthyroidism 
7
. Our 
results are also in line with two previous studies that focused on normal thyroid 
function and AF 
10,11
. The population-based study by Cappola et al. 
(2843participants >65 years) found an increased risk with higher FT4 levels, within 
the normal range of thyroid function. This study however had a mean age of almost 
75 years old and did not include younger participants. Furthermore, it did not 
provide information on potential absolute risks, differential risks or on the predictive 
ability of FT4 for AF. 
A previous report from the RS including only 1426 participants, reported an 
increased risk with high-normal thyroid function 10 with an association between 
TSH levels and an increased risk of AF and a graded non-significant association 
with FT4. Our study shows that the associated risks are mainly with increased FT4 
levels and not with TSH. Potential explanations for differences between previous 
and current report from the RS include population size (1426 vs 8740 participants), 
lack of subgroup analyses in the previous report, follow-up period and different 
characteristics of the study population. In the previous study, the included 
participants were slightly older at baseline (68.4v s 65.0 years), less AF events had 
occurred (105 vs 334) and follow-up started over 10 years earlier. A sensitivity 
analysis including only participants of this earlier study, with updated number of 
events and follow-up time showed results comparable to the findings of the current 
study, i.e. without an association with TSH but with an increased risk of AF with 
increased FT4 levels. 
Thyroid hormones are known to have numerous direct effects on the 
cardiovascular system, including altering gene-expression of several cardiac 
genes
22
, a decrease systemic vascular resistance
23
 and alter systolic and diastolic 
cardiac function 
24,25
. Thyroid hormone bioactivity is determined by the binding of 
the metabolically active form of thyroid hormone, triiodothyronine (T3), to its 
nuclear receptors, that function as transcription factors modulating gene 
expression. However, FT4 is the predominant marker of thyroid hormone in serum 
and important for the negative feedback mechanism. The level of serum FT4 is 
tightly regulated by the hypothalamic-pituitary-thyroid axis, with a different set point 
for each individual 
26,27
, which is under strong genetic influence
28
. This could 
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explain why even within the normal range of thyroid function, defined mostly by 
TSH, there is an increased risk of AF with higher FT4 levels. We find a higher risk 
of AF in both younger as well as older participants. However, in the younger 
participant group, this risk seems stronger. One explanation could be a changed 
set point among the elderly compared to younger participants. The individual set 
point can be modulated by several pathophysiological as well as physiological 
processes such as aging 
29
.Therefore, the same values of thyroid function serum 
makers, may hypothetically have different effects in younger versus older 
participants, especially over time. However, pathways possibly leading to the 
differences between different age groups still need to be determined and further 
explored. 
The results of this study could have several implications. Currently, the normal 
range of thyroid function is defined biochemically, which is solely based on the 
measurement itself rather than on adverse clinical outcomes related to these 
measurement. It has therefore been debated whether the currently applied 
reference ranges should be redefined
30,31
. Our study provides evidence that 
variations within the reference range are associated with atrial fibrillation. Future 
studies should confirm these results and investigate whether variations within the 
reference range currently applied are associated with other cardiovascular 
outcomes. 
The prevalence of AF and its burden on health care is increasing despite efforts to 
control risk factors 
2,4
. Acknowledging non-classical risk factors might aid in the 
recognition and decision making concerning AF. With this study we show that even 
“high-normal thyroid function” has implications on relative risks, absolute risks and 
prediction of developing AF and perhaps should be taken into account in further 
research concerning risk prediction or screening of AF. 
In recent years, the proportion of people treated for subclinical hypothyroidism has 
increased 
32
, mostly in an attempt to prevent possible adverse effects on the 
cardiovascular system. However, our results could suggest that treatment of 
subclinical hypothyroidism is not without danger and even when thyroid function is 
biochemically well-controlled, there can still be an increased risk of AF. Including 
only thyroid hormone users within the normal range of thyroid function, shows a 
similarly increased risk in higher FT4 level, even though not significant due to low 
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power in this specific subgroup. Population-based studies have shown that among 
patients treated with thyroid medication more than one fifth have TSH levels 
suppressed below normal. Future studies should determine whether the increased 
risk of AF is also applicable for those with high-normal thyroid hormone values due 
to replacement therapy. 
A major strength of our study is the inclusion of a large number of participants in a 
population-based cohort and with longitudinal ascertainment of a large number of 
AF events. This allowed investigation of possible differential risks in several 
subgroups and calculation of absolute risks. Other strengths are the extensive 
evaluation and case-finding of participants with AF, both at baseline as well as 
during follow-up and ability to adjust for a wide variety of confounders. A limitation 
of our study is that despite this amount of variables included in the analyses, 
residual confounding cannot be excluded. Measurements of total T3 and Free T3 
are not available in the Rotterdam Study and therefore the association between 
these thyroid function markers and AF could not be assessed. Also, we measured 
thyroid function only at baseline and therefore could not take changes in thyroid 
function into account, which is a limitation for most previous studies in this field 
33,34
. Furthermore, this study is conducted in a mainly white population of 45 years 
and older and may not be generalizable to other populations. 
Conclusions 
There is an increased risk of AF with higher FT4 levels in the normal range of 
thyroid function. There is a trend of higher absolute risk increases with increasing 
FT4 levels from 1 to 9% in those younger than 65 years of age and from 6% to 
12% in older participants. This suggests caution in decision making regarding 
intensity of treatment of subclinical hypothyroidism. Assessing thyroid function, 
even in the normal range, for risk prediction of AF development should be further 
investigated. 
 
Online supplemental material  
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-2480   
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ABSTRACT 
BACKGROUND Short-term variability of QT intervals (STVqt) is a promising 
electrocardiographic marker for ventricular arrhythmias and sudden cardiac death 
(SCD). Both hypothyroidism and hyperthyroidism have been linked to ventricular 
arrhythmias; while higher thyroid function is associated with SCD. Our objective 
was to study the association between thyroid function and STVqt. 
 
METHODS The association of thyroid function and STVqt was analyzed in a cross-
sectional study using linear regression models in the Rotterdam Study, a cohort of 
community-dwelling participants. Thyroid function was expressed by thyroid-
stimulating hormone (TSH) and free thyroxine (FT4), and by thyroid status (i.e. 
hypothyroidism, subclinical hypothyroidism, euthyroidism, subclinical 
hyperthyroidism, and hyperthyroidism). Nonlinearity was tested by adding 
polynomial terms of FT4. Analyses were stratified on age and sex. In sensitivity 
analyses we excluded users of thyroid medication, participants with anti-TPO 
antibodies above 35kU/mL and non-euthyroid participants.  
 
RESULTS The study population comprised 8,708 participants, 56.9% were women. 
The mean age was 64.5 years. FT4 had a significant quadratic association with 
STVqt; both low and high levels of FT4 associated with a higher STVqt. The 
association was significantly stronger in men than in women (p interaction FT4 
0.014; FT42 0.006). After excluding users of thyroid medication, TSH was 
significantly associated with a higher STVqt. STVqt was not significantly different 
across thyroid categories (p-trend 0.41). 
 
CONCLUSIONS Both high and low levels of FT4 are associated with a higher 
STVqt, which is stronger in men. Further studies can elucidate if the association of 
FT4 and SCD is mediated via STVqt. 
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INTRODUCTION 
The short-term variability of QT intervals (STVqt) is a marker of QT variability.
1
 QT 
variability reflects the beat-to-beat changes in QT interval duration on the 
electrocardiogram (ECG).
1-3
 It has been hypothesized that a high QT variability is 
indicative of repolarization instability. For example, QT variability has been 
investigated in studies that focused on cardiomyopathies or drug use as the 
substrate leading to repolarization instability.
2,4
 Moreover, an increase in QT 
variability has been associated with an increased risk of ventricular arrhythmias
5
 
and sudden cardiac death (SCD).
6
 
Thyroid hormones (triiodothyronine (T3) and its precursor, thyroxine (T4)), could 
also affect repolarization stability. Thyroid hormones can influence repolarization 
indirectly via the heart rate
7
, or directly via potassium, sodium and calcium 
channels
8
, or by changing the expression of Ca2+ ATPase and its inhibitor 
Phospholamban in the sarcoplasmic reticulum.
9
 The possible effect of thyroid 
hormones on repolarization instability is reflected by the fact that higher thyroid 
hormone levels are associated with an increased risk of atrial fibrillation, even in 
euthyroid subjects
10
, and that high free thyroxine (FT4), even within the normal 
range, is associated with SCD.
3
 On the other side of the thyroid spectrum, lack of 
thyroid hormone (i.e. hypothyroidism) is related to bradycardia and prolongation of 
the QT interval.
11
 Case reports have suggested that both hyperthyroidism
12-14
 and 
hypothyroidism 
11,15-17
 are associated with ventricular arrhythmias, albeit probably 
through different mechanisms. 
Although both high thyroid function
3
 and high QT variability
6
 have been associated 
with SCD, the association of thyroid function with QT variability, and the marker 
STVqt, has not yet been studied. Analysis of this association would elucidate the 
relation of thyroid function with repolarization instability, and could provide 
pathophysiological insights into why higher FT4 levels are associated with an 
increased risk of SCD. We therefore assessed the association of thyroid function 
with STVqt as measured on standard ECGs in a community dwelling middle-aged 
and elderly cohort. 
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METHODS 
Research setting 
The study is embedded in the prospective population-based Rotterdam Study. 
Design and rationale of the Rotterdam Study have been described in more detail 
elsewhere. 
18,19
 In short, 10,215 inhabitants aged 55 years and older from the well-
defined Ommoord district in the city of Rotterdam were invited from 1990 to 1993 to 
participate in the initial cohort. Of the invitees, 7,983 persons agreed to participate 
(response rate 78%). In 2000, the cohort was extended by inviting 4,472 
inhabitants of the same district who had turned 55 or who had moved into the 
district after the start of the initial cohort. In total, 3,011 individuals agreed to 
participate (response rate 67%). A second extension of the cohort was created in 
2006 by inviting 6,057 persons living in the Ommoord district aged 45 years or 
over, of whom 3,932 subjects were included in the study (response rate 65%). 
Thus, by the end of 2008, 14,926 persons were included in the Rotterdam Study. 
Follow-up examinations were conducted every four to five years. This study used 
thyroid measurements from the third examination of the first cohort and the first 
examination of the second and third cohorts, 11,740 participants in total. Thyroid 
measurements taken in the first visit of the first cohort were not used because 
these were measured with a different assay. No thyroid measurements were taken 
during the second visit of the first cohort.  
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study)”. We only included participants who provided written informed 
consent to participate in the study, to give access to information from their 
attending physicians and for follow-up monitoring. Figure 1 shows the flowchart of 
the study population. 
Assessment of thyroid function 
Thyroid function assessment included measurement of thyroid-stimulating hormone 
(TSH), FT4, and thyroid peroxidase antibodies (TPOAb) in serum samples stored at 
-80°C (electrochemiluminescence immunoassay for thyroxine, thyrotropine and 
thyroid peroxidase antibodies, “ECLIA”, Roche, Basel, Switzerland). The cut-off 
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values of the normal range of TSH were set to 0.4-4.0 mIU/L, while the reference 
range for FT4 was 11-25 pmol/L, in accordance with previous studies and in line 
with Dutch national guidelines. 
3,10,20
 TPOAb levels greater than 35 kU/mL were 
regarded as positive, as recommended by the assay manufacturer. Euthyroidism 
was defined as a TSH value within the reference range. Hypothyroidism was 
defined by TSH > 4.0 and FT4 <11, whilst subclinical hypothyroidism was defined 
as TSH > 4.0 and FT4 within the reference range. Hyperthyroidism was defined by 
TSH < 0.4 and FT4 > 25, while subclinical hyperthyroidism was defined as TSH < 
0.4 and FT4 within the reference range. 
Electrocardiography 
ECGs were recorded during the same center visit as the thyroid function 
measurements. Standard 12-lead 10-second ECGs were recorded during rest with 
an ACTA Gnosis electrocardiograph (Esaote Biomedica, Florence, Italy). We used 
a sampling frequency of 500 Hz and the ECGs were stored digitally. ECGs were 
processed by the Modular ECG Analysis System (MEANS), which has been 
described previously and has been validated and applied extensively. 
21,22
 
Exclusion criteria for ECGs were atrial fibrillation, atrial flutter, or pacemaker 
rhythm. We used short-term variability of QT intervals (STVqt)
1
 as marker for QT 
variability. STVqt is defined as 
STVqt =  ∑
|QTi+1 − QTi|
n√2
n
i=1
 
 
where QTi is the QT interval of beat i, and n is the total number of beats in the ECG 
recording. 
QT intervals were measured automatically using fiducial segment averaging (FSA). 
23
 First, MEANS determines the locations of the individual QRS complexes on the 
ECG and initial fiducial points (onset of QRS complex and end of T wave) and a 
detection function consisting of the root-mean-square ECG signal, 
24
 is computed. 
Second, the fiducial point in each individual beat is shifted in an iterative procedure 
until maximum correlation is achieved between a small signal segment of the 
detection function around this fiducial point and the average of the segments 
around the fiducial points of the remaining complexes. The amount of shifting is 
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retained and constitutes the individual beat variation in the fiducial point estimate. 
Finally, the QT interval for each beat is calculated taking into account the shifts of 
the initial QRS onset and T end. MEANS automatically detects ectopic beats, and 
excludes them from further processing. To safeguard against signal segments with 
excessive noise or baseline wander, an additional test is applied after each FSA 
iteration. If the averaged absolute amplitudes of the difference between the ST-T 
wave of an individual beat and the averaged ST-T wave of the remaining beats is 
larger than a preset value, the beat is discarded and the iteration process is 
repeated for the remaining beats. 
 
Figure 1 Flowchart of the study population 
 
 
Abbreviations: RS, Rotterdam Study; RS I-3, Third visit of the first cohort; RS II-1, First visit of the 
second cohort; RS III-1, First visit of the third cohort; ECG, electrocardiogram; TSH, Thyroid-stimulating 
hormone; AF, Atrial fibrillation 
 
 
Covariables 
The following covariables were derived from the ECG: heart rate, heart-rate 
variability, (average) QT interval, and Sokolow-Lyon index. Heart-rate variability 
was expressed as the standard deviation of normal-to-normal RR intervals (SDNN, 
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in milliseconds) 
25
 and log-transformed in the analyses to approximate a normal 
distribution. The Sokolow-Lyon index was defined as the sum of the voltages (in 
millivolt) of the S wave in lead V1 and the R wave in lead V5 or V6, whichever was 
larger. The following clinical covariables were used: age, sex, smoking, BMI, 
hypertension, coronary heart disease (CHD), and diabetes mellitus. Smoking was 
based on a home interview. Participants were classified into never, former, and 
current smokers. BMI was defined as weight/height
2
, with weight in kg and height 
in meters. Blood pressure was measured twice in the sitting position on the right 
upper arm. The average of two measurements was used. Hypertension was 
defined as a systolic blood pressure ≥140 mmHg, or a diastolic blood pressure ≥90 
mmHg, or the use of blood-pressure-lowering medication with the indication 
hypertension. CHD was defined as a history of a myocardial infarction (MI) or a 
surgical or percutaneous coronary revascularization procedure. 
26
 Diabetes mellitus 
was defined as a fasting serum glucose level ≥7.0 mmol/L or a non-fasting serum 
glucose level ≥11.1 mmol/L (if fasting serum glucose was not present), or use of 
glucose-lowering medication, or a previous diagnosis of diabetes mellitus. 
Statistical analyses 
STVqt and TSH were log-transformed to normalize their distributions for all 
continuous analyses. Zero values for STVqt (n = 14) were set to one fourth of the 
lowest nonzero value to allow log-transformation. We implemented linear 
regression models to study the association of FT4 with STVqt, using the Wald-test 
for confidence intervals (CIs) and p-values. The possibility of a nonlinear 
association between log-transformed TSH or FT4 and STVqt was tested by 
successively adding polynomial terms of FT4: FT4 
2
, FT4 
3 
and FT4 
4
. The value of 
adding these terms was assessed with the likelihood ratio test. 
All participants with a TSH measurement and an STVqt measurement were 
included in the main analysis (six missing values for FT4 were imputed). Three 
sensitivity analyses were performed. First, to assess the possible influence of drug 
use, we excluded all users of thyroid function altering preparations (Anatomical 
Therapeutic Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B), 
iodine therapy (ATC H03C), corticosteroids for systemic use (ATC H02A and 
H02B), or amiodarone. Second, we limited the analyses to euthyroid participants 
(as defined above). Third, to rule out a potential effect of auto-immunity on STVqt, 
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we excluded participants with TPOAb >35 kU/l. Furthermore, we performed pre-
specified analyses stratified by sex and stratified by age (older or younger than 65 
years). For all analyses, we created a basic model adjusted for age and sex and a 
multivariable model with adjustment for age, sex, cohort, averaged QT interval, 
heart rate, and log-transformed heart-rate variability, BMI, hypertension, smoking 
status, serum total cholesterol, prevalent diabetes mellitus, and prevalent CHD. If 
the association of STVqt with FT4 or with TSH was significant, we plotted the 
estimated regression line with 95% confidence intervals of FT4 or TSH versus 
values of STVqt. The association of thyroid function with STVqt was additionally 
assessed using thyroid status, a categorical variable with the categories 
hypothyroid, subclinical hypothyroid, euthyroid, subclinical hyperthyroid and 
hyperthyroid. This categorical variable was analyzed in a linear regression model, 
using the same covariables and sensitivity analyses as in the analyses with TSH 
and FT4. 
After selecting those participants with both a TSH measurement and an ECG, 
remaining missing values in the other covariables were imputed with five-times 
imputation. There were no variables with more than 5% missing values. For all 
analyses we used SPSS (IBM SPSS Statistics for Windows, version 21.0. Armonk, 
NY). The regression line and 95% confidence intervals were calculated in R. 
 
RESULTS 
Population characteristic 
There were 8,987 participants with a TSH measurement and an ECG (Figure 1). 
We excluded 279 participants because their ECG showed a pacemaker signal (n = 
8), atrial fibrillation (n = 138), atrial flutter (n = 13), or because their ECG had no 
usable consecutive QT intervals (n = 120). Of the remaining 8,708 participants, 
4,955 were women (56.9%) and the average age was 64.5 years, with a standard 
deviation of 9.7 years. Further characteristics of the study population are shown in 
Table 1. 
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Table 1 Baseline characteristics of included participants 
Characteristic Result 
Participants, N 8,708 
Women, N (%) 4,955 (56.9%) 
Age (years), mean (SD) 64.5 (9.7) 
Diabetes mellitus 1,604 (18.4%) 
Smoking, N (%)  
   never  2,704 (31.1%) 
   former 4,247 (48.8) 
   current                              1,711 (19.6%) 
Hypertension, N (%) 5,306 (60.9%) 
Prevalent CHD, N (%) 575 (6.6%) 
BMI (kg/m2), mean (SD) 27.3 (4.2) 
Total cholesterol (mmol/L), mean (SD) 5.7 (1.0) 
TSH (mU/l), median (IQR) 1.9 (1.3; 2.8) 
FT4 (pmol/l), mean (SD) 15.7 (2.3) 
TPOAb > 35 (kU/mL), N (%) 1,147 (13.2%) 
Hypothyroidism, N (%) 67 (0.8%) 
Subclinical hypothyroidism, N (%) 815 (9.4%) 
Euthyroidism, N (%) 7,591 (87.2%) 
Subclinical hyperthyroidism, N (%) 215 (2.5%) 
Hyperthyroidism, N (%) 20 (0.2%) 
Heart rate (bpm), mean (SD) 68.9 (10.9) 
QT interval (ms) / QTc bazett, mean (SD) 405 (30) / 431 
(24) 
SDNN (ms), median (IQR) 16.4 (10.4; 27.0) 
STVqt (ms), median (IQR) 1.8 (1.2; 3.0) 
Abbreviations: BMI, body-mass index; CHD, coronary heart disease; FT4, 
thyroxine; IQR, interquartile range; QTc, heart-rate corrected QT interval; SD, 
standard deviation; SDNN, standard deviation of normal-to-normal RR 
intervals; STVqt, short-term variability of the QT interval; TPOAb, thyroid 
peroxidase antibodies; TSH, thyroid-stimulating hormone 
 
 
The association of TSH and FT4 with STVqt 
Table 2 shows the association of TSH and FT4 with STVqt in the multivariable 
models. Both FT4 and FT4
2
 were significantly associated with STVqt, indicating a U-
shaped relationship of FT4 with STVqt. TSH was not significantly associated with 
STVqt, except in the sensitivity analysis excluding users of thyroid-affecting 
medication. Otherwise, the sensitivity analyses did not reveal relevant changes in 
the association between thyroid function and STVqt. Results of the basic model 
were very similar to the multivariate model, e.g. main analysis FT4 -0.086 (95%CI-
0.124; -0.047), FT4
2
 0.003 (95%CI 0.001; 0.004) and thus not shown for all 
analyses. 
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Table 2 Association of thyroid function with log-transformed STVqt 
Population Determinant Beta (95% CI) 
All participants log-transformed TSH
 
0.016 (-0.004; 0.036) 
n = 8,708 FT4
 
-0.079 (-0.117; -0.041) 
 FT4
2
 0.002 (0.001; 0.003) 
No thyroid medication log-transformed TSH
 
0.023 (0.001; 0.045) 
n = 8,181 FT4
 
-0.088 (-0.138; -0.039) 
 FT4
2
 0.003 (0.001; 0.004) 
Euthyroid status log-transformed TSH
 
0.013 (-0.023; 0.048) 
n = 7,591 FT4
 
-0.168 (-0.244; -0.092) 
 FT4
2
 0.005 (0.003; 0.007) 
TPOAb ≤ 35 log-transformed TSH
 
0.009 (-0.014; 0.033) 
n = 7,552 FT4
 
-0.076 (-0.122; -0.031) 
 FT4
2
 0.002 (0.001; 0.004) 
Notes: TSH and FT4 were assessed in separate linear regression models. Estimates were adjusted 
for cohort, age, sex, QT interval, heart rate and heart-rate variability, BMI, hypertension, serum total 
cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. No thyroid 
medication excludes users of thyroid function altering preparations (Anatomical Therapeutic 
Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B), iodine therapy (ATC H03C), 
corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. Bold indicates P-value 
below 0.05. 
Abbreviations: FT4, Thyroxine; STVqt, short-term variability of the QT interval; TPOAb, thyroid 
peroxidase antibodies; TSH, thyroid-stimulating hormone.  
 
 
Table 3 shows the analyses stratified on age and sex. There was a significant 
interaction of sex with FT4 and FT4
2
 (p-values 0.014 and 0.006, respectively). The 
association of FT4 with STVqt was significantly stronger in men than in women FT4: 
-0.143 (95% CI -0.202; -0.085) in men versus -0.048 (95% CI -0.096; 0.001) in 
women, FT4
2
 : 0.004 (95% CI 0.003; 0.006) in men versus 0.001, 95% CI 0; 0.001 
in women. In the stratification on age, there was no significant interaction with FT4 
or FT4
2
 when comparing those younger than 65 with those older than 65. 
Figure 2 shows the regression lines of FT4 and back-transformed STVqt, based on 
the model including all men in the left panel. The figure shows that STVqt is higher 
with an increased or a decreased FT4. Figure 2 showing the same plot for all 
women in the right panel, reveals a weaker U-shaped association between FT4 and 
STVqt. Supplementary Figure 1 and 2 show the same regression lines for men and 
women with euthyroid status, showing a similar pattern. 
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Categorical analysis of the association between thyroid status and STVqt 
The categorical analyses are shown in Supplementary Tables 1 and 2. 
Supplementary Table 1 first shows the main analysis, where subclinical 
hyperthyroid participants had the lowest beta for STVqt. However, differences with 
the other categories were not statistically significant, and the p-for trend was 0.41. 
In the sensitivity analysis excluding subjects that used thyroid function altering 
drugs, the hyperthyroid participants had the lowest beta for STVqt (Supplementary 
Table 1). When excluding participants with TPOAbs > 35, the hypothyroid 
participants had the lowest beta for STVqt. It should be noted that there were very 
low numbers (n = 8 and n = 10, respectively) in those categories. Supplementary 
Table 2 shows the categorical analysis stratified on sex. In the stratified analysis, 
no results were significant, except that hyperthyroid women had a significantly 
higher STVqt than euthyroid women. 
 
 
 
 
 
 
Table 3 Association of thyroid function with log-transformed STVqt stratified on age and sex 
 Men; n = 3,753 Women; n = 4,955 
 Beta (95% CI) Beta (95% CI) 
log-transformed TSH
 
-0.001 (-0.036; 0.034) 0.021 (-0.004; 0.046) 
(log-transformed TSH)
2
  0.022 (0.007; 0.038)  
FT4
 
-0.136 (-0.195; -0.078) -0.044 (-0.094; 0.006) 
FT4
2
 0.004 (0.002; 0.006) 0.001 (0.000; 0.003) 
   
 Age ≤ 65; n = 5,018 
Beta (95% CI) 
Age > 65; n = 3,690 
Beta (95% CI) 
log-transformed TSH
 
0.004 (-0.023; 0.030) 0.028 (-0.003; 0.058) 
FT4
 
-0.036 (-0.099; 0.026) -0.102 (-1.53; -0.052) 
FT4
2
 0.001 (-0.001; 0.003) 0.003 (0.001; 0.004) 
Notes: TSH and FT4 were assessed in separate linear regression models. Estimates were adjusted for 
cohort, age, sex, QT interval, heart rate and heart-rate variability, BMI, hypertension, serum total 
cholesterol, prevalent diabetes, prevalent coronary heart disease and smoking status. Bold indicates P-
value below 0.05 
Abbreviations: FT4, thyroxine; STVqt, short-term variability of the QT interval; TSH, thyroid-stimulating 
hormone.  
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Figure 2 Estimated regression line of STVqt by FT4 status with 95% confidence intervals in 
men (upper panel) and women (lower panel) 
 
 
STVqt was used as a log-transformed variable in the analysis and back-transformed for presentation. 
The prediction for men was based on all included men (n = 3,753) and for women on all included 
women (n = 4,955). The analysis was adjusted for cohort, age, QT interval, heart rate, heart-rate 
variability, BMI, hypertension, serum total cholesterol, prevalent diabetes, prevalent coronary heart 
disease and smoking status. The continuous line indicates the estimate, the dotted lines indicate the 
limits of the 95% confidence interval. 
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DISCUSSION 
Our study shows that there is a U-shaped association between FT4 and STVqt. 
This association is significantly stronger in men than in women. TSH was only 
significantly associated with STVqt when excluding users of thyroid-affecting drugs. 
The analysis of overt thyroid dysfunction with STVqt showed no significant results, 
probably due to small numbers in several categories. 
This is the first study that analyzes the association between thyroid function and 
QT variability.
4
 Studies of heart-rate variability (HRV) found that HRV was 
decreased in both subclinical hyperthyroidism 
27
 and overt hypothyroidism, 
28
 
suggesting a U-shaped association of thyroid function with heart-rate variability. 
Our study demonstrates a similar relationship of FT4 with STVqt. We did not find a 
significant association of TSH with STVqt in the main analysis. Similarly, in 
previous studies in the elderly, FT4, but not TSH, was associated with SCD 
3
 or 
atrial fibrillation.
10
 This might be due to changes in the set point of the 
hypothalamic-pituitary-thyroid axis, with an altered TSH secretion in reaction to 
negative feedback of thyroid hormone due to aging. 
20
 The fact that the association 
of TSH with STVqt is significant when excluding thyroid-affecting drugs could 
indicate a different association between TSH and STVqt in users of thyroid-
affecting drugs, which interferes with the association in the main analysis. 
QT variability is thought to be increased when channels of the inward rectifying 
current (Ikr) in cardiac myocytes are blocked. Blockade of Ikr delays repolarization 
and increases the QT interval. 
1
 Ikr potassium channels can be blocked by the use 
of certain drugs, 
4
 or in congenital long-QT syndromes, 
29
 which are also 
associated with an increase in QT variability. It has been shown in animal models 
that an increase in FT3 leads to a quick decrease in the Ikr current, prolonging 
repolarization. 
30
 it is possible that the Ikr potassium channels are the pathway by 
which higher levels of thyroid hormone lead to an increase in STVqt. The 
association of thyroid function and STVqt may also be indirect: case reports 
suggest that both hyperthyroidism 
31
 and hypothyroidism 
32
 can lead to dilated 
cardiomyopathy, and it is known that STVqt and other QT variability markers are 
increased in dilated cardiomyopathy. 
2,33
 However, we could not address dilated 
cardiomyopathy in our study, as we did not have data of this diagnosis, and future 
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studies should address this issue. Other possible pathways, e.g. common genetic 
factors, have also not yet been investigated.  
Previous studies have reported that an increased QT variability is associated with 
ventricular arrhythmias 
5,34
 and sudden cardiac death. 
35-38
 Our study indicates that 
both lower and higher levels of FT4 lead to an increase in STVqt, which suggests 
that both hyperthyroidism and hypothyroidism could lead to ventricular arrhythmias. 
This is supported by a number of case reports of ventricular arrhythmias and 
sudden cardiac death in both hyperthyroidism 
12-14
 and hypothyroidism. 
11,15-17
 In a 
previous study we reported an association of higher FT4 with an increased risk of 
SCD. 
3
 Also, there seemed to be a stronger positive association of FT4 with SCD in 
men than in women, but this was not statistically significant. This suggests that 
STVqt could be involved in underlying mechanisms of the association between FT4 
and SCD. In our previous study of thyroid function and SCD, 
3
 there was no 
association between a low FT4 and SCD, and it is possible that when a low FT4 
leads to a higher STVqt, other morbidity and mortality than SCD occurs. Also, the 
previously mentioned association of FT3 and the Ikr potassium channels 
30
 cannot 
explain why hypothyroidism is associated with an increased STVqt. Thus, further 
studies are needed to elucidate the role of STVqt in mortality associated with 
thyroid disease. 
We found that the (U-shaped) association of FT4 with STVqt was stronger in men 
than in women, with significant interaction terms between sex and FT4, FT4
2
. A 
previous study in the Rotterdam Study population reported that an increased FT4 
was associated with a higher risk of (average) QTc prolongation, but only in men. 
39
 
Moreover, animal studies in dogs have shown that testosterone increases 
expression of potassium channels in cardiac myocytes and the QT interval on the 
ECG. 
40
 These studies suggest that repolarization of the heart affected both by 
testosterone and by thyroid hormone, perhaps leading to interaction between the 
effects of the two hormones. 
Our study has a number of strengths and limitations. Strengths of our study include 
the use of a large population-based cohort of community-dwelling middle-aged and 
elderly participants. Furthermore, ECGs and thyroid measurements were 
performed prospectively without knowledge of the study question, and the ECGs 
were processed automatically, which reduced observer bias. 
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A limitation of our study is that most previous studies used longer ECG recordings 
(usually 3 to 5 minutes) than the standard 10-second ECGs used in this study, 
4
 
and the relationship between STVqt measured on short ECGs and STVqt 
measured on longer ECGs has not yet been studied. However, despite this 
limitation, we were able to find a significant association between FT4 and STVqt. 
Additionally, the results that are obtained in this middle-aged and elderly population 
might not be representative of younger populations. We could not evaluate 
temporal relationships between FT4 and STVqt due to the cross-sectional design of 
our study. 
In conclusion, we found that FT4 has a U-shaped association with STVqt, as 
measured on 10-second ECGs. Since STVqt is a marker of repolarization 
instability, our study suggests that both high FT4 and low FT4 levels lead to 
repolarization instability. Further studies should elucidate the role of STVqt in 
mortality associated with thyroid disease, and possible sex differences in the 
relationship between thyroid function, STVqt and sudden cardiac death.  
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Supplementary Table 1 Effect of thyroid status on log-transformed STVqt 
 All participants No thyroid 
medication 
TPOAb ≤35 
Thyroid 
status 
n β (95% CI) n β (95% CI) n β (95% CI) 
Hypothyroid 67 0.08 (-0.09; 
0.27)  
59 0.13 (-0.06 - 
0.33) 
10 -0.02 (-0.48; 
0.45) 
Sub. 
Hypothyroid 
815 0.05 (0.00; 
0.10) 
712 0.06 (0.00; 
0.12) 
502 0.08 (0.01; 0.15) 
Euthyroid  7,591 Reference 7,238 Reference 6,844 Reference 
Sub. 
Hyperthyroid 
215 -0.02 (-0.13; 
0.08) 
164 0.00; (-0.11; 
0.12) 
179 0.00 (-0.11; 
0.11) 
Hyperthyroid 20 0.06 (-0.27; 
0.39) 
8 -0.05 (-0.56; 
0.47) 
17 0.11 (-0.25; 
0.47) 
Notes: β Estimates were adjusted for cohort, age, sex, QT interval, heart rate and heart-rate variability, 
BMI, hypertension, serum total cholesterol, prevalent diabetes, prevalent coronary heart disease and 
smoking status. No thyroid medication excludes users of thyroid preparations (Anatomical Therapeutic 
Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B), iodine therapy (ATC H03C), 
corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. 
Abbreviations: STVqt, short-term variability of the QT interval; Sub, Subclinical; BMI, Body-mass index 
 
Supplementary Table 2 Effect of thyroid status on log-transformed STVqt stratified on sex 
 Men Women 
Thyroid status n β (95% CI) n β (95% CI) 
Hypothyroid 17 0.21 (-0.13; 0.55) 50 0.04 (0.01; 0.13) 
Sub. Hypothyroid 240 0.03 (-0.06; 0.13) 575 0.05 (-0.17; 0.27) 
Euthyroid  3,427 Reference 4,164 Reference 
Sub. Hyperthyroid 66 0.10 (-0.08; 0.27) 149 -0.08 (-0.20; 0.05) 
Hyperthyroid 3 0.41 (-0.40; 1.21) 17 0.00 (-0.37; 0.38) 
Notes: β Estimates were adjusted for cohort, age, sex, QT interval, heart rate and heart-rate variability, 
BMI, hypertension, serum total cholesterol, prevalent diabetes, prevalent coronary heart disease and 
smoking status. No thyroid medication excludes users of thyroid preparations (Anatomical Therapeutic 
Chemical (ATC) code H03A), anti-thyroid preparations (ATC H03B), iodine therapy (ATC H03C), 
corticosteroids for systemic use, (ATC H02A and H02B) and Amiodarone. 
Abbreviations: STVqt, short-term variability of the QT interval; Sub, Subclinical 
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Supplementary Figure 1 Estimated regression line with 95% confidence intervals of STVqt 
by FT4 status in euthyroid men (upper panel) and euthyroid women (lower panel) 
 
 
 
 
 
Notes: STVqt was used as a log-transformed variable in the analysis and back-transformed for 
presentation. The prediction was based on men with euthyroid status (n = 3,427) and women with 
euthyroid status (n = 4,164). The analysis was adjusted for cohort, age,QT interval, heart rate, heart-
rate variability, BMI, hypertension, serum total cholesterol, prevalent diabetes, prevalent coronary heart 
disease and smoking status. The continuous line indicates the estimate, the dotted lines indicate the 
limits of the 95% confidence interval. 
Abbreviations: STVqt, short-term variability of the QT interval; BMI, Body-mass index. 
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ABSTRACT  
BACKGROUND Thyroid hormones have been linked with various proatherogenic 
and antiatherogenic processes. However, the relationship of thyroid function with 
manifestations of atherosclerosis remains unclear. We therefore investigated the 
association of thyroid function with subclinical atherosclerosis, incident 
atherosclerotic cardiovascular (ASCV) events and ASCV mortality. 
 
METHODS In a prospective population-based study, 9231 community-dwelling 
participants (mean age 64.7) were included. Outcomes under study were: 
1.Presence of subclinical atherosclerosis, assessed by coronary artery calcification 
(CAC) score >100 AU; 2.ASCV events, defined as fatal and nonfatal myocardial 
infarction, other coronary heart disease (CHD) mortality or stroke; 3.ASCV 
mortality, defined as death due to CHD, cerebrovascular or other atherosclerotic 
diseases. Associations of thyroid-stimulating hormone (TSH) and free thyroxine 
(FT4) with the outcomes were assessed through logistic regression and Cox 
proportional-hazard models, adjusted for potential confounders including 
cardiovascular risk factors.  
 
RESULTS During a median follow-up of 8.9 years (interquartile range: 4.5-11.8 
years), 935 incident ASCV events and 580 ASCV deaths occurred. FT4 levels 
were positively associated with high CAC score (odds ratio [OR]; 95% confidence 
interval [CI]: 2.28; 1.30-4.03) and incident ASCV events (hazard ratio [HR]; CI: 
1.87; 1.34-2.59). The risk of ASCV mortality increased with higher FT4 levels (HR; 
CI: 2.35; 1.61-3.41 per 1 ng/dl) and lower TSH levels (HR; CI: 0.92; 0.84-1.00 per 1 
logTSH), with stronger estimates among participants with prevalent ASCV disease 
(HR; CI: 5.76; 2.79-11.89 for FT4 and 0.81; 0.69-0.95 for TSH) (p for interaction of 
FT4 and TSH with prevalent ASCV disease 0.002 and 0.04, respectively). Results 
remained similar or became stronger among euthyroid participants. 
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CONCLUSIONS FT4 levels in middle-aged and elderly subjects were positively 
associated with atherosclerosis throughout the whole disease spectrum, 
independently of cardiovascular risk factors.  
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INTRODUCTION 
Atherosclerosis progresses insidiously from a subclinical condition to the clinical 
onset of vascular events to death.
1
 Despite advances in prevention and treatment, 
atherosclerotic disease remains a leading cause of death, with a considerable 
clinical and economic burden worldwide.
2
 Hence, the identification of additional 
modifiable risk factors for atherosclerosis is of major importance. 
Thyroid function has a complex relation with various contributors to atherogenesis. 
Higher thyroid hormone (TH) concentrations have commonly been linked with 
systolic hypertension
3,4
 and hypercoagulation
5
; whereas lower circulating TH levels 
can instigate hyperlipidemia and inflammation.
6
 Although atherosclerosis is a 
continuous process, prospective epidemiological studies so far have mainly 
focused on the relation between specific ranges of thyroid function and distinct 
atherosclerotic events, such as coronary heart disease (CHD) or stroke.
7-12
 Results 
have been quite inconsistent. Some studies have reported that TSH levels ≥10 
mIU/L or high-normal TSH levels may constitute an increased risk of CHD. 
7,10
 In 
contrast, other studies have reported a positive association of thyroid function with 
CHD or stroke risk.
9,11
Others have found no association.
8,12
 Differences in study 
designs, follow-up period and age range of participants may partly explain the 
inconsistencies across studies. In addition, these inconsistencies can also stem 
from the heterogeneity in the assessment of atherosclerosis. To date, a 
comprehensive investigation exploring the link between the full range of thyroid 
function and atherosclerosis throughout its spectrum; from subclinical 
atherosclerosis to overt atherosclerosis to atherosclerotic mortality, within the same 
cohort is lacking.  
Therefore, in a large prospective population-based cohort study of middle-aged 
and elderly individuals, we examined the association of thyroid function with 
coronary artery calcification (CAC) (as a well-documented marker of subclinical 
atherosclerosis) 13, atherosclerotic cardiovascular (ASCV) events (as a measure 
of clinical atherosclerosis) and ASCV mortality. 
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METHODS 
Study population 
This study was embedded within the Rotterdam Study, a prospective population-
based cohort study that investigates the determinants, occurrence and progression 
of chronic diseases in the middle-aged and elderly. The objectives and study 
design have been described in detail previously.
14 
The Rotterdam Study was 
initiated in 1989, including 7983 participants aged 55 years or older (RS I) residing 
in Ommoord district of Rotterdam, the Netherlands. In 2000, the study was 
extended with a second cohort of 3011 subjects (RSII). In 2006, a third cohort of 
3932 subjects aged 45 years or older was added (RSIII). As of now, the Rotterdam 
Study comprises a total of 14926 subjects, who undergo extensive follow-up 
medical examinations every 3 to 5 years.  
The baseline for the current study included participants from the third visit of the 
first cohort (RS-I.3) and the first visit of the second (RS-II.1) and third cohorts (RS-
III.1). Complete data on thyroid function and incident events were available in 9231 
participants from these visits Supplemental Figure 1.  
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus University and by the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the Population Study Act Rotterdam Study. All 
participants have given written informed consent. 
Assessment of thyroid function 
Thyroid function was assessed at baseline in three study cohorts using the same 
method and assay. Measurements of thyroid-stimulating hormone (TSH), free 
thyroxine (FT4), and thyroid peroxidase antibodies (TPOAb) were performed in 
baseline serum samples stored at -80°C using the electrochemiluminescence 
immunoassay “ECLIA” Roche. The reference ranges of serum TSH (0.40–4.0 
mIU/L) and serum FT4 (0.86–1.94 ng/dL; equivalent to 11–25 pmol/L) were 
determined based on national guidelines and our previous studies.
15
 Levels of 
TPOAb >35 kU/ml were regarded as positive, as recommended by the assay 
manufacturer.
15
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Assessment of CAC, ASCV events and ASCV mortality 
Outcome measures under study were CAC, ASCV events and ASCV mortality. 
Hard outcomes were included to avoid misclassification bias.  
CAC measurements were performed at baseline in a random sample of 2002 
participants, during the third visit of the first cohort and the first visit of the second 
cohort. CAC was measured by electron beam computed tomography scans (C-150 
Imatron GE) of the coronary arteries.
14
 Calcification of the coronary arteries was 
quantified through AccuImage software (AccuImage Diagnostics Corp), displaying 
all pixels with a density >130 Hounsfield units and using the Agatston’s method.
16
 
CAC score of 100 Agatson units (AU) or greater suggests clinically significant 
atherosclerotic plaque 
2
 and has been used in past consensus statements.
17
 
Therefore, we grouped participants into CAC score lower than 100 AU and CAC 
score of 100 AU or greater. ASCV events were defined as fatal and nonfatal MI, 
other CHD mortality, or stroke, as previously described.
18
 Prevalent ASCV disease 
was defined as history of MI, stroke, coronary or other arterial revascularization.
18
 
Prevalent ASCV disease at baseline was assessed through interview and verified 
in medical records. ASCV mortality was defined as death due to CHD, 
cerebrovascular disease or other atherosclerotic diseases, and methods of 
ascertainment have been previously described.
18,19
 Non-ASCV mortality was 
defined as death due to causes other than atherosclerotic disease. In short, 
information on ASCV mortality was obtained from municipality, general 
practitioners and reports of medical specialists. The underlying cause of death was 
ascertained independently by two research physicians and subsequently validated 
by a medical specialist. 
Additional measurements 
Information on medical history and medication use was obtained from 
questionnaires in combination with medical records. Information on the history of 
thyroid disease, thyroid surgery and thyroid medication use was obtained from 
questionnaires in combination with pharmacy records. During the baseline home 
interview, participants provided information on smoking habits and the number of 
alcoholic beverages they consumed weekly. Smoking habits were categorized as 
current, former and never smoking. Serum glucose and lipid levels were measured 
by an automated enzymatic procedure (Mannheim System). Body mass index 
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(BMI) was calculated as weight in kilograms divided by height in meters squared. 
Blood pressure was measured in the sitting position on the right arm and 
calculated as the mean of two measurements using a random-zero 
sphygmomanometer. Diabetes mellitus was defined as fasting serum glucose level 
≥7 mmol/L, non-fasting plasma glucose level ≥ 11.1 mmol/L (when fasting samples 
were absent) or the use of antidiabetic medication.
20 Atrial fibrillation (AF) cases 
were ascertained by two research physicians and a cardiologist utilizing: 1) 
electrocardiograms recorded at baseline and during follow-up; 2) additional 
medical information obtained from general practitioners files, from outpatient clinics 
and from a national registry of all hospital discharge diagnoses. Heart failure (HF) 
was defined as the presence of typical symptoms and signs (i.e. breathlessness at 
rest or during exertion, ankle edema, and pulmonary crepitations), confirmed by 
the objective evidence of cardiac dysfunction (i.e. chest X-ray, echocardiography) 
or a positive response to the initiated treatment. The adjudication of HF was 
performed in accordance with the guidelines of the European Society of 
Cardiology.
21
 
Statistical analysis 
We used logistic regression models to investigate the cross-sectional association 
of thyroid function parameters with the risk of having CAC score of 100 AU or 
greater, among participants that were free of atherosclerotic cardiovascular 
disease. The association of thyroid function parameters with incident ASCV events 
was prospectively investigated through Cox proportional-hazard models. The 
analysis on incident ASCV events comprised individuals who were free of any 
ASCV event at baseline and only first events during follow-up were analyzed. The 
association of thyroid function parameters with ASCV mortality was also examined 
through Cox proportional-hazard models. We further compared the hazard ratios 
(HR) of ASCV mortality with those of non-ASCV mortality. In the analysis of 
incident ASCV events, the end date of follow-up was considered the date of 
incident ASCV event, the date of death or January 1, 2012, whichever came first. 
In the analysis of ASCV mortality, the end date of follow-up was considered the 
date of death or January 1, 2012, whichever came first. 
Additionally, we performed several sets of sensitivity analyses to explore the 
robustness of our findings: 1) We limited the study participants to only those with 
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thyroid function within the reference range, without history of thyroid disease and 
not using thyroid medications; 2) We excluded participants using thyroid function-
altering medications, such as thyroid medications, analgesics (including non-
steroidal anti-inflammatory drugs, paracetamol and muscle relaxants), 
corticosteroids or amiodarone; 3) We restricted the analyses to participants without 
history of AF and censored the incident AF cases during follow-up; 4) We restricted 
the analyses to participants without history of HF at baseline and censored the 
incident HF cases during follow-up; 5) To account for possible reverse causation, 
we investigated the association of thyroid function with incident ASCV events and 
ASCV mortality, after excluding the events that occurred during the first 2 years of 
follow-up; 6) To detect a potential influence of follow-up duration on our results, 
analyses of ASCV mortality were performed for lengths of follow-up 8, 10 and 12 
years. 
All analyses were adjusted for potential confounders, that were selected based on 
biological plausibility and previous literature. Model 1 was adjusted for age, gender 
and cohort. Model 2 was additionally adjusted for smoking status, alcohol intake, 
BMI, total cholesterol, triglycerides, systolic blood pressure, prevalent diabetes and 
use of antihypertensive and lipid-lowering medications. The analyses of ASCV 
mortality were additionally adjusted for presence of prevalent ASCV disease. 
Detailed descriptions of the research methods are provided in the Appendix. TSH 
was naturally log transformed, due to its skewed distribution. The proportional 
hazards assumption was assessed by Schoenfeld test and plots. No violation of 
the proportional hazards assumption was observed. Potential departure from 
linearity was explored by adding quadratic and cubic terms of covariates in the 
multivariable model, but none of these terms were significant. We checked for 
effect modification by separately adding product interaction terms of the exposure 
(TSH or FT4 or TPOAb) with each of the covariates of the most adjusted model.  
Multiple imputations were performed for missing data (< 5% missings for all 
covariates). Schoenfeld test and plots were performed using R (survival package 
R-project, Institute for Statistics and Mathematics, R Core Team, version 3.2.3). All 
other statistical analyses were performed using IBM SPSS version 21 (IBM Corp). 
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RESULTS 
We included 9231 participants with a maximum follow-up time of 14.7 years and a 
median of 8.9 years (interquartile range, 4.5-11.8 years). Baseline characteristics 
are presented in Table 1. The mean age of participants was 64.7 (± 9.7) years and 
57.1% were women (Table 1). A total of 935 incident ASCV events (incidence rate, 
12.8 per 1000 person-years) and 580 ASCV deaths (incidence rate, 7.6 per 1000 
person-years) occurred during follow-up. Results did not change substantially after 
primary and additional adjustments for potential confounders; therefore we further 
report the most adjusted model (Model 2). The completeness of follow-up for 
ASCV mortality was 99.0%. 
 
Table 1 Baseline characteristics of 9231 participants*   
Variable Mean (SD)* 
Age, years 64.7 (9.7) 
Female, n (%) 5268 (57.1) 
Smoking, n (%) 
 
   current 1941 (21.0)                          
   former         4375 (47.4)   
  never      2915 (31.6) 
TSH, mIU/L, median, IQR 1.9 (1.2-2.8) 
FT4, ng/dl 1.2 (0.2) 
TPOAb positive, n (%) 1221 (13.2) 
Use of thyroid medication, n (%) 294 (3.2) 
Thyroid surgery, n (%) 165 (1.8) 
History of thyroid disease, n (%) 750 (8.1) 
BMI, kg/m
2
 27.2 (4.2) 
Total cholesterol, mmol/l 5.7 (1.0) 
Triglycerides, mmol/l 1.5 (0.8) 
Use of lipid-lowering medications, n (%) 1432 (15.5) 
Systolic blood pressure, mm Hg 139.3 (21.0) 
Use of antihypertensive medications, n (%) 2095 (22.7) 
History of diabetes, n (%)     1099 (11.5) 
History of atherosclerotic cardiovascular disease, n (%) 714 (7.7) 
Follow-up time for atherosclerotic events, median years, IQR 7.1 (4.3-11.6) 
Follow-up time for atherosclerotic mortality, median years 
IQR 
8.9 (4.5-11.8) 
*unless specified otherwise 
Abbreviations: BMI, body-mass index; FT4, free thyroxine; IQR, interquartile range; TPOAb, thyroid 
peroxidase antibodies (cutoff 35 kU/ml);.TSH, thyroid-stimulating hormone  
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Thyroid function and CAC score 
Increasing FT4 levels were associated with higher odds of having CAC score of 
100 AU or greater (OR, 2.28; CI, 1.30-4.03 per 1ng/dl; p-value 0.004) (Table 2). 
However, TSH levels were not associated with having a CAC score of 100 AU or 
greater (OR, 0.94; CI, 0.84-1.05 per 1 logTSH; p-value 0.29) (Table 2). The 
association remained similar or became stronger after restricting the analyses to 
participants with thyroid function within the reference ranges (OR, 2.42; CI, 1.14-
5.13 per 1ng/dl FT4; p-value 0.02; OR, 0.91; CI, 0.72-1.16 per 1 logTSH; p-value 
0.47) (Table 2). Furthermore, we found no association of TPOAb with the odds of 
having CAC score of 100 AU or greater (OR, 0.85; CI, 0.63-1.15; p-value 0.28) 
(Supplemental Table 1). In the analyses of CAC score, the interaction terms 
between the exposure and each covariate in the most adjusted model were not 
significant.  
Thyroid function and incident ASCV events 
There was a positive association of FT4 levels (HR, 1.87; CI, 1.34-2.59 per 1ng/dl; 
p-value 0.0002), but no association of TSH levels (HR, 0.97; CI, 0.90-1.04 per 1 
logTSH; p-value 0.42) with the risk of incident ASCV events (Table 3). The 
associations became stronger after restricting the analyses to participants with 
thyroid function within the reference ranges (HR, 2.49; CI, 1.58-3.94 per 1ng/dl; p-
value <0.0001; HR, 0.96; CI, 0.82-1.11 per 1 logTSH; p-value 0.59) (Table 3). This 
corresponds to a 2.69–times higher risk of incident ASCV events, for a participant 
with a FT4 in the higher limit of the reference range (1.94 ng/dl), compared with a 
participant with a FT4 in the lower limit of the reference range (0.86 ng/dl). The 
associations became stronger after excluding participants using thyroid function-
altering medications or after censoring the analyses at the time of incident HF; and 
slightly attenuated after censoring the analyses at the time of incident AF 
(Supplemental Table 2). Results did not change substantially after excluding 
events that occurred during the first 2 years of follow-up (Supplemental Table 3). 
Furthermore, we found no association of TPOAb with the risk of incident ASCV 
events (HR, 0.95; CI, 0.78-1.16; p-value 0.61) (Supplemental Table 1). In the 
analyses of incident ASCV events, the interaction terms between the exposure and 
each covariate in the most adjusted model were not significant.  
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Thyroid function and ASCV mortality 
Higher FT4 levels were associated with a higher risk of ASCV mortality (HR, 2.35; 
CI, 1.61-3.41 per 1ng/dl; p-value <0.0001) (Table 4). In line, higher TSH levels 
were associated with a lower risk of ASCV mortality (HR, 0.92; CI, 0.84-1.00 per 1 
logTSH), though the association was borderline significant (p-value 0.06) (Table 4).  
 
Table 4 Association of thyroid function with atherosclerotic cardiovascular mortality 
Thyroid 
function  
Events/ 
TN (%) 
HR (95% CI), 
Model 1 
p-
value 
HR (95% CI), 
Model 2 
p- 
value 
Full range      
TSH, mIU/L 580/9226 
(6.3%) 
0.93 (0.85; 1.01)  0.12  0.92 (0.84; 1.00) 0.06 
FT4, ng/dl 579/9225 
(6.3%) 
2.17 (1.53; 3.08) <0.001  2.35 (1.61; 3.41) <0.001 
      
Thyroid function within the reference ranges*    
TSH, mIU/L 458/7423 
(6.2%) 
0.80 (0.67; 0.97)  0.02  0.79 (0.65; 0.95) 0.01 
FT4, ng/dl 458/7423 
(6.2%) 
3.76 (2.17; 6.54)  <0.001  3.64 (2.08; 6.37)  <0.001 
Model 1: age, gender and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total 
cholesterol, triglycerides, systolic blood pressure, prevalent diabetes, use of antihypertensive and 
lipid-lowering medications. Both models are adjusted for presence of prevalent atherosclerotic 
cardiovascular disease at baseline. *Normal reference ranges were defined as serum TSH of 0.4-4.0 
mIU/L and FT4 levels of 0.85-1.95 ng/dl, after excluding thyroid medication users and participants 
with history of thyroid disease. HRs of TSH are denoted per one unit increase of natural log 
transformed TSH (mIU/L). HRs of FT4 are per one unit increase in FT4 (ng/dl). Abbreviations: TN, 
total number; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free 
thyroxine. 
 
In the analysis of ASCV mortality, we found significant interaction terms of TSH 
and FT4 levels with prevalent ASCV disease at baseline (p for interaction 0.04 and 
0.002, respectively), with age (p for interaction 0.04 and 0.01, respectively) and 
with gender (p for interaction 0.04 and 0.008, respectively). However, these 
interaction terms were not statistically significant among euthyroid participants (p 
for interactions > 0.05). Next, we stratified our population based on prevalent 
ASCV events, age and gender (Figure 1, Supplemental Table 4). Within the strata 
of age and gender, the interaction terms of TSH or FT4 concentrations with 
prevalent ASCV disease remained significant (p for interaction <0.05), whereas 
within the strata of prevalent ASCV disease, the interaction terms of TSH or FT4 
concentrations with age or gender lost statistical significance (p for interaction 
>0.05). Therefore, the association between thyroid function and the risk of ASCV 
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mortality was assessed separately among subjects with and without ASCV disease 
(Figure 1). Among participants without prevalent ASCV disease, there was a 
positive association of FT4 levels (HR, 1.65; CI, 1.06-2.58 per 1ng/dl; p-value 
0.02), but no association of TSH levels (HR, 0.97; CI, 0.88-1.08 per 1 logTSH; p-
value 0.67) with the risk of ASCV mortality (Figure 1). Among participants with 
prevalent ASCV disease, higher FT4 (HR, 5.76; CI, 2.79-11.89 per 1ng/dl; p-value 
<0.0001) and lower TSH (HR, 0.81; CI, 0.69-0.95 per 1 logTSH; p-value 0.81) 
levels were associated with an increased risk of ASCV mortality (Figure 1).  
 
 
Figure 1 Hazard ratios of atherosclerotic cardiovascular mortality, stratified by presence of 
ASCV disease at baseline. 
 
Analyses were adjusting for age, gender, cohort, smoking, alcohol intake, body mass index, total 
cholesterol, triglycerides, systolic blood pressure, prevalent diabetes, use of antihypertensive and lipid-
lowering medications. p for interaction of TSH and FT4 with prevalent ASCV disease were 0.04 and 
0.002, respectively. Normal thyroid function was defined as serum TSH of 0.4-4.0 mIU/L and FT4 levels 
of 0.85-1.95 ng/dl, excluding thyroid medication use and thyroid disease history. Error bars represent 
the 95% CI of hazard ratios (black dots). Within brackets: Number of atherosclerotic cardiovascular 
deaths/ Total number. Abbreviations: TN, Total number; ASCV, atherosclerotic cardiovascular; TSH, 
thyroid-stimulating hormone; FT4, free thyroxine; CI, confidence interval. 
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The association of thyroid function with ASCV mortality became stronger after 
restricting the analyses to participants with thyroid function within the reference 
ranges (HR, 3.64; CI, 2.08-6.37 per 1ng/dl; p-value <0.0001; HR, 0.79; CI, 0.65-
0.95 per 1 logTSH; p-value 0.01) (Table 4, Figure 1). This corresponds to a 3.93–
times higher risk of ASCV mortality, for a participant with a FT4 in the higher limit of 
the reference range (1.94 ng/dl), compared with a participant with a FT4 in the 
lower limit of the reference range (0.86 ng/dl). The associations became stronger 
after excluding participants using thyroid function-altering medications or after 
censoring the analyses at the time of incident HF; and slightly attenuated after 
censoring the analyses at the time of incident AF (Supplemental Table 2). Results 
did not change substantially after excluding events that occurred during the first 2 
years of follow-up (Supplemental Table 3). Results of the main analysis were 
consistent with those of the 8, 10 and 12-year follow-up (Supplemental Table 5). 
The magnitude of association for ASCV mortality was larger than for non-ASCV 
mortality (Supplemental Table 6). Furthermore, we found no association of TPOAb 
with the risk of ASCV mortality (HR, 1.01; CI, 0.78-1.31; p-value 0.93) 
(Supplemental Table 1). 
 
DISCUSSION 
In this large prospective population-based cohort study, higher FT4 levels were 
consistently associated with an increased risk of atherosclerosis, independently of 
cardiovascular risk factors. The association was consistent throughout the 
spectrum of atherosclerosis; from subclinical atherosclerosis to overt 
atherosclerosis to atherosclerotic mortality. The association of thyroid function with 
atherosclerotic mortality was most pronounced in the presence of preexisting 
atherosclerotic disease. 
Various cardiovascular risk factors have been implicated in the pathways linking 
thyroid function to atherosclerosis. Low thyroid function has been associated with 
unfavorable levels of blood lipids and BMI
6
, whereas high thyroid function has been 
associated with an increased prevalence of AF.
15
 Our study suggests that the 
association of thyroid function with atherosclerosis is independent of these 
cardiovascular risk factors, as our results remained statistically significant after 
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accounting for serum lipid levels, BMI and AF. After accounting for AF, our risk 
estimates slightly attenuated, suggesting that AF could be involved in the pathways 
linking thyroid function to atherosclerosis but does not fully explain the association. 
Thyroid autoimmunity has been suggested as another potential contributor to 
atherogenesis. Thus far, it has been speculated that thyroid autoantibodies may 
target the arterial wall and ultimately enhance the development of atherosclerotic 
plaque.
22,23
 However, we found no association between TPOAb positivity and 
atherosclerotic outcomes. Taken together, these data suggest that the link 
between thyroid function and atherosclerosis could be explained by yet unexplored 
cardiovascular risk factors, alternative markers of thyroid autoimmunity (eg. TSH 
receptor antibodies) or alternative pathways.  
Plausible mechanisms that can link high thyroid function to atherosclerosis include 
endothelial damage, hemostasis, thrombosis and hemodynamic changes. First, 
excess TH concentrations can increase the production of reactive oxygen species 
that further induce the expression of adhesion molecules on endothelial cells
24
 
Hence, hyperthyroidism has been commonly associated with early atherosclerosis 
and markers of endothelial dysfunction such as E-selectin, intracellular adhesion 
molecule-1 and vascular cell-adhesion molecule.
25
 Second, TH regulates the 
synthesis of procoagulant proteins.
26
 Excess FT4 levels have been linked with 
increased concentrations of various procoagulant proteins, namely von Willebrand 
factor, fibrinogen, factors VIII and IX, that can accelerate plaque vulnerability and 
rupture 
5
. Third, high levels of TH can generate increased cardiac contractility and 
workload, augmenting myocardial oxygen demand that could eventually precipitate 
ischemic events and death.
3
 These deleterious effects of high thyroid function may 
also be extended to the high-normal range of thyroid function.
11
 Future research 
should pinpoint the exact mechanisms underlying the association of thyroid 
function with atherogenesis. 
Our large cohort study sought to disentangle the association of thyroid function with 
atherosclerotic vs non-atherosclerotic mortality. The effect of thyroid function on 
atherosclerotic mortality was greater compared with non-atherosclerotic mortality, 
indicating that atherosclerosis plays a major role in the pathways linking high 
thyroid function to increased mortality risk. 
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Previous cohort studies among middle-aged and elderly subjects have mainly 
reported an increased mortality risk with higher thyroid function.
27-30
 In an attempt 
to identify potential subgroups at risk, prior research has suggested that the effect 
of thyroid function on mortality might be age- 
27-30
 or gender- dependent.
28,29
 
Generally, studies performed in older participants have reported an increased risk 
of mortality with higher FT4 levels
28,29
, whereas studies including younger 
participants have failed to show an association.
31,32
 Additional studies have 
reported an association of thyroid function with mortality risk exclusively in men 
33
 
or women.
7
 Our data on atherosclerotic mortality primarily revealed an effect 
modification by age and gender, with generally stronger risk estimates in males 
and older subjects. However, the effect disappeared after stratifying by preexisting 
atherosclerotic disease. This might indicate that the presence of atherosclerotic 
disease per se rather than aging or gender can potentiate the link between thyroid 
function and atherosclerotic mortality. Prevalent atherosclerotic disease can 
therefore be an effect modifier of the association between thyroid function and 
atherosclerotic mortality. Alternatively, one might argue that TH is not a contributor, 
but rather a marker of subclinical atherosclerosis or a marker of increased mortality 
in the setting of chronic atherosclerosis. In particular, it could be hypothesized that 
health problems underlying atherosclerotic disease can affect thyroid parameters. 
This condition, known as non-thyroidal illness, is typically characterized by normal 
serum TSH levels combined with low serum triiodothyronine and FT4 levels.
34
 In 
contrast, we found an association of higher rather than lower FT4 levels with an 
increased risk of atherosclerotic manifestations. Additionally, non-thyroidal illness 
occurs mainly in critically ill patients, whereas our population consists of relatively 
healthy community-dwelling adults. Furthermore, our study showed that higher FT4 
levels among participants without preexisting atherosclerotic disease were 
associated with higher risk of atherosclerotic events and atherosclerotic mortality. 
We took reverse causation into account by excluding events that occurred during 
the first 2 years of follow-up; and results remained similar. Overall, these data 
suggest that it is more likely that thyroid function affects atherosclerotic 
manifestations than vice-versa. 
Variations of thyroid function within the reference range markedly affected the risk 
of atherosclerotic morbidity and mortality in our participants. In line with these 
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results, a recent individual participant data analysis reported a positive association 
between thyroid function within the reference range and the risk of stroke.
9
 
However, another analysis from the same collaboration failed to show an 
association between thyroid function within the reference range and the risk of 
CHD
8
, though this could be due to the relatively low proportion of CHD deaths 
(3.3%). Notably, we observed larger risk estimates after restricting the analyses to 
participants with thyroid function within the reference range, without history of 
thyroid disease and not using thyroid function-altering medications. It could 
therefore be argued that participants with thyroid dysfunction could have become 
more health conscious and prone to treatment, which could have reduced their risk 
for atherosclerotic morbidity and mortality over time. Finally, these data provide 
supporting evidence for a re-evaluation of TSH and FT4 reference ranges, which 
are currently based on arbitrary statistical approaches (2.5
th
 and 97.5
th
 percentiles) 
rather than on clinical outcomes. Previous prospective studies have also reported 
that variations in thyroid function within the reference range are associated with an 
increased risk of various adverse outcomes.
9,11
 Thus, the challenge for future 
research will be to integrate the associated risk of relevant adverse outcomes, in 
order to eventually define the clinically relevant normal range of thyroid function.  
In our study population, there was a positive association between FT4 levels and 
atherosclerotic outcomes. Although the association between TSH levels and 
atherosclerotic outcomes was in the expected opposite direction of FT4, it 
sometimes did not reach statistical significance. Similar observations have been 
also reported by studies investigating the relationship of thyroid function with 
various clinical endpoints.
9,28
 Serum FT4 levels are tightly regulated by the 
hypothalamic-pituitary-thyroid axis, with a different set point for each individual. 
This might explain why FT4 levels are associated with various clinical endpoints, 
especially within the euthyroid range which is generally defined by TSH. 
Alternatively, these results may reflect a slight shift in the TSH-FT4 set point, which 
may be due to aging.
35
 To our knowledge, this is the first population-based cohort 
study to investigate the relationship of thyroid function with atherosclerosis 
throughout its spectrum; from subclinical atherosclerosis to overt atherosclerosis to 
atherosclerotic mortality. Another major strength is our prospective design with 
long-term follow-up (maximum follow-up time was almost 15 years). Moreover, we 
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included a large number of participants with extensive data on covariates and 
outcomes. Our large numbers further allowed us to perform multiple sensitivity 
analyses which provided consistent findings. Several limitations should also be 
considered. Thyroid function was measured only at baseline and we had no 
information regarding its fluctuations over time. Nevertheless, due to the intra-
individual variability of TSH and FT4 levels, the lack of repeated measurements 
would tend to underestimate the association between thyroid function and 
atherosclerotic outcomes rather than generate spurious findings
36
 In addition, our 
results were consistent within the normal range of thyroid function, which is 
considered to be stable with very small intra-individual variability.
37
 We lacked 
information on serum triiodothyronine levels. However, TSH and FT4 represent the 
most relevant measurements of thyroid function in clinical practice. Though thyroid 
function and CAC score were measured in a subpopulation, the general 
characteristics of that subpopulation were not substantially different from those of 
the larger population. Given that our study comprised mainly white middle-aged 
and older adults, the generalizability of our findings to nonwhite and younger 
populations remains to be investigated. Lastly, the possibility of residual 
confounding in an observational study design cannot be entirely ruled out. 
Conclusions 
Higher FT4 levels in middle-aged and elderly subjects were associated with an 
increased risk of atherosclerotic morbidity and mortality, independently of 
cardiovascular risk factors. The association of thyroid function with atherosclerotic 
mortality was most pronounced in the presence of atherosclerotic disease. These 
findings suggest that FT4 measurement can be a predictive marker of 
atherosclerotic mortality, especially among subjects with atherosclerotic disease. 
Furthermore, our findings underscore the importance of identifying the modifiable 
mediators of the association between thyroid function and atherogenesis. 
Preventive strategies targeting thyroid function or certain mediators could further 
lead to a reduction in atherosclerotic events. Lastly, our findings provide supporting 
evidence for a re-evaluation of the current reference ranges of TSH and FT4 tests, 
which are based on arbitrary statistical approaches rather than on clinical 
outcomes such as atherosclerotic morbidity and mortality.  
Supplemental material can be found online.  
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ABSTRACT 
BACKGROUND Reference ranges of thyroid stimulating hormone (TSH) and free 
thyroxine (FT4) are defined by their distribution in apparently healthy populations, 
(2.5th and 97.5th percentiles) irrespective of disease risk and used as cut-offs for 
defining and clinically managing thyroid dysfunction. Our objective is to provide a 
proof of concept in defining thyroid function optimal health ranges based on 
cardiovascular disease (CVD) mortality risk. 
 
METHODS A total of 9,233 participants from the Rotterdam Study (mean age 65.0 
years) were followed up (median 8.8 years) from baseline to date of death or end 
of follow-up (2012), which ever came first (689 cases of CVD mortality). We 
calculated 10-year absolute risks of CVD mortality (defined according to SCORE 
project) using a Fine and Grey competing risk model per percentile of TSH and 
FT4, modelled non-linearly and sex- and age-adjusted.  
 
RESULTS Overall, FT4 > 90th percentile was associated with a predicted 10-year 
CVD mortality risk >7.5% (p =0.005). In men, FT4 > 97
th 
percentile was associated 
with a risk of 10.8% (p<0.001). In participants ≥ 65 years, absolute risk estimates 
were <10.0% below the 30
th
 percentile (~14.5 pmol/L or 1.10 ng/dL) and ≥15.0% 
above the 97
th
 percentile of FT4 (~22 pmol/L or 1.70 ng/dL).  
 
CONCLUSIONS We describe absolute 10-year CVD mortality risks according to 
thyroid function (TSH and FT4) and suggest optimal health ranges for thyroid 
function can be defined according to disease risk and are possibly sex and age-
dependent. These results need to be replicated with sufficient samples and 
representative populations. 
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INTRODUCTION 
Reference ranges of blood and other clinical tests are predominantly statistically 
defined using the 2.5
th
 and 97.5
th
 percentile interval of the population distribution in 
an apparently healthy population. These reference ranges are typically established 
under the assumption of a normal distribution or a log-normal distribution and are 
therefore also referred to as “normal ranges”. This definition of a reference range 
does not account for whether individuals are symptomatic or at risk of potential 
adverse events or disease. Nevertheless, these biochemically defined reference 
values are frequently used to define sickness and health in clinical practice 
ignoring the inherent risk of the population. 
The reference ranges of thyroid function tests, defined by thyroid stimulating 
hormone (TSH) and free thyroxine (FT4), are examples of reference ranges 
defined by their distribution. TSH and FT4 reference ranges are currently used as 
cut-offs to define subclinical and overt thyroid disease, and guide treatment 
decisions. However, accumulating evidence suggests that subclinical thyroid 
dysfunction, defined by TSH outside of the reference range but FT4 within the 
reference range, is also associated with various clinical adverse outcomes, 
including coronary heart disease (CHD) and cardiovascular mortality, at the 
extremes.
1,2
 Moreover, even differences in thyroid function within the defined 
reference range are associated with differing risk of cardiovascular events 
including atrial fibrillation, stroke, sudden cardiac death and cardiovascular 
mortality.
3-7
 Based on the increased risk of CHD in subclinical hypothyroidism, 
current guidelines advocate treatment with levothyroxine above a TSH of 10 mIU/L, 
independent of FT4.
8
 Extending this concept, the re-evaluation of thyroid function 
ranges could take clinical adverse events into account and thus move from 
reference ranges towards “optimal health ranges” for thyroid function. 
This approach has been successfully applied to management of myocardial 
infarction, stroke and diabetes using cholesterol, blood pressure or glucose 
measurements.
9
 For example, the defined range for total cholesterol does not rely 
on the distribution of total cholesterol in a specific population, but rather on the 
associated 10-year risk of cardiovascular mortality.
9
 Pursuing the same strategy for 
thyroid function might not be as straightforward as for other biomarkers. The risk of 
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adverse events is relevant for both high and low thyroid function, suggesting a non-
linear association, in contrast to cholesterol for example, where the focus is on the 
high end of the measurement. Furthermore, thyroid dysfunction is not solely 
associated with cardiovascular disease (CVD), but has important implications for 
bone health and possibly also cognitive health. 
10-13
 
We therefore aimed to calculate the 10-year absolute risk of cardiovascular 
mortality in a large population-based cohort study by the two most commonly used 
parameters of thyroid function, TSH and FT4. We further aimed to define optimal 
health ranges based on provided absolute risk estimates in the whole cohort as 
well as by sex and age groups.  
 
METHODS 
The Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study that 
investigates determinants and occurrence of age-related diseases in a middle-
aged and elderly population in Rotterdam, the Netherlands. The aims and design 
of the Rotterdam Study have been described in detail elsewhere.
14
 The Rotterdam 
Study consists of three independent cohorts: RS Cohort 1 (RSI), including 7,983 
participants aged ≥55 (baseline 1990-1993), RS Cohort II (RSII), including 3,011 
participants aged ≥55 (baseline 2000-2001) and RS Cohort 3 (RSIII), including 
3,932 participants aged ≥45 (baseline 2006-2008). The Rotterdam Study has been 
approved by the medical ethics committee according to the Population Screening 
Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of 
the Netherlands.  
Study population 
We selected data from participants from the third visit of the first cohort (1997-
1999, n=4797) and the first visits of the second (2000-2001, n=3011) and third 
cohort (2006-2008, n=3932), if TSH or FT4 measurements were performed and 
participants were not using thyroid function altering medication, including 
levothyroxine, anti-thyroid drugs, amiodarone or corticosteroids. We did not use the 
first visit of the first cohort as thyroid function was measured with a different assay. 
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All participants in the present analysis provided written informed consent to 
participate and to obtain information from their treating physician. All study 
participants were followed up from the day of baseline laboratory testing to date of 
death or end of follow-up January 1, 2012 which ever came first. 
Assessment of thyroid function and other baseline measurements 
TSH and FT4 measurements were performed using the same methods and assay 
in blood samples collected between 1997 and 2008, depending on the cohort and 
stored at -80°C (electrochemiluminescence immunoassay for free thyroxine and 
thyrotropin, “ECLIA”, Roche). Body mass index was calculated as body mass (kg) 
divided by the square of the body height (m). Serum cholesterol was measured 
using standard laboratory techniques. Systolic blood pressure was calculated as 
the average of two consecutive measurements. Over 95% of participants were in 
fasting state when blood was drawn (morning) at the Rotterdam Study center visit. 
Information on tobacco smoking was derived from baseline questionnaires. 
Information on medication use was obtained from questionnaires in combination 
with pharmacy records.  
Outcome definition 
As primary outcome of interest we selected CVD since it is a leading burden of 
disease, morbidity and mortality.
15
 Additionally, the association of subclinical and 
overt thyroid dysfunction with CVD mortality are well-established.
1
 Secondary 
outcomes of interest were CHD and stroke (fatal and non-fatal). Methods for 
collection of data and outcome definitions have been previously described.
14,16,17
 
Information on the vital status of all participants was obtained on a weekly basis 
from the central registry of the municipality in Rotterdam and through digital linkage 
with records from GPs working in the study area. The cause of death was 
established by abstracting information from the medical records of the general 
practitioners or nursing home physicians and hospital discharge letters. 
Cardiovascular mortality was defined as according to the SCORE project definition 
of fatal CVD including the ICD-10 codes I10-25, I44-51, I61-73, and R96.
9,18
 To test 
the robustness of our findings we repeated the absolute risk estimate calculations 
using the CVD mortality defined according to previously published definition of the 
Rotterdam Study, which also included non-atherosclerotic cardiovascular 
mortality.
16
 CHD was defined as myocardial infarction, cardiac revascularization 
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procedure or CHD mortality. Stroke was defined according to World Health 
Organization (WHO) criteria as a syndrome of rapidly developing clinical signs of 
focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or 
longer or leading to death, with no apparent cause other than of vascular origin, 
including ischemic or hemorrhagic strokes. Outcomes were adjudicated by a 
committee who were blinded to lab results. 
Statistical analysis 
Absolute values of TSH and especially FT4 are assay dependent, but the different 
immunoassays of TSH or FT4 correlate well in non-pregnant adult populations
19,20
, 
as previously also shown in the Rotterdam Study.
21
 Therefore, to enhance 
generalizability of our results, we analyzed the association of TSH or FT4 in 
percentiles with the outcomes defined below. Absolute 10-year risk estimates of 
CVD mortality used the percentiles of TSH and FT4 and were calculated according 
to the Fine and Gray model, taking the competing risk of non-CVD deaths into 
account and were adjusted for age and sex.
22
 The competing risk for the CHD and 
stroke analyses were non-CHD and non-stroke deaths respectively. In addition, we 
performed predefined analyses stratifying for age categories and gender. We 
performed sensitivity analyses using a Rotterdam Study based definition for CVD 
mortality
16
, additionally adjusting the TSH analyses for FT4 and vice versa as well 
as additionally adjusting the analyses for cardiovascular risk factors used in the 
SCORE project charts (i.e. smoking, systolic blood pressure, and cholesterol).
9
 We 
used the following cut-offs for the risk estimates and color denomination of risk 
categories, which were slightly adjusted from the SCORE project due to the higher 
average age in our population: low risk (< 2.0%, blue), low-intermediate risk (2.0-
5.0%, green), intermediate risk (5.0-7.5%, yellow), high-intermediate risk (7.5-
10.0%, orange) and high risk (≥ 10.0%, red). 
For the CHD analyses we excluded all those with prevalent or missing information 
on CHD at baseline (n=685). For the stroke analyses we excluded all participants 
with missing information at baseline or a history of stroke (n=319). We performed a 
goodness-of-fit test for the Fine and Gray model for the absolute risk estimations, 
using the Zou Laird Fine test, and this revealed no linear, quadratic or log time 
varying effects of TSH or FT4 (p-value > 0.1 for all analyses). Linearity of absolute 
risk estimates was tested with restricted cubic splines with 3 knots at the 10
th
, 50
th
 
Optimal thyroid function health ranges 
151 
and 90
th
 percentile. Analyses were performed in R (survival, rms, crrSC and 
cmprsk packages R-project, Institute for Statistics and Mathematics, R Core Team 
(2013), Vienna, Austria, version 3.0.2). 
 
RESULTS 
We included a total of 9,233 participants with a mean age of 65.0 (standard 
deviation 9.8) years of which 55.9% were female (Table 1). During an average 
follow-up of 8.8 years, with a total of 75,981 person-years, 2166 deaths occurred of 
which 689 were CVD deaths according to the SCORE criteria and 692 according to 
the Rotterdam Study criteria. There were 642 CHD events and 553 stroke events 
during follow-up. Completeness of follow-up was 99.6%.
23
 
 
Table 1 Baseline characteristics of included participants in the study 
Variable Mean (SD)
a 
Number of participants 9233 
Age, years 65.0 (9.8) 
Female, N (%) 5157 (55.9) 
History of diabetes, N (%) 1097 (11.9) 
BMI kg/m2 27.2 (4.2) 
Cholesterol mmol/L 5.7 (1.0) 
Smoking, N (%) 
 
   current 1975 (21.4) 
   past 4380 (47.4) 
   never 2878 (31.2) 
Systolic BP, mmHg 139.5 (21.0) 
TSH ImU/L median (IQR) 1.90 (1.29-2.74) 
FT4 pmol/L 15.6 (2.2) 
FT4 ng/dL 1.21 (0.2) 
a 
Values are means and SD unless otherwise specified Abbreviations: BMI = body-mass index; BP = 
blood pressure; FT4 = free thyroxine; IQR = inter-quartile range; N= number; SD = standard deviation; 
TSH = thyroid-stimulating hormone 
 
Absolute risk estimates cardiovascular mortality 
Ten-year absolute risk estimates for CVD mortality across the range of TSH and 
FT4 are plotted in Figure 1. CVD mortality increased with higher FT4 levels (p-
value 0.005) and lower TSH levels, although not statistically significantly for the 
latter. The best fit for both TSH and FT4 analyses was non-linear (p for non-
linearity < 0.001, Figure 1). Table 2 shows the different percentile cut-offs of TSH 
and FT4 values with the predicted absolute 10-year risk estimates, based on the 
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non-linear association. Overall, FT4 values above the 97
th 
percentile (absolute level 
of approximately 22 pmol/L or 1.7 ng/dL) were associated with a predicted 10-year 
risk of 9.6% (p-value = 0.005). FT4 levels above the 90
th
 percentile corresponded 
to an increased risk of 7.5% and higher for CVD mortality (absolute level of 
approximately 19 pmol/L or 1.5 ng/dL). Sensitivity analyses did not change the 
definition of the cut-offs meaningfully (Supplemental Table 1). TSH levels were 
inversely associated with CVD mortality but not statistically significant (Table 1). 
For men, a risk of ≥10.0% occurred at the 97
th
 percentile of FT4 (p-value < 0.001) 
and a risk of ≥7.5% already occurred at the 60
th
 percentile (Table 3). In women, 
there was no association of the thyroid function markers and risk of CVD mortality 
(Table 3). In participants younger than 65 years of age, the risk of CVD mortality 
increased with decreasing TSH levels (p-value = 0.009) with a risk of ≥ 2.0 % from 
the 30
th
 percentile and lower (~1.40 mIU/L), while FT4 levels were not association 
with CVD mortality (Table 4). In participants older than 65 years of age (Table 4), 
the absolute risk estimates were <10.0% below the 30
th
 percentile and ≥ 15.0% 
higher than the 97
th
 percentile of FT4. 
Absolute risk estimates CHD and stroke 
Supplemental Figure1 plots the absolute risk estimates of CHD and stroke against 
the continuous FT4 and TSH levels. In the Fine and Grey models, the association 
of TSH or FT4 with CHD events was not statistically significant (p-value > 0.5). 
Higher FT4 levels were associated with an increased risk of stroke (p-value = 
0.009). TSH levels were inversely associated with the risk of stroke, but this did not 
reach statistical significance. The best fit for the CHD analyses was linear, while 
the best fit for the stroke analyses was non-linear (p for non-linearity <0.001, 
Supplemental Figure 1).  
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Figure 1 Absolute 10-year risk of CVD mortality by TSH and FT4  
 
 
 
 
 
Absolute 10-years risks of CVD mortality were calculated taking competing risk of death by other 
causes into account, and are plotted against TSH and FT4 percentiles and absolute values, with 95% 
confidence intervals. P for non-linearity < 0.001 for both TSH and FT4 analyses. Abbreviations: CVD 
cardiovascular disease FT4 free thyroxine, TSH thyroid-stimulating hormone. 
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DISCUSSION 
This is the first study to propose reference ranges of TSH and FT4 to be based 
upon the disease risk (i.e. absolute risk estimates of CVD) as a proof of concept. 
Based on our findings, the proposed upper limit for FT4 could be the 90
th
 
percentile, independent of TSH levels. The optimal health ranges for thyroid 
function based on cardiovascular disease seem to differ between men and women 
and the associations were not statistically significant in women. In participants 
older than 65 years of age, the absolute risk estimates of CVD were <10.0% below 
the 30
th
 percentile (~14.5 pmol/L or 1.1 ng/dL) and ≥ 15.0% higher than the 97
th
 
percentile of FT4 (~22 pmol/L or 1.7 ng/dL). The associations of TSH and FT4 with 
CVD mortality were non-linear. The association of thyroid function with stroke 
followed a similar pattern, but the association with CHD showed a linear 
association. 
Reference ranges for the thyroid function biomarkers TSH and FT4 have been 
derived mainly statistically from the 2.5
th
 and 97.5
th
 percentile, similar to reference 
ranges of other laboratory results and clinical tests.
24-26
 Subclinical and overt 
thyroid disease are subsequently defined by these biochemical and statistical 
reference ranges which, in general, do not take future health and disease risks into 
account. However, some guidelines do uphold additional cutoffs for treatment 
based on studies showing an increased risk of cardiovascular disease at certain 
levels.
8,27
 For example, the European Thyroid Association guidelines on subclinical 
hypothyroidism 
8
, make a distinct separation between TSH levels below and above 
10 mIU/L for consideration of levothyroxine treatment. These recommendations are 
based on a study by the Thyroid Studies Collaboration that provided evidence for a 
higher relative risk of CHD with TSH levels higher than 10 mIU/L.
1
 However, to our 
knowledge, there are no studies specifically addressing the optimal health ranges 
based on absolute risk estimates of adverse health outcomes.  
Overall, our study shows an absolute 10-year risk of 7.5% or higher with FT4 levels 
above the 90
th
 percentile, corresponding to a cut-off level of FT4 approximately 19 
pmol/L (~1.5 ng/dL). This is however, as expected, different in participants younger 
than 65 years of age compared to those older than 65 years. Also, there seems to 
be a differential association of thyroid function with absolute risk of CVD when 
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comparing men to women. This can, at least partially, be attributed to the 
difference in background absolute risk between the two sexes, where, also in our 
study, women have an inherent lower risk of CVD. However, aside from 
background risk of CVD, there also seems to be a thyroid dependent differential 
risk when comparing men to women, which could be explained by e.g. a difference 
in set point between the sexes. 
28
 Our findings need to be confirmed and validated 
across different populations, but could suggest a sex-specific reference range 
ought to be considered. These findings need to be confirmed and validated across 
different populations, but could suggest a sex-specific reference range is needed. 
In our study, higher FT4 levels are associated with an increased risk of CVD 
mortality whereas TSH levels showed an expected opposite relation with CVD 
mortality which did not reach statistical significance. The current study is not the 
first to report an association of FT4 with clinical events, while the association is 
lower or absent with TSH.
3,6,21
 Based on the log-linear relationship between TSH 
and FT4, TSH is perceived as the most sensitive marker in subjects with thyroid 
disease. The lack of association with TSH is therefore remarkable. One 
explanation could be that in euthyroid subjects, TSH predominantly reflects the 
pituitary-thyroid axis set point rather than disease risk,
29
 while, independent of 
TSH, circulating FT4 (and subsequently FT3 acting intracellular) represents the 
bioavailable thyroid hormone that can be taken up by cells, thereby leading to 
clinical consequences of thyroid hormones peripherally.  
Cholesterol is a modifiable risk factor for CVD mortality and diagnosis and 
treatment targets for cholesterol are included within optimal primary and secondary 
prevention of CVD mortality. In our study, we show that FT4 is also a potentially 
modifiable risk factor for CVD and CVD mortality, especially in men and the elderly. 
For cholesterol, the average risk difference, as derived from the SCORE risk chart 
for low risk countries 
9
, when comparing 65 year old men with a cholesterol level of 
7 mmol/L to 65 year-old men with a cholesterol level of 4 mmol/L is approximately 
4.0%. This is similar to the risk difference when comparing men with an average 
age of 65 years in the highest 10th percentile of FT4 (cut-off ~ 1.5 ng/dL) to those 
in lowest 10th percentile (cut-off ~ 1.0 ng/dL), namely 4.3%. Whether modifying 
higher FT4 levels with anti-thyroid drugs will indeed result in this cardiovascular 
mortality risk reduction still needs to be determined. 
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There are several strengths to our study including the population-based design, the 
large size of the study population, the completeness of follow-up and the fact that 
outcomes were defined independently from baseline thyroid function. Nevertheless, 
the currently proposed optimal health ranges should be interpreted with caution. 
First of all, even though CVD is one of the most important clinical outcomes, the 
presented absolute risk estimates are solely based on cardiovascular mortality and 
our findings as such should be considered as a proof of concept. Furthermore, The 
Netherlands is classified as a low cardiovascular mortality risk country by the 
European Society of Cardiology and therefore estimates are not generalizable to 
countries with higher CVD mortality risk.
30
 The Rotterdam Study consists of 
participants of 45 years and older and mainly Caucasians with, on average, a 
sufficient iodine status.
31,32
 Also, only one baseline measurement of thyroid 
function was available, which holds true for most population-based cohort studies. 
The intra-individual set-point is much tighter than the inter-individual set-point, 
meaning that within an individual the changes in time are much smaller than 
between individuals.
33
 Nevertheless, we could not investigate how changes in 
thyroid function could affect CVD risk and whether repeated measurements of 
thyroid function could better differentiate risk among cohort participants. The 
absolute levels of TSH and especially FT4 depend on the assay used and are 
therefore variable. Immunoassays for FT4 are affected by changes in serum 
binding proteins that occur in disease and pregnancy.
34
 We therefore used the 
percentiles of the measurements to study the associations and define the optimal 
health ranges, because of the strong correlation between the different assays of 
TSH or FT4 in community-dwelling non-pregnant populations. These results are 
therefore potentially more generalizable to other populations. This is also the 
reason to advice that the calculation of these percentiles is country, iodine status, 
region and if possible even laboratory specific. 
The mentioned limitations of our study also highlight the need for further research. 
Therefore our approach to define thyroid function adequacy focused on 
cardiovascular mortality need to be confirmed in similar populations but also 
replicated in complementary populations such as younger participants, other 
ethnicities and in regions with different current and historical iodine status.
35
 
Cardiovascular disease is an established and well-studied outcome in relation to 
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thyroid function. However, recently, there is increasing interest in the association of 
thyroid function with other outcomes as well, such as cognition. Therefore, 
importantly, consensus is needed on which clinical outcomes are or could be 
relevant in defining the optimal health ranges for thyroid function, beyond 
cardiovascular disease. Lastly, and beyond the discussion on thyroid function 
optimal health ranges, consensus is also needed on which cardiovascular risk is 
considered too high and whether this is similar for all populations. For example, a 
10-year absolute risk of 2.5% for CVD mortality for a person of 45 years of age 
might not be deemed equally acceptable compared to the same risk in a person of 
75 years. 
This is a population-based study, and therefore risks and benefits of treatment 
decisions were not explored. While randomized controlled trials are the best 
evidence for defining treatment cut-offs, they are costly and not always able to 
address the timeliest issues. In the absence of results from such trials in the near 
future, defining the optimal health ranges by determining the absolute risk 
estimates of disease, in various observational studies from representative 
populations, is perhaps the most feasible.  
In summary, we propose an approach to define thyroid function based not only on 
population’s distribution but taking into account health and disease risk. We 
describe the absolute 10-year risk of cardiovascular mortality associated with TSH 
and FT4 and provide an example of defining optimal health ranges based on 
cardiovascular mortality risk using data from a large population-based study. 
Further research is needed to investigate optimal health ranges based on thyroid-
relevant clinical outcomes in sufficiently powered studies with representative 
samples from multiple populations.  
 
Online supplemental material 
https://academic.oup.com/jcem/article-abstract/doi/10.1210/jc.2017-
00410/3828544/Defining-optimal-health-range-for-thyroid-
function?redirectedFrom=fulltext  
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ABSTRACT 
BACKGROUND Subclinical thyroid dysfunction has been associated with coronary 
heart disease, but the risk of stroke is unclear. Our aim is to combine the evidence 
on the association between subclinical thyroid dysfunction and the risk of stroke in 
prospective cohort studies. 
 
METHODS We searched Medline (OvidSP), Embase, Web-of-Science, Pubmed 
Publisher, Cochrane and Google Scholar from inception to November 2013 using a 
cohort filter, but without language restriction or other limitations. Reference lists of 
articles were searched. Two independent reviewers screened articles according to 
pre-specified criteria and selected prospective cohort studies with baseline thyroid 
function measurements and assessment of stroke outcomes. Data were derived 
using a standardized data extraction form. Quality was assessed according to 
previously defined quality indicators by two independent reviewers. We pooled the 
outcomes using a random-effects model. 
 
RESULTS Of 2274 articles screened, six cohort studies, including 11,309 
participants with 665 stroke events, met the criteria. Four of six studies provided 
information on subclinical hyperthyroidism including a total of 6029 participants and 
five on subclinical hypothyroidism (n=10,118). The pooled hazard ratio (HR) was 
1.08 (95% CI: 0.87-1.34) for subclinical hypothyroidism (I² of 0%) and 1.17 (95% 
CI: 0.54-2.56) for subclinical hyperthyroidism (I² of 67%) compared to euthyroidism. 
Subgroup analysis yielded similar results. 
 
CONCLUSIONS Our systematic review provides no evidence supporting an 
increased risk for stroke associated with subclinical thyroid dysfunction. However, 
the available literature is insufficient and larger datasets are needed to perform 
extended analyses. Also, there were insufficient events to exclude clinically 
significant risk from subclinical hyperthyroidism, and more data are required for 
subgroup analyses.  
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INTRODUCTION 
Thyroid disease has been associated with several metabolic disorders as well 
cardiovascular disease 
1,2
 and cardiovascular mortality.
3,4
 The cardiovascular 
system is one of the main targets of thyroid hormones, which decrease systemic 
vascular resistance 
5
, alter systolic and diastolic cardiac function 
4
 and directly 
increase cardiac contractility and heart rate.
6
 They also have effects on several 
cardiovascular risk factors including changed lipid profile 
7
 and increased risk of 
atrial fibrillation and other supraventricular arrhythmias 
8
. Many of these effects are 
also seen in subclinical thyroid dysfunction.
9
 
Subclinical thyroid dysfunction is defined by serum thyroid stimulating hormone 
(TSH) values outside the reference range, but with normal concentrations of free 
thyroxine (T4), as well as free triiodothyronine (T3) in the case of subclinical 
hyperthyroidism.
10,11
 The reference ranges depend on several factors including the 
thyroid function assay used
10
 and iodine status of the population.
12
 Thyroid 
dysfunction in the subclinical range is very common, with a prevalence of 
subclinical hypothyroidism varying between 4-14% in adults 
13-15
 which increases 
with age.
14
 Subclinical hyperthyroidism is less common in the general population 
with a prevalence ranging from 0.7% 
16
 up to 10% in women.
17
 
Two meta-analyses of individual participant data of prospective cohorts showed an 
increased risk of coronary heart disease in subclinical hypothyroidism
18
, as well as 
subclinical hyperthyroidism.
19
 Stroke, which is worldwide the second most common 
cause of death and one of the leading causes of disability 
20
, shares many of the 
same risk factors as other cardiovascular disease, including high blood pressure, 
high cholesterol, obesity and atrial fibrillation. The link between overt 
hyperthyroidism and atrial fibrillation 
2
 and ischemic stroke has been established, 
even in young adults.
21
 The association between overt hypothyroidism, atrial 
fibrillation and cardioembolic stroke has been suggested, but is not established.
2,22
 
While subclinical thyroid dysfunction influences several of the mentioned 
cardiovascular risk factors, there remains debate to what extent this actually affects 
stroke risk.
9
 Prior studies assessing this association are few, with conflicting 
outcomes and have never been systematically analyzed. With this meta-analysis, 
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we aim to determine whether subclinical thyroid dysfunction is associated with an 
increased risk of stroke in prospective cohort studies. 
 
METHODS 
Eligibility criteria 
We searched for published studies of prospective cohorts that satisfy the following 
criteria: (i) measurement of thyroid function at baseline in subjects above the age 
18, (ii) assessment of stroke and/or transient ischemic attack (TIA) outcomes (iii) 
inclusion of subclinical thyroid dysfunction group and a comparison group with 
euthyroidism and (iv) evaluation of the association of altered thyroid function on 
stroke providing a measure of this association with either a risk ratio, odds ratio or 
hazard ratio. We excluded studies including participants with only overt thyroid 
disease or only participants taking thyroid-function altering medication, or with only 
stroke and/or TIA patients. We did include studies with a proportion of participants 
taking thyroid function altering medication. In prospective cohort studies this will 
probably not exceed 10% of the studied population. We did however conduct a 
sensitivity analysis excluding those studies. Our outcome of interest was fatal and 
non-fatal stroke.  
Study search and identification 
We conducted a systematic literature search for studies on the association 
between subclinical thyroid dysfunction and stroke published between earliest 
inception and November 2013 in several databases (Supplemental Material). The 
databases searched were: Medline (OvidSP), Embase, Web-of-Science, Pubmed 
Publisher, Cochrane and Google Scholar. We used a cohort filter designed by BMJ 
Evidence Centre information specialists 
23
 to select prospective studies for both the 
Medline as well as the Embase database, but not for the other databases. Filters 
for observational studies have shown to perform well in Medline and Embase with 
a sensitivity of >99% and reduce the amount of retrieved articles up to 30%.
24
 We 
did not use any other filters or restrictions including language restrictions. In 
addition, we searched in other sources including bibliographies of key articles in 
the field and those included in this review.  
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Study selection 
Two reviewers (LC, CB) screened the abstracts and titles of the search result 
independently and in duplicate. Articles of prospective cohorts studying the 
association between subclinical thyroid dysfunction and stroke and/or TIA were 
included. When potentially eligible studies were retrieved, the full text publications 
were evaluated according to the eligibility criteria. The inter-reviewer agreement 
was calculated according to the kappa-statistic (κ), which was fair to good (κ= 0.61) 
for abstract and title, and excellent (κ= 1.0) for full-text screening. Disagreements 
were resolved by either consensus or discussion with a third independent reviewer 
(RP). Subclinical hypothyroidism was defined as an elevated TSH and normal free 
T4 (FT4), subclinical hyperthyroidism as a decreased TSH and normal (F)T4/T3. 
We used TSH and (F) T4/T3 -cutoffs as reported by each cohort separately.  
Data Collection and Quality Assessment process  
Standardized data collection forms were used to extract data from the individual 
cohorts of the included studies concerning participant characteristics, used 
reference ranges for thyroid function measurements, including the minimally and 
maximally adjusted HR’s for the outcome events of interest, types of analysis and 
covariates adjusted for (Table 1). The correctness of the abstracted information 
was confirmed by a second reviewer (RP) and corrected and/or completed where 
needed. Two independent reviewers assessed study quality using previous criteria 
for the assessment of key indicators of cohort study quality.
25
 The components 
assessed were: (i) whether the study was population based, (ii) whether the study 
had a formal adjudication procedures for stroke defined as having clear criteria for 
the outcome that were reviewed by experts for each potential case, (iii) which 
methods were used for stroke ascertainment, (iv) which if any adjudication was 
performed without knowledge of thyroid status, (v) what was the loss of follow-up 
and (vi) what were the adjustments for the multivariate analysis, if any. We also 
assessed study quality using the Newcastle Ottawa Scale (NOS) for cohort 
studies.
26
 Two reviewers (LC, CB) rated all studies for quality and any 
disagreement was resolved by a third reviewer (OF).  
Statistical analysis 
We used the most adjusted HRs and 95% confidence intervals (CI) available 
provided by the included studies as the primary analysis. We used the random-
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effects method by DerSimonian and Laird 
27
 to assess the pooled estimates and 
95% CIs of the risk of subclinical hypothyroidism and hyperthyroidism on stroke. In 
addition we also conducted a fixed-effect analysis for comparison. We used the 
Cochrane Q test and I² index with a conservative p-value of 0.10 to evaluate 
heterogeneity across individual studies.
28
 I² values of <25% indicate low, 25 and 
50% moderate and > 50% high heterogeneity. We also evaluated publication bias 
visually through funnel plots and statistically with an Egger test.
29
  
For the analyses we used Review Manager (RevMan) Version 5.2. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. To explore 
sources of heterogeneity, we planned sensitivity analyses to exclude non-
population based studies, exclude studies including a proportion of levothyroxine 
users, including only studies with a adjudication procedure, including studies with 
(F)T4/T3 measured in all participants and a sensitivity analysis using only the 
minimally adjusted HRs. We also planned subgroup analyses stratifying for 
different age groups, gender, TSH levels. 
 
RESULTS 
Study selection 
We identified 3095 reports, of which 2274 remained after removing duplicates 
(Figure 1). We excluded 2258 based on the title and abstract as they were 
unrelated to the association between subclinical thyroid dysfunction and stroke. Of 
the remaining 16 articles, we excluded 10 articles because they did not meet 
inclusion criteria after full-text screening,  leaving six reports that met the eligibility 
criteria and were included in further qualitative and quantitative analyses.  
Study Characteristics  
The 6 studies selected for the analysis enrolled 11,309 participants in total (Table 
1) and included 665 stroke events. The included studies were from Europe, Japan 
and the USA. Out of the six studies, five studies provided information on subclinical 
hypothyroidism analyzing a total of 10118 participants with 620 stroke events, and 
four studies provided data on subclinical hyperthyroidism analyzing a total of 6029 
participants with 301 stroke events. 
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Figure 1 Study Selection 
 
 
The mean age ranged from 58.5 up to 74.7 years at baseline, while the overall 
mean age was 69 years. Out of the 6 cohorts, 3 excluded participants with thyroid-
altering medication and three studies measured T4 (and/or T3) only in abnormal 
TSH values. None of the studies evaluated stroke as a primary outcome and none 
specified the type of stroke. The percentage of subclinical thyroid dysfunction 
varied across studies ranging from 1.5% to 5.9% for subclinical hyperthyroidism 
and from 5.1% to 15.3% in subclinical hypothyroidism. The TSH cut-offs for 
subclinical hyperthyroidism ranged between 0.1 mIU/L and 0.6 mIU/L and for 
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subclinical hypothyroidism between 4.0 mIU/L and 5.0 mIU/L. The follow-up 
duration varied from 4 years up to 12.5 years. All studies except for one 
30
 used a 
second or third generation TSH-assay. The first-generation TSH-assay used by 
this study is insufficiently sensitive to detect a TSH in the range of subclinical 
hyperthyroidism.  However, the Nagasaki Study did not provide information on 
subclinical hyperthyroidism and was only included in the subclinical hypothyroidism 
analysis.  
Quality assessment 
Five out of the 6 studies were population based and one study was a randomized 
clinical trial (Table 1). Three studies had formal adjudication procedure for stroke of 
which 2 studies also reported adjudication without knowledge of thyroid status. The 
studies with no formal adjudication procedure used the International Classification 
of Diseases (ICD) to ascertain stroke outcomes. None except for one cohort 
31
 
reported loss to follow-up and all but one 
31
 reported HR adjusted for covariates 
(Supplemental Material Table S1). The studies showed similar scores on the NOS 
assessment scale overall, but scored differently on the separate quality item 
(Supplemental Material Table S2). As an overall quality check, and in order to 
ensure transparent reporting of this systematic review and meta-analysis, the 
PRISMA guidelines were followed and the PRISMA checklist is provided 
(Supplemental Material Table S3). 
Subclinical hyperthyroidism and stroke 
Of the 6 included studies, 4 provided data on subclinical hyperthyroidism and the 
risk of stroke. Two studies included in this analysis 
31,32
 showed an increased risk, 
with one study providing an adjusted HR reaching statistical significance with a HR 
3.39 (95% CI 1.15 – 10.00) 
32
. The two other studies showed a statistically non-
significant decreased risk for stroke associated with subclinical hyperthyroidism 
33,34
 (Table 2). The overall pooled estimated HR using a random effects model 
showed no association of subclinical hyperthyroidism with stroke with a HR of 1.17 
(95% CI: 0.54 to 2.56) and substantial heterogeneity (Q-statistic p- value < 0.05 
and I² of 67%, Figure 2A). Sensitivity analyses excluding studies without formal 
stroke adjudication procedures, not population based or including participants on 
levothyroxine yielded similar results (Table 2).  
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Figure 2 Forest Plots for subclinical thyroid disease and risk of stroke 
 
2A. Subclinical Hyperthyroidism and stroke. 2B. Subclinical Hypothyroidism and stroke. Overall hazard 
ratios are displayed as diamonds. The forest plots are ordered by study weight. 4D = Die Deutsche 
Diabetes Dialyse Studie, CHS = Cardiovascular Health Study, HABC = Health, Aging and Body 
Composition study. 
 
Subclinical hypothyroidism and stroke 
In the five studies that included results on the effect of subclinical hypothyroidism 
on the risk of stroke the pooled HR was 1.08 (95% CI: 0.87 to 1.34) without 
evidence for heterogeneity (p- value of 0.70, I² of 0%) (Figure 2B). The results were 
mainly due to the large weight (75%) of one particular study. Sensitivity analyses 
did not show any relevant difference in the results, except stratifying by age with a 
higher risk in the population aged < 65 years (HR 1.90, CI 95% 0.50 – 7.29), but 
with only one study contributing with participants with a mean age below 65 years 
old. 
Subgroup and sensitivity analyses 
Pre-specified subgroup analyses were performed on different age categories, 
different cut-off points for TSH levels as well as the inclusion of levothyroxine users 
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in the study and showed no significant differences. Due to the lack of data, no 
subgroup analysis on gender could be performed (Table 2). Sensitivity analysis 
using only minimally adjusted HRs did not alter the risk estimates substantially 
(Table 2). 
Evaluation of publication bias 
Neither the visual assessment of the funnel plots (Supplemental Material Figure 
S1) nor the Egger test (p=0.76) showed signs for publication bias for the 
association between subclinical hypothyroidism and the risk of stroke. However the 
Egger test did show significant publication bias for the analysis on subclinical 
hyperthyroidism (p= 0.003) Furthermore, the funnel plots for subclinical 
hyperthyroidism and risk of stroke also showed publication bias with the 
Frederiksberg study being a possible outlier. Excluding this study in a sensitivity 
analysis yielded different risk estimates for subclinical hyperthyroidism, slightly 
reducing statistical heterogeneity (Table 2). The results for subclinical 
hypothyroidism did not change by this additional analysis. 
 
DISCUSSION 
In our systematic review and meta-analysis we did not find evidence supporting an 
increased risk of stroke in participants with subclinical thyroid dysfunction. This is in 
line with previous studies that found no association between subclinical 
hyperthyroidism and stroke 
19,35
 or subclinical hypothyroidism and stroke.
35,36
 The 
number of studies retrieved was low and the study quality (assessed by scoring 
key indicator of quality and the NOS scale) was heterogeneous with few studies 
reporting adjudication of the outcome without prior knowledge of the thyroid status. 
Five studies adjusted for at least age and sex, but all studies included a different 
number of additional covariates for both minimal as maximal adjustment making 
them hard to compare. For example, only three out of the six studies corrected for 
smoking status.
30,33,37
 while smoking is associated with both stroke as with thyroid 
disease.
38
 Smoking is negatively associated with hypothyroidism and positively 
associated with hyperthyroidism with current smokers having lower levels of TSH.
38
  
It has even been suggested that smoking might mediate  the associations found 
between thyroid function and BMI 
39
. 
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Stroke shares many of the same risk factors with other cardiovascular diseases. 
Subclinical hyperthyroidism significantly increases the risk of atrial fibrillation, as 
demonstrated in an individual participant level meta-analysis by Collet et al.
19
 In 
subclinical hypothyroidism, relevant changes in low-density lipoprotein cholesterol 
(LDL-cholesterol) were seen, mainly with a TSH higher than 10 mIU/L.
40
 Although 
the association between subclinical thyroid dysfunction and various risk factors for 
stroke have been established, the risk of stroke in subclinical thyroid dysfunction 
remains unclear.  
This is the first systematic review and meta-analysis on the association between 
subclinical thyroid dysfunction and the risk of stroke. We conducted an extensive 
literature search in several electronic databases with as little limitations as possible 
in order to retrieve the maximum amount of literature available on the topic. 
However, the number of retrieved papers was still small, revealing a scarcity of 
literature on this issue. Moreover almost all studies were conducted in populations 
of 65 years or older, limiting the generalizability to other populations. The only 
study with a younger population looking at subclinical hypothyroidism found an 
increased risk with a hazard ratio of 1.90, even though statistically not significant.
30
  
Looking at different age groups would be of special interest  as previous studies 
evaluating the association between subclinical thyroid dysfunction, cardiovascular 
disease and mortality suggest an age dependent effect.
25,41
 
Another important limitation is the lack of information on different TSH levels. 
Previous studies showed an association between different TSH levels and the risk 
of cardiovascular disease 
18
 and cardiovascular mortality.
19
 Only one study 
37
 in our 
meta-analysis included different TSH-levels in the analysis, showing no clear dose-
response relation. Only two 
32,33
 out of the four studies included in the subclinical 
hyperthyroidism analysis provided information on atrial fibrillation, which did not 
allow for stratification. We were not able to explore age-related nor TSH level 
associated risks of stroke in subclinical thyroid dysfunction in our meta-analysis, 
due to limited data. Also, we were not able to stratify for follow-up time, in order to 
take into account the time between exposure and outcome, due to the difference in 
definition of follow-up time (Table 1).
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Furthermore, we were not able to take possible treatment during follow-up into 
account, neither did we have information on the progression of the thyroid function 
or thyroperoxidase (TPO) autoantibody status of participants. Finally, (Free)T3 was 
not measured or taken into account in all studies allowing for possible 
misclassification of subclinical hyperthyroidism, which might have been the case in 
two studies.
31,33
 
Reference ranges differed substantially between the individual studies, especially 
for subclinical hyperthyroidism, with lower limits of TSH ranging from 0.1 to 0.6 
mIU/L. This might be one of the reasons for heterogeneity. All included studies 
evaluated stroke as a secondary outcome next to other cardiovascular diseases 
and deaths or total mortality. This is reflected by the lack of subgroup analyses per 
cohort and the inability of our study to stratify for different possible risk populations, 
such as gender specific analyses. For the subclinical hyperthyroidism analysis we 
found statistically significant heterogeneity, complicating the interpretation of the 
meta-analysis results. One of the reasons might be the underlying differences in 
populations ranging from healthy volunteers 
32
 to patients on hemodialysis 
34
 and 
from multiracial 
33,37
 to a solely Asian population 
30
, leading to possible selection 
bias. In order to examine the issue of heterogeneity in the subclinical 
hyperthyroidism analysis, we conducted sensitivity and subgroup analyses, which 
led to a reduction in heterogeneity by excluding studies that included levothyroxine 
users, including studies with formal stroke adjudication procedures only and 
stratifying by age (e.g. cut-off at 70 years of age). However, these analyses 
included no more than 2 studies and none reached statistical significance for the 
outcome measure. Furthermore, the visual assessment of publication bias, showed 
no evidence for publication bias for the analysis on subclinical hypothyroidism but 
some for subclinical hyperthyroidism. This remains a concern in meta-analyses, 
especially when only a small number of studies are retrieved. 
While we could not provide evidence for an effect of subclinical thyroid dysfunction 
on the risk of stroke, these results should be interpreted with caution. Thyroid 
dysfunction, even in the subclinical range gives rise to several cardiovascular risk 
factors. In subclinical hypothyroidism some seem to be reversible if treated with 
levothyroxine.
42,43
 Furthermore, restoring thyroid function with levothyroxine 
treatment in subclinical hypothyroid individuals showed a reduction of almost 10% 
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of the carotid artery mean intima media thickness (IMT).
44
 As IMT has shown to be 
a risk factor of cardiovascular disease and stroke
45
, this decline in IMT might also 
result in a decreased risk of stroke. Also, the association between subclinical 
hyperthyroidism and atrial fibrillation has been clearly demonstrated
19
 and 
therefore an association between subclinical hyperthyroidism and stroke could be 
presumed. However, we were not able to demonstrate this expected risk increase 
in our meta-analysis for subclinical hyper- nor for hypothyroidism. This might be 
due to the limited number of populations evaluated and gathered (hence the lack of 
power) by the included studies, not representing specific populations at risk. 
Treatment of subclinical thyroid dysfunction in relation to cardiovascular disease is 
still controversial and highly debated. Consensus guidelines have advocated 
treatment of subclinical hyperthyroidism but only in the elderly or patients with 
cardiac risk factors, heart disease or osteoporosis.
46
. Levothyroxine treatment has 
shown to improve several subclinical cardiovascular disease markers, e.g. IMT and 
endothelial dysfunction 
43,47,48
, in subclinical hypothyroidism, but no large controlled 
trials have been performed to evaluate the effect in preventing cardiovascular 
events. Moreover, there are concerns about the risk of overtreatment, as 
population-based studies reported that among patients treated with thyroid 
medication, only 60% were within the normal biochemical range of TSH with more 
than one fifth having a TSH level that was suppressed below normal.
15
 
Randomized clinical trials, like the ongoing IEMO 80+ Thyroid Study and Thyroid 
Hormone Replacement for Subclinical Hypothyroidism (TRUST) trial 
(ClinicalTrials.gov Identifier: NCT01660126), are expected to give more insight into 
the benefit of treatment in the general population as well as specific subgroups. 
In summary, we found no association between subclinical thyroid dysfunction and 
the risk of stroke. However, the available literature is insufficient and more 
research is needed. Future studies should focus on the association between 
subclinical thyroid dysfunction and the risk of stroke as a primary outcome and be 
adequately powered to conduct subgroup analyses including different age groups, 
TSH levels and gender differences. 
 
Online supplemental material 
https://link.springer.com/article/10.1007%2Fs10654-014-9946-8 
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ABSTRACT 
BACKGROUND There is paucity in literature concerning the association of 
subclinical hypothyroidism with the subsequent risk of stroke.  
 
METHODS Published prospective cohort studies were identified through a 
systematic search through November 2013 without restrictions in several 
databases. Unpublished studies were identified through the Thyroid Studies 
Collaboration. We collected individual participant data (IPD) on thyroid function and 
stroke outcome. Euthyroidism was defined as thyrotropin (TSH) levels 0.45-4.49 
mIU/L, subclinical hypothyroidism as TSH levels 4.5-19.9 mIU/L with normal 
thyroxin levels. 
 
RESULTS We collected IPD on 47,573 adults (3451 subclinical hypothyroidism) 
from 17 cohorts, followed-up 1972-2014 (489,192 person-years). Age- and sex-
adjusted pooled hazard ratio (HR) for participants with subclinical hypothyroidism 
compared to euthyroidism was 1.05 (95% CI, 0.91-1.21) for stroke events 
(combined fatal and non-fatal stroke) and 1.07 (95% CI, 0.80-1.42) for fatal stroke. 
Stratified by age, the HR for stroke events was 3.32 (95% CI, 1.25-8.80) for 
individuals aged 18-49 years. There was an increased risk of fatal stroke in the age 
groups 18-49 and 50-64 years with a HR of 4.22 (95% CI, 1.08-16.55) and 2.86 
(95% CI, 1.31-6.26), respectively (p trend 0.04). We found no increased risk for 
those 65-79 years (HR 1.00, 95% CI, 0.86-1.18) or ≥80 years (HR 1.31, 95% CI, 
0.79-2.18). There was a pattern of increased risk of fatal stroke with higher TSH 
concentrations. 
 
CONCLUSIONS Although no overall effect of subclinical hypothyroidism on stroke 
could be demonstrated, an increased risk in subjects younger than 65 years and 
those with higher TSH concentrations was observed.   
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INTRODUCTION 
Subclinical hypothyroidism is defined as an elevated thyrotropin (TSH) level above 
the upper limit of the reference range with a free thyroxin (FT4) value that is normal 
1-3
. It has a prevalence varying between 4-14% in adults 
4-6
 with a higher 
prevalence in iodine-sufficient populations 
7
 and older individuals 
5
. Subclinical 
hypothyroidism has been associated with hypercholesterolemia 
6,8,9
, 
atherosclerosis 
10
, and an increased carotid intima-media thickness (IMT ) 
11
. 
Furthermore, the association between subclinical hypothyroidism and risk of 
clinical cardiovascular outcomes such as coronary heart disease 
12
 and heart 
failure 
13
, has been established in specific subgroups with higher TSH levels 
12
. 
Also, higher risks of cardiovascular disease (CVD) in subclinically hypothyroid 
individuals have been found in younger populations but not in the oldest old 
14,15
. 
Although CVD and stroke share risk factors, published data on the association 
between subclinical hypothyroidism and stroke are insufficient and conflicting 
16
. 
Even the largest prospective cohort studies have limited power, with most studies 
suffering from lack of generalizability and inability to conduct subgroup analyses on 
specific age groups or different TSH levels 
17-19
. A recent systematic review and 
meta-analysis of published data showed no association between subclinical 
hypothyroidism and the risk of stroke 
16
. However, meta-analysis of aggregated 
published data does not always allow for examination of specific subgroups that 
may have differential risk. Hence, we aimed to evaluate the association between 
subclinical hypothyroidism and stroke by conducting an individual participant data 
(IPD) analysis, with pre-specified stratified analyses to examine the effects of age, 
sex and degree of TSH elevation on this association. 
 
METHODS 
Data sources and study selection 
We conducted a systematic review and meta-analysis, contacted experts in the 
field and reviewed reference lists to identify eligible studies 
16
. The systematic 
literature search was conducted in Medline (OvidSP), EMBASE, Web-of-science, 
PubMed publisher, Cochrane and Google Scholar from inception to the 18
th
 of 
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November 2013 (Supporting Information). We included publications from 
longitudinal studies that measured at least TSH and (F)T4 at baseline in adults and 
assessed stroke events and/or fatal stroke prospectively. Further details of the 
systematic literature search and meta-analysis have been previously described in 
detail elsewhere 
16
. We identified six studies 
17-22
 that met the inclusion criteria. We 
identified additional studies with unpublished data within the Thyroid Studies 
Collaboration (TSC), a consortium of cohort studies investigating the association 
between thyroid dysfunction and clinical outcomes. Through contact with experts in 
the field, we were able to identify one more unpublished study 
23
. Investigators 
from eligible studies were invited to join the IPD analysis, of which one declined to 
participate 
22
. This study included 549 euthyroid subjects with 23 stroke events and 
31 subclinical hypothyroid subjects with 1 stroke event. 
Data extraction 
We requested individual participant characteristics related to prior cardiovascular 
risk factors and disease, including total cholesterol, systolic blood pressure (both 
as continuous variables), history of diabetes, smoking and previous 
cerebrovascular disease. We also collected available information on medication 
use (thyroid hormone replacement, anti-thyroid, lipid-lowering and anti-
hypertensive therapy), demographic information (age, sex and ethnicity), 
anthropometric measurements (height and weight) and the outcome. Primary 
outcome measures were stroke events (fatal and non-fatal) and fatal stroke. Stroke 
was defined according to World Health Organization (WHO) criteria as a syndrome 
of rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with no 
apparent cause other than of vascular origin, including ischemic or hemorrhagic 
strokes. Some studies 
24,25
 used variations of this definition (Supplemental Table 
1).  
Thyroid function testing 
We used a common definition of subclinical hypothyroidism and euthyroidism in 
order to increase comparability between the different studies and in concordance 
with previous analyses 
12,13,26
, expert reviews 
1,3
 and several large cohorts 
17,25,27
. 
We defined subclinical hypothyroidism as a serum TSH level of 4.5 mIU/L or 
greater to less than 20.0 mIU/L, with a normal (free) T4 concentration. 
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Euthyroidism was defined as TSH level between 0.45 and 4.49 mIU/L. Most 
studies used a third-generation TSH radioimmunoassay, but the Whickham Survey 
used a first-generation assay that reports higher measured TSH values than 
current assays,
28
 for which we adjusted the range to 6.0 – 21.4 mIU/L to define 
subclinical hypothyroidism, as previously described 
12,29
. In addition the Whickham 
Survey was the only study to perform total T4 assays 
29
; the remainder performed 
free T4 (FT4) assays.  
For (F)T4 values, we used site- and method-dependent cutoffs, as these 
measurements are more assay dependent. We excluded participants with TSH 
levels below 0.45 mIU/L or above 19.9 mIU/L and those with abnormal (F)T4 
values (n=3967). When (F)T4 values were missing (n= 10,541), we considered 
participants with a TSH level between 4.5 and 20 mIU/L as having subclinical 
hypothyroidism, due to a low likelihood of overt hypothyroidism with this degree of 
TSH elevation 
30
.  
Statistical analysis 
We performed a Cox proportional hazard model in each cohort separately to 
assess the association between subclinical hypothyroidism and stroke events and 
fatal stroke (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM 
Corp). The Cox-proportional hazard assumption was met by each cohort, as 
assessed by Schoenfeld residual plots. We used a random-effects model 
according to DerSimonian and Laird
31
 to pool estimates of the outcomes. Pooled 
estimates were summarized in forest plots using the metafor package for R (R-
project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, 
Austria, version 3.0.2). Heterogeneity across studies was measured using the I
2 
statistic and tested using the Q-statistic 
32
. 
We adjusted for age and sex in the primary analysis. We also conducted a 
multivariable analysis additionally adjusting for systolic blood pressure, smoking, 
total cholesterol and diabetes. These covariates were available in all cohorts 
except for the Birmingham cohort 
21
. We conducted multiple imputation in cohorts 
when there was ≥ 5% of missing data for the smoking, total cholesterol, systolic 
blood pressure and prevalent diabetes covariates. We considered the age and sex 
adjusted analysis the primary analysis because 1) covariates used in the 
multivariable analyses could also be considered as mediators 2) it includes all 
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studies in contrast to the multivariable analysis that does not include the 
Birmingham cohort.  
In order to identify populations at risk and possible sources of heterogeneity, we 
conducted pre-defined subgroup and sensitivity analyses. We performed stratified 
analyses by age, sex and degree of TSH elevation. Based on expert reviews 
1,3
 
and following our previous approach 
12,13
 we stratified subclinical hypothyroidism 
into the following TSH categories: 4.5-6.9 mIU/L, 7.0-9.9 mIU/L and 10.0-19.9 
mIU/L. If a study did not have an event in the (stratified) study-specific analysis, we 
used Firth's penalized maximum likelihood bias reduction method for the Cox 
model 
33,34
 to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).  
We conducted the following sensitivity analyses: 1) excluding three 
20,23,35
 studies 
that did not have stroke events (non-fatal and fatal) in the subclinical 
hypothyroidism group 2) excluding participants who had thyroid-function altering 
medication at baseline and during follow-up 3) excluding studies that included 
transient ischemic attack (TIA) as a stroke event 4) excluding participants with a 
history of stroke 5) excluding participants with missing (F)T4 levels 6) using only 
unimputed data 7) cohorts with potential co-morbidities and 8) including the 
published risk estimates of the study that declined to participate in the meta-
analysis 
22
. We assessed age- and sex-adjusted funnel plots and conducted Egger 
tests 
36
 to evaluate potential publication bias.  
 
RESULTS 
We found 18 prospective cohort studies that met the criteria. From these we 
included 17 from the United States 
17,19,35
, Europe 
15,20,21,23,24,27,29,37-40
, Australia 
25
, 
Brazil 
41
 and Japan 
18
 that prospectively assessed stroke outcomes and agreed to 
share individual participant data (Table 1, Supplemental Figure 1). 
Subclinical hypothyroidism and stroke: an IPD meta-analysis 
193 
 
T
a
b
le
 1
 B
a
s
e
lin
e
 C
h
a
ra
c
te
ri
s
ti
c
s
 o
f 
In
d
iv
id
u
a
ls
 i
n
 t
h
e
 I
n
c
lu
d
e
d
 S
tu
d
ie
s
 (
n
 =
 4
7
,5
7
3
) 
S
tu
d
y
, 
S
ta
rt
 
y
e
a
r 
D
e
s
c
ri
p
ti
o
n
 o
f 
S
tu
d
y
 S
a
m
p
le
 
N
o
. 
M
e
d
ia
n
 A
g
e
 
(R
a
n
g
e
),
 
y
e
a
rs
a
 
W
o
m
e
n
 
N
o
. 
(%
) 
S
u
b
c
li
n
ic
a
l 
H
y
p
o
th
y
ro
id
is
m
 
N
o
. 
(%
) 
T
h
y
ro
id
 
M
e
d
ic
a
ti
o
n
 
N
o
. 
(%
) 
a
t 
b
a
s
e
li
n
e
b
 
T
h
y
ro
id
 
M
e
d
ic
a
ti
o
n
 
N
o
. 
(%
) 
fo
ll
o
w
 u
p
c
 
M
e
d
ia
n
 
D
u
ra
ti
o
n
 
(I
Q
R
),
 y
e
a
rs
 
4
D
 S
tu
d
y
2
0
, 
1
9
9
8
 
T
ri
a
l 
o
f 
a
to
rv
a
s
ta
ti
n
 i
n
 t
y
p
e
 2
 
d
ia
b
e
te
s
 a
n
d
 h
e
m
o
d
ia
ly
s
is
 
p
a
ti
e
n
ts
, 
G
e
rm
a
n
y
 
8
8
3
 
6
6
 (
3
0
-8
3
) 
4
0
0
 (
4
5
.3
) 
1
0
 (
1
.1
) 
4
4
 (
5
.0
) 
6
2
 (
7
.0
) 
1
.5
 (
0
.2
-3
.6
) 
B
ra
z
ili
a
n
 T
h
y
ro
id
 
S
tu
d
y
4
1
, 
1
9
9
9
 
A
d
u
lt
s
 f
ro
m
 J
a
p
a
n
e
s
e
 d
e
s
c
e
n
t 
liv
in
g
 i
n
 S
ã
o
 P
a
u
lo
, 
B
ra
z
il 
9
9
1
 
5
7
 (
3
0
-9
2
) 
5
2
3
 (
5
2
.8
) 
1
0
1
 (
1
0
.2
) 
0
 
N
A
 
7
.3
 (
7
.0
-7
.5
) 
B
u
s
s
e
lt
o
n
 H
e
a
lt
h
 
S
tu
d
y
2
5
, 
1
9
8
1
 
A
d
u
lt
s
 i
n
 B
u
s
s
e
lt
o
n
, 
W
e
s
te
rn
 
A
u
s
tr
a
lia
 
2
0
0
1
 
5
1
 (
1
8
-9
0
) 
9
8
4
 (
4
9
.2
) 
8
9
 (
4
.4
) 
1
5
 (
0
.7
) 
3
3
 (
1
.6
) 
2
0
 (
1
9
.5
-2
0
.0
) 
B
ir
m
in
g
h
a
m
 
S
tu
d
y
2
1
, 
1
9
8
8
 
C
D
A
's
 a
g
e
d
 ≥
 6
0
 y
 f
ro
m
 p
ri
m
a
ry
 
c
a
re
 p
ra
c
ti
c
e
 i
n
 B
ir
m
in
g
h
a
m
, 
E
n
g
la
n
d
 
1
1
0
7
 
6
9
 (
6
0
-9
4
) 
6
2
8
 (
5
6
.7
) 
9
2
 (
8
.3
) 
0
 
2
9
 (
2
.6
) 
1
0
.2
 (
5
.7
-1
0
.6
) 
C
a
rd
io
v
a
s
c
u
la
r 
H
e
a
lt
h
 S
tu
d
y
1
7
, 
1
9
8
9
  
C
D
A
’s
 w
it
h
 M
e
d
ic
a
re
 e
lig
ib
ili
ty
 i
n
 
4
 U
S
 c
o
m
m
u
n
it
ie
s
 
3
0
1
7
 
7
1
 (
6
4
-1
0
0
) 
1
8
1
2
 (
6
0
.1
) 
4
9
2
 (
1
6
.3
) 
0
 
1
5
3
 (
5
.1
) 
1
3
.9
 (
8
.6
-1
6
.4
) 
E
P
IC
-N
o
rf
o
lk
 
S
tu
d
y
2
7
, 
1
9
9
5
 
A
d
u
lt
s
 l
iv
in
g
 i
n
 N
o
rf
o
lk
, 
E
n
g
la
n
d
 1
2
7
0
9
 
5
8
 (
4
0
-7
8
) 
6
8
7
4
 (
5
4
.1
) 
7
2
3
 (
5
.7
) 
0
 
N
A
 
1
3
.4
 (
1
2
.6
-
1
4
.3
) 
H
e
a
lt
h
, 
A
g
in
g
, 
a
n
d
 B
o
d
y
 
C
o
m
p
o
s
it
io
n
 
S
tu
d
y
1
9
, 
1
9
9
7
 
C
D
A
’s
 w
it
h
 M
e
d
ic
a
re
 e
lig
ib
ili
ty
 i
n
 
2
 U
S
 c
o
m
m
u
n
it
ie
s
 
2
6
7
7
 
7
4
 (
6
9
-8
1
) 
1
3
4
6
 (
5
0
.3
) 
3
3
5
 (
1
2
.5
) 
2
3
2
 (
8
.7
) 
3
3
8
 (
1
2
.6
) 
1
1
.9
 (
7
.5
-1
2
.2
) 
In
C
H
IA
N
T
I 
S
tu
d
y
3
7
, 
1
9
9
8
 
A
d
u
lt
s
 a
g
e
d
 2
0
-1
0
2
 y
e
a
rs
 l
iv
in
g
 
in
 C
h
ia
n
ti
 g
e
o
g
ra
p
h
ic
 a
re
a
, 
It
a
ly
 
1
0
9
9
 
7
1
 (
2
1
-1
0
2
) 
6
1
2
 (
5
5
.7
) 
3
3
 (
3
.0
) 
2
1
 (
1
.9
) 
N
A
 
9
.0
7
 (
8
.1
-9
.2
) 
L
e
id
e
n
 8
5
-p
lu
s
 
S
tu
d
y
1
5
, 
1
9
9
7
 
A
d
u
lt
s
 a
g
e
d
 8
5
 y
e
a
rs
 l
iv
in
g
 i
n
 
L
e
id
e
n
, 
T
h
e
 N
e
th
e
rl
a
n
d
s
 
4
9
3
 
8
5
 (
N
A
) 
3
2
2
 (
6
5
.3
) 
3
5
 (
7
.1
) 
1
4
 (
2
.8
) 
2
0
 (
4
.1
) 
5
.2
 (
2
.5
-8
.6
) 
M
rO
S
 S
tu
d
y
3
5
, 
2
0
0
0
 
C
o
m
m
u
n
it
y
-d
w
e
lli
n
g
 U
.S
. 
m
e
n
 
a
g
e
d
 6
5
 y
e
a
rs
 a
n
d
 o
ld
e
r 
1
5
5
8
 
7
3
 (
6
5
-9
9
) 
0
 
1
4
8
 (
9
.5
) 
1
1
0
 (
7
.1
) 
N
A
 
1
2
.0
 (
8
.2
-1
2
.7
) 
 
Chapter 3.2 
194 
T
a
b
le
 1
 B
a
s
e
lin
e
 C
h
a
ra
c
te
ri
s
ti
c
s
 o
f 
In
d
iv
id
u
a
ls
 i
n
 t
h
e
 I
n
c
lu
d
e
d
 S
tu
d
ie
s
 (
n
 =
 4
7
,5
7
3
) 
(c
o
n
ti
n
u
e
d
) 
S
tu
d
y
, 
S
ta
rt
 y
e
a
r 
D
e
s
c
ri
p
ti
o
n
 o
f 
S
tu
d
y
 S
a
m
p
le
 
N
o
. 
M
e
d
ia
n
 A
g
e
 
(R
a
n
g
e
),
 
y
e
a
rs
a
 
W
o
m
e
n
 N
o
. 
(%
) 
S
u
b
c
li
n
ic
a
l 
H
y
p
o
th
y
ro
id
is
m
 
N
o
. 
(%
) 
T
h
y
ro
id
 
M
e
d
ic
a
ti
o
n
 
N
o
. 
(%
) 
a
t 
b
a
s
e
li
n
e
b
 
T
h
y
ro
id
 
M
e
d
ic
a
ti
o
n
 
N
o
. 
(%
) 
fo
ll
o
w
 u
p
c
 
M
e
d
ia
n
 
D
u
ra
ti
o
n
 
(I
Q
R
),
 y
e
a
rs
 
N
a
g
a
s
a
k
i 
A
d
u
lt
 
H
e
a
lt
h
 S
tu
d
y
1
8
, 
1
9
8
4
 
A
to
m
ic
 b
o
m
b
 s
u
rv
iv
o
rs
 i
n
 
N
a
g
a
s
a
k
i,
 J
a
p
a
n
 
2
7
6
6
 
5
7
 (
3
8
-9
2
) 
1
6
8
8
 (
6
1
.0
) 
4
2
4
 (
1
5
.3
) 
3
9
 (
1
.4
) 
6
 (
0
.2
) 
1
3
.0
 (
1
2
.3
-
1
3
.6
) 
P
is
a
 c
o
h
o
rt
3
9
, 
2
0
0
0
 
P
a
ti
e
n
ts
 a
d
m
it
te
d
 t
o
 c
a
rd
io
lo
g
y
 
d
e
p
a
rt
m
e
n
t 
in
 P
is
a
, 
It
a
ly
d
 
2
9
2
2
 
6
3
 (
1
9
-9
2
) 
9
3
5
 (
3
2
.0
) 
2
2
7
 (
7
.8
) 
1
2
 (
0
.4
) 
0
 
2
.5
 (
1
.6
-3
.7
) 
P
R
E
V
E
N
D
 
S
tu
d
y
2
3
, 
1
9
9
7
 
A
d
u
lt
s
 l
iv
in
g
 i
n
 G
ro
n
in
g
e
n
, 
T
h
e
 
N
e
th
e
rl
a
n
d
s
 
2
5
6
2
 
4
6
 (
2
8
-7
5
) 
1
3
0
6
 (
5
1
) 
5
1
 (
2
.0
) 
2
7
 (
1
.1
) 
3
4
 (
1
.3
) 
1
0
.9
 (
1
0
.6
-
1
1
.1
) 
P
R
O
S
P
E
R
 t
ri
a
l4
0
, 
1
9
9
7
 
T
ri
a
l 
o
n
 t
h
e
 b
e
n
e
fi
ts
 o
f 
p
ra
v
a
s
ta
ti
n
 
v
s
. 
p
la
c
e
b
o
 i
n
 a
d
u
lt
s
  
5
5
2
5
 
7
5
 (
6
9
-8
3
) 
2
8
0
1
 (
5
0
.7
) 
4
4
6
 (
8
.1
) 
2
1
1
 (
3
.8
) 
2
6
4
 (
4
.8
) 
3
.3
 (
3
.0
-3
.5
) 
R
o
tt
e
rd
a
m
 
S
tu
d
y
1
0
, 
3
8
, 
1
9
8
9
 
A
d
u
lt
s
 ≥
5
5
 y
e
a
rs
 l
iv
in
g
 i
n
 
R
o
tt
e
rd
a
m
, 
T
h
e
 N
e
th
e
rl
a
n
d
s
 
1
6
9
7
 
6
8
 (
5
5
-9
3
) 
1
0
3
6
 (
6
1
.0
) 
1
0
4
 (
6
.1
) 
3
0
 (
1
.8
) 
N
A
 
1
6
.8
 (
1
1
.1
-
1
8
.9
) 
S
H
IP
 S
tu
d
y
2
4
, 
1
9
9
7
 
A
d
u
lt
s
 i
n
 W
e
s
t 
P
o
m
e
ra
n
ia
, 
N
o
rt
h
-
E
a
s
t 
o
f 
G
e
rm
a
n
y
 
3
1
1
8
 
4
7
 (
2
0
-8
1
) 
1
5
8
7
 (
5
0
.9
) 
1
3
 (
0
.4
) 
1
5
9
 (
5
.1
) 
2
1
4
 (
6
.9
 
1
1
.3
 (
1
0
.6
-
1
1
.8
) 
W
h
ic
k
h
a
m
 
S
u
rv
e
y
2
9
, 
1
9
7
2
 
A
d
u
lt
s
 l
iv
in
g
 i
n
 &
 n
e
a
r 
N
e
w
c
a
s
tl
e
 
u
p
o
n
 T
y
n
e
, 
E
n
g
la
n
d
 
2
4
4
8
 
4
6
 (
1
8
-9
2
) 
1
3
0
8
 (
5
4
.4
) 
1
2
8
 (
5
.2
) 
9
9
 (
4
.0
) 
 
7
1
 (
2
.9
) 
1
9
 (
1
5
.0
-2
0
.0
) 
O
v
e
ra
ll
 
 
4
7
,5
7
3
 
6
5
 (
1
8
-1
0
2
) 
2
4
,1
6
2
 (
5
0
.8
) 
3
4
5
1
 (
7
.3
) 
1
1
0
3
 (
2
.3
) 
1
2
2
4
 (
2
.6
) 
1
1
.6
 (
5
.0
-1
3
.8
) 
A
b
b
re
v
ia
ti
o
n
s
: 
C
D
A
 =
 c
o
m
m
u
n
it
y
-d
w
e
lli
n
g
 a
d
u
lt
; 
IQ
R
 =
 i
n
te
rq
u
a
rt
ile
 r
a
n
g
e
 (
2
5
th
-7
5
th
 p
e
rc
e
n
ti
le
);
 N
A
 =
 n
o
t 
a
v
a
ila
b
le
. 
 
a
 P
a
rt
ic
ip
a
n
ts
 y
o
u
n
g
e
r 
th
a
n
 1
8
 y
e
a
rs
 o
f 
a
g
e
 w
e
re
 n
o
t 
in
c
lu
d
e
d
 
b
 P
a
rt
ic
ip
a
n
ts
 w
it
h
 m
is
s
in
g
 i
n
fo
rm
a
ti
o
n
 o
n
 t
h
y
ro
id
 m
e
d
ic
a
ti
o
n
 a
t 
b
a
s
e
lin
e
: 
C
H
S
 1
, 
H
A
B
C
 7
, 
W
h
ic
k
h
a
m
 3
, 
R
S
 4
8
2
, 
M
rO
S
 6
4
 
c
 P
a
rt
ic
ip
a
n
ts
 w
it
h
 m
is
s
in
g
 i
n
fo
rm
a
ti
o
n
 o
n
 t
h
y
ro
id
 m
e
d
ic
a
ti
o
n
 a
t 
fo
llo
w
-u
p
: 
B
ir
m
in
g
h
a
m
 1
0
2
6
, 
W
h
ic
k
h
a
m
 1
4
8
9
 
d
 E
x
c
lu
d
e
d
 p
a
ti
e
n
ts
 w
it
h
 a
c
u
te
 c
o
ro
n
a
ry
 s
y
n
d
ro
m
e
 o
r 
s
e
v
e
re
 i
lln
e
s
s
 
 
Subclinical hypothyroidism and stroke: an IPD meta-analysis 
195 
One study 
42
 was excluded from our analyses because no outcome events 
occurred. The included studies provided information on a total of 47,573 
participants with a follow-up from 1972 to 2014, a median follow-up ranging 
between 1.5 and 20 years and a total follow-up of 489,192 person-years. All 
studies, except one 
43,44
, included both female (50.8%) and male participants. The 
prevalence of subclinical hypothyroidism ranged from 0.4 to 16.3%, with an overall 
average of 7.3% (n= 3451) of which 62% were female. All cohorts reported fatal 
stroke and 12 studies also reported stroke events, including fatal and non-fatal 
stroke, contributing to the stroke events analysis among 37,842 participants. 
During follow-up 2547 stroke events occurred and 1014 participants had a fatal 
stroke.  
All studies provided information on the proportion of participants taking thyroid 
medication at baseline, which varied from 0 to 8.7%. All but five studies also 
provided follow-up information on thyroid function-altering medication use, with a 
range between 0 and 12.6%. One study
24
 used questionnaires for the assessment 
of stroke events. Formal adjudication, defined as having clear criteria for the 
outcomes that were reviewed by experts for each potential case, was used for 
stroke events in six studies 
10,15,17,19,22,40
 and for fatal stroke in two additional 
studies 
35,39
. Three studies 
18,35,39
 required multiple imputation due to more than 5% 
missing data for covariates. 
The age- and sex-adjusted pooled HR for participants with subclinical 
hypothyroidism compared to euthyroidism was 1.05 (95% CI, 0.91-1.21) for stroke 
events and 1.07 (95% CI, 0.80-1.42) for fatal stroke (Figure 1). We found no 
heterogeneity for the stroke events analysis (I
2
=0%) and little heterogeneity for fatal 
stroke (I
2
=25%). 
Subsequent subgroup analyses showed an increased risk of stroke events (HR 
3.32, 95% CI, 1.25-8.80) and fatal stroke (HR 4.22, 95% CI, 1.08-16.55) in the 18-
49 year age group with subclinical hypothyroidism compared to euthyroidism, but 
the number of events was small (Table 2, Figure 2). For the 50-64 year age group, 
we found an increased risk of fatal stroke with a HR of 2.86 (95% CI, 1.31-6.26), p 
for trend across age groups = 0.04.  
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Figure 1 The Risk of Stroke Events and Fatal Stroke in Subclinical Hypothyroidism vs 
Euthyroidism
a 
 
a Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares. Sizes of 
data markers are proportional to the inverse of the variance of the hazard ratios.  
b Data for stroke events were available in 12 studies. Three hundred eighty-seven participants were 
excluded from the analysis of stroke event due to missing follow-up data. 
c Data for fatal stroke were available in 17 studies. Three hundred twenty-nine participants were 
excluded from the analysis of fatal stroke, due to missing cause of death.  
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Figure 2 Hazard Ratios (HRs) for Stroke Events and Fatal Stroke for Subclinical 
Hypothyroidism Stratified by Age vs Euthyroidism and According to Elevated Thyroid–
Stimulating Hormone (TSH) Categories
a 
 
a 
Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares. Sizes of 
data markers are proportional to the inverse of the variance of the hazard ratios. Unfilled squares 
indicate the reference categories. For the analysis stratified by age, HRs for stroke events and fatal 
stroke were adjusted for sex and age as a continuous variable to avoid residual confounding within age 
strata. 
b 
Data for stroke events were available in 12 studies. Three hundred eighty-seven participants were 
excluded from the analysis of stroke event due to missing stroke event data.  
c 
Data for fatal stroke were available in 17 studies. Three hundred twenty-nine participants were 
excluded from the analysis of fatal stroke, due to missing cause of death.
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When participants were pooled into two categories, younger and older than 65 
years, in a post-hoc analysis, we found a significantly increased risk of fatal stroke 
with a HR of 2.51 (95% CI, 1.42-4.44) in the younger group, p for interaction = 
0.003 (Table 2). When looking at incidence rate per 100,000 person-years for 
stroke events in the pooled dataset within each age group we find 58 for the18-49 
year age group, 330 for the 50-64 year group, 1127 for the 65-79 group and 2991 
for those 80 years and older. For fatal stroke this was 11, 74, 370 and 1183 per 
100,000 person-years for the respective age groups. 
There was a non-significant pattern of increased risk of fatal stroke with higher TSH 
concentrations. In the age- and sex-adjusted analyses, the HR for fatal stroke was 
1.18 (95% CI, 0.83-1.69) in participants with TSH levels between 4.5 and 6.9 
mIU/L, 1.63 (95% CI, 1.09-2.43) for those with TSH levels between 7.0 and 9.9 
mIU/L, and 1.69 (95% CI, 0.88-3.27) for those with TSH levels between 10.0 and 
19.9 mIU/L, compared to the euthyroid group (p for trend 0.07). There was no 
observed difference by sex (p for interaction > 0.5). 
Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, systolic 
blood pressure and history of diabetes yielded similar results, with the exception of 
fatal stroke analysis in the age group between 50 and 65 years of age, which was 
attenuated after adjustment (Table 2). This was likely due to eliminating 
heterogeneity in this subgroup, with an I
2
 of 29% in the age- and sex-adjusted 
analysis and 0% in the multivariable analysis. 
Sensitivity analyses excluding several studies, excluding thyroid medication users, 
using only non-imputed data, additional adjustments and other sensitivity analyses 
did not meaningfully affect the risk estimates (Supplemental Table 2). We found no 
evidence of publication bias, either with visual assessment of age- and sex-
adjusted funnel plots or with the Egger test for stroke events (p = 0.67) or fatal 
stroke (p = 0.58).  
 
DISCUSSION 
In our IPD analysis of 47,573 participants from 17 prospective cohort studies, no 
overall effect of subclinical hypothyroidism was observed on the risk of stroke 
events or fatal stroke compared to euthyroidism in age- and sex-adjusted analyses. 
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However, younger participants had an increased risk of stroke events and fatal 
stroke in subclinical hypothyroidism compared to euthyroidism. There was an 
increase in fatal stroke in those younger than 65 years and in participants with a 
TSH level of 7.0 to 9.9 mIU/L, but a non-significant p for trend (0.07). This is the 
first IPD analysis to investigate the association between subclinical hypothyroidism 
and stroke. We are also the first to detect differences by age in associations 
between subclinical hypothyroidism and a clinical outcome in an IPD analysis. 
The mechanisms by which subclinical hypothyroidism increases the risk of stroke, 
as found in specific subgroups, could be explained by the increased prevalence of 
cardiovascular risk factors in those with subclinical hypothyroidism. Thyroid 
hormones have direct effects on the cardiovascular system and are known to 
decrease systemic vascular resistance 
45
 and alter systolic and diastolic cardiac 
function 
46
. Thyroid hormone deficiency increases the risk of several cardiovascular 
risk factors including hypertension 
47
, dyslipidemia 
48
 and atherosclerosis
49
. These 
changes have also been observed in subclinical thyroid dysfunction
10,50
. However, 
our multivariable IPD analyses yielded similar results to the age- and sex-adjusted 
analyses. Adjusting for smoking, total cholesterol, systolic blood pressure and 
diabetes only slightly changed the risk estimates in the age-stratified analysis of 
fatal stroke for participants between 50 and 65 years old. The fact that adjustment 
for traditional cardiovascular risk factors did not substantially alter risk estimates 
suggests an independent association of subclinical hypothyroidism on the risk of 
stroke and also indicates that total cholesterol, systolic blood pressure and 
diabetes are not relevant factors mediating the hypothetical pathway between 
subclinical hypothyroidism and stroke. Another explanation might be that this is due 
to some unmeasured confounders or mediators.  
Various abnormalities in the hemostatic system have been reported in overt 
51,52
 
and subclinical hypothyroidism
53-55
. Alterations in coagulability and the fibrinolytic 
system have been linked to a high risk of CVD 
56
. This might also be one of the 
mechanisms that play a role in the increased risk of stroke in subclinical 
hypothyroidism. We were not able to discriminate between haemorragic and 
ischemic stroke in the current study as most cohorts did not collect these data. 
Another pathway linked with both thyroid function and risk of stroke is atrial 
fibrillation 
26
. This however, seems unlikely as atrial fibrillation is linked to overt and 
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subclinical hyperthyroidism and not to hypothyroidism 
26
. The exact mechanistic 
relationship between subclinical hypothyroidism and the risk of stroke still remains 
to be determined. 
In our study, younger individuals with subclinical hypothyroidism had a higher risk 
of stroke events and fatal stroke compared with euthyroid subjects within the same 
age groups. Although a higher risk in those younger than 65 years of age has 
previously been reported in a meta-analysis of published data studying the 
association between subclinical thyroid disease and coronary heart disease
57
, this 
was not confirmed by an IPD analysis investigating the same association
12
. Several 
population based studies and published data meta-analysis found an association 
between subclinical hypothyroidism and various clinical outcomes, including self-
reported health 
58
, ischemic heart disease 
14,18,29,57
 and cognition 
15
 when including 
younger age groups but not in older populations. However, these differences in 
association by age have not been observed in IPD analyses prior to ours.  
In our IPD-analysis, the relationship between subclinical hypothyroidism and the 
risk of stroke seen in younger individuals does not seem to hold in populations of 
65 years and older. This seems counterintuitive as both the prevalence and 
incidence of subclinical hypothyroidism and stroke are higher in elderly than in 
younger populations. An explanation for the absence of the association in elderly 
subjects could be that adverse outcomes of subclinical hypothyroidism (e.g. 
hyperlipidemia) are leveled out in this particular group due to slowing of metabolic 
rate and energy expenditure 
59
, reduced sensitivity to adrenergic stimulation 
60
 or 
other counterbalancing protective factors. Also, differences in stroke etiology in 
younger versus older individuals could explain the difference in risk estimates by 
age group. For example, stroke in younger adults is more often hemorrhagic 
compared to older individuals 
61
. Subclinical and overt hypothyroidism are linked to 
hypocoagulability 
51
 and could through this pathway have a stronger effect on 
younger adults rather than on the elderly. There might also be the possibility of 
competing risk of events in the elderly. However, this rarely leads to meaningful 
changes in relative risk estimates of the hazard ratio 
62
. Another possible 
explanation for the different risks across age groups might be a changed 
hypothalamus-pituitary-thyroid set point in elderly, leading to higher TSH levels 
63,64
. In this case subclinical hypothyroidism, defined with a TSH > 4.5 mIU/L may 
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not reflect thyroidal status as well as in younger individuals 
65-67
 and subclinical 
hypothyroidism and stroke would exist simultaneously rather than have a causal 
relation in those older than 65 years of age. It is debated whether age-specific 
reference ranges are needed to define the normal range and herewith also the 
altered state of thyroid function. Some studies have found relevant reclassification 
of thyroid status by applying age-specific reference ranges of TSH 
68
, while others 
have not 
69
. The question remains whether the definition of the normal range 
should be based on age-specific biochemical cut-offs or rather based on risk of 
clinical adverse events associated with these cut-offs. The findings of our study 
suggest that for older subjects a TSH cut-off higher than 4.5 ImU/L could be 
applied, while this cut-off might be too high for younger individuals. However, 
further studies are needed to determine the risks and benefits of redefining the cut-
offs of thyroid function.  
We found a higher risk of fatal stroke in a subset of subclinically hypothyroid 
individuals with TSH levels between 7.0 and 9.9 mIU/L, when compared to 
individuals with values within the TSH reference range. We were not able to 
demonstrate an association for the subgroup with a TSH level between 10.0 and 
19.9 mIU/L, which is probably due to lack of power, as the point estimate for fatal 
stroke was higher than for TSH levels between 7.0 and 9.9 mIU/ml, suggesting a 
dose-response relationship.  
The strengths of our study is that we were able to perform an IPD analysis 
including over 47,000 participants from 17 cohort studies, based on published and 
unpublished data. We did an extensive literature search and included all available 
published data on the association between subclinical hypothyroidism and the risk 
of stroke and fatal stroke. Furthermore we were able to find additional cohorts with 
unpublished longitudinal data with information on thyroid function and stroke 
outcomes. One of the advantages of performing an IPD analysis is that it enables 
the standardization of the definition of exposures and covariates used for the time-
to-event analyses, allowing a more uniform interpretation. Although we found 
similar overall results in this IPD analysis compared to the previous study-level 
meta-analysis 
16
, we did observe additional important findings in subgroups that 
were not detected by meta-analyzing the aggregate data. This highlights the 
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strength of an IPD analysis, as it provides a better opportunity for subgroup and 
sensitivity analyses. 
Despite the large number of participants, we had limited power mainly for the 
stratified analyses. Power calculations showed that our study had a statistical 
power of 80% to detect a HR of 1.57 for stroke events and a HR of 1.61 for stroke 
mortality. The power was limited especially in the age subgroup analyses under 50 
where the number of events was decreased, reflected in the wide confidence 
intervals. There were also limited numbers of events in those with TSH levels 
between 10.0 and 19.9 mIU/L. Information on thyroid medication use during follow-
up, which could alter risk over time, was not available for some cohorts. We were 
unable to perform analyses stratified by type of stroke (ischemic vs. hemorrhagic) 
due to limited number of events in each stratum or by race due to having few non-
white participants. Furthermore, thyroid function was determined only at baseline in 
most cohorts and therefore it was not possible to take the evolution of thyroid 
dysfunction over time into account. As a number of participants with mildly elevated 
TSH levels will normalize in the course of time, a second measurement of thyroid 
function would have enabled us to specifically investigate participants with 
persistent subclinical hypothyroidism, where perhaps the effects are more 
pronounced. 
In summary we found no association between subclinical hypothyroidism and 
overall risk of stroke events or fatal stroke. In stratified analyses, younger 
participants, particularly those under the age of 50 years, had increased stroke risk, 
though the number of events was small. Those with TSH of 7.0-9.9 mIU/L also had 
an increased risk of fatal stroke compared to their euthyroid counterparts. Our data 
are reassuring for those over the age of 65 years and those with TSH levels 
between 4.5 and 6.9 mIU/L, who represent the majority of participants with 
subclinical hypothyroidism. Whether treatment of subclinical hypothyroidism will 
result in a decrease of risk of stroke in younger subjects or those with higher TSH 
levels needs to be answered by a sufficiently powered randomized clinical trial. 
 
Online supplemental material 
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-1438  
Chapter 3.2 
204 
CHAPTER REFERENCES 
1. Surks MI, Ortiz E, Daniels GH, et al. 
Subclinical thyroid disease: 
scientific review and guidelines for 
diagnosis and management. JAMA. 
2004;291(2):228-238. 
2. Gharib H, Tuttle RM, Baskin HJ, 
Fish LH, Singer PA, McDermott MT. 
Subclinical thyroid dysfunction: a 
joint statement on management 
from the American Association of 
Clinical Endocrinologists, the 
American Thyroid Association, and 
the Endocrine Society. Journal of 
Clinical Endocrinology & 
Metabolism. 2005;90(1):581-585; 
discussion 586-587. 
3. Helfand M, Force USPST. 
Screening for subclinical thyroid 
dysfunction in nonpregnant adults: 
a summary of the evidence for the 
U.S. Preventive Services Task 
Force. Annals of Internal Medicine. 
2004;140(2):128-141. 
4. Aghini-Lombardi F, Antonangeli L, 
Martino E, et al. The spectrum of 
thyroid disorders in an iodine-
deficient community: the 
Pescopagano survey. Journal of 
Clinical Endocrinology & 
Metabolism. 1999;84(2):561-566. 
5. Aoki Y, Belin RM, Clickner R, 
Jeffries R, Phillips L, Mahaffey KR. 
Serum TSH and total T4 in the 
United States population and their 
association with participant 
characteristics: National Health and 
Nutrition Examination Survey 
(NHANES 1999-2002). Thyroid. 
2007;17(12):1211-1223. 
6. Canaris GJ, Manowitz NR, Mayor 
G, Ridgway EC. The Colorado 
thyroid disease prevalence study. 
Archives of Internal Medicine. 
2000;160(4):526-534. 
7. Teng W, Shan Z, Teng X, et al. 
Effect of iodine intake on thyroid 
diseases in China. New England 
Journal of Medicine. 
2006;354(26):2783-2793. 
8. Bauer DC, Ettinger B, Browner WS. 
Thyroid functions and serum lipids 
in older women: a population-based 
study. American Journal of 
Medicine. 1998;104(6):546-551. 
9. Biondi B. Cardiovascular effects of 
mild hypothyroidism. Thyroid. 
2007;17(7):625-630. 
10. Hak AE, Pols HA, Visser TJ, 
Drexhage HA, Hofman A, Witteman 
JC. Subclinical hypothyroidism is an 
independent risk factor for 
atherosclerosis and myocardial 
infarction in elderly women: the 
Rotterdam Study. Annals of Internal 
Medicine. 2000;132(4):270-278. 
11. Gao N, Zhang W, Zhang YZ, Yang 
Q, Chen SH. Carotid intima-media 
thickness in patients with subclinical 
hypothyroidism: a meta-analysis. 
Atherosclerosis. 2013;227(1):18-25. 
12. Rodondi N, den Elzen WP, Bauer 
DC, et al. Subclinical 
hypothyroidism and the risk of 
coronary heart disease and 
mortality. JAMA. 
2010;304(12):1365-1374. 
13. Gencer B, Collet TH, Virgini V, et al. 
Subclinical thyroid dysfunction and 
the risk of heart failure events: an 
individual participant data analysis 
from 6 prospective cohorts. 
Circulation. 2012;126(9):1040-
1049. 
14. Razvi S, Shakoor A, Vanderpump 
M, Weaver JU, Pearce SH. The 
influence of age on the relationship 
between subclinical hypothyroidism 
and ischemic heart disease: a 
metaanalysis. Journal of Clinical 
Endocrinology & Metabolism. 
2008;93(8):2998-3007. 
15. Gussekloo J, van Exel E, de Craen 
AJ, Meinders AE, Frolich M, 
Westendorp RG. Thyroid status, 
disability and cognitive function, 
and survival in old age. JAMA. 
2004;292(21):2591-2599. 
16. Chaker L, Baumgartner C, Ikram 
MA, et al. Subclinical Thyroid 
Dysfunction and the Risk of Stroke: 
a Systematic Review and Meta-
Analysis European Journal of 
Epidemiology. 2014. 
Subclinical hypothyroidism and stroke: an IPD meta-analysis 
205 
17. Cappola AR, Fried LP, Arnold AM, 
et al. Thyroid status, cardiovascular 
risk, and mortality in older adults. 
Jama. 2006;295(9):1033-1041. 
18. Imaizumi M, Akahoshi M, Ichimaru 
S, et al. Risk for ischemic heart 
disease and all-cause mortality in 
subclinical hypothyroidism. J Clin 
Endocrinol Metab. 
2004;89(7):3365-3370. 
19. Rodondi N, Newman AB, Vittinghoff 
E, et al. Subclinical hypothyroidism 
and the risk of heart failure, other 
cardiovascular events, and death. 
Archives of Internal Medicine. 
2005;165(21):2460-2466. 
20. Drechsler C SA, Gutjahr-Lengsfeld 
L, Kroiss M, Carrero JJ, Krane V, 
Allolio B, Wanner C, Fassnacht M. 
Thyroid Function, Cardiovascular 
Events, and Mortality in Diabetic 
Hemodialysis Patients. Am J 
Kidney Dis. 2013. 
21. Parle JV, Maisonneuve P, 
Sheppard MC, Boyle P, Franklyn 
JA. Prediction of all-cause and 
cardiovascular mortality in elderly 
people from one low serum 
thyrotropin result: a 10-year cohort 
study. Lancet (London, England). 
2001;358(9285):861-865. 
22. Schultz M, Kistorp C, Raymond I, et 
al. Cardiovascular events in thyroid 
disease: a population based, 
prospective study. Hormone & 
Metabolic Research. 
2011;43(9):653-659. 
23. Hillege HL, Janssen WM, Bak AA, 
et al. Microalbuminuria is common, 
also in a nondiabetic, 
nonhypertensive population, and an 
independent indicator of 
cardiovascular risk factors and 
cardiovascular morbidity. Journal of 
Internal Medicine. 2001;249(6):519-
526. 
24. Volzke H, Alte D, Schmidt CO, et al. 
Cohort profile: the study of health in 
Pomerania. International Journal of 
Epidemiology. 2011;40(2):294-307. 
25. Walsh JP, Bremner AP, Bulsara 
MK, et al. Subclinical thyroid 
dysfunction as a risk factor for 
cardiovascular disease. Archives of 
Internal Medicine. 
2005;165(21):2467-2472. 
26. Collet TH, Gussekloo J, Bauer DC, 
et al. Subclinical hyperthyroidism 
and the risk of coronary heart 
disease and mortality. Archives of 
internal medicine. 
2012;172(10):799-809. 
27. Boekholdt SM, Titan SM, Wiersinga 
WM, et al. Initial thyroid status and 
cardiovascular risk factors: the 
EPIC-Norfolk prospective 
population study. Clin Endocrinol 
(Oxf). 2010;72(3):404-410. 
28. Nicoloff JT, Spencer CA. Clinical 
review 12: The use and misuse of 
the sensitive thyrotropin assays. 
Journal of Clinical Endocrinology & 
Metabolism. 1990;71(3):553-558. 
29. Razvi S, Weaver JU, Vanderpump 
MP, Pearce SH. The incidence of 
ischemic heart disease and 
mortality in people with subclinical 
hypothyroidism: reanalysis of the 
Whickham Survey cohort. Journal 
of Clinical Endocrinology & 
Metabolism. 2010;95(4):1734-1740. 
30. Hollowell JG, Staehling NW, 
Flanders WD, et al. Serum TSH, 
T(4), and thyroid antibodies in the 
United States population (1988 to 
1994): National Health and Nutrition 
Examination Survey (NHANES III). 
Journal of Clinical Endocrinology & 
Metabolism. 2002;87(2):489-499. 
31. DerSimonian R, Laird N. Meta-
analysis in clinical trials. Controlled 
Clinical Trials. 1986;7(3):177-188. 
32. Higgins JP, Thompson SG. 
Quantifying heterogeneity in a 
meta-analysis. Statistics in 
Medicine. 2002;21(11):1539-1558. 
33. Firth D. Bias Reduction of 
Maximum Likelihood Estimates. 
Biometrika. 1993;80:27-38. 
34. Heinze G, Schemper M. A solution 
to the problem of monotone 
likelihood in Cox regression. 
Biometrics. 2001;57(1):114-119. 
35. Waring AC, Harrison S, Samuels 
MH, et al. Thyroid function and 
mortality in older men: a 
prospective study. J Clin Endocrinol 
Metab. 2012;97(3):862-870. 
Chapter 3.2 
206 
36. Egger M, Davey Smith G, 
Schneider M, Minder C. Bias in 
meta-analysis detected by a simple, 
graphical test. BMJ. 
1997;315(7109):629-634. 
37. Ferrucci L, Bandinelli S, Benvenuti 
E, et al. Subsystems contributing to 
the decline in ability to walk: 
bridging the gap between 
epidemiology and geriatric practice 
in the InCHIANTI study. Journal of 
the American Geriatrics Society. 
2000;48(12):1618-1625. 
38. Hofman A, Darwish Murad S, van 
Duijn CM, et al. The Rotterdam 
Study: 2014 objectives and design 
update. European Journal of 
Epidemiology. 2013;28(11):889-
926. 
39. Iervasi G, Molinaro S, Landi P, et 
al. Association between increased 
mortality and mild thyroid 
dysfunction in cardiac patients. 
Archives of Internal Medicine. 
2007;167(14):1526-1532. 
40. Nanchen D, Gussekloo J, 
Westendorp RG, et al. Subclinical 
thyroid dysfunction and the risk of 
heart failure in older persons at high 
cardiovascular risk. Journal of 
Clinical Endocrinology & 
Metabolism. 2012;97(3):852-861. 
41. Sgarbi JA, Matsumura LK, 
Kasamatsu TS, Ferreira SR, Maciel 
RM. Subclinical thyroid 
dysfunctions are independent risk 
factors for mortality in a 7.5-year 
follow-up: the Japanese-Brazilian 
thyroid study. European Journal of 
Endocrinology. 2010;162(3):569-
577. 
42. Iacoviello M, Guida P, 
Guastamacchia E, et al. Prognostic 
role of sub-clinical hypothyroidism 
in chronic heart failure outpatients. 
Current Pharmaceutical Design. 
2008;14(26):2686-2692. 
43. Blank JB, Cawthon PM, Carrion-
Petersen ML, et al. Overview of 
recruitment for the osteoporotic 
fractures in men study (MrOS). 
Contemporary Clinical Trials. 
2005;26(5):557-568. 
44. Orwoll E, Blank JB, Barrett-Connor 
E, et al. Design and baseline 
characteristics of the osteoporotic 
fractures in men (MrOS) study--a 
large observational study of the 
determinants of fracture in older 
men. Contemporary Clinical Trials. 
2005;26(5):569-585. 
45. Klein I, Ojamaa K. Thyroid 
hormone: targeting the vascular 
smooth muscle cell. Circulation 
Research. 2001;88(3):260-261. 
46. Klein I, Ojamaa K. Thyroid hormone 
and the cardiovascular system. 
New England Journal of Medicine. 
2001;344(7):501-509. 
47. Nagasaki T, Inaba M, Kumeda Y, et 
al. Increased pulse wave velocity in 
subclinical hypothyroidism. Journal 
of Clinical Endocrinology & 
Metabolism. 2006;91(1):154-158. 
48. Duntas LH. Thyroid disease and 
lipids. Thyroid. 2002;12(4):287-293. 
49. Cappola AR, Ladenson PW. 
Hypothyroidism and 
atherosclerosis. J Clin Endocrinol 
Metab. 2003;88(6):2438-2444. 
50. Biondi B, Cooper DS. The clinical 
significance of subclinical thyroid 
dysfunction. Endocrine Reviews. 
2008;29(1):76-131. 
51. Erem C. Coagulation and 
fibrinolysis in thyroid dysfunction. 
Endocrine. 2009;36(1):110-118. 
52. Erem C, Kavgaci H, Ersoz HO, et 
al. Blood coagulation and fibrinolytic 
activity in hypothyroidism. 
International Journal of Clinical 
Practice. 2003;57(2):78-81. 
53. Guldiken S, Demir M, Turgut B, 
Altun BU, Arikan E, Kara M. Global 
fibrinolytic capacity in patients with 
subclinical hypothyroidism. 
Endocrine Journal. 2005;52(3):363-
367. 
54. Jorde R, Figenschau Y, Hansen JB. 
Haemostatic function in subjects 
with mild subclinical 
hypothyroidism. The Tromso study. 
Thrombosis & Haemostasis. 
2006;95(4):750-751. 
55. Canturk Z, Cetinarslan B, Tarkun I, 
Canturk NZ, Ozden M, Duman C. 
Hemostatic system as a risk factor 
Subclinical hypothyroidism and stroke: an IPD meta-analysis 
207 
for cardiovascular disease in 
women with subclinical 
hypothyroidism. Thyroid. 
2003;13(10):971-977. 
56. Wiman B, Andersson T, Hallqvist J, 
Reuterwall C, Ahlbom A, deFaire U. 
Plasma levels of tissue 
plasminogen activator/plasminogen 
activator inhibitor-1 complex and 
von Willebrand factor are significant 
risk markers for recurrent 
myocardial infarction in the 
Stockholm Heart Epidemiology 
Program (SHEEP) study. 
Arteriosclerosis, Thrombosis & 
Vascular Biology. 2000;20(8):2019-
2023. 
57. Ochs N, Auer R, Bauer DC, et al. 
Meta-analysis: subclinical thyroid 
dysfunction and the risk for 
coronary heart disease and 
mortality. Ann Intern Med. 
2008;148(11):832-845. 
58. Razvi S, Ingoe LE, McMillan CV, 
Weaver JU. Health status in 
patients with sub-clinical 
hypothyroidism. European Journal 
of Endocrinology. 2005;152(5):713-
717. 
59. Kim B. Thyroid hormone as a 
determinant of energy expenditure 
and the basal metabolic rate. 
Thyroid. 2008;18(2):141-144. 
60. Silva JE, Bianco SD. Thyroid-
adrenergic interactions: 
physiological and clinical 
implications. Thyroid. 
2008;18(2):157-165. 
61. Singhal AB, Biller J, Elkind MS, et 
al. Recognition and management of 
stroke in young adults and 
adolescents. Neurology. 
2013;81(12):1089-1097. 
62. Putter H, Fiocco M, Geskus RB. 
Tutorial in biostatistics: Competing 
risks and multi-state models. 
Statistics in Medicine. 
2007;26(11):2389-2430. 
63. Surks MI, Hollowell JG. Age-
specific distribution of serum 
thyrotropin and antithyroid 
antibodies in the US population: 
implications for the prevalence of 
subclinical hypothyroidism. Journal 
of Clinical Endocrinology & 
Metabolism. 2007;92(12):4575-
4582. 
64. Pearce SHB, G.; Duntas, L. H.; 
Monzani, F.; Peeters, R. P.; Razvi, 
S.; Wemeau, J. L. 2013 ETA 
Guideline: Management of 
Subclinical Hypothyroidism. Eur 
Thyroid J. 2013;2(4):215-228. 
65. Lewis GF, Alessi CA, Imperial JG, 
Refetoff S. Low serum free 
thyroxine index in ambulating 
elderly is due to a resetting of the 
threshold of thyrotropin feedback 
suppression. Journal of Clinical 
Endocrinology & Metabolism. 
1991;73(4):843-849. 
66. Bremner AP, Feddema P, Leedman 
PJ, et al. Age-related changes in 
thyroid function: a longitudinal study 
of a community-based cohort. 
Journal of Clinical Endocrinology & 
Metabolism. 2012;97(5):1554-1562. 
67. Waring AC, Arnold AM, Newman 
AB, Buzkova P, Hirsch C, Cappola 
AR. Longitudinal changes in thyroid 
function in the oldest old and 
survival: the cardiovascular health 
study all-stars study. J Clin 
Endocrinol Metab. 
2012;97(11):3944-3950. 
68. Vadiveloo T, Donnan PT, Murphy 
MJ, Leese GP. Age- and gender-
specific TSH reference intervals in 
people with no obvious thyroid 
disease in Tayside, Scotland: the 
Thyroid Epidemiology, Audit, and 
Research Study (TEARS). Journal 
of Clinical Endocrinology & 
Metabolism. 2013;98(3):1147-1153. 
69. Kahapola-Arachchige KM, Hadlow 
N, Wardrop R, Lim EM, Walsh JP. 
Age-specific TSH reference ranges 
have minimal impact on the 
diagnosis of thyroid dysfunction. 
Clinical Endocrinology. 
2012;77(5):773-779. 
 
  
  
  
 
 
 
CHAPTER 3.3   
VARIATIONS WITHIN THYROID REFERENCE RANGE AND 
THE RISK OF STROKE EVENTS AND FATAL STROKE: A 
META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA 
 
Chaker L, Baumgartner C, den Elzen WP, Collet TH, Ikram MA, Blum 
MR, Dehghan A, Drechsler C, Luben RN, Portegies ML, Iervasi G, 
Medici M, Stott DJ, Dullaart RP, Ford I, Bremner A, Newman AB, 
Wanner C, Sgarbi JA, Dörr M, Longstreth WT Jr, Psaty BM, Ferrucci 
L, Maciel RM, Westendorp RG, Jukema JW, Ceresini G, Imaizumi M, 
Hofman A, Bakker SJ, Franklyn JA, Khaw KT, Bauer DC, Walsh JP, 
Razvi S, Gussekloo J, Völzke H, Franco OH, Cappola AR, Rodondi 
N, Peeters RP; for the Thyroid Studies Collaboration 
J Clin Endocrinol Metab. 2016 
  
Chapter 3.3 
210 
ABSTRACT  
BACKGROUND The currently applied reference ranges for thyroid function are 
under debate. Despite evidence that thyroid function within the reference range is 
related with several cardiovascular disorders, its association with the risk of stroke 
has not been evaluated previously. 
 
METHODS We identified studies through systematic literature search and the 
Thyroid Studies Collaboration, a collaboration of prospective cohort studies. 
Studies measuring baseline thyroid-stimulating hormone (TSH), free thyroxine 
(FT4) and stroke outcomes were included and we collected Individual Participant 
Data (IPD) from each study, including thyroid function measurements and incident 
all stroke (combined fatal and non-fatal) and fatal stroke. The applied reference 
range for TSH levels was between 0.45-4.49 mIU/L.  
 
RESULTS We collected IPD on 43,598 adults with TSH within the reference range 
from 17 cohorts, with median follow-up of 11.6 years (interquartile range 5.1-13.9), 
including 449,908 person-years. Age- and sex-adjusted pooled HR for TSH was 
0.78 (95% Confidence Interval [CI], 0.65-0.95, across the reference range of TSH) 
for all stroke and 0.83 (95% CI, 0.62-1.09) for fatal stroke. For the FT4 analyses, 
the HR was 1.08 (95% CI, 0.99-1.15, per SD increase) for all stroke and 1.10 (95% 
CI, 1.04-1.19) for fatal stroke. This was independent of cardiovascular risk factors 
including systolic blood pressure, total cholesterol, smoking and prevalent 
diabetes.  
 
CONCLUSIONS Higher levels of TSH within the reference range may decrease 
risk of stroke, highlighting the need for further research focusing on the clinical 
consequences associated with differences within the reference range of thyroid 
function.   
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INTRODUCTION 
Subclinical hypothyroidism is associated with hypertension, hyperlipidemia, 
atherosclerosis and an increased risk of coronary artery disease (CAD) whereas 
subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation 
and CAD.
1-4
 Subclinical thyroid dysfunction is defined by a thyroid-stimulating 
hormone (TSH) outside the reference range with a free thyroxine (FT4) within the 
reference range.  
However, the currently applied reference ranges for thyroid function are under 
debate 
5,6
 as thyroid function within these reference ranges is also associated with 
several adverse health outcomes.
7-9
 A previous systematic review found that lower 
TSH values and higher FT4 values within the reference range are associated with 
reduced bone mineral density, atrial fibrillation and an increased risk of fractures.
8
 
Furthermore, higher levels of TSH and lower levels of FT4 within the reference 
range are associated with cardiovascular events and an unfavorable metabolic 
profile.
8
 On the other hand, a previous individual participant data (IPD) analysis 
provided no evidence for a higher risk of coronary heart disease within the 
reference range as currently defined.
10
 
A considerable amount of data exist on the association of thyroid function within 
the reference range and cardiovascular risk factors such as atrial fibrillation, 
hypercholesterolemia and hypertension.
8
 While these risk factors related to 
differences within the reference range are also associated with cardiovascular 
disease, few data are available on clinical outcomes and no data are available on 
the risk of stroke, the second major vascular cause of morbidity and mortality 
worldwide.
11
 A previous study-level meta-analysis on the association of subclinical 
thyroid dysfunction and stroke risk included only a small number of studies and did 
not include any analyses on TSH within the reference range.
12
 Assessing the 
consequences of differences within the reference range of thyroid function on 
clinical outcomes is important for understanding the definition of the reference 
range and to improve care and preventive measures. Furthermore, it can help 
identify clinical outcomes that need to be addressed in future randomized 
controlled trials assessing the benefits and risks of thyroid treatment in subclinical 
thyroid dysfunction.
13
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Therefore we aimed to investigate the association between TSH and FT4 
differences within the reference range and the risk of stroke (fatal and non-fatal) in 
an IPD analysis. An IPD analysis provides the opportunity to standardize definitions 
of thyroid function and statistical analyses, include unpublished data and pool 
results from several cohorts. Also, an IPD can provide the opportunity to conduct 
subgroup analyses due to the large number of events included.  
 
METHODS 
Data sources and study selection 
Studies were identified through the Thyroid Studies Collaboration (TSC). The TSC 
is a consortium of cohorts with thyroid function measurements at baseline and 
prospective follow-up of cardiovascular outcomes.
1,4,10,14-16
 Its primary purpose is to 
examine the association of subclinical thyroid dysfunction and cardiovascular 
disease. Eligible cohorts were originally identified through systematic literature 
reviews
1
 and this has been described in detail previously.
12
  From the 19 cohorts 
identified by these two literature searches, 17 cohorts had information available on 
baseline thyroid function and follow-up stroke incidence, agreed to participate and 
were therefore eligible for the current study. No additional inclusion criteria were 
applied. None of the cohorts has previously published on the risk of stroke within 
the reference range of thyroid function, and 5 cohorts 
17-21
 previously published on 
the association of subclinical thyroid dysfunction and the risk of stroke (Table 1). 
Investigators from the 17 eligible studies were invited to join the IPD analysis. The 
local Medical Ethics Committees of each included study approved the distinct 
original study protocols, and informed consent was obtained from all study 
participants by the original cohort studies. 
Data extraction 
We requested individual participant characteristics related to prior cardiovascular 
risk factors and disease, including systolic blood pressure, serum total cholesterol, 
history of diabetes, smoking, previous cardiovascular disease and previous stroke. 
We also collected available information on demographic information (age, sex, 
race), anthropometric measurements (height and weight), medication use (thyroid 
hormone replacement, lipid-lowering and anti-hypertensive therapy) and the 
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outcome. Individual participant information from all cohorts were collected and 
analyzed in one center (Rotterdam, The Netherlands). The primary outcome 
measures were all stroke (combined fatal and non-fatal) and fatal stroke. Stroke 
was defined according to World Health Organization (WHO) criteria as a syndrome 
of rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with no 
apparent cause other than of vascular origin, including ischemic or hemorrhagic 
strokes. 
Thyroid function testing definition 
We used a common definition of the reference range of thyroid function (i.e. 
euthyroidism) in order to increase comparability among the different studies and in 
concordance with previous analyses, 
1,4,16
 expert reviews 
22,23
 and several large 
cohorts.
17,24,25
 Euthyroidism was defined as TSH level between 0.45 and 4.49 
mIU/L.
1
 Most studies used a third-generation TSH radioimmunoassay, but the 
Whickham Survey used a first-generation assay that reports higher measured TSH 
values than current assays, 
26
 for which we adjusted the range to 0.5-6.0 mIU/L to 
define euthyroidism, as previously described.
1,15,27
 In addition, the Whickham 
Survey was the only study to perform total T4 assays 
27
; the remainder of the 
cohorts performed FT4 assays.  
For FT4 values, we excluded studies that only measured FT4 in TSH values 
outside of the reference range for these analyses.
17,20,21,28
 In studies that measured 
FT4 independent of TSH values, we used all FT4 levels with individuals with TSH 
in the reference range, not limited by the FT4 reference range.  
Data synthesis and statistical analysis 
We performed a Cox proportional hazards model in each cohort separately to 
assess the association of TSH or FT4 continuously with all stroke and fatal stroke 
(IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). We 
investigated the linearity assumption using cubic restricted splines (rms package, 
R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, 
Austria, version 3.0.2). Due to departure from linearity for the TSH analysis in the 
4D cohort (p for non-linearity = 0.03), TSH was log transformed for all continuous 
analyses (natural logarithm). We found no departure from non-linearity in the 
transformed TSH or any of the FT4 analyses and no threshold effect was therefore 
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detected. The analyses are presented as Hazard Ratios (HR) across the reference 
range of TSH (0.45-4.49 mIU/L). This corresponds to the HR when comparing 
participants with a TSH in the upper limit of the reference range (4.49 mIU/L) to 
participants with a TSH in the lower limit of the reference range (0.45 mIU/L). The 
FT4 analyses were performed in a standardized manner (per SD) as well as per 1 
ng/dL increase, for which the Whickham study 
27
 was excluded. We assessed the 
proportional hazard assumption in each cohort for each outcome, by Schoenfeld 
residual plots and the Schoenfeld test. All studies met the proportional hazard 
assumption except for the Birmingham study and PROSPER trial for the analyses 
with TSH, for which we performed a sensitivity analysis excluding these two 
cohorts. There was no interaction between FT4 and TSH levels for the all stroke 
events or stroke mortality analyses (p=0.099 and p = 0.28 respectively), as 
assessed by introducing an interaction term between FT4 (ng/dL) and TSH values. 
We used a random-effects model according to DerSimonian and Laird 
29
 to pool 
outcomes estimates (two-step approach). Pooled estimates were summarized in 
forest plots using the metafor package for R (R-project, Institute for Statistics and 
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). Heterogeneity 
across studies was measured using the I
2 
statistic and 95% confidence interval 
(95% CI).
30
 
The primary analyses were adjusted for age and sex. We also conducted 
multivariable analyses additionally adjusting for systolic blood pressure, smoking, 
total cholesterol and diabetes. These covariates were available in all cohorts 
except for the Birmingham cohort, where none was available 
20
. We conducted 
multiple imputation of covariates in cohorts when there was ≥ 5% of missing data 
for the smoking, total cholesterol, systolic blood pressure or prevalent diabetes 
covariates, which was the case for one study.
19
 We considered the age and sex 
adjusted analysis the primary analysis because 1) covariates used in the 
multivariable analyses could also be considered as mediators 2) it includes all 
studies, whereas the multivariable analysis does not include the Birmingham 
cohort. 
In order to evaluate the robustness of our findings and identify possible sources of 
heterogeneity and populations at risk, we conducted pre-defined subgroup and 
sensitivity analyses. We performed stratified analyses by age, sex, history of 
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stroke, subtype of stroke (including only classified strokes) and race, in 
concordance with previous reports.
1,4
 If the parameter estimates were infinite due 
to a small number of events in a stratified study-specific analysis, we used Firth's 
penalized maximum likelihood bias reduction method for the Cox proportional 
hazards model 
31,32
 to estimate hazard ratios (HRs) and 95% CIs. 
For the continuous TSH analyses, we conducted the following sensitivity analyses: 
1) excluding participants who had thyroid-hormone replacement at baseline and 
during follow-up 2) excluding studies that included transient ischemic attack as a 
stroke event 3) excluding studies with self-reported stroke data 4) excluding studies 
that did not meet the proportional hazard assumption 5) excluding cohorts with 
potential co-morbidities (e.g. diabetes patients) and 6) excluding studies without 
formal adjudication procedures. We also conducted additional multivariable 
analyses including prevalent atrial fibrillation, prevalent cardiovascular disease, 
body mass index (BMI) or lipid-lowering, and anti-hypertensive therapy at baseline 
to the previous multivariable model. Furthermore, we performed the following 
methodological sensitivity analyses: 1) perform the meta-analysis in a two-step 
approach using the restricted maximum-likelihood estimator also using the metafor 
package and 2) calculate the risk estimates using a one-step frailty Cox 
proportional hazards model (coxme package, R-project, Institute for Statistics and 
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2.) We assessed 
age- and sex-adjusted funnel plots and conducted Egger tests 
33
 to evaluate 
potential publication bias statistically. There was no specific funding for this study. 
 
RESULTS 
We identified 17 cohorts from the United States 
17,21,34
, Europe 
18,20,24,27,28,35-40
, 
Australia 
25
, Brazil 
41
 and Japan 
19
 that assessed stroke outcomes prospectively 
and agreed to share IPD (Table 1). The included studies provided information on a 
total of 43,598 participants with thyroid function within the reference range and a 
follow-up from 1972 to 2014, a median follow-up ranging between 1.5 and 20 years 
and a total follow-up of 450,684 person-years. All studies, except one 
34
, included 
both female (49.6%) and male participants. All cohorts reported fatal stroke and 12 
studies reported both fatal and non-fatal stroke, contributing to the all stroke 
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analyses among 34,853 participants. During follow-up, 2271 participants had a 
stroke, with an incidence rate of 6.3 per 1000 person-years and 907 a fatal stroke 
with 2.0 per 1000 person-years. The FT4 analyses included 24,888 participants for 
all stroke and 32,580 for fatal stroke. Two studies 
25,39
 used variations of the WHO 
criteria to define all stroke and fatal stroke (Supplemental Table 1) and four studies 
included information on type of stroke (hemorrhagic versus ischemic).
17,21,28,40
 One 
study
39
 used questionnaires for the assessment of non-fatal stroke. Formal 
adjudication, defined as having clear criteria for the outcomes that were reviewed 
by experts for each potential case, was used for all stroke in six studies 
17,21,28,36,42,43
 and for fatal stroke in two additional studies.
34,38
 
All but three cohorts had information on participants' race.
18,24,25
 For the additional 
multivariate analyses, information on AF at baseline was available for eight 
studies.
17,18,21,25,35,36,39,40,42
 Data on lipid-lowering and hypertensive medications 
were not available in all but two studies.
19,24
 Data on history of cardiovascular 
disease were not available for two studies.
34,35
 
All studies provided information on the proportion of participants taking thyroid 
hormone medication at baseline. In all but four cohorts, none of the participants 
used thyroid medication at baseline. In the cohorts where thyroid medication was 
used, the proportion varied from 1 to 6%. All but six studies also provided follow-up 
information on thyroid hormone replacement use, with a range between 0 and 3%.  
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The association between TSH and the risk of stroke 
The age- and sex-adjusted pooled HR for all stroke was 0.78 (95% CI, 0.65-0.95, 
across the reference range of TSH mIU/L) and for fatal stroke 0.83 (95% CI, 0.62-
1.09) (Figure 1). This corresponds to a 1.28-fold and 1.20-fold increase in all and 
fatal stroke risk respectively for a participant with a TSH in the lower limit of the 
reference range (0.45 mIU/L) compared to a participant with a TSH in the upper 
limit of the reference range (4.49 mIU/L).We found no heterogeneity for the 
analyses of all stroke or fatal stroke analyses (I
2
=0%). Multivariable analyses, 
adjusting for sex, age, smoking, total cholesterol, systolic blood pressure and 
history of diabetes yielded similar results with a HR of 0.76 (95% CI, 0.63-0.91) for 
all stroke and 0.78 (95 % CI, 0.58-1.07) for fatal stroke (Table 2).  
Subsequent subgroup analyses did not show a differential risk when stratifying by 
sex, age groups, history of stroke or race (Table 2). The information on type of 
stroke was available in a subgroup of 11,192 participants in four studies 
17,21,28,40
. 
Stratifying by type of stroke showed a lower estimate in hemorrhagic fatal stroke 
compared to ischemic stroke (HR 0.37, 95% CI 0.12-1.12 vs HR 0.78, 95% CI 
0.33-1.80), but with an insignificant p for interaction (p= 0.30). Sensitivity analyses 
excluding specific studies or participants using thyroid hormone replacement 
therapy did not meaningfully affect the risk estimates (Supplemental Table 2). 
Additional adjustment for prevalent atrial fibrillation, prevalent cardiovascular 
disease (defined as previous coronary heart disease or stroke), BMI or lipid-
lowering and anti-hypertensive therapy did not attenuate the associations. 
Estimates derived by the methodological sensitivity analyses were similar to the 
results of the two-step random-effects model according to DerSimonian and Laird 
(Supplemental Table 3). We did not find any evidence of publication bias for the 
TSH analyses, either with visual assessment of age- and sex-adjusted funnel plots 
or with the Egger test for all stroke (p = 0.75) or fatal stroke (p = 0.29).  
  
Thyroid reference range and stroke 
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Figure 1 The association between TSH and risk of all stroke and fatal stroke* 
 
 
 
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares across the 
reference range of TSH (0.45 and 4.49 mIU/L). Sizes of data markers are proportional to the inverse of 
the variance of the hazard ratios. Data for all stroke were available in 12 studies. Three hundred ninety- 
three participants were excluded from the analysis of all stroke due to missing follow-up data. Data for 
fatal stroke were available in 17 studies. Two hundred sixty-five participants were excluded from the 
analysis of fatal stroke, due to missing cause of death. Abbreviations: TSH = thyroid-stimulating 
hormone.
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Figure 2 The association between standardized FT4 and risk of all stroke and fatal stroke* 
 
 
 
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares and are per 
one increase of one standard deviation of FT4. Sizes of data markers are proportional to the inverse of 
the variance of the hazard ratios. Data for all stroke were available in 9 studies. Three hundred eighty-
seven participants were excluded from the analysis of all stroke due to missing follow-up data. Data for 
fatal stroke were available in 13 studies. Twenty-seven participants were excluded from the analysis of 
fatal stroke, due to missing cause of death.  Abbreviations: FT4 = free thyroxine 
Chapter 3.3 
224 
 T
a
b
le
 3
  
S
tr
a
ti
fi
e
d
 a
n
a
ly
s
e
s
 f
o
r 
th
e
 a
s
s
o
c
ia
ti
o
n
s
 b
e
tw
e
e
n
 s
ta
n
d
a
rd
iz
e
d
 F
T
4
 a
n
d
 t
h
e
 r
is
k
 o
f 
a
ll 
s
tr
o
k
e
 a
n
d
 f
a
ta
l 
s
tr
o
k
e
* 
 
 
 
A
ll
 S
tr
o
k
e
†
 
 
F
a
ta
l 
S
tr
o
k
e
‡
 
 
 
 
N
o
. 
e
v
e
n
ts
/ 
T
o
ta
l 
 
A
g
e
 &
 S
e
x
 a
d
ju
s
te
d
 
H
R
 (
9
5
%
 C
I)
 
M
u
lt
iv
a
ri
a
b
le
 §
 
H
R
 (
9
5
%
 C
I)
 
I2
 
N
o
. 
e
v
e
n
ts
/ 
T
o
ta
l 
A
g
e
 &
 S
e
x
 a
d
ju
s
te
d
 
H
R
 (
9
5
%
 C
I)
 
M
u
lt
iv
a
ri
a
b
le
 §
 
H
R
 (
9
5
%
 C
I)
 
I2
 
T
o
ta
l 
 
 
1
3
0
7
/2
4
,8
8
8
 
1
.0
8
 (
0
.9
9
, 
1
.1
7
) 
1
.0
6
 (
0
.9
9
, 
1
.1
5
) 
5
5
%
 
5
9
8
/3
2
,5
8
0
 
1
.1
0
 (
1
.0
4
, 
1
,1
9
) 
1
.0
9
 (
1
.0
2
, 
1
.1
8
) 
0
%
 
S
e
x
 I
I 
M
e
n
 
6
3
9
/1
1
,8
4
8
 
1
.0
2
 (
0
.9
4
, 
1
.1
1
) 
1
.0
0
 (
0
.9
2
, 
1
.0
8
) 
0
%
 
2
8
4
/1
6
,6
5
1
 
1
.1
0
 (
0
.9
9
, 
1
.2
4
) 
1
.0
8
 (
0
.9
6
, 
1
.2
1
) 
0
%
 
 
W
o
m
e
n
 
6
6
8
/1
3
,0
4
0
 
1
.1
0
 (
0
.9
9
, 
1
.2
2
) 
1
.1
0
 (
1
.0
1
, 
1
.2
0
) 
5
2
%
 
3
1
4
/1
5
,9
2
9
 
1
.1
2
 (
1
.0
3
, 
1
.2
3
) 
1
.1
2
 (
1
.0
1
, 
1
.2
4
) 
0
%
 
 
p
 f
o
r 
in
te
ra
c
ti
o
n
 
 
0
.2
7
 
0
.1
2
 
 
 
0
.7
9
 
0
.6
5
 
 
A
g
e
¶
 
1
8
 –
 4
9
y
 
5
9
/8
2
8
9
 
0
.8
1
 (
0
.6
1
, 
1
.0
7
) 
0
.7
5
 (
0
.5
5
, 
1
.0
3
) 
0
%
 
1
2
/9
5
0
7
 
1
.5
0
 (
0
.6
2
, 
3
.6
7
) 
0
.9
3
 (
0
.3
2
, 
2
.7
1
) 
3
6
%
 
 
5
0
 –
 6
4
y
 
3
4
2
/9
0
1
9
 
1
.0
3
 (
0
.9
3
, 
1
.2
9
) 
1
.0
3
 (
0
.8
4
, 
1
.2
7
) 
6
6
%
 
9
9
/1
1
,9
2
9
 
1
.0
9
 (
0
.8
8
, 
1
.3
5
) 
1
.0
6
 (
0
.8
4
, 
1
.3
2
) 
0
%
 
 
6
5
 -
7
9
y
 
7
5
9
/6
8
0
3
 
1
.1
2
 (
1
.0
5
, 
1
.1
9
) 
1
.1
0
 (
1
.0
4
, 
1
.1
7
) 
0
%
 
3
7
6
/9
8
9
7
  
1
.1
1
 (
1
.0
1
, 
1
.2
2
) 
1
.0
9
 (
0
.9
9
, 
1
.2
1
) 
0
%
 
 
≥
8
0
 
1
4
7
/7
7
7
 
1
.1
5
 (
0
.9
8
, 
1
.3
5
) 
1
.1
5
 (
0
.9
6
, 
1
.3
8
) 
0
%
 
1
1
1
/1
2
4
7
 
1
.1
2
 (
0
.9
4
, 
1
.3
3
) 
1
.0
9
 (
0
.8
9
, 
1
.3
3
) 
0
%
 
 
p
 f
o
r 
tr
e
n
d
 
 
0
.0
2
4
 
0
.0
1
5
 
 
 
0
.5
4
 
0
.7
6
 
 
S
tr
o
k
e
 h
is
to
ry
**
 
N
o
 
1
0
1
3
/2
2
,4
4
6
 
1
.0
6
 (
0
.9
5
, 
1
.1
8
) 
1
.0
5
 (
0
.9
5
, 
1
.1
5
) 
5
8
%
 
4
7
2
/2
7
,2
5
6
 
1
.1
0
 (
1
.0
2
, 
1
.1
9
) 
1
.0
9
 (
1
.0
0
, 
1
.1
8
) 
0
%
 
 
Y
e
s
 
1
0
4
/4
8
3
 
1
.1
1
 (
0
.9
5
, 
1
.2
9
) 
1
.1
2
 (
0
.9
5
, 
1
.3
2
) 
0
%
 
6
0
/6
6
8
 
1
.0
7
 (
0
.7
8
, 
1
.4
5
) 
1
.1
5
 (
0
.7
7
, 
1
.7
3
) 
2
6
%
 
 
p
 f
o
r 
in
te
ra
c
ti
o
n
 
 
0
.6
4
 
0
.5
1
 
 
 
0
.8
7
 
0
.8
0
 
 
S
tr
o
k
e
 t
y
p
e
‡
‡
 
H
e
m
o
rr
h
a
g
ic
 
1
7
/1
5
7
7
 
1
.3
7
 (
0
.8
2
-2
.2
9
) 
1
.1
5
 (
0
.6
4
-2
.0
7
) 
N
A
 
1
0
/1
5
7
7
 
1
.1
5
 (
0
.6
3
-2
.1
2
) 
1
.0
1
 (
0
.4
9
, 
2
.0
7
) 
N
A
 
 
Is
c
h
e
m
ic
 
1
5
7
/1
5
7
7
 
1
.3
0
 (
1
.1
4
-1
.4
7
) 
1
.2
0
 (
1
.0
6
-1
.3
7
) 
N
A
 
3
9
/1
5
7
7
 
1
.0
0
 (
0
.7
1
-1
.4
1
) 
0
.9
0
 (
0
.6
2
-1
.2
8
) 
N
A
 
 
p
 f
o
r 
in
te
ra
c
ti
o
n
 
 
0
.8
4
 
0
.8
8
 
 
 
0
.7
0
 
0
.7
7
 
 
R
a
c
e
§
§
 
W
h
it
e
 
6
1
7
/1
0
,2
0
8
 
1
.1
2
 (
0
.9
9
, 
1
.2
6
) 
1
.1
1
 (
0
.9
9
 1
.2
3
) 
5
1
%
 
3
1
9
/1
4
,5
2
8
 
1
.1
3
 (
1
.0
3
, 
1
.2
3
) 
1
.1
0
 (
1
.0
0
 1
.2
1
) 
0
%
 
 
A
s
ia
n
 
N
A
 
N
A
 
N
A
 
N
A
 
6
3
/3
2
2
8
 
1
.2
7
 (
0
.7
4
, 
2
.1
8
) 
1
.2
7
 (
0
.7
4
, 
2
.1
8
) 
5
8
%
 
 
B
la
c
k
 
N
A
 
N
A
 
N
A
 
N
A
 
2
/4
8
 
0
.9
4
 (
0
.2
3
, 
3
.8
8
) 
1
.0
0
 (
0
.1
4
, 
7
.0
9
) 
N
A
 
 
 p
 f
o
r 
in
te
ra
c
ti
o
n
 
 
N
A
 
N
A
 
 
 
0
.8
9
 
0
.8
7
 
 
A
b
b
re
v
ia
ti
o
n
s
: 
C
I,
 c
o
n
fi
d
e
n
c
e
 i
n
te
rv
a
l;
 H
R
, 
h
a
z
a
rd
 r
a
ti
o
; 
F
T
4
, 
fr
e
e
 t
h
y
ro
x
in
e
. 
N
A
, 
n
o
t 
a
p
p
lic
a
b
le
. 
H
R
s
 a
re
 p
e
r 
o
n
e
 i
n
c
re
a
s
e
 i
n
 F
T
4
 S
D
. 
*T
h
e
 W
h
ic
k
h
a
m
 
S
u
rv
e
y
 m
e
a
s
u
re
d
 t
o
ta
l 
T
4
. 
†
 D
a
ta
 v
a
ila
b
le
 f
ro
m
 1
2
 s
tu
d
ie
s
, 
3
8
4
 p
a
rt
ic
ip
a
n
ts
 e
xc
lu
d
e
d
 d
u
e
 t
o
 m
is
s
in
g
 s
tr
o
k
e
 e
v
e
n
t 
d
a
ta
. 
‡
2
7
 p
a
rt
ic
ip
a
n
ts
 e
xc
lu
d
e
d
 d
u
e
 t
o
 
m
is
s
in
g
 d
a
ta
 o
n
 d
e
a
th
 c
a
u
s
e
. 
§
 A
d
ju
s
te
d
 f
o
r 
s
e
x
, 
a
g
e
, 
s
y
s
to
lic
 b
lo
o
d
 p
re
s
s
u
re
, 
to
ta
l 
c
h
o
le
s
te
ro
l,
 s
m
o
k
in
g
 a
n
d
 p
re
v
a
le
n
t 
d
ia
b
e
te
s
 a
t 
b
a
s
e
lin
e
. 
II
 N
o
t 
a
d
ju
s
te
d
 
fo
r 
s
e
x
. 
¶
 H
R
s
 a
d
ju
s
te
d
 f
o
r 
s
e
x
 a
n
d
 a
g
e
 a
s
 c
o
n
ti
n
u
o
u
s
 v
a
ri
a
b
le
 t
o
 a
v
o
id
 r
e
s
id
u
a
l 
c
o
n
fo
u
n
d
in
g
. 
**
 I
n
fo
rm
a
ti
o
n
 o
n
 s
tr
o
k
e
 h
is
to
ry
 n
o
t 
a
v
a
ila
b
le
 f
o
r 
P
is
a
 c
o
h
o
rt
, 
B
ir
m
in
g
h
a
m
 S
tu
d
y
 a
n
d
 B
u
s
s
e
lt
o
n
 H
e
a
lt
h
 S
tu
d
y
. 
D
a
ta
 o
n
 s
tr
o
k
e
 h
is
to
ry
 w
e
re
 m
is
s
in
g
 f
o
r 
6
4
 s
u
b
je
c
ts
. 
‡
‡
 I
n
fo
rm
a
ti
o
n
 o
n
 t
y
p
e
 o
f 
s
tr
o
k
e
 a
va
ila
b
le
 f
o
r 
R
o
tt
e
rd
a
m
 S
tu
d
y
. 
§
§
In
fo
rm
a
ti
o
n
 o
n
 r
a
c
e
 n
o
t 
a
v
a
ila
b
le
 f
o
r 
4
D
 s
tu
d
y
, 
B
u
s
s
e
lt
o
n
 H
e
a
lt
h
 S
tu
d
y
 a
n
d
 E
P
IC
-N
o
rf
o
lk
 S
tu
d
y
. 
E
x
c
lu
d
e
d
 9
6
 p
a
rt
ic
ip
a
n
ts
 f
ro
m
 M
rO
s
 
S
tu
d
y
 d
u
e
 t
o
 n
o
 e
v
e
n
ts
 i
n
 s
u
b
g
ro
u
p
. 
 
Thyroid reference range and stroke 
 
225 
The association between FT4 and the risk of stroke 
The age- and sex-adjusted pooled HR for the per SD increase of FT4 and stroke 
analyses were 1.08 (95% CI, 0.99-1.15) for all stroke and 1.10 (95% CI, 1.04-1.19) 
for fatal stroke (Table 3, Figure 2). We found substantial heterogeneity for the 
analyses on all stroke (I
2
=55%) but no heterogeneity for fatal stroke (I
2
=0%,). When 
analyzing the association per 1 ng/dL FT4 increase and risk of stroke, the age- and 
sex-adjusted pooled HRs were 1.40 (95% CI, 0.95-2.05) for all stroke and 1.44 
(95% CI, 1.10-1.89) for fatal stroke (Supplemental Table 4). Multivariable analyses, 
adjusting for sex, age, smoking, total cholesterol, systolic blood pressure and 
history of diabetes did not change risk estimates substantially (Table 3).  
Subsequent subgroup analyses showed a differential risk for the different age 
categories, where the risk estimates went from protective to deleterious with 
increasing age (p for trend 0.024, Table 3). When stratifying by sex, history of 
stroke or race no differential effects were detected. Stratifying for type of stroke 
also did not show differential risk (Table 3), but this was only possible in one study 
that was included in the FT4 analyses. We did not find any evidence of publication 
bias for the FT4 and stroke analyses, either with visual assessment of age- and 
sex-adjusted funnel plots or with the Egger test for all stroke (p = 0.41) or for fatal 
stroke (p = 0.28). 
 
DISCUSSION 
In the current IPD analysis of 43,598 participants from 17 prospective cohort 
studies, higher levels of TSH within the reference range of thyroid function were 
significantly associated with a lower risk of stroke in age- and sex-adjusted and in 
multivariable analyses. The analyses concerning the association between TSH 
levels and fatal stroke were qualitatively similar but did not reach statistical 
significance. The analyses on the association between FT4 and all stroke and fatal 
stroke support the finding of a higher risk of stroke with differences within the 
reference range of thyroid function.  
Thyroid dysfunction is defined by the biochemical reference ranges for TSH and 
FT4. These reference ranges, defining the normal range, depend on the assay 
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used, the distribution of thyroid measurements in the population, or both. A thyroid 
function within the “normal range” would imply that the levels of circulating thyroid 
hormone are not accompanied by symptoms, an increased risk of disease or 
adverse events. In recent years, the applied reference ranges have been debated 
in the context of mainly the latter two: adverse events and diseases. Higher levels 
of TSH within the reference range are associated with an increase in systolic and 
diastolic blood pressure.
44,45
 Moreover, increased TSH levels within the reference 
range are linearly associated with an unfavorable serum lipid profile.
46
 On the other 
hand, lower TSH levels within the reference range are associated with an 
increased risk of heart failure, coronary heart disease and atrial fibrillation in an 
elderly population.
7
 The arbitrary nature of the cut-offs currently used is an 
important factor hampering decision making on screening and treatment of thyroid 
dysfunction.
13
 In the context of defining the reference range of thyroid function, our 
study provides additional evidence that lower levels of TSH and higher levels of 
FT4 within the reference range are associated with a negative clinical outcome, 
namely stroke, a major cause of morbidity and mortality. In contrast to blood 
pressure or cholesterol, reference ranges for thyroid function are currently based 
on distribution in the population rather than risks of major diseases. It is more 
challenging to establish reference ranges for thyroid function based on risk of 
outcomes than for cardiovascular risk factors such as blood pressure and 
cholesterol, where the increase in risk mainly occurs for values higher than the 
upper limit. However, both low and high thyroid function is associated with clinical 
disease, also within the reference range. Furthermore, a previous study from the 
TSC provided no evidence for a higher risk of coronary heart disease within the 
normal reference range as currently defined
10
. Also, thyroid function is not solely 
associated with cardiovascular disease but also a wide variety of clinical outcomes 
including fracture risk and possibly cognitive function decline.
7,14
 Therefore, future 
research should investigate if re-evaluation of the currently used reference ranges 
for thyroid function is meaningful, and if so, to what extent this should be done for 
specific populations or subgroups (e.g. elderly). 
Several pathways could explain the relation between thyroid function and stroke. 
Thyroid hormone has direct effects on the cardiovascular system and is known to 
decrease systemic vascular resistance
47
, increase left ventricular contractile 
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function and alter systolic and diastolic cardiac function.
48
 Differences in thyroid 
hormone function are associated with the risk of several cardiovascular risk factors 
including hypertension, 
49
 dyslipidemia 
50
 and atherosclerosis.
51
 These changes 
have also been reported in subjects with subclinical thyroid dysfunction 
42
 and 
some also with differences of thyroid function within the reference range.
44-46
 The 
fact that adjustment for these cardiovascular risk factors in our multivariable 
analyses did not substantially alter risk estimates, suggests an effect on the risk of 
stroke, which is independent of classical risk factors such as hypertension.  
Another explanation might be that the lack of effect of multivariable adjustment is 
due to residual confounding or unmeasured mediators. For example, in the current 
analysis, additional adjustment for atrial fibrillation, a plausible biological mediator 
for the association between thyroid function and the risk of stroke 
52
, did not alter 
risk estimates substantially. However, detecting an effect may have been 
hampered by the lack of information on prevalent atrial fibrillation in nine studies 
and insufficient incidence information. There was no sufficient information available 
on anti-coagulant medication use of participants, which did not allow for further 
exploration of possible mediating and confounding effects. 
Various abnormalities in the hemostatic system have been reported in overt 
53
 and 
subclinical thyroid dysfunction.
54
 Hypercoagulability is seen in hyperthyroidism 
while hypothyroidism has been associated with mainly hypocoagulability.
55,56
 
Alterations in coagulability and the fibrinolytic system have been linked to a higher 
risk of cardiovascular disease.
57
 Whether hemostasis is also affected within the 
reference range of thyroid function is not known but might be one of the pathways 
that play a role in the increased risk of stroke associated with differences in thyroid 
function within the reference range. Changes in coagulation patterns due to thyroid 
hormone could imply that thyroid function tending towards hyperthyroidism might 
increase the risk of ischemic stroke mainly. We only had a small subgroup of 
studies including information on type of stroke (hemorrhagic vs ischemic), limiting 
our analysis on type of stroke. The exact mechanism explaining the association 
between differences in thyroid function within the reference range and the risk of 
stroke therefore remains to be determined. 
Previous studies have reported that the association of thyroid dysfunction with the 
risk of cardiovascular disease is influenced by age or sex. A study on the 
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association of thyroid disorders and stroke found a decreased risk of ischemic 
stroke in treated male patients with thyroid disorders, but not in females.
58
 A study 
level meta-analysis found that subclinical hypothyroidism was associated with 
increased risk of ischemic heart disease and cardiovascular mortality only in 
younger populations.
59
 In line, a study in participants of 85 years in the general 
population, revealed no adverse effects of abnormally high levels of TSH.
36
 In 
contrast, an IPD meta-analysis of 55 287 participants did not show significant trend 
in risk of CHD across different age groups.
1
 In our study, stratification by age, sex 
and race did not reveal differential risk patterns. It should however be noted that no 
study to date has looked at the association of thyroid function within the reference 
range and stroke by age or sex and this could be one of the reasons for the 
discrepancies found between previous literature and our study. 
The association of TSH with the risk of stroke in participants without a prior history 
of stroke was similar to the overall analyses, while in participants with a prior 
stroke, the association was not present. The total number of participants with a 
history of stroke was small and therefore, the power to detect a possible differential 
risk between participants with and without history of stroke could have been limited. 
The risk of all stroke associated with FT4 levels seemed to increase with older age. 
However, this finding was not replicated in the TSH or fatal stroke analyses. 
Strengths of our study include the ability to perform an IPD analysis including 
43,598 participants from 17 studies, based on published and unpublished data. By 
performing an IPD analysis we were able to standardize the definition of reference 
range thyroid function and covariates within our study for the analyses. There were 
differences between the study populations regarding age and sex distribution, 
amongst others. Nevertheless, there was limited to no heterogeneity of the 
outcome estimates between the studies. This could indicate the robustness of the 
findings.  
Despite the large number of participants, we had limited numbers of events in 
those with a history of stroke and only four studies included data on type of stroke. 
Information needed for certain stratification and sensitivity analyses e.g. by race or 
prevalent atrial fibrillation was not available for some cohorts. Also, there was no 
information available on anti-coagulant use or anticoagulant factor levels, 
hampering analyses concerning possible underlying pathways. Furthermore, TSH 
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and FT4 measurements were performed only at baseline and data on thyroid 
medication use during follow-up were not complete, which could change risk over 
time, in almost all cohorts and therefore it was not possible to take changes of 
thyroid function over time into account. Residual confounding cannot be excluded, 
as is the case in all observational studies. 
Conclusions 
In summary, higher TSH levels within the reference range were associated with a 
lower risk of all stroke. The analyses for fatal stroke and FT4 were qualitatively 
similar. These data provide additional evidence that differences within the 
reference range of thyroid function, as currently defined, are associated with an 
increased risk of a major adverse event. Future studies should investigate if re-
evaluation of the currently used reference ranges for thyroid function, which are 
based on fixed biochemical parameters instead of health and treatment outcomes 
and risk of disease and mortality, should be considered. This is pivotal information 
when designing randomized controlled trials sufficiently equipped to address 
possible risks and benefits of thyroid function treatment. 
 
Online supplemental material 
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ABSTRACT 
BACKGROUND Data are conflicting regarding the association of thyroid function 
with dementia risk and the possible underlying pathophysiological mechanisms. 
We therefore aimed to study the role of thyroid function in dementia, cognitive 
function, and subclinical vascular brain disease using MRI. 
 
METHODS Analyses were performed within the Rotterdam Study (baseline 1997), 
a prospective population-based cohort. We evaluated the association of thyroid-
stimulating hormone (TSH) and free thyroxine (FT4) with incident dementia using 
Cox models adjusted for age, sex, cardiovascular risk factors, and education. 
Absolute risks were calculated accounting for death as a competing risk factor. 
Associations of thyroid function with cognitive test scores and subclinical vascular 
brain disease (white matter lesions, lacunes, and mircobleeds) were assessed 
using linear or logistic regression. Additionally, we stratified by sex and restricted 
analyses to normal thyroid function. 
 
RESULTS We included 9,446 participants with a mean age of 65 years. During 
follow-up (mean 8.0 years), 601 participants had developed dementia. Higher TSH 
was associated with lower dementia risk in both the full and normal ranges of 
thyroid function, Hazard Ratios (HR) 0.90 (95% Confidence Interval [CI], 0.83-0.98) 
and 0.76 (CI, 0.64-0.91), respectively. This association was independent of 
cardiovascular risk factors. Dementia risk was higher in individuals with higher FT4 
(HR, 1.04; CI, 1.01-1.07). Absolute 10-year dementia risk decreased from 15% to 
10% with higher TSH in older women. Higher TSH was associated with better 
global cognitive scores (p = 0.021). Thyroid function was not related to subclinical 
vascular brain disease as indicated by MRI. 
 
CONCLUSIONS High and high-normal thyroid function are associated with 
increased dementia risk. Thyroid function is not related to vascular brain disease 
as assessed by MRI, suggesting a role for thyroid hormone in non-vascular 
pathways leading to dementia. 
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INTRODUCTION 
Dementia is one of the leading causes of morbidity and mortality and its underlying 
etiology is multifactorial
1,2
. Vascular disease and vascular risk factors have been of 
particular interest in recent years as modifiable risk factors for dementia
3
. 
Thyroid hormone plays key roles in most organs, including the brain, with its most 
profound effects occurring during perinatal development. However, it also 
influences neurogenesis during adulthood
4
. Thyroid hormone has well-known 
effects on the cardiovascular system
5
, and both hypothyroidism and 
hyperthyroidism are risk factors linked to cardiovascular disease
5,6
. These 
associations have also been reported for variations within the normal range of 
thyroid function
7
. 
Several studies have investigated the association between thyroid function and 
dementia
8-18
. To date, most studies investigating the association between thyroid 
function and dementia have been cross-sectional
8,9,18
, or have had several other 
limitations, including small sample sizes 
10-14,17
. Most importantly, the risk of 
dementia across the continuous range of thyroid function, including the normal 
range, has not been investigated. Moreover, the relationship between thyroid 
function and MRI markers of vascular brain disease, a plausible pathophysiological 
pathway through which thyroid function may influence dementia 
19-21
, is still 
unknown.  
The main objective of this study was to determine the association between thyroid 
function and dementia risk and to investigate the relationship between thyroid 
function and cognitive function and MRI markers of vascular brain disease.  
 
METHODS 
Study participants 
All analyses were performed on data from the Rotterdam Study (RS), a prospective 
population-based cohort study that investigates the determinants and occurrences 
of cardiovascular, neurological, ophthalmologic, psychiatric, and endocrine 
diseases in the middle-aged and the elderly. The aims and the design of RS have 
been described in detail elsewhere
22
.  
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For the current study, we included participants from the third visit of RSI (n = 4,797) 
and the baseline visits of RSII (n = 3,011) and RSIII (n = 3,932). Baseline TSH or 
FT4 measurements (from 1997) were available in 9,702 of the above participants. 
We excluded 116 participants due to prevalent dementia, 133 due to missing 
information on dementia prevalence, and 7 due to missing follow-up information, 
leaving a total of 9,446 participants. All study participants were followed up from 
the day of the baseline laboratory testing to the date of dementia onset, death, or 
until December 31st, 2013, whichever came first. 
Standard protocol approvals, registrations, and patient consents 
The Medical Ethics Committee of the Erasmus University and the Ministry of 
Health, Welfare, and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)” approved 
the study protocols. All included participants provided written informed consent to 
participate in the study and consented to us obtaining information from their family 
physicians. 
Assessment of thyroid function 
Thyroid function was assessed using measurements of TSH and FT4 (using the 
electrochemiluminescence immunoassay for thyroxine and thyrotropine, “ECLIA”, 
Roche) in serum samples stored at -80°C. We used 0.4-4.0 mIU/L as the reference 
range for normal TSH levels and 11-25 pmol/L (= 0.85-1.95 ng/dL) as the reference 
range for normal FT4 levels, according to national guidelines and our previous 
studies
23,24
. Thyroid peroxidase antibody (TPOAb) levels >35 kU/mL were regarded 
as positive, as recommended by the assay manufacturer 
(electrochemiluminescence immunoassay for thyroid perioxidase antibodies, 
“ECLIA”, Roche). 
Dementia screening  
Participants were screened for dementia at baseline and in follow-up examinations 
using a three-step protocol
25
. Screening was performed using the Mini-Mental 
State Examination (MMSE) and the Geriatric Mental Schedule (GMS) organic level. 
Those with an MMSE score <26 or a GMS >0 subsequently underwent an 
examination and an informant interview using the Cambridge Examination for 
Mental Disorders in the Elderly (CAMDEX). Additionally, the total cohort was 
continuously monitored for dementia through a computerized linkage of medical 
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records from general practitioners and the regional institute for outpatient mental 
healthcare with the study database. Available neuroimaging data were used when 
required for establishing a diagnosis. For all suspected cases of dementia, a 
consensus panel led by a consultant neurologist (PJK) decided on the final 
diagnosis in accordance with standard criteria for dementia (DSM-III-R) and 
Alzheimer’s disease (NINCDS-ADRDA). 
Cognitive function assessment 
Cognitive function was assessed in detail using a test battery comprised of the 
Stroop test (time in seconds taken for completing each of three tasks: word 
reading, color naming, and a reading/color naming interference task), the letter-
digit substitution task (number of correct digits in 1 minute), the verbal fluency test 
(number of animal species within 1 minute), the word learning test (recall and 
recognition of visually-presented words), and the Purdue pegboard test for fine 
motor skills (pairs of pins placed with both hands in 30 seconds)
26
. For each 
participant, z-scores were calculated for each test separately by dividing the 
difference between individual test scores and the mean test score by the standard 
deviation. We calculated a general cognitive factor (g-factor) by performing 
principal component analysis incorporating the letter-digit substitution task, the 
verbal fluency test, the world learning test (average of z-scores of immediate and 
delayed recall), and the inverse of two components of the Stroop test in a total of 
6,685 participants. The median age difference between thyroid function testing and 
cognitive testing was 3.9 years (interquartile range [IQR] 0.00-4.41 years). The g-
factor explains 49.3% of all variance in cognitive tests, which is in accordance with 
previous literature
26
. 
MRI acquisition and processing 
We obtained brain MRI scans using a 1.5-T scanner (GE Healthcare, Milwaukee, 
Wisconsin, USA) in RS from 2005 onwards. Details of the MRI protocol have been 
described extensively before
27
. In short, the protocol included a T1-weighted (T1w) 
sequence, a proton density-weighted (PDw) sequence, a fluid-attenuated-
inversion-recovery (FLAIR) sequence, and a T2*-weighted gradient echo (GRE) 
sequence. No contrast material was administered. We used an automated brain 
tissue classification method based on a k-nearest-neighbor-classifier algorithm with 
an extended white matter lesion segmentation
28,29
 to quantify intracranial volume 
Chapter 3.4 
240 
and white matter lesion volume (in cubic millimeters). We determined the presence 
of lacunar and cortical infarcts on the FLAIR, PDw, and T1w sequences, and the 
presence of cerebral microbleeds on the T2*GRE sequence according to our 
previously described protocol
27,30
. We included a total of 4,178 participants with 
thyroid function and MRI measurements with a median time between thyroid 
function testing and MRI assessment of 0.09 years (IQR 0.04-4.52 years). 
Assessment of other variables 
Blood pressure was measured at the right brachial artery using a random-zero 
sphygmomanometer after 5 minutes of rest with the participants in a sitting 
position. The mean of two consecutive measurements was used. Hypertension 
was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure 
≥90 mmHg, or anti-hypertensive medication use at baseline. Total cholesterol was 
measured in fasting serum using an enzymatic method. Smoking information was 
derived from baseline questionnaires. The patients were categorized as never, 
previous, and current smokers. Body-mass index (BMI) was calculated using 
weight in kilograms divided by height in meters squared.  
History of diabetes was defined by repeated impaired fasting glucose levels of ≥7 
mmol/L, a non-fasting glucose level of ≥7 mmol/L (when fasting samples were 
absent), or the use of anti-glycemic medication at baseline. Educational level was 
assessed during a baseline home interview and the participants were classified into 
7 categories ranging from low levels of education (primary only) through high 
education levels (university). Coronary heart disease at baseline was defined as a 
history of myocardial infarction, percutaneous coronary intervention, or coronary 
artery bypass graft or other cardiac revascularization procedures
31
. Atrial fibrillation 
was assessed using three methods: 1) ECGs at baseline and during follow-up, 
assessed by a cardiologist, 2) medical information obtained from general 
practitioners, after ascertainment of ECG, and 3) national registry of hospital 
discharge diagnosis
32
. Assessment of depressive symptoms was performed using 
the validated Dutch version of the Center for Epidemiological Studies Depression 
(CES-D) score
33
. Stroke was defined according to the World Health Organization 
criteria as a syndrome of rapidly developing clinical signs of focal or global 
disturbance of cerebral function with symptoms lasting 24 hours or longer or 
leading to death, with no apparent cause other than that of vascular origin
34
. 
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Incident stroke cases were reviewed and verified by an experienced vascular 
neurologist (PJK) using hospital letters, and information from practitioners and 
nursing home physicians.  
Statistical analysis 
Detailed descriptions of the statistical analyses, including the models used and the 
procedure of testing assumptions, are shown in Supplemental Methods. We 
evaluated the association between thyroid function and dementia risk using a Cox 
proportional hazards model. For the analyses in the normal range of thyroid 
function, we excluded individuals with abnormal TSH and FT4 levels and those 
using thyroid hormone replacement therapy. We investigated the association 
between TSH or FT4 and dementia continuously, across the reference range, and 
in quartiles within the normal range. The results across the reference range 
correspond to the HRs when comparing the risks of participants with TSH or FT4 
levels in the upper limit of the reference range to those with TSH or FT4 levels in 
the lower limit of the reference range. Pre-defined stratification by gender, age 
categories (cutoff age of 65 years), and type of dementia (Alzheimer’s vs. other) 
was performed.  
We estimated 10-year absolute risk probabilities using the covariates of the primary 
Cox proportional hazards model while taking the competing risk of death into 
account. We performed the following sensitivity analyses: 1) additionally adjusting 
for CES-D scores at baseline, 2) excluding the first 4 years of follow-up, and 3) 
censoring participants at time of stroke incidence.  
We cross-sectionally assessed the association of TSH and FT4 levels with 
cognitive function tests, the g-factor, and white matter lesions using linear 
regression models. The association of thyroid function with lacunar infarcts and 
microbleeds was assessed using logistic regression. We performed multiple 
imputations for missing data of the covariates (<5% for all covariates). The 
proportional hazard and linearity assumptions were met for all analyses. The 
presented HRs and betas are per one unit increase in logTSH (mIU/L) and per one 
unit increase in FT4 (pmol/L). 
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RESULTS 
We included a total of 9,446 participants (mean age of 64.9 years) in this study. 
Baseline characteristics are shown in Table 1. Of the included participants, five 
lacked TSH data, six lacked FT4 data, and 11 lacked TPO antibody 
measurements. For the normal range analyses, we only included participants with 
both TSH and FT4 measurements who were not using thyroid replacement therapy 
(n = 7,966). At a mean follow-up time of 8.0 years (IQR 5.5-10.7), corresponding to 
74,209 person-years, 601 participants developed dementia, of which 487 were of 
Alzheimer’s type. This corresponds to an incidence rate of 8 per 1,000 person-
years.  
Thyroid function and dementia 
Higher levels of TSH were associated with a lower risk of dementia both in the full 
range (Hazard Ratio [HR] 0.90, 95% Confidence Interval [CI], 0.83-0.98) and the 
normal range of thyroid function (HR 0.76, 95% CI 0.64-0.91), in age-, sex- and 
cohort-adjusted models (Table 2).  
 
Table 1 Baseline characteristics of participants in the Rotterdam Study with baseline TSH 
or FT4 measurements and incident dementia data
 
Variable Mean (SD)
 a
 
Number of participants 9,446 
Age, years 64.9 (9.7) 
Female (%) 5,358 (56.7) 
Hypertension (%) 4,935 (52.2) 
Cholesterol, mmol/L 5.7 (1.0) 
Smoking (%)  
current 1,911 (20.2) 
past 4,567 (48.3) 
never 2,968 (31.5) 
BMI, kg/m
2
 27.3 (4.2) 
Diabetes Mellitus (%) 861 (9.1) 
Education, median (range) 3 (1-7) 
Coronary heart disease (%) 669 (7.1) 
Atrial Fibrillation (%) 416 (4.4) 
CES-D score, median (IQR) 5.0 (1.0-12.6) 
TSH mIU/L, median (IQR) 1.91 (1.29 - 2.77) 
FT4 pmol/L 15.7 (2.3) 
TPOAb positive, >35 kU/L (%) 1,244 (13.2) 
Use of thyroid medication (%) 264 (2.8) 
a 
Values are means and standard deviation unless otherwise specified. Abbreviations: CES-D = Center 
for Epidemiologic Studies Depression Scale; BMI = body mass index; TSH = thyroid-stimulating 
hormone, FT4 = free thyroxine; SD = Standard deviation; IQR = inter-quartile range; TPOAb = thyroid 
peroxidase antibodies. 
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Table 2 Association of thyroid function with incident dementia  
Variable 
Cases 
N 
Total 
N 
HR (95% CI) 
model 1
a 
HR (95% CI) 
model 2
b 
HR (95% CI) 
model 3
c 
TSH
d 
601 9,441 0.90 (0.83-0.98) 0.90 (0.84-0.98) 0.90 (0.83-0.97) 
FT4
e 
600 9,440 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07) 
TPOAb 
positivity
f
 600 9,435 0.72 (0.55-0.93) 0.71 (0.55-0.92) 0.70 (0.54-0.92) 
      
Within normal range of TSH and FT4
g
, excluding thyroid medication users 
TSH 496 7,966 0.73 (0.62-0.87) 0.74 (0.62-0.87) 0.73 (0.62-0.87) 
FT4 496 7,966 1.04 (1.00-1.09) 1.04 (1.00-1.09) 1.04 (1.00-1.09) 
TPOAb 
positivity
 
495 7,958 0.71 (0.51-0.99) 0.71 (0.51-0.99) 0.72 (0.51-1.01) 
 
Across the normal range of TSH and FT4
g
, excluding thyroid medication users 
TSH
h 
496 7,966 0.49 (0.33-0.72) 0.49 (0.33-0.73) 0.49 (0.33-0.73) 
FT4
i 
496 7,966 1.85 (1.01-3.43) 1.78 (0.97-3.26) 1.80 (0.99-3.34) 
  
TSH quartiles  
0.41 - 1.28 166 2,000 
1 
(REFERENCE) 1 (REFERENCE) 1 (REFERENCE) 
1.29 - 1.80 113 1,971 0.79 (0.62-1.00) 0.79 (0.62-0.99) 0.78 (0.62-1.00) 
1.81 - 2.48 116 2,004 0.80 (0.63-1.01) 0.79 (0.62-1.00) 0.79 (0.62-1.01) 
2.49 - 3.99 101 1,991 0.65 (0.51-0.84) 0.66 (0.52-0.85) 0.66 (0.52-0.85) 
p for trend 
  
<0.001 <0.001 0.001 
    
 
 
FT4 quartiles  
11.01-14.35 111 1,988 
1 
(REFERENCE) 1 (REFERENCE) 1 (REFERENCE) 
14.36-15.63 113 1,998 1.01 (0.77-1.31) 1.01 (0.78-1.31) 1.04 (0.80-1.35) 
15.64-16.99 141 1,989 1.29 (1.01-1.66) 1.28 (0.99-1.64) 1.28 (1.00-1.65) 
17.00-24.90 131 1,991 1.16 (0.90-1.50) 1.14 (0.88-1.47) 1.15 (0.89-1.48) 
p for trend 
  
0.044 0.062 0.135 
a
Model 1 adjusted for age, sex, and cohort. 
b
Model 2 = model 1 + hypertension, cholesterol, smoking, BMI, 
and diabetes at baseline. 
c 
Model 3 = model 2 + highest attained education, prevalent coronary heart 
disease, and prevalent atrial fibrillation. 
d 
The HRs are per one unit increase in logTSH (mIU/L). Five 
participants had missing TSH data. 
e 
The HRs are per one unit increase in FT4 (pmol/L). Six participants 
had missing FT4 values. 
f 
TPOAb were regarded positive if >35 kU/mL. Eleven participants had missing 
TPOAb values. 
g 
normal range of TSH was 0.4-4.0 mIU/L and the normal range of FT4 was 11-25 pmol/L. 
h
 
This corresponds to the HR when comparing participants with TSH values in the upper limit of the 
reference range (4.0 mIU/L) to participants with TSH values in the lower limit of the reference range (0.40 
mIU/L). 
i
 This corresponds to the HR when comparing participants with FT4 values in the upper limit of the 
reference range (25 pmol/L) to participants with FT4 values in the lower limit of the reference range (11 
pmol/L). 
Abbreviations: FT4 = free thyroxine; TSH = thyroid-stimulating hormone; HR = hazard ratio; CI = 
confidence interval; TPOAb = thyroid peroxidase antibodies.
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Multivariable adjustment did not alter the risk estimates substantially. When 
comparing participants with TSH levels in the upper limit of the reference range 
(4.0 mIU/L) to participants with TSH levels in the lower limit of the reference range 
(0.40 mIU/L), HR was 0.49 (95% CI, 0.33-0.72).  
Dementia risk was significantly higher with higher levels of FT4 (HR 1.04, 95% CI 
1.01-1.07) and was similarly increased within the normal range of thyroid function 
(HR 1.03, 95% CI 0.99-1.08). TPOAb positivity was associated with a reduced risk 
of incident dementia (Table 2), which was attenuated slightly after correcting for 
thyroid function in the normal range.  
Stratified and sensitivity analyses 
Stratification by sex in multivariable TSH analyses suggested a lower risk of 
dementia in women with higher levels of TSH, with a HR of 0.67 (95% CI, 0.54-
0.82). This was not the case for men (HR 0.94, 95% CI 0.69-1.27, Table e-1, p for 
interaction = 0.074). An apparent differential risk by age was detected for 
participants younger than 65 when compared to those older than 65 years of age. 
However, this differential risk was not significant (Table e-1). There were no 
differences in risk estimates when stratifying for Alzheimer’s vs. other types of 
dementia. We calculated absolute 10-year risks taking the competing risk of death 
into account, and plotted these absolute risks of dementia against TSH serum 
values within the normal range for both sexes and age categories separately 
(Figure 1). In women older than 65, the absolute risk of dementia decreased with 
higher levels of TSH from almost 15% to less than 10%. Additionally, adjusting for 
CES-D scores, excluding the first 4 years of follow-up in the analysis, or censoring 
at time of stroke did not alter the risk estimates (Table e-2).  
Cognitive function and MRI 
In the multivariable analyses, higher serum TSH levels were associated with a 
better z-score of global cognition (Beta 0.032 [95% CI 0.005-0.059] for g-factor, 
Table 3). Higher levels of TSH were also associated with better scores on some of 
the cognitive function tests, including the Verbal Fluency and Word Learning Tests 
(Table e-3). There was no association between FT4 levels and any cognitive 
function test, except for the Word Learning Test (Tables 3 and e-3). There was no 
association between TSH or FT4 level and white matter lesions, lacunar infarcts, or 
cerebral microbleeds (Table 4).  
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Figure 1 Absolute 10-year risk of dementia by TSH values within the normal range. 
 
 
Absolute 10-years risks of dementia were calculated taking the competing risk of death into account. 
They are plotted against TSH values within the normal range for both sex and age categories 
separately.
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DISCUSSION 
We report an increased incidence of dementia with high and high-normal thyroid 
function, while low to low-normal thyroid function is protective. This is confirmed by 
FT4 analyses, as higher FT4 levels are associated with a higher risk of incident 
dementia. The absolute 10-year risk of incident dementia decreases up to 5% with 
increasing TSH levels in older women, while this risk was not altered in men within 
the normal range of TSH. In cross-sectional analyses, higher TSH levels are 
associated with better cognitive function, while thyroid function is not associated 
with vascular damage-related brain features on MRI.  
Our study includes detailed descriptions of dementia risk outside and within the 
normal range of thyroid function, as well as the exploration of vascular pathways as 
mediators of the relationship. Two prospective studies
10,35
 have previously 
investigated the association of thyroid function within the normal range and 
dementia risk, and their results conflict with ours. The Framingham Heart Study 
investigated the association between the normal range of thyroid function and 
dementia in 1,864 participants, using only TSH levels and reported no significant 
associations.
10
 In a report from the Cardiovascular Health Study, Cappola et al. find 
that individuals with TSH levels in the fourth quartile had a lower risk of dementia
35
 
than those with TSH levels in the first quartile. Important differences between these 
two studies and ours include the average age of the participants (>70 years vs. 65 
years for our population) and sample size (<3000 vs. >9000 in our study). In 
addition, neither of the above studies investigated associations with FT4 levels, 
evaluated cognitive function, or investigated vascular pathways that might explain 
the relationship. Our larger sample size specifically enabled us to quantify more 
precise relative risks as well as absolute risk estimates, particularly within the 
normal range of TSH levels.  
There have been several possible mechanisms described in the literature to 
explain the relationship between high thyroid function and dementia risk. Thyroid 
hormone has important effects on the cardiovascular system. In fact, higher thyroid 
function is associated with several cardiovascular risk factors, such as atrial 
fibrillation and systolic hypertension. These cardiovascular risk factors may 
mediate the association between thyroid function and the development of dementia 
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through vascular brain damage. However, adjusting analyses for various 
cardiovascular risk factors and assessing stroke as an intermediate for the 
association did not alter risk estimates. Furthermore, thyroid function was not 
associated with vascular damage-related brain features on MRI. The similar risk 
estimates for Alzheimer’s disease and other type of dementia on the one hand and 
the lack of an association between thyroid function and vascular markers on MRI 
on the other may suggest a specificity of the association of thyroid function with 
neurodegenerative dementias. However, less than 20% of dementia cases in our 
population were classified as non-Alzheimer’s (i.e. other type). We were therefore 
not able to investigate this association. Moreover, it is possible that there is a 
certain degree of mixed pathology even among the Alzheimer’s disease cases, 
given that the diagnoses were mostly made based on clinical evidence. 
An alternative explanation of the relationship between high thyroid function and 
dementia risk is that thyroid hormone excess changes gene expression in relevant 
pathways
4,36
. Furthermore, excess thyroid hormone may lead to neurotoxicity due 
to increased oxidative stress and neuronal death
37
.  
Another possible explanation for the association between thyroid function and 
dementia is that participants with pre-clinical dementia may have behavioral 
changes (e.g. malnutrition) leading to changes in thyroid function (i.e. reverse 
causality). In other words, we may not be observing a true effect of thyroid 
hormone on dementia risk, but rather the opposite. However, this is highly unlikely, 
as excluding the first four years of follow-up did not change risk estimates. 
Furthermore, low thyroid function was associated with better cognitive test scores. 
More research is needed to unravel the exact causal pathophysiological link 
between thyroid function and dementia. Defining causal pathophysiological 
mechanisms not only provides more insight into the development of dementia, but 
could also uncover potential future screening or novel treatment options. More 
immediate implications lie in the treatment of (subclinical) thyroid disease. In recent 
years, clinicians have been prone to start treatment of subclinical and mild 
hypothyroidism at lower ranges of TSH. Thus, overtreatment is becoming more 
prevalent
38
. Whether the effects of exogenous thyroid function on the risk of 
dementia are similar to those of endogenous thyroid still needs to be determined, 
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but our results may suggest more prudency in the adjustment of levothyroxine 
treatment in mild hypothyroidism.  
The strengths of our study include the large number of participants and the detailed 
information on the covariates included in the analyses. Furthermore, we were able 
to assess possible intermediate factors, such as stroke and brain features on MRI 
related to vascular damage. The long follow-up allowed for the calculation of 10-
year absolute risk estimates. A limitation of our study is that thyroid function was 
measured only once at baseline, which a limitation for most observational cohort 
studies
10,12
. Compared to other studies investigating incident dementia, our cohort 
has a younger mean age. However, in the subgroup analysis including only 
participants over the of age 65 years, we still find a decreased risk of dementia with 
higher TSH levels. In addition, we were not able to longitudinally investigate the 
association between thyroid function and vascular brain disease on MRI. Finally, 
residual confounding cannot be excluded in an observational study, even with 
adjustments for the large number of potential confounders performed in our 
analyses.  
High and high-normal thyroid function is associated with an increased risk of 
dementia. This association does not seem to be mediated through vascular 
pathways. Further research is needed to clarify the pathways involved in the 
relationship between thyroid function and dementia risk. 
 
Online supplemental material 
http://www.neurology.org/content/87/16/1688.long  
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ABSTRACT 
BACKGROUND Thyroid hormone (TH) is crucial during neurodevelopment but 
high levels of TH have been linked to neurodegenerative disorders. No data on the 
association of thyroid function with brain imaging in the general population are 
available.  
 
METHODS We therefore investigated the association of thyroid-stimulating 
hormone and free thyroxine (FT4) with MRI-derived total intracranial volume, brain 
tissue volumes and diffusion tensor imaging (DTI) measures of white matter 
microstructure in 4,683 dementia- and stroke-free participants (mean age 60.2, 
range 45.6-89.9 years).  
 
RESULTS Higher FT4 levels were associated with larger total intracranial volumes 
(=6.73mL, 95% confidence interval 2.94-9.80). Higher FT4 levels were also 
associated with larger total brain and white matter volumes in younger individuals, 
but with smaller total brain and white matter volume in older individuals (p-
interaction 0.02). There was a similar interaction by age for the association of FT4 
with mean diffusivity on DTI (p-interaction 0.026).  
 
CONCLUSIONS These results are in line with differential effects of TH during 
neurodevelopmental and neurodegenerative processes and can improve 
understanding of the role of thyroid function in neurodegenerative disorders.  
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INTRODUCTION  
Thyroid hormone impacts different essential neuronal processes including 
neurogenesis, myelination, and neural differentiation in childhood and throughout 
adulthood 
1,2
. Already during intrauterine neurodevelopment, thyroid hormone 
impacts on several processes including neuronal cell proliferation, differentiation 
and migration 
1,3
. Suboptimal thyroid hormone availability during early life can have 
profound impact on brain function later in life. This is illustrated by the link between 
congenital hypothyroidism and cretinism, a condition characterized by severely 
impaired physical and mental development. Mild forms of both low and high thyroid 
function during the gestational period have been associated with a lower child IQ 
and differences in brain morphology during later life 
4
.  
However, the effects of thyroid hormone on the brain are age dependent because 
in addition to its effects during development, thyroid hormone is also related to 
neurodegeneration. In older adults, higher thyroid function has been associated 
with a higher risk of neurodegenerative disorders and poorer cognition 
5,6
. A meta-
analysis of cohort studies showed that higher thyroid function is associated with 
higher risk of cognitive impairment 
7
. We previously described an increased risk of 
dementia with high-normal to high thyroid function and a protective effect of low 
and low-normal thyroid function 
8
. This risk did not seem to be explained by 
cardiovascular risk factors or subclinical vascular brain damage. The underlying 
mechanisms explaining the link between thyroid function and dementia are yet 
unclear, but possible and yet unexplored pathways are through subclinical changes 
in microstructural organization or brain tissue atrophy.  
Due to the link with cognitive impairment, we hypothesized that thyroid hormone 
could have adverse effects on processes affecting brain volumes and white matter 
microstructure in older age. We also hypothesized that this effect could be age-
dependent, due to the different effects of thyroid hormone during the 
neurodevelopmental period. Therefore, we investigated the association of thyroid 
function with intracranial brain volume (as a marker of development), total brain, 
white matter and grey matter volumes on MRI (as markers of neurodegeneration). 
Furthermore, we tested whether the association of thyroid function and diffusion 
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tensor imaging (DTI) measures related to white matter microstructural organization 
were different in younger versus older participants. 
 
METHODS 
Setting 
The study was performed in the context of the Rotterdam Study (RS), a 
prospective population-based cohort study that investigates determinants and 
occurrence of cardiovascular, neurological, ophthalmologic, psychiatric, and 
endocrine diseases in the middle-aged and elderly population. The aims and 
design of the Rotterdam Study have been described in detail elsewhere 
9
. We 
included participants from three independent cohorts within the Rotterdam Study. 
The RS Cohort 1 (RSI) includes participants aged 55 years and older and baseline 
data were collected during 1990-1993. RS Cohort II (RSII) includes participants 
aged 55 years and older and baseline data were collected from 2000-2001. For the 
RS Cohort 3 (RSIII), persons included were aged 45 years and over and baseline 
data were collected from 2006 to 2008. Thyroid function assessment was 
determined in a random subset of 9,689 participants in all three cohorts and brain 
MRI was included in the core protocol of the Rotterdam Study since 2005. The 
study protocol was approved by the Medical Ethics Committee of the Erasmus 
University and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study)”. All included participants provided a written informed consent in 
accordance with the Declaration of Helsinki to participate in the study and to obtain 
information from their family physicians. 
Study population 
We included all participants from the Rotterdam Study, cohort I wave 3, cohort II 
wave I and cohort III wave I, with thyroid function measurements, MRI 
measurements and free of dementia at baseline (n=5104). We excluded 248 
participants with prevalent stroke and with MRI-defined cortical infarcts and 173 
participants using thyroid function altering medication (levothyroxine, anti-thyroid 
drugs, amiodarone or corticosteroids). Final study population included 4,683 
participants of which 3,852 also had DTI measurements (Figure 1). 
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Assessment of thyroid function 
Thyroid function was measured through thyroid-stimulating hormone (TSH) and 
free thyroxine (FT4) using the same methods and assay for all cohorts (The 
electrochemiluminescence immunoassay for thyroxine and thyrotropine, “ECLIA”, 
Roche) in serum samples stored at -80°C. We determined the reference values for 
normal range TSH as 0.4-4.0 mIU/L and FT4 as 11-25 pmol/L (= 0.85-1.95 ng/dL) 
according to national guidelines as well as our previous studies 
8,10
. 
MRI acquisition and analysis 
Multi-sequence brain MR Imaging was performed on a 1.5 tesla MRI scanner (GE 
Signa Excite). The imaging protocol and sequence details were described 
extensively elsewhere 
11
. Scans were automatically segmented supra tentorially 
into grey matter, white matter, cerebrospinal fluid (CSF) and background tissue. 
Intracranial volume (ICV) (excluding the cerebellum and surrounding CSF) was 
estimated by summing total grey and white matter and CSF volumes 
12
. Total brain 
volume was estimated by summing total grey and white matter volumes 
12
. A post-
processing white matter lesion classification, based on the FLAIR image and the 
tissue segmentation, was used to obtain white matter lesion volumes (natural-log 
transformed to account for their skewed distribution) 
13
. All segmentations were 
visually inspected and were corrected if needed. Cortical infarcts were visually 
rated on structural sequences, and were classified as cortical infarcts in case of 
involvement of cortical grey matter. In a subset of our study population (N=2,449) 
cerebellar volume was processed automatically using FreeSurfer 4.5. This 
procedure, based on probabilistic information obtained from a manually labeled 
training set, assigns a neuroanatomical label to each voxel in an MRI volume. This 
is explained in more detail elsewhere 
14
. In this subset we computed intracranial 
volume, including cerebellar volume, and total cerebellar volume. 
Diffusion-MRI processing 
For characterization of white matter microstructural organization with DTI, a single 
shot, diffusion-weighted spin echo echo-planar imaging sequence was performed. 
Maximum b-value was 1000 s/mm
2
 in 25 non-collinear directions and three 
volumes were acquired without diffusion weighting (b-value = 0 s/mm
2
). For the 
diffusion acquisition, due to technical issues 1165 participants were scanned with 
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the phase and frequency encoding directions swapped leading to a mild ghost 
artifact 
15
. We corrected for this potential confounder in our analyses. Diffusion data 
were pre-processed using a standardized pipeline (including correction for motion 
and eddy currents) as previously described 
16
. A diffusion tensor model was 
estimated in each voxel, and co-registration between structural imaging and 
diffusion image space was performed 
15
. Through averaging of the diffusion 
measurements inside the normal appearing white matter (voxels with white matter 
lesions were excluded from the analysis) we obtained global mean fractional 
anisotropy (FA), mean diffusivity (MD), radial diffusivity, and axial diffusivity 
15
. The 
median time between thyroid function measurement and MRI scan was 0.21 years 
(interquartile range: 0.06-10.16). 
Assessment of other variables 
Blood pressure was measured at the right brachial artery using a random-zero 
sphygmomanometer after 5 minutes of rest with the participants in sitting position. 
The mean of two consecutive measurements was used. Information regarding the 
use of blood pressure lowering medication for the indication of hypertension was 
derived from structured home interviews and linkage to pharmacy records. Serum 
total and high density lipoprotein (HDL) cholesterol were measured in fasting 
serum by enzymatic method. Smoking information was derived from baseline 
questionnaires and categorized in never, previous and current smokers. Alcohol 
consumption was documented as intake in grams per day. Body-mass index (BMI) 
was calculated as weight kilograms divided by height in meters squared. History of 
diabetes mellitus was defined by a repeated (two measurements within one year) 
impaired fasting glucose ≥ 7 mmol/L or a non-fasting glucose of ≥ 11 mmol/L 
(when fasting samples were absent) or use of anti-glycemic medication at 
baseline.
17
 Educational level was assessed during a baseline home interview and 
people were classified into 7 categories: from low level of education (primary only) 
to high (university). Prevalent dementia and clinical stroke were ascertained as 
previously described.
18,19
 In short, participants were evaluated for dementia using a 
three strep protocol. All participants were screened using the Mini-Mental State 
Examination (MMSE) 
20
 and Geriatric Mental State schedule (GMS) 
21
. Persons 
scoring ≤ 25 on the MMSE or >0 on the GMS underwent an examination and 
informant interview with the Cambridge Examination for Mental Disorders of the 
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Elderly. Persons suspicious of having dementia underwent further 
neuropsychological testing if necessary. Furthermore, in addition to the above 
screening method, persons were continuously monitored for the dementia 
diagnosis through computerized linkage of the study database and medical records 
of the general practitioner’s office and Regional Institute for Outpatient Mental 
Health Care (RIAGG). The accepted DSM-III-R criteria were used for the dementia 
diagnosis
22
. 
Statistical analysis 
We used ordinary least squares linear regression models with restricted cubic 
splines at three knots 
23
, which provided the best fit with the data without 
overfitting, for all analyses, to account for possible non-linear associations. Primary 
analyses for brain volume measurements were adjusted for age, sex, cohort, time 
between laboratory measurement and MRI scan and intracranial volume. We 
included intracranial volume as a covariate in our model to correct for the inter-
individual variability in head size 
24
. In a second model, we additionally adjusted for 
several cardiovascular risk factors including total cholesterol, HDL-cholesterol, 
systolic blood pressure, diastolic blood pressure, smoking, prevalent diabetes 
mellitus, BMI, alcohol use and educational level. For the analyses of intracranial 
volume, we did not adjust for the variable itself. 
Primary analyses for diffusion measurements adjusted for age, sex, cohort, time 
between laboratory measurement and MRI scan, intracranial volume, white matter 
volume and white matter lesion volume. A second model additionally adjusted for 
total cholesterol, HDL-cholesterol, systolic blood pressure, diastolic blood pressure, 
smoking, prevalent diabetes, BMI, alcohol use and educational level. TSH was 
natural log-transformed for all analyses to approximate normality and interaction of 
TSH or FT4 with age (as a continuous measure) or sex was tested for all analyses. 
We conducted sensitivity analyses 1) constricting analyses to the reference range 
of thyroid function (n=4141) and 2) excluding participants with time interval above 1 
year between laboratory measurement and MRI scan (n=2527). In order to quantify 
the effects in different age groups we additionally stratified our main analyses by 
the mean age of our population (~ 60 years of age). Missing covariates (< 5% for 
all covariates but alcohol [6.7%]) were imputed using multiple imputations creating 
5 data sets according to the Markov Chain Monte Carlo method and pooled 
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subsequently (IBM SPSS Statistics for Windows, version 21.0. Armonk, NY). 
Statistical analyses were conducted and plots were produced using R statistical 
software (rms, Himsc, visreg packages, R-project, Institute for Statistics and 
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). 
 
RESULTS 
We included a total of 4683 participants, with an average age of 60.2 years (range 
45.6-89.9) of which 54.9% were female (Table 1). Figure 1 shows the participant 
selection procedure. As the results of the two tested models are comparable we 
present both for illustration, but only report the most adjusted model in the 
manuscript. Linearity assumption was met for all main analyses and indicated in 
tables if otherwise. 
 
Figure 1 Flow chart of participant selection 
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Table 1 Characteristics of the 4,683 study participants
 
Variable Mean (SD)
 a
 
Age, years 60.2 (7.3) 
Female sex n, % 2,571 (54.9) 
TSH, ImU/L median (IQR) 1.97 (1.36 - 2.78) 
FT4, pmol/L 15.5 (2.1) 
Intracranial volume, mL 1140.0 (115.5) 
Grey matter volume, mL 529.4 (53.6) 
White matter volume, mL 409.2 (59.1) 
White matter lesion volume, mL, median, 
IQR 
2.9 (1.7-6.0) 
Mean fractional anisotropy 0.34 (0.02) 
Mean diffusivity, 10
-3
 mm
2
/s 0.74 (0.03) 
BMI, kg/m
2
  27.1 (4.0) 
Total cholesterol, mmol/L 5.70 (1.02) 
HDL-cholesterol, mmol/L 1.42 (0.41) 
Systolic blood pressure, mmHg 134.8 (19.3) 
Diastolic blood pressure, mmHg 79.9 (10.9) 
Prevalent diabetes n, % 399 (8.5) 
Smoking  
      Current n, % 1,029 (22.0) 
      Past n, % 2,211 (47.2) 
      Never n, % 1,443 (30.8) 
Alcohol use, grams per day, median, IQR 15.0 (6.3-21.4) 
Time between thyroid function measurement 
and scan (in years) median, IQR 
0.21 (0.06-10.16) 
a 
Values are means and (standard deviation) unless otherwise specified. 
 There were 13 participants with missing values for BMI, 5 total cholesterol, 17 HDL-cholesterol, 14 
systolic and diastolic, 17 smoking, 18 for prevalent diabetes and 313 for alcohol use.  
Abbreviations: BMI = body-mass index; TSH = thyroid-stimulating hormone, FT4 = free thyroxine; SD = 
Standard deviation; IQR = inter-quartile range 
 
 
Brain tissue volumes and intracranial volume 
Higher FT4 levels were associated with larger intracranial volume with a beta () of 
6.23 mL per one unit increase of FT4 pmol/L (95% Confidence Interval [CI], 2.80, 
9.66, Table 2), and the association was not different according to age (Figure2, 
Supplemental Table 1, Supplemental Table 2). There was no association of TSH 
levels with intracranial volume. Higher FT4 levels were associated with larger brain 
volume overall ( 2.26, CI, 1.10, 3.43, Table 2) and white matter volume in 
particular ( 1.43, CI, 0.25, 2.62, Table 2), but not in elderly (Figure 2, 
Supplemental Table 2). The p for interaction of age with total brain volume was 
0.002 and for age with white matter volume was 0.038 (Supplemental Table 1). 
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The associations of FT4 and TSH with total brain volume were mainly attributable 
to white matter and not gray matter volume (Table 2).  
Higher levels of TSH were associated with smaller brain volumes ( -1.35, CI, -
2.26, -0.45, Table 2). Higher FT4 levels were associated with a larger white matter 
volume ( 1.43, CI, 0.24, 2.62), but not gray matter volume ( 0.78, CI, -0.25, 
1.80). Higher TSH levels were associated with a smaller white matter volume ( - 
1.58, CI,-2.50, -0.67), but not grey matter volume ( 0.19, CI, -0.61, 0.99). 
Constricting analyses to the reference range of thyroid function or excluding 
participants with time interval between laboratory measurement and MRI scan > 1 
year did not change effect estimates (Table 3). There was no significant interaction 
of FT4 or TSH with sex on the association with any of the studied outcomes (p> 
0.10). There was no significant interaction of TSH with age on the association with 
any of the studied outcomes (p> 0.35, Supplemental Table 1).  
Total cerebellar volume  
The additional analysis using a subgroup of 2249 persons with cerebellar volume 
data measured with FreeSurfer, yielded a similar albeit a more pronounced 
association of FT4 with intracranial volume ( 10.13, CI, 3.61, 16.64, Supplemental 
Table 3). FT4 was positively associated with cerebellar volume ( 0.68.13, CI, 
3.61, 16.64, Supplemental table 3). No associations were observed for TSH with 
intracranial volume or cerebellar volume (Supplemental Table 3). 
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Figure 2 Total intracranial and brain volume according to FT4 serum values 
 
 
 
 
Plot A) depicts the association of FT4with intracranial volume and plot B) depicts the association of FT4 
with total brain volume. Plot C) depicts the interaction of FT4 with age continuously for the intracranial 
volume analysis and D) depicts interaction of FT4 with age continuously for the total brain volume 
analysis. All analyses are adjusted for age, sex, cohort and time between laboratory measurements and 
MRI scan, and the analyses with brain volume were additionally adjusted for intracranial volume. 
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White matter microstructural organization 
There was no overall association of TSH or FT4 with diffusion properties of white 
matter, neither FA nor MD (Table 4). However, there was a significant interaction 
with age for the association of FT4 and MD (p for interaction 0.026, Figure 3, 
Supplemental Table 1). In older participants, higher FT4 values were associated 
with a lower FA (albeit not statistically significant interaction, p = 0.052, 
Supplemental Table 1) and higher MD, generally indicating reduced matter 
microstructural integrity (Supplemental Table 4). In contrast, in younger 
participants, higher FT4 levels were associated with a higher FA and lower MD, 
generally indicating increased white matter integrity. The associations for radial and 
axial diffusivity followed the same pattern as mean diffusivity (Figure 3).  
We corrected the p-value (alpha level of 0.05) for multiple comparisons using Šidák 
correction 
25
. The number of independent tests resulted in a threshold for 
significance of p<0.009. All results survive this threshold except for the association 
of FT4 in the full range with white matter volume. 
 
 
Table 4 Association of full range TSH or FT4 with Z-scores of Diffusion Tensor Imaging 
parameters of white matter (n=3,852) 
 FA  (95% CI ) MD  (95% CI )
 
RD  (95% CI ) AD  (95% CI ) 
TSH     
     Model 1 -0.00(-0.03, 0.03) 0.01(-0.01, 0.03) 0.01(-0.01, 0.03) 0.01(-0.01, 0.03) 
     Model 2 -0.00(-0.03, 0.03) 0.01(-0.01, 0.03) 0.01(-0.01, 0.03) 0.01(-0.01, 0.03) 
FT4     
     Model 1 -0.01(-0.05, 0.02) 0.02(-0.01, 0.04) 0.01(-0.01, 0.04) 0.02(-0.01, 0.04) 
     Model 2 -0.01(-0.04, 0.03) 0.01(-0.02, 0.04)  0.01(-0.02, 0.04) 0.01(-0.01, 0.04) 
Model 1: age, sex, cohort, time between laboratory measurement and MRI scan, intracranial volume, 
white matter volume and white matter lesions. Model 2= Model 1 + total cholesterol, HDL-cholesterol, 
systolic blood pressure, diastolic blood pressure, blood pressure lowering medication with indication of 
hypertension, smoking, prevalent diabetes, BMI, alcohol use and educational level. Abbreviations: CI = 
confidence interval; FA = fractional anisotropy; FT4 = free thyroxine; MD = mean diffusivity; RD = radial 
diffusivity; AD = axial diffusivityTSH = thyroid stimulating hormone 
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Figure 3 DTI measurements according to FT4 serum values 
 
 
 
 
Plot depicting the interaction of FT4 with age for z-scores of A) fractional anisotropy, B) mean diffusivity, 
C) radial diffusivity and D) axial diffusivity . All analyses are adjusted for age, sex, cohort, time between 
laboratory measurements and MRI scan, intracranial volume, white matter and white matter lesion 
volume.  
 
DISCUSSION 
We report an association of higher FT4 with larger intracranial volume, 
independent of age. Higher FT4 levels are also associated with a larger total brain 
volume, mainly attributable to white matter volume. However this association was 
age-dependent. In older participants (over ~70 years old) higher FT4 levels were 
associated with a smaller total brain volume, primarily white matter. We also found 
a differential effect of age on the association of FT4 with DTI measures that can be 
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linked to white matter integrity. In older participants, higher FT4 were associated 
with DTI measures reflecting poorer white matter integrity. In younger participants 
(especially those <50 years), higher FT4 levels were associated with DTI measures 
reflecting better white matter integrity, primarily lower MD. These findings could 
indicate an age-dependent effect of thyroid hormone on brain morphology and 
microstructural organization, beneficial in younger age and deleterious in older 
age. To our knowledge, there are no previous studies assessing the association of 
thyroid function with brain volumes and white matter microstructure in the general 
population. Based on our results, we hypothesize that the findings in younger 
participants could reflect a positive role of thyroid hormone balance in myelination, 
sustainability and protection of neurons during early stages of life. In contrast, in 
older age, high thyroid function could be deleterious by causing neuronal damage 
and in turn neurodegeneration.  
Thyroid hormone is important for growth, development and metabolism in virtually 
all organs and effects on the brain are numerous. Fetal neurogenesis is thyroid 
hormone dependent and both lack and excess of thyroid hormone availability can 
hamper brain development and has deleterious effects on brain morphology 
1,2,26
. 
In older age, mainly high thyroid function has been linked to neurodegeneration 
and cognitive impairment 
6,7,10
. Higher thyroid hormone levels are related to a 
higher basal metabolic rate and oxygen consumption. In turn, this can affect 
oxidative stress, either due to increased reactive oxygen species production or 
lower activity of antioxidants, potentially leading to oxidative damage 
27,28
. These 
effects are reported to be tissue specific, but oxidative damage may be most 
pronounced in metabolic active organs such as the brain possibly leading to 
negative effects on neuronal integrity
28
. Free radical injury has been suggested to 
associate with white matter changes on DTI 
29
. With microstructural changes 
thought to accumulate to macrostructural tissue change, this could be one of the 
pathways explaining the association of thyroid function with lower white matter 
volume and poorer integrity in elderly, potentially also the previously described 
relation with the risk of dementia. The pathophysiology of dementia is multifactorial, 
but implication of oxidative stress has also been proposed 
30,31
. Alternatively, a 
common genetic predisposition could underlie the association of thyroid function 
with dementia and white matter integrity.  
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Thyroid function is known to affect several cerebrovascular risk factors. However, 
deleterious cardiovascular risk factors, such as dyslipidemia and increased blood 
pressure, are mainly consequences observed in hypothyroidism. Furthermore, we 
previously described lack of association of thyroid function with small vessel 
disease on MRI, including white matter lesions, lacunar infarcts and cerebral 
microbleeds 
8
. Also, adjusting for various cardiovascular risk factors in the current 
study did not change the associations meaningfully. This, together with the current 
results, suggests that the association of thyroid function with measures of white 
matter microstructure in elderly is independent of these risk factors and mediated 
through other pathways (e.g. oxidative stress). Thyroid hormone also has distinct 
effects on myelin formation and regeneration 
32,33
. However, thyroid hormone and 
thyroid hormone repletion is mainly associated with acceleration of myelination and 
remyelination in different animal studies and patient populations 
32-34
. This 
demonstrates the potential complexity of the pathophysiology 
2
 and more research 
is needed to unravel the exact pathophysiological link between thyroid function, 
white matter microstructure and dementia. Discovery of underlying pathways is not 
only needed to understand the pathophysiology of dementia, but also to identify 
persons at risk and determine promising treatment targets.  
Another implication of our study may lie in the possible effects of overtreatment of 
hypothyroidism. In recent years, physicians have commenced levothyroxine 
treatment in people at lower serum TSH thresholds, i.e. milder cases of 
hypothyroidism 
35
. It was found that in patients treated with levothyroxine for 
hypothyroidism, a substantial proportion was not within treatment target, with over 
10% being overtreated and actually classifying as iatrogenic hyperthyroidism 
35
. 
Our study results suggest that endogenous high FT4 values may negatively affect 
brain volume and brain tissue in older age. Although we have not investigated 
whether high thyroid function due to levothyroxine (i.e. exogenous thyroxine) use 
has comparable effects on brain volumes and DTI measurements as endogenous 
thyroid hormone, we speculate that this is plausible. Further research is needed to 
confirm this hypothesis. 
Strengths of our study include the large sample size and availability of detailed 
phenotypical information. Also, we were able to adjust for a wide variety of 
confounders. Nevertheless, residual confounding cannot be excluded in an 
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observational study, even with adjustments for the large number of potential 
confounders performed in our analyses. Another limitation of our study is that 
thyroid function was measured only once, which is a limitation for most 
observational cohort studies, and therefore changes over time could not be 
assessed. A sensitivity analysis limited to participants with thyroid function within 
the reference range (n=4141), which are known to be relatively stable over time 
36,37
, yielded similar results. Nevertheless, our results need to be confirmed in study 
preferably with a longitudinal design. Furthermore; no conclusions can be drawn on 
the causality of the associations due to the cross-sectional design. We used 
averaged diffusion parameters, aggregated over all the normal-appearing white 
matter voxels. This did not allow us to assess brain changes on a more regional 
level. Finally, the Rotterdam Study constitutes of mainly Caucasian participants of 
45 years and older, so our results may be less generalizable to younger or other 
ethnic populations.  
Conclusions 
In summary, our study shows that higher FT4 levels are associated with larger 
brain volumes and higher white matter microstructural integrity in younger 
individuals, but not in elderly. Furthermore, our results highlight the need for 
caution in overtreatment in mild hypothyroidism. Thyroid hormone excess is a risk 
factor for dementia and further studies should evaluate whether this is indeed 
mediated through poorer white matter microstructural integrity.   
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ABSTRACT 
BACKGROUND The association of thyroid function with risk of type 2 diabetes 
remains elusive. We aimed to investigate the association of thyroid function with 
incident prediabetes, diabetes and progression from prediabetes to diabetes in a 
population-based prospective cohort study. 
 
METHODS We included 8452 participants (mean age 65 years) with thyroid 
function measurement, defined by thyroid-stimulating hormone (TSH) and free 
thyroxine (FT4), and longitudinal assessment of prediabetes and diabetes 
incidence. Cox-models were used to investigate the association of TSH and FT4 
with prediabetes, diabetes and progression from prediabetes to diabetes. 
Multivariable models adjusted for age, sex, HDL cholesterol, and glucose at 
baseline, amongst others.  
 
RESULTS During a mean follow-up of 7.9 years, 798 diabetes cases occurred. 
Higher TSH levels were associated with a higher diabetes risk (Hazard Ratio [HR] 
1.13, 95% confidence interval [CI], 1.08-1.18, per logTSH), even within reference 
range of thyroid function (HR 1.24, CI, 1.06-1.45). Higher FT4 levels were 
associated with a lower diabetes risk amongst all participants (HR 0.96, CI, 0.93-
0.99, per 1 pmol/L) and in participants within the reference range of thyroid function 
(HR 0.96, CI, 0.92-0.99). The risk of progression from prediabetes to diabetes was 
higher with low-normal thyroid function (HR 1.32, CI, 1.06-1.64 for TSH and HR 
0.91, CI, 0.86-0.97 for FT4). Absolute risk of developing diabetes type 2 in 
participants with prediabetes decreased from 35% to almost 15% with higher FT4 
levels within the normal range. 
 
CONCLUSIONS Low and low-normal thyroid function are risk factors for incident 
diabetes, especially in individuals with prediabetes. Future studies should 
investigate whether screening for and treatment of (subclinical) hypothyroidism is 
beneficial in subjects at risk of developing diabetes. 
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INTRODUCTION 
Diabetes mellitus and thyroid disease are the two most common endocrine 
disorders and not rarely co-exist in patients 
1
. The role of auto-immunity has been 
well-recognized in the link between auto-immune thyroid disease and type 1 
diabetes mellitus 
2
. A relation between thyroid dysfunction and type 2 diabetes 
mellitus has also been suggested, but the possible underlying mechanisms are 
divers and show complex interactions 
3
. 
Thyroid hormone is a major regulator of metabolism and energy expenditure, is 
directly involved in the control of insulin secretion and glucose homeostasis 
3,4
 and 
has been shown to preserve beta-cell viability and proliferation 
5,6
. Hyperthyroid 
individuals have an increased insulin secretion 
7
 and free triiodothyronine levels 
are specifically associated with improved insulin secretion in individuals with 
prediabetes 
8
. However, the deleterious effect of thyrotoxicosis on glucose 
metabolism has also been recognized for decades 
9
. Excess thyroid hormone (i.e. 
hyperthyroidism) causes increased liver gluconeogenesis and peripheral insulin 
resistance and is associated with glucose intolerance 
10-13
. Interestingly, lack of 
thyroid hormone is also associated with a decrease of peripheral insulin sensitivity 
and glucose intolerance 
14
 and treatment of hypothyroidism has been shown to 
improve insulin sensitivity 
14,15
. 
Results concerning the association between thyroid function and type 2 diabetes 
are conflicting, with register-based studies reporting an association of hyperthyroid 
and hypothyroidism with type 2 diabetes 
16-18
 while a recent cross-sectional large 
population based study found no association between thyroid dysfunction and type 
2 diabetes 
19
. As a consequence, there is no consensus on whether patients with 
type 2 diabetes should be screening for thyroid dysfunction.  
To date, there are no prospective population-based cohort studies investigating the 
association across the full range of thyroid function, including the normal range, 
with the risk of incident prediabetes and diabetes. Also, to our knowledge, no 
studies so far have examined the role of thyroid function on the early development 
of diabetes type 2 (prediabetes). Therefore, we aimed to investigate the 
association of thyroid function with the incidence of pre-diabetes, type 2 diabetes 
Chapter 4.1 
282 
and the progression from prediabetes to diabetes in the Rotterdam Study, a large 
prospective population-based cohort study. 
 
METHODS 
The Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study that 
investigates determinants and occurrence of age related diseases in Ommoord, 
Rotterdam, the Netherlands. The aims and design of the Rotterdam Study have 
been described in detail elsewhere 
20
. The Rotterdam Study consists of three 
independent cohorts.: RS Cohort 1 (RSI), including 7,983 participants aged ≥55 
(baseline 1990-1993), RS Cohort II (RSII), including 3,011 participants aged ≥55 
(baseline 2000-2001) and RS Cohort 3 (RSIII), including 3,932 participants aged 
≥45 (baseline 2006-2008). 
The Rotterdam Study has been approved by the medical ethics committee 
according to the Population Screening Act: Rotterdam Study, executed by the 
Ministry of Health, Welfare and Sports of the Netherlands.  
Study population 
We selected data from participants from the third visit of the first cohort (1997-
1999, n=4797) and the first visit of the second (2000-2001, n=3011) and third 
cohort (2006-2008, n=3932), if thyroid-stimulating hormone (TSH) or free thyroxine 
(FT4) measurements were performed and if information on diabetes was available. 
All participants in the present analysis provided written informed consent to 
participate and to obtain information from their treating physician. All study 
participants were followed up from the day of baseline laboratory testing to date of 
onset of (pre-)diabetes, to death, or to January 1, 2012, whichever came first. 
Assessment of thyroid function 
Thyroid function was measured using the same methods and assay, and samples 
were collected between 1997 and 2008, depending on the cohort. TSH and FT4 
measurements were performed in serum samples stored at -80°C (The 
electrochemiluminescence immunoassay for thyroxine and thyrotropin, “ECLIA”, 
Roche). We determined cut-off values for the reference range of TSH as 0.4-4.0 
mIU/L and FT4 as 11-25 pmol/L (0.86-1.94 ng/dL) according to guidelines as well 
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as our previous studies 
21
. Thyroid peroxidase antibodies (TPOAb) levels greater 
than 35 kU/mL were regarded as positive, as recommended by the assay 
manufacturer (The electrochemiluminescence immunoassay for thyroid 
perioxidase antibodies, “ECLIA”, Roche).  
Ascertainment of prediabetes and type 2 diabetes 
The participants were followed from the date of baseline center visit onwards. At 
baseline and during follow-up, cases of prediabetes and type 2 diabetes were 
ascertained through active follow-up using general practitioners’ records, hospital 
discharge letters and serum glucose measurements from Rotterdam Study visits 
which take place approximately every 4 years 
22
. Normoglycemia, prediabetes and 
diabetes were defined according to recent WHO guidelines 
23
. Normoglycemia was 
defined as a fasting serum glucose < 6.0 mmol/L; prediabetes was defined as a 
fasting serum glucose > 6.0 mmol/L and < 7.0 mmol/L or a non-fasting serum 
glucose > 7.7 mmol/L and < 11.1 mmol/L (when fasting samples were absent); 
type 2 diabetes was defined as a fasting serum glucose ≥7.0 mmol/L, a non-fasting 
serum glucose ≥ 11.1 mmol/L (when fasting samples were absent), or the use of 
blood glucose lowering medication. Information regarding the use of blood glucose 
lowering medication was derived from both structured home interviews and linkage 
to pharmacy records. At baseline, more than 95% of the Rotterdam Study 
population was covered by the pharmacies in the study area. All potential events of 
prediabetes and type 2 diabetes were independently adjudicated by two study 
physicians. In case of disagreement, consensus was sought with an 
endocrinologist 
22
.  
Baseline measurements  
Body mass index was calculated as body mass (kg) divided by the square of the 
body height (m). Serum HDL cholesterol and glucose were measured using 
standard laboratory techniques. Information on tobacco smoking was derived from 
baseline questionnaires. Systolic and diastolic blood pressure was calculated as 
the average of two consecutive measurements. Insulin was measured using an 
immunoassay (electrochemiluminscence immunoassay “ECLIA”, Roche). Over 
95% of participants were in a fasting state when blood was drawn at the Rotterdam 
Study center visit. Information on medication use was obtained from questionnaires 
in combination with pharmacy records. Thyroid medication, including thyroid 
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hormone replacement therapy, was prescribed by participant’s own GP or 
specialist and within the context of regular treatment and blinded to measurements 
of the Rotterdam Study. 
Statistical methods 
We used Cox-proportional hazards models to assess the association of TSH or 
FT4 with incident diabetes or prediabetes. We also assessed the association of 
thyroid function measurements and incident diabetes in participants with 
prediabetes separately. We conducted these analyses first in all included 
participants and then only in those with normal TSH and FT4 values, after 
excluding levothyroxine users. The primary model, model 1, adjusted for age, sex, 
cohort, fasting glucose and tobacco smoking. Model 2 additionally adjusted for 
possible confounders or intermediate factors, including fasting serum insulin, 
systolic blood pressure, diastolic blood pressure, use of blood pressure lowering 
medication (diuretics, anti-adrenergic agents, β blockers, calcium channel blockers 
and RAAS inhibitors), HDL cholesterol and BMI. Furthermore, we assessed the 
association of TSH and FT4 tertiles in the normal reference range with progression 
from prediabetes to diabetes and calculated absolute risk estimates for the tertiles, 
using the covariates of the multivariable model. We performed the following 
sensitivity analyses 1) excluding participants using levothyroxine at baseline 2) 
excluding participants using thyroid function altering medication, including 
levothyroxine, anti-thyroid drugs (e.g. thiamazole), amiodarone and corticosteroids 
at baseline and follow-up 3) additionally excluding participants with TSH and FT4 
values outside the normal range. We stratified by possible effect modifiers 
including age categories (cut-off of 65 years), and sex. The natural logarithm of 
TSH was used for the continuous models. The proportional hazards assumption 
was assessed by performing Schoenfeld tests and plots and was met for all 
analyses. There was no departure from linearity as assessed by restricted cubic 
splines or adding quadratic terms of TSH, FT4 or age to the model. Reporting of 
the results is according to the STROBE statement.  
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RESULTS 
We included a total of 8452 participants with thyroid function measurements and 
free of diabetes at baseline (Figure 1). The mean age of the included participants 
was 64.9 years and 58% was female. Baseline characteristics are shown in Table 
1. During a mean follow-up of 7.9 years (standard deviation 4.0 years), 1100 
participants developed prediabetes (incidence rate [IR] 14 per 1000 person-years) 
and 798 developed diabetes (IR 12 per 1000 person-years). Completeness of 
follow-up was 99.4% 
24
. 
 
Figure 1 Participants selection 
 
 
Thyroid function and incident diabetes 
Higher TSH levels were associated with a higher risk of diabetes with a Hazard 
Ratio (HR) of 1.13 in model 1 (95% confidence interval [CI], 1.08-1.18, Table 
2).Within the normal range the risk of diabetes was 1.24 times higher with higher 
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TSH levels. In model 2, this association attenuated slightly (HR 1.21, CI, 1.03-1.42, 
Table 2). In the most adjusted model (model 2), higher FT4 levels were associated 
with a decreased risk of diabetes (HR 0.96, 95% CI, 0.93-0.99), also within the 
normal range (HR 0.94, 95% CI, 0.90-0.98). Sensitivity analyses did not change 
risk estimates meaningfully (Supplemental Table 1). Stratifying the analyses by 
age category or sex did not show effect modification for incident diabetes (p for 
interaction > 0.05 for all).  
 
 
Table 1 Baseline characteristics of included participants 
Variable Mean (SD)* 
Number of individuals in the study 8452 
Age, in years 64.6 (9.7) 
Female, n (%)  4899 (58.0) 
BMI, kg/m
2 
26.5 (4.05) 
Total Cholesterol, mmol/L 5.76 (1.01) 
HDL Cholesterol, mmol/L 1.43 (0.41) 
Smoking, n (%)  
        Current 1742 (20.6) 
        Former 4020 (47.6) 
        Never 2691 (31.8) 
Systolic blood pressure, mmHg 139 (21) 
Diastolic blood pressure, mmHg 79 (11) 
Antihypertensive medication use, n (%) 1881 (22.3) 
TSH, median (IQR) 1.91 (1.29-2.76) 
FT4, pmol/L 15.7 (2.32) 
TPOAb positivity, n (%) 1119 (13.2%) 
Levothyroxine use, n (%) 233 (2.8) 
*unless specified otherwise 
TPOAb levels >35 kU/mL were regarded as positive. 
Abbreviations: BMI Body mass index, IQR interquartile range, FT4 free thyroxine, SD standard 
deviation, TPOAb thyroid peroxidase antibodies, TSH Thyroid-Stimulating Hormone, n number 
 
 
Thyroid function and incident prediabetes 
In model 2, the risk of developing prediabetes was higher with higher TSH levels 
(HR 1.04, 0.97-1.12, Table 2) but not significantly and significantly lower with 
higher FT4 levels (HR 0.98, 95% CI, 0.95-1.00). When restricting the analyses to 
the normal range, HR was 1.12 (95% CI, 0.97-1.12) and 0. 96 (95% CI 0.93-0.99) 
for TSH and FT4 respectively (Table 2).  
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Table 2 Association between thyroid function and the risk of incident prediabetes and 
diabetes 
Thyroid function 
measurements 
HR (95% CI) 
Model 1 
HR (95% CI) 
Model 2 
Incident 
Cases 
Total 
participants 
Incident Diabetes     
Full range of 
measurement 
    
TSH mIU/L 1.13 (1.08-1.18) 1.09 (1.00-1.19) 798 8447 
Free T4 pmol/L 0.96 (0.93-0.99) 0.96 (0.93-0.99) 797 8446 
     
Normal TSH and FT4 
values 
    
TSH mIU/L 1.24 (1.06-1.45) 1.21 (1.03-1.42) 685 7188 
Free T4 pmol/L 0.96 (0.92-0.99) 0.94 (0.90-0.98) 685 7188 
     
Incident Prediabetes     
Full range of 
measurement 
    
TSH mIU/L 1.06 (0.99-1.14) 1.04 (0.97-1.12) 1100 7110 
Free T4 pmol/L 0.97 (0.94-0.99) 0.98 (0.95-1.00) 1100 7110 
     
Normal TSH and FT4 
values 
    
TSH mIU/L 1.15 (1.00-1.32) 1.12 (0.98-1.29) 936 6051 
Free T4 pmol/L 0.96 (0.92-0.99) 0.96 (0.93-0.99) 936 6051 
     
Progression from Prediabetes to Diabetes   
Full range of 
measurement 
    
TSH mIU/L 1.25 (1.11-1.41) 1.19 (1.05-1.36) 412 1337 
Free T4 pmol/L 0.92 (0.89-0.97) 0.93 (0.89-0.98) 411 1336 
     
Normal TSH and FT4 
values 
    
TSH mIU/L 1.39 (1.11-1.74) 1.32 (1.06-1.64) 358 1137 
Free T4 pmol/L 0.90 (0.85-0.95) 0.91 (0.86-0.97) 358 1137 
Model 1: adjusted for sex, age, smoking, fasting serum glucose levels and cohort. Model 2: adjusted for 
sex, age, smoking, cohort, fasting serum glucose levels, fasting serum insulin measurements, systolic 
blood pressure, diastolic blood pressure, blood pressure lowering medication, HDL cholesterol and 
body mass index. Normal range of TSH is defined by 0.4-4.0 mIU/L and normal range FT4 is defined by 
11-25 pmol/L and participants not using levothyroxine.  
Abbreviations: CI confidence interval, FT4 free thyroxine, HR hazard ratio, TSH thyroid-stimulating 
hormone. 
   
Chapter 4.1 
288 
Figure 2 Association of TSH and FT4 Levels in tertiles within the normal range and Incident 
Diabetes in individuals with prediabetes 
 
 
 
The normal range of TSH defined as 0.4-4.0 mIU/L and of FT4 as 11-25 pmol/, thyroid hormone 
medication users were excluded. Analyses adjusted for sex, age, smoking, cohort, fasting glucose, 
serum insulin measurements, systolic blood pressure, diastolic blood pressure, blood pressure lowering 
medication, cholesterol and body mass index. Abbreviations: AF = atrial fibrillation, TSH = thyroid-
stimulating hormone, FT4 = free thyroxine, HR = hazard ratio, CI = confidence interval. 
 
Thyroid function and progression of prediabetes to diabetes 
In participants with prediabetes, the risk of developing diabetes was 1.19 times 
higher per 1 unit of log transformed TSH levels mIU/L (95% CI, 1.05-1.36, Table 2). 
The risk of incident diabetes in participants with prediabetes is 0.93 times lower 
with each 1 pmol/L increase of FT4 (95% CI, 0.89-0.98). In the normal range, the 
risk of developing diabetes was 1.44 times higher (95% CI, 1.13-1.93) when 
comparing the highest to the lowest tertile of TSH in the normal range in model 1 
(Supplemental Table 3). This corresponds to an absolute risk difference of 8.5% for 
a follow-up of 7 years. Comparing the highest tertile of FT4 to the lowest tertile, the 
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HR for developing diabetes in individuals with prediabetes was 0.63 (95% CI, 0.48-
0.82, Supplemental Table 3). Additionally adjusting analyses for TPOAb positivity 
did not change risk estimates meaningfully (data not shown). This corresponds to a 
1.59 times higher risk and an absolute risk difference of 9.6% of progression to 
diabetes when comparing the lowest to the highest tertile of FT4 (Supplemental 
Table 3). These associations attenuated only slightly in model 2 (Figure 2, 
Supplemental Table 3). Absolute risk of diabetes type 2 in participants with 
prediabetess decreased from 35% to almost 15% with higher FT4 levels within the 
normal range (Figure 3). 
 
Figure 3 The 7-year absolute risk of type 2 diabetes is plotted against TSH and FT4 values 
within the normal range.  
 
 
These analyses are adjusted for sex, age, smoking, cohort, fasting serum glucose levels, fasting serum 
insulin measurements, systolic blood pressure, diastolic blood pressure, blood pressure lowering 
medication, HDL cholesterol and body mass index. Abbreviations: TSH = thyroid-stimulating hormone, 
FT4 = free thyroxine. 
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DISCUSSION  
To our knowledge, this is the first prospective population-based cohort study 
describing the relation between thyroid function and the risk of progression from 
normoglycemia to prediabetes and type 2 diabetes. Higher TSH levels and lower 
FT4 levels, both outside as well as within the reference range, are associated with 
an increased risk of diabetes and progression from pre-diabetes to diabetes.  
In contrast to the study by Brandt et al., reporting an increased risk of diabetes in 
hyperthyroid individuals, based on the same Danish nationwide registry data 
16
, we 
do not find an increased risk of diabetes in high thyroid function. 
There are no other studies addressing the relation between diabetes and thyroid 
function in the euthyroid range or in individuals with prediabetes. Our results differ 
from the findings of Fleiner et al. 
19
 that do not find a higher prevalence of 
hypothyroidism in type 2 diabetes patients. However the results by Fleiner et al. 
were cross-sectional and therefore did not address the risk of diabetes 
development (i.e. temporality). In addition FT4 measurements were not performed 
in all participants. Our results are in contrast to a Danish nationwide registry study, 
that reported an increased risk of diabetes in hyperthyroid individuals 
16
, whereas 
we do not find an increased risk of diabetes in high thyroid function. However our 
results are h largely in line with two register-based studies reporting an increased 
risk of diabetes in hypothyroid individuals 
17,18
. 
There are several pathways that may explain the observed relation between low 
and low-normal thyroid function and the risk of diabetes. Overt and subclinical 
hypothyroidism are associated with a decreased insulin sensitivity and glucose 
tolerance, partially due to a decreased ability of insulin to increase glucose 
utilization in mainly muscle 
14,25
. Other mechanisms, such as downregulation of 
plasma membrane glucose transporters and direct effects on insulin degradation 
have also been described 
26-28
. Treatment of hypothyroidism has been shown to 
restore insulin sensitivity and the secretion of glucoregulatory hormones 
15
. 
Furthermore, hypothyroidism is associated with several components of the 
metabolic syndrome and could therefore indirectly relate to the increased risk of 
diabetes 
29
. However, in our analyses, adjusting for several cardiovascular risk 
factors and components of the metabolic syndrome did not shift risk estimates 
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towards the null. Also, excluding participants using thyroid hormone replacement 
therapy at baseline only slightly altered the results. Even though overt 
hyperthyroidism is also associated with insulin resistance, our data show that high 
and high-normal thyroid function are protective for developing of or progressing to 
diabetes. It could be that insulin resistance in hyperthyroid patients is 
counterbalanced by other mechanisms associated with prolonged thyroid hormone 
excess, such as improved beta-cell function and increase insulin secretion 
6
. 
However, the exact pathophysiological mechanisms through which thyroid function 
could affect diabetes risk in the general population still has to be determined. 
The clinical importance of these findings could be several. First of all, the 
association of thyroid function with development from prediabetes to diabetes is 
prominent. Thus, individuals with a low-normal thyroid function, which includes a 
large proportion of the population, are yet at a higher risk of progression from 
prediabetes to diabetes. Secondly, with aging and increasingly obese populations, 
there is need for better screening and prevention options for diabetes 
30
. One could 
hypothesize that in individuals with prediabetes with low or low-normal thyroid 
function (i.e. high TSH and low FT4), lifestyle interventions or diabetes treatment 
could be prompted in an earlier phase than those with normal or high thyroid 
function. Alternatively, having prediabetes could be an argument to start treatment 
of subclinical hypothyroidism to aim for prevention of overt diabetes. Current 
guidelines do not recommend or specifically address screening of thyroid function 
or treatment of thyroid dysfunction in individuals with diabetes 
31,32
. 
despite the high prevalence of both conditions in the general population, the 
relation between thyroid dysfunction and diabetes had been largely unexplored. 
Further research is needed to determine to what extend this is driven by thyroid 
hormone related acceleration of development of diabetes or perhaps by other 
mechanisms such as a common genetic predisposition. Subsequent studies should 
focus on screening and prevention strategies as well as questions concerning 
treatment of patients with subclinical hypothyroidism in patients at risk for diabetes. 
Strengths of our study include the large number of individuals, the variety of 
available confounders adjusted for and the long follow-up. Furthermore, we were 
able to investigate both diabetes and prediabetes. Limitations of our study should 
also be acknowledged. Residual confounding cannot be excluded in an 
Chapter 4.1 
292 
observational study, even with the large number of potential confounders adjusted 
for in our analyses. Furthermore, the Rotterdam Study constitutes of dominantly 
white participants of 45 years and older and results may therefore not be 
generalizable to other populations. 
Conclusions 
In conclusion, low and low-normal thyroid function are related to an increased risk 
of diabetes and prediabetes. In individuals with prediabetes, the risk of progression 
to diabetes with low and low-normal thyroid function is more prominent. These data 
provide new insights into the magnitude of the risk of diabetes and prediabetes 
associated with variations of thyroid function. More research is needed confirming 
these current findings in additional populations and addressing possible screening 
and treatment modalities for both diabetes and thyroid dysfunction.  
 
Online supplemental material 
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0693-4 
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ABSTRACT 
BACKGROUND Although thyroid function is associated with several risk factors of 
non-alcoholic fatty liver disease (NAFLD), its role in NAFLD development remains 
unclear. We aimed to prospectively investigate the association between variations 
in thyroid function and NAFLD.  
 
METHODS The Rotterdam Study, a large population-based, prospective cohort 
study. 
Participants and main outcome measures: Participants with thyroid function 
measurements at baseline and NAFLD data (i.e. at baseline fatty liver index/ at 
follow-up ultrasound) were eligible. Transient elastography was performed to 
assess the presence of fibrosis in patients with NAFLD, using the liver stiffness 
measurements ≥8 kilopascals as cut-off for clinically relevant fibrosis. The 
association between thyroid parameters and incident NAFLD was explored by 
using logistic regression models.  
 
RESULTS A total of 9419 participants (mean age 64.75 years) were included. The 
median follow-up time was 10.04 years (interquartile range: 5.70-10.88 years). 
After adjusting for age, sex, cohort, follow-up time, use of hypolipidemic drugs and 
cardiovascular risk factors, higher free thyroxine levels were associated with a 
decreased risk of NAFLD (Odds ratio [OR], 0.42; 95% confidence interval [CI], 
0.28-0.63). In line, higher thyroid-stimulating hormone levels were associated with 
an increased risk of having clinically relevant fibrosis in NAFLD (OR, 1.49; CI, 1.04-
2.15). Compared to euthyroidism, hypothyroidism was associated with a 1.24-fold 
higher NAFLD risk (CI, 1.01-1.53). Moreover, NAFLD risk decreased gradually 
from hypothyroidism to hyperthyroidism (p-trend 0.003).  
 
CONCLUSIONS Lower thyroid function is associated with an increased NAFLD 
risk. These findings may lead to new avenues regarding NAFLD prevention and 
treatment. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is one of the the most common chronic 
liver conditions worldwide.
1
 It comprises a broad spectrum ranging from simple 
steatosis to non-alcoholic steatohepatitis (NASH) with fibrosis, which can 
eventually progress to cirrhosis and hepatocellular carcinoma.
2,3 
NASH-related 
cirrhosis is anticipated to become the leading indication for liver transplantation by 
2030.
4
 Moreover, accumulating evidence has shown that NAFLD, either 
independently or in combination with other metabolic risk factors, is associated with 
extrahepatic complications such as cardiovascular disease, type 2 diabetes, 
chronic kidney disease, malignancy and all-cause mortality.
5 
Despite improved 
understanding and treatment of its risk factors (e.g. diabetes and dyslipidemia), 
prevalence of NAFLD has rapidly increased.
6 
Hence, investigation of additional 
modifiable risk factors is urgently needed. 
Thyroid hormone is the major regulator of metabolic rate. Although hypothyroidism 
has been implicated in the etiology of NAFLD
7
,
 
prior studies regarding the 
association between thyroid function and NAFLD risk have yielded controversial 
results, varying from a strong
8,9
 to no association.
10,11 
Studies confined to euthyroid 
subjects have been inconsistent as well, reporting that FT4 alone,
12 
TSH alone 
13
,
 
both 
8
,
 
or neither of them
14
, are linked with NAFLD. These discrepancies are mainly 
due to small sample sizes and cross-sectional design of previous studies. 
The only prospective study to date focused exclusively on the risk of NAFLD in 
subclinical hypothyroidism.
15 
As a consequence, the risk of NAFLD has not been 
explored prospectively in the remaining categories of thyroid function, other than 
subclinical hypothyroidism. A recent review has also highlighted the need for 
prospective research on the association between normal thyroid function and 
NAFLD risk.
16
 Moreover, it remains unclear whether and to what extent thyroid 
function affects fibrosis risk in NAFLD patients. Therefore, we prospectively 
investigated the association between variations in thyroid function and NAFLD 
spectrum, in a large population-based cohort study. 
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MATERIALS AND METHODS 
Study population 
The Rotterdam Study (RS) is a large, prospective, population-based cohort study, 
conducted among middle aged and elderly inhabitants of the Ommoord district in 
Rotterdam, The Netherlands. The complete rationale and study design have been 
described in detail previously.
17 
In brief, all residents of Ommoord aged 55 years or 
older were invited to participate. Firstly, 7983 participants were enrolled between 
1990 and 1993 (RSI). In 2000, the study was extended with a second cohort of 
3011 subjects (RSII). In 2006, a third cohort of 3932 subjects aged 45 years and 
over was added (RSIII), and thereafter the study population comprised a total of 
14926 subjects.Participants from study cohorts RSI visit 3 (RSI-3), RSII visit 1 
(RSII-1) and RSIII visit 1 (RSIII-1) were eligible for the study if they had thyroid 
function measurements and data available on ultrasound-diagnosed NAFLD at 
follow-up or fatty liver index (FLI) at baseline. We considered the date of baseline 
laboratory testing, which comprised the assessment of thyroid function and FLI 
components, the start date of follow-up. The end date of follow-up was considered 
the date of the ultrasound measurement (Supplemental Figure 1). The Medical 
Ethics Committee of the Erasmus University and the Ministry of Health, Welfare 
and Sport of the Netherlands approved the study protocols, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All 
included participants provided a written informed consent in accordance with the 
Declaration of Helsinki to participate in the study and to obtain information from 
their family physicians. 
Assessment of thyroid function 
We performed thyroid function tests in the three independent RS cohorts using the 
same method and assay. Thyroid function assessment was performed for thyroid-
stimulating hormone (TSH), free thyroxine (FT4) and thyroid peroxidase antibodies 
(TPOAb) in baseline serum samples stored at -80°C (The 
electrochemiluminescence immunoassay for thyroxine, thyrotropin and thyroid 
peroxidase antibodies, “ECLIA”, Roche). We determined the reference range of 
TSH (0.4-4.0 mIU/L) and FT4 (0.85-1.95 ng/dl [to convert to picomoles per liter, 
multiply by 12.871] [alternatively 11-25 pmol/L]), according to national guidelines 
Thyroid function and NAFLD 
301 
and previous reports from the Rotterdam Study.
18 
Thyroid function was defined as 
euthyroid if serum TSH was within the reference range. Subclinical hypothyroidism 
was defined as serum TSH >4.0 mIU/L and FT4 levels within the reference range. 
Overt hypothyroidism was defined as serum TSH >4.0 mIU/L and FT4 levels <0.85 
ng/dl. Subclinical hyperthyroidism was defined as serum TSH <0.4 mIU/L and FT4 
levels within the reference range. Overt hyperthyroidism was defined as serum 
TSH <0.4 mIU/L and FT4 levels >1.95 ng/dl. Levels of TPOAb >35 kU/ml were 
regarded as positive, as recommended by the assay manufacturer. 
Assessment of NAFLD  
Assessment of NAFLD comprised abdominal ultrasonographies at follow-up and 
FLI measurements at baseline. To assess incident NAFLD during follow-up, 
abdominal ultrasonography was performed by a single trained technician and 
subsequently images were reevaluated by an experienced hepatologist.
17 
NAFLD 
was defined by the presence of liver steatosis on abdominal ultrasound, in the 
absence of secondary causes as excessive alcohol consumption (>14 alcoholic 
beverages weekly), hepatitis B surface antigen and/or hepatitis C virus positivity, 
and use of fatty liver inducing pharmacological agents (i.e. amiodarone, tamoxifen, 
corticosteroids, and methotrexate). 
At baseline, ultrasound measurements were not available and instead, we utilized 
FLI measurements. FLI, an algorithm based on levels of triglycerides, gamma-
glutamyl transferase (GGT), body mass index (BMI) and waist circumference 
(WC), was calculated by the formula previously described by Bedogni et al.
19
 The 
accuracy of FLI in the detection NAFLD has been demonstrated in various studies, 
including the Rotterdam Study.
20-22
 FLI ≥ 60 has a probability of 82.3% to identify 
the presence of NAFLD.
21
 Therefore, we used a cut-off of 60 to classify participants 
into low and high probability of NAFLD, after primarily excluding subjects with a 
secondary cause of hepatic steatosis. 
Liver stiffness (LS) was examined using transient elastography (Fibroscan; 
Echosens, Paris, France). LS measurements were performed by a single operator, 
on the right lobe of the liver, through the intercostal spaces, with the participant 
lying flat on his back with the right arm laying in maximal abduction. Either M- or 
XL-probe was applied, based on the manufacturer’s instructions. Reliability of LS 
measurements was defined according to the criteria by Boursier et al.
23 
LS 
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measurements were considered poorly reliable if interquartile range /median LS 
>0.30 with median LS ≥7.1 kilopascals (kPa). A total of 48 participants with NAFLD 
diagnosis had unreliable LS measurements and were therefore excluded from the 
analyses involving LS. LS ≥8.0 kPa was used as a cutoff suggesting clinically 
relevant fibrosis. A high positive predictive value of this cutoff has been previously 
reported.
24,25
 
Assessment of other baseline measurement 
Information was obtained from each participant through a home questionnaire 
concerning demographics, medical history, alcohol intake, tobacco smoking and 
medication use. Blood lipids, glucose, GGT, were measured using automatic 
enzymatic procedures (Roche Diagnostics GmbH, Mannheim, Germany). BMI was 
calculated as weight in kilograms divided by height in meters squared. WC was 
measured in centimeters, at the level midway between the lower rib margin and the 
iliac crest with participants in standing position without heavy outer garments and 
with emptied pockets, breathing out gently. Blood pressure was calculated as the 
average of two consecutive measurements, realized in the sitting position at the 
right upper arm with a random-zero-sphygmomanometer. Hypertension was 
defined as a systolic blood pressure ≥140 mmHg or a diastolic blood pressure ≥90 
mmHg or the use of blood pressure-lowering drugs prescribed for hypertension. 
Diabetes was defined as fasting plasma glucose level ≥7 mmol/L, non-fasting 
plasma glucose level ≥ 11.1 mmol/L (when fasting samples were absent) or the 
use of antidiabetic medication. 
Statistical analysis 
We prospectively assessed the association between thyroid parameters (TSH, FT4 
and TPOAb) and incident NAFLD, by using logistic regression models. 
Subsequently, we restricted the analyses to those with baseline FLI values <60, to 
minimize the possibility of misclassification of cases with incident NAFLD.  
We explored differences in the risk of NAFLD throughout tertiles of FT4, taking the 
highest tertile as reference. After our primary analyses, we performed sensitivity 
analyses, restricting to subjects with TSH and FT4 within the reference ranges, 
excluding thyroid medication users and participants with previous thyroid surgery.  
Next, we evaluated the risk of NAFLD throughout thyroid status categories of 
participants, taking euthyroid subjects as reference group. After excluding thyroid 
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medication users and participants with previous thyroid surgery, we investigated 
the association between thyroid function/status and the risk of having a 
combination of NAFLD and LS ≥ 8 kPa.  
After excluding thyroid medication users and participants with previous thyroid 
surgery, we cross-sectionally assessed the association between thyroid function 
and NAFLD, performing logistic regression analysis. Herein, NAFLD was defined 
on basis of categorized FLI, in the absence of secondary causes of hepatic 
steatosis. 
In longitudinal analyses, we first adjusted for age, sex, cohort, alcohol intake, 
smoking and follow-up time (model 1). Further adjustments were made for the use 
of hypolipidemic drugs, total cholesterol, triglycerides, BMI, hypertension, diabetes 
(model 2). Lipids, BMI, hypertension, diabetes could act as confounders as well as 
possible mediators depending on the presumed pathway through which thyroid 
function is related to NAFLD and therefore included in the multivariable model 
(model 2). In mediation analyses, we calculated the percentage of excess risk 
mediated [(ORcon adj − ORcon + med adj)/(ORcon adj − 1)] × 100%, where ORcon adj is the 
confounder-adjusted OR and ORcon + med adj is the confounder and mediator–
adjusted OR. 
In cross-sectional analyses, we adjusted for the aforementioned covariates, 
excluding lipids and BMI, as these variables are used to calculate FLI. High-density 
lipoprotein cholesterol and WC were not included as covariates in the multivariable 
model to avoid multicollinearity. TSH was naturally log transformed in the 
continuous analyses in order to approximate a normal distribution. We checked for 
risk modification by adding an interaction term of the exposure (TSH or FT4) with 
covariates of the multivariable model, but none of the interaction terms were 
significant. There was no departure from linearity for the TSH and FT4 analyses, 
assessed by adding quadratic terms of covariates in the multivariable model. 
Multiple imputations were performed in case of missing covariates (less than 2% 
for all covariates). Statistical analyses were conducted using IBM SPSS version 21 
(IBM Corp) and R statistical software (R-project, Institute for Statistics and 
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). Reporting is 
done according to the STROBE statement. 
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RESULTS 
We included 9419 eligible participants with thyroid function measurements at 
baseline and data available on ultrasound-diagnosed NAFLD at follow-up or FLI at 
baseline. Table 1 and Supplemental Table 1 summarize the baseline 
characteristics of included participants.  
 
 
The mean age was 64.7 years and 56.5% were females. Amongst 5324 
participants in whom follow-up data were available, we documented 1763 cases of 
incident hepatic steatosis, of which 1217 cases of incident NAFLD (median follow-
up time 10.0 years, interquartile range 5.7-10.9 years). A total of 546 subjects with 
hepatic steatosis had secondary causes, comprising 460 subjects with excessive 
alcohol consumption, 54 subjects with known steatosis- inducing drugs, 15 
subjects with viral hepatitis and 17 with combinations of the above. After excluding 
thyroid medication users and participants with previous thyroid surgery, reliable LS 
measurements were available in 805 participants with ultrasound-diagnosed 
NAFLD, of which 69 (8.6%) had LS ≥8.0 kPa.  
Table 1 Baseline characteristics of 9419 participants  
Characteristics Mean (SD)* 
Age, years 64.7 (9.7) 
Female, n (%) 5321 (56.5) 
Smoking, n (%)  
  Current 1989 (21.1) 
  Past  4490 (47.7) 
  Never 2940 (31.2) 
Use of hypolipidemic medication, n (%)       1508 (16.0) 
Use of thyroid medication, n (%) 296 (3.1) 
Total cholesterol, mmol/l 5.7 (1.0) 
HDL-C, mmol/l 1.4 (0.4) 
Triglycerides, mmol/l 1.5 (0.8) 
Body-mass index, kg/m2 27.2 (4.2) 
Waist circumference, cm 93.7 (12.1) 
Hypertension, n (%) 5881 (62.4) 
Diabetes, n (%) 1073 (11.4) 
TSH, mIU/L, median (IQR) 1.9 (1.3-2.8) 
FT4, ng/dl 1.2 (0.1) 
TPOAb positive, n (%) 1240 (13.2) 
*Data are mean and standard deviation, unless otherwise specified. 
Abbreviations: sd, standard deviation; HDL-C, high density lipoprotein cholesterol; BMI, body-mass 
index; TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine; TPOAb, thyroid 
peroxidase antibodies. 
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Thyroid parameters / status and the risk of NAFLD 
The risk of NAFLD decreased gradually with higher FT4 levels (Odds ratio [OR], 
0.33; 95% confidence interval [CI], 0.22-0.48 per 1ng/dl) (Table 2). These results 
remained similar after further adjustments for cardiovascular risk factors (OR, 0.42; 
CI, 0.28-0.63), and also after restricting the analyses to participants with baseline 
FLI <60 (OR, 0.42; CI, 0.24-0.74). In the multivariable adjusted model, participants 
in the lowest FT4 tertile had a 1.31 times higher risk of NAFLD, compared to those 
in the highest tertile (CI, 1.11-1.56) (Supplemental Table 2). There was a positive 
linear association between TSH levels and NAFLD risk (OR, 1.09; CI, 1.01-1.19 
per 1 logTSH), which was attenuated after additional adjustment for cardiovascular 
risk factors (OR, 1.07; CI, 0.98-1.17) (Table 2).  
 
Table 2 Longitudinal association between thyroid function and NAFLD risk 
 NAFLD 
events/ 
total number 
OR (95% CI)  Model 1 OR (95% CI)  Model 2 
All participants    
TSH 1216/5321 1.09 (1.01; 1.19) 1.07 (0.98; 1.17) 
FT4 1217/5320 0.33 (0.22; 0.48) 0.42 (0.28; 0.63) 
Baseline FLI < 60    
TSH 553/3379 1.13 (1.00; 1.27) 1.08 (0.95; 1.23) 
FT4 553/3376 0.42 (0.24; 0.74) 0.52 (0.29; 0.92) 
Model 1: age, sex, cohort, alcohol intake, smoking, follow-up time. 
Model 2: predictors in model 1, use of hypolipidemic drugs, total cholesterol, triglycerides, body mass 
index, hypertension, diabetes. Abbreviations: NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; 
CI, confidence interval; TSH, thyroid-stimulating hormone, is per one unit increase of log transformed 
TSH (mIU/L); FT4, free thyroxine, is per one unit increase of FT4 (ng/dl); FLI, fatty liver index. 
 
After separate and simultaneous additions of cardiovascular risk factors to model 
1, BMI and triglycerides were held accountable for the attenuation (Supplemental 
Table 3). The percentage of excess risk mediated by BMI and triglycerides was 
22.2% in the association of TSH with NAFLD and 13.4% in the association of FT4 
with NAFLD; that is 22.2% and 13.4% of the respective associated effect size of 
TSH and FT4 on NAFLD is explained by BMI and triglycerides.
 
No significant 
association was observed for TPOAb and NAFLD risk (OR, 1.09; CI, 0.89-1.32) 
(Supplemental Table 2). There was a significant trend (p for trend 0.003) in the 
decrease of NAFLD risk (OR from 2.08 to 0.54), across categories of thyroid 
function from clinical hypothyroidism to clinical hyperthyroidism (Figure 1, 
Supplemental Table 4).  
Chapter 4.2 
306 
 
Figure 1 Longitudinal association between thyroid status and NAFLD 
 
 
 
Point estimates for NAFLD (non-alcoholic fatty liver disease) were plotted against thyroid status of 
participants, taking euthyroid subjects as reference, after adjusting for age, sex, cohort, alcohol intake, 
smoking, follow-up time. Euthyroidism was defined as TSH (thyroid-stimulating hormone) within 
reference range (0.4-4.0 mIU/l); overt hypothyroidism as TSH>4.0 mU/L and FT4 (free thyroxine)<0.85 
ng/dl; subclinical hypothyroidism as TSH>4.0 mU/L and FT4 0.85-1.95 ng/dl; overt hyperthyroidism as 
TSH<0.4 mU/L and FT4>1.95 ng/dl; subclinical hyperthyroidism as TSH<0.4 mU/L and FT4 0.85-1.95 
ng/dl. Dashed lines represent confidence intervals. Within brackets: NAFLD events/Total number. 
 
Compared to euthyroidism, hypothyroidism was associated with a 1.24-fold (CI, 
1.01-1.53) higher risk of NAFLD (Table 3). Cross-sectional analyses, based on 
categorized FLI, demonstrated a significant association of TSH (OR, 1.11; CI, 1.04-
1.18) and FT4 (OR, 0.45; CI, 0.34-0.60) with NAFLD (Supplemental Table 5). We 
found similar results in sensitivity analyses conducted only among euthyroid 
subjects, after excluding thyroid medication users and participants with previous 
thyroid surgery (Supplemental Table 2, Supplemental Table 5). 
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Table 3 Longitudinal association between thyroid status and NAFLD risk 
 NAFLD events/ 
total number 
OR (95% CI)  
Model 1 
OR (95% CI)  
Model 2 
Hypothyroidism * 155/536 1.32 (1.08; 1.62) 1.24 (1.01; 1.53) 
Euthyroidism 1035/4664 1 (Reference) 1 (Reference) 
Hyperthyroidism * 26/121 0.88 (0.56; 1.36) 0.88 (0.54; 1.37)  
Model 1: age, sex, cohort, alcohol intake, smoking, follow-up time. 
Model 2: predictors in model 1, use of hypolipidemic drugs, total cholesterol, triglycerides, body mass 
index, hypertension, diabetes. * includes subclinical and clinical range.  
Abbreviations: NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval. 
 
 
Table 4 Longitudinal association between thyroid function/ status and the risk of having a 
combination of NAFLD and LS ≥8 kPa*# 
 NAFLD with LS  
≥8.0 kPa/ Total 
number 
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2 
Longitudinal association between thyroid function and the risk of having combined NAFLD 
&LS ≥ 8.0 kPa 
TSH 69/4762 1.55 (1.09; 2.20) 1.49 (1.04; 2.15) 
FT4 69/4762 0.41 (0.09; 1.73) 0.59 (0.13; 2.59) 
    
Longitudinal association between thyroid status and the risk of having combined NAFLD & 
LS ≥ 8.0 kPa 
Clinical hypothyroidism 2/31 5.93 (0.93; 20.85) 6.64 (1.04; 23.98) 
Subclinical hypothyroidism 11/408 2.30 (1.12; 4.31) 2.14 (1.04; 4.07) 
Euthyroidism 55/4240 1 [Reference] 1 [Reference] 
Subclinical 
hyperthyroidism 
1/81 0.87 (0.04; 4.11) 0.80 (0.04; 3.91) 
Clinical hyperthyroidism NA NA NA 
P value for trend  0.002 0.004 
Model 1: age, sex, cohort, alcohol intake, smoking, follow-up time. 
Model 2: predictors in model 1, use of hypolipidemic drugs, total cholesterol, triglycerides, body mass 
index, hypertension, diabetes. #For this analysis, we excluded thyroid medication users and participants 
with previous thyroid surgery. *LS ≥8.0 kilopascals suggests clinically relevant fibrosis.Abbreviations: 
NAFLD, non-alcoholic fatty liver disease; LS, Liver stiffness; kPa, kilopascals, OR, odds ratio; CI, 
confidence interval; TSH, thyroid-stimulating hormone, is per one unit increase of log transformed TSH 
(mIU/L); FT4, free thyroxine, is per one unit increase of FT4 (ng/dl); NA, not applicable. 
 
Thyroid parameters / status and the risk of having a combination of NAFLD 
and LS ≥ 8 kPa 
There was a positive association between TSH levels and the risk of having a 
combination of NAFLD and LS ≥8.0 kPa (OR, 1.55; CI, 1.09-2.20). In line, higher 
FT4 levels were associated with a lower risk of having a combination of NAFLD 
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and LS ≥8.0 kPa, but not significantly (OR 0.41; CI, 0.09-1.73) (Table 4). The risk 
of having a combination of NAFLD and LS ≥ 8.0 kPa decreased gradually from 
hypothyroidism to hyperthyroidism (p for trend 0.002) (Table 4). Compared to 
euthyroidism, subclinical hypothyroidism was associated with a 2.30-fold (CI, 1.12-
4.31) higher risk of having a combination of NAFLD and LS ≥8 kPa (Table 4). 
Results remained similar after further adjustments for cardiovascular risk factors 
(Table 4). In euthyroid subjects, higher TSH and lower FT4 concentrations were 
associated with an increased risk of having a combination of NAFLD and LS ≥8 
kPa, but not significantly (OR, 1.13; CI, 0.63-2.03 for TSH) (OR, 0.81; CI, 0.11-5.75 
for FT4). 
 
DISCUSSION 
The current study is the first prospective population-based study to evaluate the 
relation between the whole spectrum of thyroid function and subsequent risk of 
NAFLD. We demonstrated a negative linear association between FT4 levels and 
incident NAFLD, even among euthyroid subjects, as well as a positive linear 
association for TSH levels. Moreover, the risk of NAFLD progressively decreased 
from a hypothyroid to a hyperthyroid state. Hypothyroidism was associated with a 
higher NAFLD risk compared to euthyroidism. Lower thyroid function was also 
associated with an increased risk of having NAFLD with fibrosis. We demonstrate 
for the first time that subclinical hypothyroidism is associated with an increased risk 
of having NAFLD with fibrosis in the general population.  
There are various pathways via which the beneficial effects of thyroid hormone on 
NAFLD risk can be mediated. Thyroid dysfunction is related to several 
cardiovascular risk factors that are in turn associated with an increased NAFLD risk 
(e.g. higher BMI and dyslipidemia). When we add BMI and triglycerides into the 
model, the risk estimates of the association between thyroid function and NAFLD 
attenuate, indeed suggesting a mediating role of these factors. 
Studies in rodents have demonstrated a regression of hepatic steatosis after 
treatment with liver-targeted thyroid hormone receptor (TR) agonists.
26-28 
Thyroid 
hormone induces intrahepatic lipolysis through lipophagy, that involves the 
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sequestration and degradation of lipid droplets within hepatic lysosomes.
29 
Moreover, TR-mediated lipophagy enhances fatty acid oxidation, which may 
accelerate the clearance of liver lipids and reduce hepatosteatosis.
29 
Conversely, the decreased activity of hepatic lipases that occurs under hypothyroid 
conditions can promote NAFLD via decreased triglyceride clearance and hepatic 
triglyceride accumulation.
30
 In addition, the insulin resistance state associated with 
hypothyroidism
31
 can contribute to NAFLD by concomitantly inducing “de novo” 
lipogenesis and generating a flux of free fatty acids from adipose tissue to the 
liver.
32 
Furthermore, decreased thyroid hormones might affect circulating levels of 
adipocytokines, such as tumor necrosis factor-α, leptin and adiponectin.
32,33 
Altered 
adipocytokines may then contribute to hepatic inflammation and fibrosis, by 
exerting direct hepatotoxic effects or promoting oxygen radicals.
34
  
A putative role of thyroid autoimmunity has also been suggested in NAFLD 
pathogenesis, since various autoantibodies such as antinuclear antibodies and 
anti-smooth muscle antibodies, have been reported in patients with NAFLD.
35 
However, our findings do not support this hypothesis, as there was no association 
between TPOAb and NAFLD. 
Our findings consistently demonstrate that low thyroid function is associated with 
an increased risk of developing NAFLD, as well as higher risk of having NAFLD 
with fibrosis. Therefore, it can be hypothesized that a hypothyroid state might 
accelerate the progression of liver steatosis to fibrosis. Alternatively, low thyroid 
function might contribute on the development of liver fibrosis, independently of 
steatosis. Additional prospective research is needed to address these underlying 
mechanisms and possible mediating role of cardiovascular risk factors. 
The results of the present study confirm a negative linear association between FT4 
levels and the risk of NAFLD. Based on the negative feedback regulation of 
hypothalamus-pituitary-thyroid axis, we would expect an analogous opposite 
association for TSH. Although there was a positive linear relationship between TSH 
levels and NAFLD risk, it attenuated among euthyroid subjects and after 
adjustment for cardiovascular risk factors. Several comparable studies exploring 
the association between thyroid function and different clinical endpoints have 
shown that FT4, rather than TSH, is significantly related to the outcome risk,
18,36,37
 
particularly within the euthyroid range.
18,36 
This may be ascribed to the distinct 
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central and peripheral effects of thyroid hormone, as pituitary gland and liver differ 
in thyroid hormone transporters, receptors and deiodinases.
38 
Also, genetic 
determinants and aging can modify the TSH-FT4 set point of the feedback 
mechanism, accounting for the weaker TSH-FT4 association predominantly among 
euthyroid subjects.
39,40
  
Our study has several important strengths. To our knowledge, it represents the first 
population-based prospective study to assess the effect of the whole spectrum of 
thyroid function on NAFLD and presence of clinically relevant fibrosis. The large 
sample size allowed us to conduct multiple sensitivity analyses. Other strengths 
include the extensive data on potential confounding factors and the laboratory 
assessment of thyroid parameters. In addition, we minimized the possibility of 
misclassification of cases with incident NAFLD, by excluding individuals with 
baseline FLI ≥ 60 (thus highest probability of already having NAFLD), which 
however did not affect our results. 
One limitation of our study is that we could not restrict the analysis to participants 
with baseline FLI values <30, due to a large sample size reduction (over 70% of 
the total population and over 80% of the NAFLD cases). Moreover, the diagnosis of 
NAFLD was based on ultrasonographic examination, whereas liver biopsy is 
considered the gold standard for the detection of mild steatosis or liver fibrosis. 
However, liver biopsies are not conducted routinely in NAFLD diagnosis and are 
considered unethical in population-based studies, because of invasiveness and 
potential complications. Also, abdominal ultrasonography has a sensitivity of 80-
90% for detecting liver steatosis compared to histology, and its accuracy for 
diagnosing steatosis meets other imaging modalities.
41
 In addition, transient 
elastography is considered reproducible and effective in liver fibrosis 
assessment.
24,25 
Thyroid parameters were tested only at baseline and we lacked 
information regarding their variations over time. However, this would generate an 
underestimation of the association strength, rather than a spurious finding. Serum 
triiodothyronine measurements were not available in our study. Nevertheless, 
thyroid function is clinically defined by the combined TSH and FT4 measurement. 
Furthermore, the generalizability of our findings to non-caucasian populations 
remains uncertain. Finally, we cannot dismiss the possibility of residual 
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confounding in an observational study design, even though we accounted for a 
large number of covariates. 
Conclusions 
In summary, individuals with hypothyroidism are at increased risk of NAFLD 
compared to euthyroid subjects. The current study also reveals a negative linear 
association between FT4 levels and the subsequent risk of NAFLD, even within the 
euthyroid reference range. Lower thyroid function is associated with an increased 
risk of fibrosis in NAFLD patients.  
Our findings highlight the need for future investigations on preventive measures 
(e.g. screening of thyroid function in NAFLD patients) and possible therapeutic 
interventions (e.g. decision of treatment in subclinical thyroid dysfunction). 
 
Online supplemental material 
https://academic.oup.com/jcem/article-abstract/101/8/3204/2835059/Thyroid-
Function-and-the-Risk-of-Nonalcoholic?redirectedFrom=fulltext 
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ABSTRACT 
BACKGROUND In vitro and in vivo experiments have assigned both 
oncosuppressive and oncogenic properties to thyroid hormones. Population-based 
studies found inconclusive results. We aimed to prospectively assess the relation 
between thyroid function and incident cancer in a population based setting.  
 
METHODS The current study is a prospective population-based cohort study 
including 10,318 participants for whom baseline measurements of free thyroxine 
(FT4) and/or thyrotropin (TSH) were available. Cox proportional hazards models 
were used to assess hazard ratios (HRs) of any solid non-skin cancer, as well as 
lung, breast, prostate and gastrointestinal cancer specifically.  
 
RESULTS Higher FT4 levels were associated with a higher risk of any solid cancer 
(HR: 1.42; 95% confidence interval (CI): 1.12-1.79), lung cancer (HR: 2.33; 95% 
CI: 1.39-3.92) and breast (HR: 1.77; 95% CI: 1.10-2.84) cancer. The risk estimates 
were similar after exclusion of thyroid-altering medication, but the association lost 
significance for breast cancer. Compared to the lowest FT4 tertile, the highest 
tertile was associated with a 1.13 fold increased risk of any solid, 1.79 fold 
increased risk of lung and 1.14 fold increased risk of breast cancer (p for trend < 
0.05 for all). For TSH levels we found no associations with cancer risk. There was 
no differential effect of sex or age on the association between thyroid function and 
cancer risk.  
 
CONCLUSIONS Higher FT4 levels are significantly associated with an increased 
risk of any solid, lung and breast cancer. Further research should elucidate the 
underlying pathophysiological mechanisms. 
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INTRODUCTION   
Thyroid hormone plays an important role in growth, differentiation, development 
and metabolism. Via binding to nuclear thyroid hormone receptors (TRs), thyroid 
hormone can induce or inhibit gene transcription.
1,2
 Many pathways influenced by 
thyroid hormone also play a role in tumorigenesis. For example, induction of 
deiodinase 3 (D3), an enzyme inactivating thyroid hormone, sustains proliferation 
in colon carcinoma, suggesting a link between local hypothyroidism and tumor 
growth.
3
 In addition, it has been demonstrated that thyroid hormone has a direct 
effect on oncogenic pathways, such as the PI3K- and ERK1/2-pathways.
4-7
 Thyroid 
hormone and TRs have been linked to increased proliferation in breast, ovarian 
and prostate cancer cell lines.
2
 On the other hand, protective effects of thyroid 
hormone have also been hypothesized.
1,2
 Thyroid hormone suppresses 
unregulated cell proliferation by inhibiting activating protein 1 (AP1).
1,2
 Various 
tumor types, such as lung, breast and liver cancer, are associated with inactivating 
mutations in TRs that block access of wild-type TRs to the target genes, yielding 
lower thyroid hormone action.
1,2
 Restoring wild-type expression of TRβ1 in liver 
and breast cancer cell lines retards tumor growth and suppresses tumor 
invasiveness and metastasis.
8
  
Population-based studies have associated both overt and subclinical 
hyperthyroidism to cancer.
9,10
 Hyperthyroidism has been associated with an 
increased risk of prostate
11
, breast
12-14
 and lung cancer
9
, whereas hypothyroidism 
is linked to a decreased risk of prostate cancer
11
 and both an increased
15
 and 
decreased 
13,16
 risk of breast cancer.  
However, the data regarding the link between thyroid dysfunction and cancer do 
not provide conclusive evidence mainly due to differences in study design. 
Previous reports suffered from a small sample size (< 30)
12
 or a retrospective study 
design and/or unavailability of thyroid function serum measurements 
10,13,16
. Also, 
most studies restricted their analyses to a specific cancer type
11-16
 or cancer 
mortality
17
, instead of focusing on any cancer occurrence and did not assess the 
relation in a time-to-event analysis.
11-16
  
There is only one large longitudinal study investigating the association between 
thyroid function and cancer risk. A study by Hellevik et al.
9
, linked low TSH levels 
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to a higher risk of cancer. However, in this record-linkage study thyroid function of 
participants was measured only in a subsample of the population and FT4 
measurements were only performed in subjects with TSH values suggesting 
hyperthyroidism. Furthermore, risk estimates were only adjusted for a limited 
number of potential confounders and no information on thyroid medication use was 
available. 
For this reason, our objective was to assess the association between thyroid 
function in the full range (i.e. as a continuous variable, comprising both the normal 
range and values outside the reference interval of thyroid hormone) and incident 
cancer in general and lung, breast, prostate and gastrointestinal cancer in 
particular in a large prospective cohort study.  
 
METHODS 
Study design and population 
The Rotterdam Study is a prospective cohort study that started in 1990. By the end 
of 2008 14,926 subjects aged 45 years or over were included. The Rotterdam 
Study consists of three cohorts, RS I, RS II and RS III. RS I started in 1990 and 
recruited 7,983 subjects aged 55 years and over from Ommoord, Rotterdam. In 
2000 RS II started and 3,011 people who had turned 55 years or had moved into 
the study district were added to the cohort. The third extension, RS III started in 
2006 and included 3,392 Ommoord residents of 45 years and over that had not 
been previously invited to participate. This study was approved by the Erasmus 
MC Medical Ethics Committee and the Dutch Ministry of Health, Welfare and 
Sports. Details on the Rotterdam Study can be found elsewhere.
18,19
 
We included participants for whom we had measurements of thyrotropin (TSH) 
and/or free thyroxine (FT4) and who had given informed consent for follow-up (n = 
10,318). Patients with a cancer diagnosis before the measurement of thyroid 
function were excluded from the analyses. We excluded patients with a history of 
the cancer type specific for that analysis. Based on these criteria, 4,949 subjects 
were excluded from the analyses. Subjects were followed from their date of 
laboratory measurements until any cancer diagnosis, death or January 1
st
 2012, 
whichever occurred first.  
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Assessment of thyroid function 
For RS I-1, TSH (TSH Lumitest; Henning, Berlin, Germany) and FT4 (FT4; Vitros, 
ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, Amersham, UK) were 
assessed in blood samples collected in 1990. For RS I-3, II-1 and III-1, TSH and 
FT4 (electrochemiluminescence immunoassay for thyroxine and thyrotropin, 
“ECLIA”, Roche) were assessed in blood samples collected between 1997 and 
2008, depending on the RS cycle.
20
 The moment of blood drawing was considered 
the study baseline.
21
 The normal range of TSH was 0.4-4.0 mU/L, as 
recommended by national guidelines and our previous reports.
20,21
 For FT4, the 
normal range comprised 0.85-1.94 ng/dL (11-25 pmol/L).
20
 The measurements of 
the two assays were highly correlated (Spearman correlation co-efficient (r) = 0.96 
for TSH, P < 0.0001 and r = 0.81 for FT4, P < 0.0001). 
Assessment of cancer outcomes 
The primary outcome of interest was the occurrence of any solid cancer, except for 
non-melanoma skin cancers. Furthermore lung cancer (ICD-10; C34), breast 
cancer (ICD-10; C50), prostate cancer (ICD-10; C61) and gastrointestinal cancer 
(ICD-10; C15-C21) were assessed separately.  
Occurrence of cancer was determined through information obtained by four-yearly 
follow-up rounds from the general practitioners (including discharge letters from 
hospitals) and by linkage with a nationwide registry of histo- and cytopathology in 
the Netherlands (PALGA).
22
 Two research physicians independently assessed the 
first date and diagnosis of cancer. All events are pathology based and were 
classified according to the International Classification of Diseases (ICD) tenth 
edition. In case of discrepancy, consensus was sought or a cancer epidemiologist 
decided. 
Baseline measurements 
Highest attained education was taken as a proxy for socioeconomic status (SES) 
and was derived from questionnaires. Alcohol intake and tobacco smoking were 
determined by questionnaires. Alcohol intake was measured in grams per day and 
smoking status was defined as non-smoker, former smoker or current smoker. 
Body mass index (BMI) was assessed during physical examination by dividing the 
body weight in kilograms by the squared height in meters. Blood pressure was the 
average of two measurements during physical examination. Hypertension was 
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defined as a systolic blood pressure of ≥ 140 mm Hg, a diastolic blood pressure of 
≥ 90 mm Hg or the use of antihypertensive drugs. Diabetes mellitus was defined as 
a fasting plasma glucose level of ≥ 7 mmol/L, a non-fasting plasma glucose level of 
≥ 11.1 mmol/L (if fasting glucose was not present) or the use of antidiabetic 
medication. Serum cholesterol (mmol/L) was measured in laboratories of the 
Erasmus Medical Center. Furthermore, subjects provided information on breast 
cancer specific confounders (including number of pregnancies, hormone use, 
menarche age, menopause age and menopausal status). Hormone use referred to 
use of female hormones for menopausal complaints or use of oral contraceptives 
within 7 years of menopause and was categorized as ever or never. The 
reproductive lifespan was calculated by subtracting the menarche age from the 
menopause age. Menopausal status was defined as being perimenopausal or 
postmenopausal.  
Statistical analysis 
We used Cox proportional hazards models to obtain hazard ratios (HRs) with their 
95% confidence interval (95% CI) for the association between thyroid function and 
cancer. We conducted analyses in the full range of FT4 and TSH and if an 
association was present, we also assessed the association between thyroid 
hormone tertiles and incident cancer separately. Furthermore, we calculated the 
incidence rate per 10,000 person-years per tertile. In our first model, we adjusted 
for age (as a continuous variable), sex and cohort. In a second model, we 
additionally adjusted for potential confounders in line with the previously published 
literature
10,11,14-17
: SES, alcohol consumption, smoking status, BMI, hypertension, 
diabetes mellitus and serum cholesterol. For the breast cancer analyses, we 
adjusted for number of pregnancies, hormone use, reproductive life span and 
menopausal status additional to the second model. To control for missing values of 
the confounders, we used the Markov Chain Monte Carlo method to create 5 
imputed datasets which were pooled for analyses (missingness was < 2% for all 
covariates, except for alcohol consumption, number of pregnancies and 
reproductive life span, which was < 15%).  
We conducted predefined stratification analyses by age (cut-off of 65 years) and 
sex. The cut-off value for age is conform previously published literature and 
guidelines.
20,21
 We used interaction terms of age with FT4/TSH and sex with 
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FT4/TSH to assess effect modification. A sensitivity analysis was performed 
excluding subjects receiving thyroid-function altering medication. We performed a 
sensitivity analysis including cancer cases that were not histopathologically 
confirmed. Furthermore we performed a sensitivity analysis excluding the first 2 
years of follow-up to assess the possibility of reverse causality.  
We used log-transformed TSH in all continuous analyses, because of the skewed 
distribution of TSH.  
There was no departure from linearity, assessed by using 3 restricted cubic splines 
(P > 0.30 for all). There was no departure from the proportional hazards 
assumption, as assessed by the Schoenfeld test. All analyses were conducted in 
IBM SPSS Statistics 21, except for the linearity assumption which was assessed in 
R (rms package, R-project, Institute for Statistics and Mathematics, R Core Team 
(2013), Vienna, Austria, version 3.0.2) and the proportional hazards assumption, 
which was assessed using the Schoenfeld test in R (survival package, R-project, 
Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, 
version 3.0.2).  
 
RESULTS 
We included 10,318 participants with a median age of 61.3 years, of whom 57% 
were female. A total of 1,465 cases of any solid cancer occurred during a median 
follow-up duration of 10.4 years (interquartile range (IQR): 4.9-15.5) with an 
incidence rate of 14 per 1,000 person-years. Baseline characteristics of the study 
population are shown in Table 1.  
There was a positive association between FT4 and any solid cancer (HR: 1.42; 
95% CI: 1.12-1.79; per one ng/dL of FT4), lung cancer (HR: 2.33; 95% CI: 1.39-
3.92) and breast cancer (HR: 1.77; 95% CI: 1.10-2.84) (Table 2). In line with the 
negative relation between TSH and FT4, higher serum TSH levels were inversely 
associated with cancer, but only reached statistical significance in the first lung 
cancer analysis (HR: 0.84; 95% CI: 0.73-0.97).  
For any solid cancer, breast cancer and lung cancer, we also assessed the relation 
with FT4 tertiles, taking the first tertile as reference (Table 3). The HRs for the 
highest tertile compared to the reference, were 1.13 for any solid cancer, 1.79 for 
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lung cancer and 1.14 for breast cancer but only the HR for lung cancer was 
significantly increased. However, the HR increased per tertile in all three groups (P 
for trend < 0.05 for all). The incidence rate per 10,000 person-years significantly 
increased per FT4 tertile for any solid cancer and lung cancer. For breast cancer, 
the incidence rate in the middle and highest FT4 tertile was similar, but significantly 
higher than the incidence rate in the first tertile (Table 3). The HRs of any solid 
cancer, lung cancer and breast cancer are plotted against FT4 tertiles in Figure 1.  
 
 
Table 1 Baseline characteristics of the 10,318 study participants with FT4 and TSH 
measurements. 
Variable N (%)
a
 
Start age, years, median (IQR)  61.3 (57.3-68.4) 
Sex, female  5886 (57.0) 
FT4, ng/dL, mean (SD) 1.23 (0.2) 
TSH, mU/L, median (IQR)  1.9 (1.2-2.7) 
Alcohol intake, g/day, median (IQR) 13.8 (1.1-19.9) 
Smoking status 
Current  
Former  
Never  
 
2381 (23.1) 
4654 (45.1) 
3283 (31.8) 
BMI, kg/m
2
, median (IQR) 26.5 (24.3-29.2) 
Hypertension 
Diabetes mellitus 
5486 (53.2) 
929 (9.0) 
Total serum cholesterol, mmol/L, mean (SD) 6.1 (1.2) 
Pregnancies, mean (SD) 
Hormone use
b 
Reproductive life span
c
, mean (SD) 
Postmenopausal status 
2.2 (1.4) 
1212 (20.6) 
35.2 (5.5) 
5400 (91.7) 
a 
Unless stated otherwise; 
b 
Ever use of female hormones for menopausal complaints or start oral contraceptives within 7 years of 
menopause; 
c 
The difference between menarche age and menopause age;  
FT4 indicates free thyroxine; TSH, thyrotropin; BMI, body mass index; and IQR, interquartile range. 
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Figure 1 Association between FT4 tertiles and cancer 
 
 
Hazard ratios for any solid, lung and breast cancer were plotted against FT4 tertiles. The first tertile 
(0.12-1.14 ng/dL) was taken as the reference category. The second tertile comprised 1.14-1.29 ng/dL 
and the third tertile 1.29-4.73 ng/dL. Hazard ratios are adjusted for age, sex, cohort, socioeconomic 
status, alcohol consumption, smoking status, body mass index, hypertension, diabetes mellitus and 
serum cholesterol; For breast cancer hazard ratios are also adjusted for no. of pregnancies, hormone 
use (use of female hormones for menopausal complaints or start oral contraceptives within 7 years of 
menopause), reproductive life span (difference between menarche age and menopause age) and 
menopausal status. 
 
 
Excluding participants with thyroid-function altering medication resulted in similar 
risk estimates, but the association with breast cancer lost statistical significance 
(Table 4). There was no effect modification by age or sex (P > 0.05 for all 
interaction terms) (Supplemental Table 1). Risk estimates of the most adjusted 
models also remained similar when cancer cases that were not pathology based 
were included as outcome (Supplemental Table 2) and when the first 2 years of 
follow-up were excluded (Supplemental Table 3). 
Chapter 5.1 
328 
T
a
b
le
 2
  
A
s
s
o
c
ia
ti
o
n
 b
e
tw
e
e
n
 t
h
y
ro
id
 f
u
n
c
ti
o
n
 a
n
d
 c
a
n
c
e
r 
in
c
id
e
n
c
e
 
 
 
F
T
4
 (
n
g
/d
L
) 
H
a
z
a
rd
 R
a
ti
o
 (
9
5
%
 C
I)
a
 
 
T
S
H
 (
m
U
/L
) 
H
a
z
a
rd
 R
a
ti
o
 (
9
5
%
 C
I)
a
 
C
a
n
c
e
r 
ty
p
e
 
E
v
e
n
ts
 N
/ 
S
u
b
je
c
ts
 N
b
 
M
o
d
e
l 
1
c
 
M
o
d
e
l 
2
d
 
E
v
e
n
ts
 N
 /
 
S
u
b
je
c
ts
 N
b
 
M
o
d
e
l 
1
c
 
M
o
d
e
l 
2
d
 
A
n
y
 S
o
lid
 
1
4
4
2
/9
8
8
2
 
1
.4
8
 (
1
.1
7
-1
.8
6
)e
 
1
.4
2
 (
1
.1
2
-1
.7
9
)e
 
1
4
6
5
/9
9
7
2
 
0
.9
6
 (
0
.9
1
-1
.0
2
) 
0
.9
7
 (
0
.9
4
-1
.0
0
) 
L
u
n
g
 
2
0
1
/1
0
2
0
6
 
2
.7
2
 (
1
.7
5
-4
.2
3
)e
 
2
.3
3
 (
1
.3
9
-3
.9
2
)e
 
2
0
4
/1
0
2
9
5
 
0
.8
4
 (
0
.7
3
-0
.9
7
)e
 
0
.8
9
 (
0
.7
7
-1
.0
3
) 
B
re
a
s
t 
2
2
7
/5
6
9
8
 
1
.7
3
 (
1
.0
9
-2
.7
4
)e
 
1
.7
7
 (
1
.1
0
-2
.8
4
)e
 
2
2
9
/5
7
5
3
 
0
.9
7
 (
0
.8
5
-1
.1
1
) 
0
.9
5
 (
0
.8
3
-1
.0
9
) 
P
ro
s
ta
te
 
2
8
6
/4
3
6
0
 
1
.1
1
 (
0
.5
9
-2
.0
7
) 
1
.1
8
 (
1
.0
1
-1
.4
0
)e
 
2
9
3
/4
3
9
5
 
1
.0
0
 (
0
.8
6
-1
.1
6
) 
0
.9
9
 (
0
.9
2
-1
.0
7
) 
G
I 
3
5
3
/1
0
1
6
3
 
1
.4
1
 (
0
.8
8
-2
.2
6
) 
1
.3
4
 (
0
.8
4
-2
.1
5
) 
3
5
5
/1
0
2
5
2
 
1
.0
0
 (
0
.8
9
-1
.1
3
) 
1
.0
1
 (
0
.8
9
-1
.1
4
) 
a
 T
h
e
 s
h
o
w
n
 H
a
z
a
rd
 R
a
ti
o
s
 a
re
 p
e
r 
u
n
it
 i
n
c
re
a
s
e
 o
f 
F
T
4
 o
r 
lo
g
-t
ra
n
s
fo
rm
e
d
 T
S
H
; 
b
 S
u
b
je
c
ts
 a
re
 t
h
e
 s
tu
d
y
 p
a
rt
ic
ip
a
n
ts
 w
it
h
 b
a
s
e
lin
e
 T
S
H
 a
n
d
/o
r 
F
T
4
 
m
e
a
s
u
re
m
e
n
ts
 a
n
d
 n
o
 h
is
to
ry
 o
f 
th
a
t 
s
p
e
c
if
ic
 c
a
n
c
e
r 
ty
p
e
; 
c
 M
o
d
e
l 
1
 i
s
 a
d
ju
s
te
d
 f
o
r 
a
g
e
, 
s
e
x
 a
n
d
 c
o
h
o
rt
; 
d
 M
o
d
e
l 
2
 =
 M
o
d
e
l 
1
 +
 s
o
c
io
e
c
o
n
o
m
ic
 s
ta
tu
s
, 
a
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
, 
s
m
o
k
in
g
 s
ta
tu
s
, 
b
o
d
y
 m
a
s
s
 i
n
d
e
x
, 
h
y
p
e
rt
e
n
s
io
n
, 
d
ia
b
e
te
s
 m
e
lli
tu
s
 a
n
d
 s
e
ru
m
 c
h
o
le
s
te
ro
l;
 F
o
r 
b
re
a
s
t 
c
a
n
c
e
r 
m
o
d
e
l 
2
 i
s
 a
ls
o
 a
d
ju
s
te
d
 
fo
r 
n
o
. 
o
f 
p
re
g
n
a
n
c
ie
s
, 
h
o
rm
o
n
e
 u
s
e
, 
re
p
ro
d
u
c
ti
v
e
 l
if
e
 a
n
d
 m
e
n
o
p
a
u
s
a
l 
s
ta
tu
s
; 
e
 P
-v
a
lu
e
 <
0
.0
5
. 
F
T
4
 i
n
d
ic
a
te
s
 f
re
e
 t
h
y
ro
x
in
e
; 
T
S
H
, 
th
y
ro
tr
o
p
in
. 
 Ta
b
le
 3
 A
s
s
o
c
ia
ti
o
n
 b
e
tw
e
e
n
 F
T
4
 t
e
rt
ile
s
 a
n
d
 c
a
n
c
e
r 
in
c
id
e
n
c
e
 
 
A
n
y
 S
o
li
d
 C
a
n
c
e
r 
L
u
n
g
 C
a
n
c
e
r 
B
re
a
s
t 
C
a
n
c
e
r 
F
T
4
 t
e
rt
il
e
 
(n
g
/d
L
) 
E
v
e
n
ts
/ 
S
u
b
je
c
ts
 N
a
 
H
a
z
a
rd
 R
a
ti
o
  
(9
5
%
 C
I)
b
 
IR
c
 
E
v
e
n
ts
/ 
S
u
b
je
c
ts
 N
a
 
H
a
z
a
rd
 R
a
ti
o
 
(9
5
%
 C
I)
b
 
IR
c
 
E
v
e
n
ts
/ 
S
u
b
je
c
ts
 N
a
 
H
a
z
a
rd
 R
a
ti
o
  
(9
5
%
 C
I)
b
 
IR
c
 
1
 (
0
.1
2
-1
.1
4
) 
4
4
4
/3
3
0
5
 
R
E
F
E
R
E
N
C
E
 
1
2
7
 
4
2
/3
4
0
9
 
R
E
F
E
R
E
N
C
E
 
1
1
 
7
4
/2
0
4
3
 
R
E
F
E
R
E
N
C
E
 
3
3
 
2
 (
1
.1
4
-1
.2
9
) 
4
8
9
/3
2
9
4
 
1
.1
1
 (
1
.0
4
-
1
.1
9
)d
 
1
4
4
 
7
3
/3
4
0
0
 
1
.6
8
 (
1
.1
5
-
2
.4
6
)d
 
2
0
 
8
0
/1
8
8
9
 
1
.1
8
 (
0
.8
6
-
1
.6
2
) 
3
8
 
3
 (
1
.2
9
-4
.7
3
) 
5
0
9
/3
2
7
7
 
1
.1
3
 (
0
.9
9
-1
.2
8
) 
1
5
1
 
8
6
/3
3
9
4
 
1
.7
9
 (
1
.2
3
-
2
.5
9
)d
 
2
3
 
7
3
/1
7
6
2
 
1
.1
4
 (
0
.8
2
-
1
.5
8
) 
3
7
 
P
 f
o
r 
tr
e
n
d
  
0
.0
0
4
 
0
.0
0
2
 
0
.0
1
9
 
a
 S
u
b
je
c
ts
 a
re
 t
h
e
 s
tu
d
y
 p
a
rt
ic
ip
a
n
ts
 w
it
h
 b
a
s
e
lin
e
 T
S
H
 a
n
d
/o
r 
F
T
4
 m
e
a
s
u
re
m
e
n
ts
 a
n
d
 n
o
 h
is
to
ry
 o
f 
th
a
t 
s
p
e
c
if
ic
 c
a
n
c
e
r 
ty
p
e
; 
b
 H
a
z
a
rd
 r
a
ti
o
s
 a
re
 a
d
ju
s
te
d
 
fo
r 
a
g
e
, 
s
e
x
, 
c
o
h
o
rt
, 
s
o
c
io
e
c
o
n
o
m
ic
 s
ta
tu
s
, 
a
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
, 
s
m
o
k
in
g
 s
ta
tu
s
, 
b
o
d
y
 m
a
s
s
 i
n
d
e
x
, 
h
y
p
e
rt
e
n
s
io
n
, 
d
ia
b
e
te
s
 m
e
ll
it
u
s
 a
n
d
 s
e
ru
m
 c
h
o
le
s
te
ro
l;
 
F
o
r 
b
re
a
s
t 
c
a
n
c
e
r 
h
a
z
a
rd
 r
a
ti
o
s
 a
re
 a
ls
o
 a
d
ju
s
te
d
 f
o
r 
n
o
. 
o
f 
p
re
g
n
a
n
c
ie
s
, 
h
o
rm
o
n
e
 u
s
e
, 
re
p
ro
d
u
c
ti
v
e
 l
if
e
 s
p
a
n
  
a
n
d
 m
e
n
o
p
a
u
s
a
l 
s
ta
tu
s
; 
c
 In
c
id
e
n
c
e
 R
a
te
 p
e
r 
1
0
,0
0
0
 p
e
rs
o
n
-y
e
a
rs
; 
d
 P
-v
a
lu
e
 <
0
.0
5
. 
F
T
4
 i
n
d
ic
a
te
s
 f
re
e
 t
h
y
ro
x
in
e
; 
T
S
H
, 
th
y
ro
tr
o
p
in
. 
 
Thyroid function and cancer risk 
329 
T
a
b
le
 4
 A
s
s
o
c
ia
ti
o
n
 b
e
tw
e
e
n
 t
h
y
ro
id
 f
u
n
c
ti
o
n
 a
n
d
 c
a
n
c
e
r 
in
c
id
e
n
c
e
 a
ft
e
r 
e
x
c
lu
s
io
n
 o
f 
th
y
ro
id
 a
lt
e
ri
n
g
 m
e
d
ic
a
ti
o
n
a
 u
s
e
 
 
F
T
4
 (
n
g
/d
L
) 
T
S
H
 (
m
U
/L
) 
 
 
 
H
a
z
a
rd
 R
a
ti
o
 (
9
5
%
 C
I)
b
 
 
 
H
a
z
a
rd
 R
a
ti
o
 (
9
5
%
 C
I)
b
 
C
a
n
c
e
r 
T
y
p
e
 
E
v
e
n
ts
 
(N
) 
S
u
b
je
c
ts
 
(N
)c
 
M
o
d
e
l 
1
d
 
M
o
d
e
l 
2
e
 
E
v
e
n
ts
 
(N
) 
S
u
b
je
c
ts
 
(N
)c
 
M
o
d
e
l 
1
d
 
M
o
d
e
l 
2
e
 
A
n
y
 S
o
lid
 
1
3
8
2
 
9
4
3
9
 
1
.5
9
 (
1
.2
2
-2
.0
7
)f
 
1
.4
9
 (
1
.1
5
-1
.9
5
)f
 
1
4
0
5
 
9
5
2
3
 
0
.9
5
 (
0
.8
9
-1
.0
1
) 
0
.9
6
 (
0
.9
1
-1
.0
1
) 
L
u
n
g
 
1
9
4
 
9
7
4
2
 
3
.7
2
 (
2
.1
6
-6
.4
0
)f
 
2
.5
5
 (
1
.4
6
-4
.4
8
)f
 
1
9
7
 
9
8
2
5
 
0
.8
3
 (
0
.7
1
-0
.9
6
)f
 
0
.8
8
 (
0
.7
5
-1
.0
2
) 
B
re
a
s
t 
2
1
4
 
5
3
4
5
 
1
.7
2
 (
0
.9
3
-3
.1
7
) 
1
.7
6
 (
0
.9
5
-3
.2
5
) 
2
1
6
 
5
3
9
4
 
0
.9
5
 (
0
.8
3
-1
.1
0
) 
0
.9
4
 (
0
.8
1
-1
.0
8
) 
P
ro
s
ta
te
 
2
7
7
 
4
2
5
5
 
1
.1
5
 (
0
.6
0
-2
.2
1
) 
1
.2
2
 (
1
.0
0
-1
.4
9
) 
2
8
4
 
4
2
9
0
 
0
.9
6
 (
0
.8
2
-1
.1
3
) 
0
.9
5
 (
0
.8
8
-1
.0
3
) 
G
I 
3
3
8
 
9
7
0
4
 
1
.4
7
 (
0
.8
6
-2
.5
1
) 
1
.3
6
 (
0
.8
0
-2
.3
4
) 
3
4
0
 
9
7
8
7
 
1
.0
9
 (
0
.8
9
-1
.1
5
) 
1
.0
1
 (
0
.8
9
-1
.1
5
) 
a
 U
s
e
 o
f 
a
m
io
d
a
ro
n
e
, 
c
o
rt
ic
o
s
te
ro
id
s
, 
le
v
o
th
y
ro
x
in
e
, 
p
ro
p
y
lt
h
io
u
ra
c
il,
 c
a
rb
a
m
a
z
o
le
, 
th
ia
m
a
z
o
le
 a
n
d
/o
r 
io
d
in
e
; 
b
 T
h
e
 s
h
o
w
n
 H
a
z
a
rd
 R
a
ti
o
s
 a
re
 p
e
r 
u
n
it
 i
n
c
re
a
s
e
 o
f 
F
T
4
 o
r 
lo
g
-t
ra
n
s
fo
rm
e
d
 T
S
H
; 
c
 S
u
b
je
c
ts
 a
re
 t
h
e
 s
tu
d
y
 p
a
rt
ic
ip
a
n
ts
 w
it
h
 b
a
s
e
lin
e
 T
S
H
 a
n
d
/o
r 
F
T
4
 m
e
a
s
u
re
m
e
n
ts
, 
n
o
 h
is
to
ry
 o
f 
th
a
t 
s
p
e
c
if
ic
 c
a
n
c
e
r 
ty
p
e
 a
n
d
 n
o
 u
s
e
 o
f 
th
y
ro
id
-f
u
n
c
ti
o
n
 
a
lt
e
ri
n
g
 m
e
d
ic
a
ti
o
n
; 
d
 M
o
d
e
l 
1
 i
s
 a
d
ju
s
te
d
 f
o
r 
a
g
e
, 
s
e
x
 a
n
d
 c
o
h
o
rt
; 
e
 M
o
d
e
l 
2
 i
s
 a
d
ju
s
te
d
 f
o
r 
m
o
d
e
l 
1
, 
s
o
c
io
e
c
o
n
o
m
ic
 s
ta
tu
s
, 
a
lc
o
h
o
l 
c
o
n
s
u
m
p
ti
o
n
, 
s
m
o
k
in
g
 s
ta
tu
s
, 
b
o
d
y
 m
a
s
s
 i
n
d
e
x
, 
h
y
p
e
rt
e
n
s
io
n
, 
d
ia
b
e
te
s
 m
e
lli
tu
s
 a
n
d
 
s
e
ru
m
 c
h
o
le
s
te
ro
l;
 F
o
r 
b
re
a
s
t 
c
a
n
c
e
r 
m
o
d
e
l 
2
 i
s
 a
ls
o
 a
d
ju
s
te
d
 f
o
r 
n
o
. 
o
f 
p
re
g
n
a
n
c
ie
s
, 
h
o
rm
o
n
e
 u
s
e
 (
u
s
e
 o
f 
fe
m
a
le
 h
o
rm
o
n
e
s
 f
o
r 
m
e
n
o
p
a
u
s
a
l 
c
o
m
p
la
in
ts
 o
r 
s
ta
rt
 o
ra
l 
c
o
n
tr
a
c
e
p
ti
v
e
s
 w
it
h
in
 7
 y
e
a
rs
 o
f 
m
e
n
o
p
a
u
s
e
),
 r
e
p
ro
d
u
c
ti
v
e
 l
if
e
 s
p
a
n
 (
d
if
fe
re
n
c
e
 b
e
tw
e
e
n
 m
e
n
a
rc
h
e
 a
g
e
 a
n
d
 m
e
n
o
p
a
u
s
e
 a
g
e
) 
a
n
d
 m
e
n
o
p
a
u
s
a
l 
s
ta
tu
s
; 
f  P
-v
a
lu
e
 <
0
.0
5
; 
F
T
4
 i
n
d
ic
a
te
s
 f
re
e
 t
h
y
ro
x
in
e
; 
T
S
H
, 
th
y
ro
tr
o
p
in
. 
 
Chapter 5.1 
330 
DISCUSSION 
In this prospective population-based cohort study, higher FT4 levels were 
associated with an increased risk of any solid cancer, lung cancer and breast 
cancer. Overall, there was a negative association between TSH and cancer 
incidence, but not significantly. To our knowledge, this is the first prospective 
cohort study to assess the relation between the full range of thyroid function and 
cancer incidence.  
Our findings differ in some respects from the results of the study by Hellevik et al..
9
 
This prospective study in nearly 30,000 subjects found that low levels of TSH 
compared to the euthyroid reference group were associated with higher risk of 
cancer, mainly lung and prostate cancer.
9
 In our study, FT4 and not TSH, was 
associated with the risk of cancer in general and lung and breast cancer in 
particular. However, there are several differences between our study and the study 
by Hellevik et al. First, in the study by Hellevik and colleagues thyrotropin 
measurements were only performed in specific subsamples of the study 
population, possibly leading to selection bias. Also, they did not assess thyroid 
function in the full range and FT4 measurements were only performed in subjects 
with TSH values suggesting hyperthyroidism. Furthermore risk estimates were 
adjusted only for age, sex, smoking and BMI and no information on thyroid 
medication was available.
9
  
Based on the hypothalamus-pituitary-thyroid axis, one would expect that our 
findings on the association of higher FT4 levels and increased cancer risk would 
also be accompanied by a higher cancer incidence in association with decreasing 
TSH levels. However, even though lower TSH values were associated with a 
higher risk of cancer, this only reached significance in the first analysis with lung 
cancer. An association with FT4, but not with TSH, is in line with previous 
population based studies investigating the association between thyroid function 
and clinical outcomes.
20,21,23,24
 A potential explanation for the weaker association 
with TSH might be that, given the mean age of 63 years in our study, our results 
are due to an altered set point of the hypothalamus-pituitary-thyroid axis. It has 
been described that serum TSH levels increase with age while FT4 levels remain 
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unchanged. This might explain the lack of an association with TSH in this elderly 
population.
25
  
There are several pathways that might explain the relation between thyroid 
hormone and cancer. Firstly, binding of thyroid hormone to TRs can activate the 
oncogenic phosphatidylinositol-3-kinase (PI3K) pathway, independent of DNA 
binding.
5
 This pathway subsequently induces the expression of the transcription 
factor hypoxia-inducible factor 1 (HIF1). HIF1 target genes play a prominent role in 
tumor development, growth, invasion and metastasis. Secondly, thyroid hormone 
can bind the protein integrin αvβ3. This leads to activation of the PI3K and the 
ERK1/2 pathway. Via the latter pathway, fibroblast growth factor 2 (FGF2) is 
induced, which in turn stimulates angiogenesis and thus tumor growth.
5
 Also, 
thyroid hormone can activate mitogen-activated protein kinase (MAPK).
26
 In the 
cell nucleus MAPK leads to serine phosphorylation of thyroid receptors, which 
induces angiogenesis and tumor proliferation.
26
  
Thyroid hormone has also been found to stimulate expression of the programmed 
death-ligand 1 (PD-L1) gene. The PD1/PD-L1 checkpoint plays a key role in 
protecting cancer cells from T-cell mediated destruction.
27
 Other mechanisms of 
anti-apoptotic effects of thyroid hormone have also been described. Thyroid 
hormone decreases expression of tumor necrosis factor-α (TNF-α) and FAS ligand, 
both which are cell surface factors that activate apoptosis.
28
 Furthermore, thyroid 
hormone up regulates various anti-apoptotic genes, while down regulating pro-
apoptotic gene expression. An important example of the latter is the decreased 
activity of caspases, resulting in a reduction of DNA breakdown.
28
  
Tumor specific effects of thyroid hormones have been described as well. In 
prostate cancer cells, thyroid hormone can down regulate B-cell translocation gene 
2 (BTG2), resulting in increased proliferation.
2
 Furthermore, thyroid hormone can 
alter the expression level of cyclin D1, a protein that regulates the cell cycle, and of 
cyclin dependent kinases, leading to various tumor types, such as breast cancer 
and neural cancers.
1
 Action of thyroid hormone on estrogen and androgen 
receptors may also contribute to breast and prostate cancer respectively.
29,30
 Also, 
thyroxine phosphorylates the estrogen receptor α (ERα) and increases the 
expression of proliferating cell nuclear antigen (PCNA) via induction of αvβ3. 
These processes are associated with proliferation of ovarian and lung cancer 
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cells.
31,32
 Lastly, the tumor suppressor protein p53 inhibits thyroid hormone-thyroid 
receptor complexes, while thyroid receptor in turn counteracts stimulation of p53 
target genes.
2
 Future studies could focus on which of these pathways are involved 
in the relation between thyroid function and cancer and whether this differs per 
cancer site and stage.  
At baseline, 4.5% of women (n = 263) used levothyroxine and 0.4% (n = 22) used 
anti-thyroid drugs. In our sensitivity analysis excluding participants with thyroid 
function-altering medication, the association of FT4 with breast cancer lost 
statistical significance, although the effect estimates remained similar. It seems 
that these results became borderline non-significant due to a reduction in sample 
size, since predominantly women suffer from thyroid disorders and use thyroid-
altering medication.
33
 Although use of levothyroxine is associated with higher FT4 
levels
34
, this could not have driven the found associations in our main analyses. In 
that case, one would expect smaller effect estimates in the sensitivity analysis, 
whereas we found similar or even strengthened associations. Furthermore, > 97% 
of the included participants did not use any thyroid-altering medication. 
An important strength of our study is the prospective population-based design, 
large sample size and detailed information on potential confounders. Furthermore, 
we only looked at the occurrence of pathology confirmed cancer cases and were 
able to assess the effect of thyroid function in the full range. In contrast to 
previously conducted studies on this topic
9,10
, we have taken thyroid altering 
medication and a wide range of mediators and confounders into account. Also, risk 
estimates remained similar after exclusion of the first 2 years of follow-up, making 
reverse causality unlikely. A limitation of our study is that thyroid function is only 
measured at baseline; therefore we were unable to assess changes in TSH and 
FT4 levels in relation to cancer incidence. However, this is a limitation for most 
population-based cohort studies.
9,17,35,36
 Because of a limited number of cases, we 
were not able to assess the association between thyroid function and thyroid 
cancer. Also, like most observational studies, we cannot exclude residual or 
unmeasured confounding. Furthermore, the Rotterdam Study consists of a mainly 
Caucasian population aged 45 years and over, therefore results might not be 
generalizable to other populations.  
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Conclusion 
Serum FT4 levels are positively associated with an increased incidence of any 
solid cancer, lung cancer and breast cancer. Comparing the highest FT4 tertile to 
the lowest, there was a 1.13 fold increased risk of any solid, a 1.14 fold increased 
risk of breast cancer, and the risk of lung cancer nearly doubled. Future studies are 
needed to further elucidate the possible role of thyroid function in the pathogenesis 
of cancer, mainly lung cancer.  
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ABSTRACT 
BACKGROUND Thyroid dysfunction has been associated with kidney dysfunction, 
but mainly in cross-sectional studies. Therefore we aimed to determine the 
association between thyroid and kidney function in a prospective population-based 
cohort study longitudinally. 
 
METHODS Participants aged ≥45 years from the Rotterdam Study with thyroid and 
kidney function assessment were included. Kidney function and new onset chronic 
kidney disease (CKD) were defined using estimated glomerular filtration ate 
(eGFR), with CKD defined as eGFR <60 ml/min/1.73 m2 according to the CKD-EPI 
formula. 
 
RESULTS We included 5103 participants (mean age of 63.6 years) with a mean 
follow-up of 8.1 years. Cross-sectionally, higher TSH levels were associated with 
lower eGFR (Beta [β] -1.75 ml/min, 95% confidence interval [CI]; -2.17, -1.33), in 
multivariable models adjusting for several cardiovascular risk factors including 
smoking, hypertension and history coronary heart amongst others. In contrast, 
longitudinally, higher TSH levels were associated with less annual eGFR decline (β 
-0.06 ml/min, CI; -0.11, -0.01) and lower CKD incidence (Odds Ratio 0.85, CI; 0.75, 
0.96). Compared to euthyroid participants, subclinical hyperthyroid individuals had 
an increased risk for CKD whereas hypothyroid individuals had a decreased risk (p 
for trend =0.04).  
 
CONCLUSIONS Hyperactive thyroid function is associated with increased risk of 
kidney function decline while hypothyroidism is associated with a decreased CKD 
risk. More insight is needed in the pathophysiological pathways connecting high 
thyroid function and kidney function decline.  
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INTRODUCTION 
Thyroid hormone has an impact on renal tubular function, the renin–angiotensin 
system and is associated with hemodynamic and cardiovascular alterations that 
interfere with renal blood flow.
1,2
 Hypothyroidism has been associated with a low 
glomerular filtration rate and chronic kidney disease (CKD).
3,4
 On the other hand, 
chronic kidney disease can also lead to changes in thyroid function for example 
through non-thyroidal illness, metabolic acidosis or selenium deficiency.
5-7
 The co-
existence of (subclinical) hypothyroidism and renal dysfunction in patients has 
prompted investigation into the effects of thyroid hormone replacement therapy on 
CKD 
8,9
. However, most evidence concerning the association between thyroid and 
kidney function has been based on cross-sectional studies and included mostly 
patients with chronic kidney disease or thyroid dysfunction.
3,10,11
 The understanding 
of the temporal relationship between thyroid and kidney dysfunction therefore 
remains largely unexplored. So far, only two prospective studies in specific 
populations have investigated this association with conflicting results.
4,12
 One study 
was conducted in 555 participants of 85 years-old and found no association 
between thyroid status and change in renal function.
12
 The second study was a 
large cohort study including only euthyroid subjects and reported an increased 
CKD risk with low-normal thyroid function.
4
 To date, there are no large population-
based cohort studies investigating the continuous and full range of thyroid function 
and the risk of kidney function decline and CKD. Therefore, in the current 
prospective study, we aimed to investigate the association of thyroid function with 
the risk of kidney function decline and CKD in the general population.  
 
METHODS 
Study population  
The Rotterdam Study (RS) is a prospective population-based cohort study that 
investigates determinants and occurrence of cardiovascular, neurological, 
ophthalmologic, psychiatric, and endocrine diseases in the middle-aged and elderly 
living in Ommoord, a suburb of Rotterdam. The aims and design of the RS have 
been described in detail elsewhere.
13
 For this analysis we included participants 
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from three independent cohorts within the RS. The RS Cohort 1 (RSI) started in 
1990 and included a total of 7,983 participants (response rate 78 percent) aged 55 
years and older. RS Cohort II (RSII) includes a total of 3,011 participants (response 
rate 67 percent) aged 55 years and older and baseline data were collected from 
2000-2001. For the RS Cohort 3 (RSIII), all residents of Ommoord aged 45 years 
and over and who had not been invited before, were asked to participate and 
baseline data were collected from 2006 to 2008. A total of 3,932 participants 
entered the study (response rate 65 percent). Participants from study cohorts RSI 
(RSI-3), RSII (RSII-1) and RSIII (RSIII-1) were eligible for the study if TSH and FT4 
measurements as well as serum creatinine were available at baseline and follow-
up.  
The Medical Ethics Committee of the Erasmus University approved the study 
protocols and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study)”. All included participants provided a written informed consent in 
accordance with the Declaration of Helsinki to participate in the study and to obtain 
information from their family physicians. 
Assessment of thyroid function 
We performed thyroid function tests measurements in the three RS cohorts in 9762 
subjects. All samples were collected between 1997 and 2008, depending on the 
cohort, and measured using the same methods and assay. Thyroid function 
assessment was performed for TSH and FT4 in all three cohorts in serum samples 
stored at -80°C (The electrochemiluminescence immunoassay for thyroxine, 
thyrotropin and thyroid perioxidase antibodies, “ECLIA”, Roche). We determined 
the cut-off values for normal range of TSH as 0.4-4.0 mIU/L and FT4 as 11-25 
pmol/L (0.86-1.94 ng/dL) according to national guidelines as well as our previous 
studies. Thyroid function was defined as euthyroid if TSH was in the normal range 
(0.4-4.0 mIU/L). Overt hyperthyroidism was defined by a TSH level below the 
normal range (< 0.4 mIU/L) and FT4 above the normal range (> 25 pmol/L), while 
in subclinical hyperthyroidism FT4 values were within the normal range (11-25 
pmol/L). Overt hypothyroidism was defined by TSH levels above the upper range 
of normal (> 4.0 mIU/L) and FT4 below the normal range (< 11 pmol/L), while in 
subclinical hypothyroidism FT4 values were within the normal range (11-25 
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pmol/L). The laboratory measurements of thyroid function were not reported back 
to the participants and any thyroid therapy prescribed by their own GP or specialist 
is within the context of regular treatment and blinded to measurements of the RS.  
Kidney function and chronic kidney disease 
Serum creatinine was determined using an enzymatic assay method and 
determined using an enzymatic assay method using the same technique at the 
same laboratory for all three cohorts. Inter-assay and intra-assay coefficient 
variations were < 0.92% and <1.37%, respectively.
14
 Creatinine values were 
standardized to isotope-dilution mass spectrometry(IDMS)–traceable 
measurements. In order to calibrate, we aligned the mean values of serum 
creatinine with serum creatinine values of the participants of the Third National 
Health and Nutrition Examination Survey (NHANES III) in different gender and age 
groups (<50,50-59, 60-69, ≥70 years). Estimated Glomerular filtration rate (eGFR) 
was calculated according to the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula.
15
 To calculate the annual eGFR decline, we first 
subtracted the eGFR estimates of the follow-up examination from the eGFR 
estimates at baseline and then divided by the time, in years, between the two 
visits. For these analyses we used all participants with available eGFR 
measurements. Chronic kidney disease (CKD) was defined as eGFR < 60 
ml/min/1.73 m
2
. New CKD cases were defined among the individuals free of CKD 
at baseline (defined by eGFR >60 ml/min/1.73 m
2
), who had a decline in eGFR to 
less than 60 ml/min/1.73 m
2
 between the two periodical examinations.  
Baseline measurements 
Information on smoking was derived from computerized baseline questionnaires 
and categorized in current, previous and never smokers. Systolic and diastolic 
blood pressure were calculated as the average of two consecutive measurements, 
using a random-zero mercury sphygmomanometers. Information on anti-
hypertensive medication use was based on home interview at baseline. Serum 
glucose, total serum cholesterol and high-density lipoprotein cholesterol (HDL-C) 
were measured using standard laboratory techniques. History of diabetes was 
defined by a repeated impaired fasting glucose ≥ 7 or use of anti-glycemic 
medication at baseline. Body-mass index (BMI) was calculated as weight in 
kilograms divided by height squared in meters.  
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Statistical analysis 
We first jointly analysed RS cohort I and II and then replicated the results in RS 
cohort III, which provided similar sample sizes for discovery and replication. We 
present the combined multivariable analyses (RSI, RSII and RSIII) as our primary 
results. Linear regression models were used to evaluate the association of FT4 or 
TSH with baseline eGFR (based on creatinine) or decline in eGFR. Logistic 
regression models were performed to estimate the odds ratio (OR) for the 
association of FT4 or TSH with incident CKD.  
Due to a skewed distribution, TSH was log-transformed for all continuous statistical 
analyses.  
Our primary model included adjustment for age and sex. The multivariable models 
were additionally adjusted for systolic blood pressure, diastolic blood pressure, 
smoking, total cholesterol, high density lipoprotein cholesterol, diabetes mellitus, 
antihypertensive medications, and body mass index.  
We performed an analysis of covariance where mean values of decline in eGFR 
were compared across categories of thyroid function. We also assessed incidence 
of CKD in categories of thyroid function using logistic regression. For the thyroid 
function analyses all thyroid hormone users were excluded. 
We performed multiple imputation for missing data in the covariates (< 1% for all 
covariates), using a Markov Chain Monte Carlo method. 
We assessed differential risk by age or sex by adding an interaction term with the 
exposure variable. For the longitudinal TSH and FT4 analyses we performed the 
following sensitivity analyses: 1) restricting the analyses to participants with TSH 
and FT4 values within the normal range 2) excluding participants using thyroid 
function altering medication (including levothyroxine, anti-thyroid drugs, 
amiodarone and corticosteroids) or prevalent thyroid disease. There was no 
departure from linearity for the TSH, FT4 or thyroid function analyses. All statistical 
analyses were performed using SPSS version 21 (SPSS IBM, New York, U.S.A). 
Reporting of this study is according to the STROBE Statement.  
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RESULTS 
Baseline characteristics of included participants from the Rotterdam Study
13
, a 
population-based prospective cohort study, are shown in Table 1. Out of the 5103 
included participants (Figure 1) who had thyroid function and serum creatinine 
measurements, 43.6% were male (mean age of 64 years), with a mean follow-up 
of 8.1 years. A total of 4488 participants were euthyroid (87.9%), 467 had 
subclinical hypothyroidism (9.2%), 32 had hypothyroidism (0.6%), 106 were 
subclinically hyperthyroid (2.1%), 10 were hyperthyroid (0.2%) at baseline.  
 
Table 1 Baseline characteristics 
Variable N = 5103 
Age, years 63.6 (9.4) 
Men  2227 (43.6) 
Systolic blood pressure, mmHg 136.3 (19.8) 
Diastolic blood pressure, mmHg 80.3 (11.0) 
Smoking   
   Current 1057 (20.7) 
   Former 2419 (47.4) 
Total cholesterol, mmol/l 5.7 (1.01) 
High densitiy lipoprotein cholesterol, mmol/l 1.4 (0.4) 
Body mass index, kg/m
2
 27.3 (4.2) 
Diabetes mellitus 409 (8.0) 
History of coronary heart disease 188 (3.7) 
Glomerular filtration rate (creatinine), mL/min/1.73 m
2
 84.1 (14.1) 
TSH mIU/L 2.0 (1.4, 2.8) 
FT4 pmol/L 15.6 (2.2) 
Levothyroxine use 150 (2.9) 
Categorical variables are presented as numbers (percentages), continuous variables as means 
(standard deviations) and TSH is presented as median (interquartile range). 
Missing data: blood pressure (n=10), smoking (n=19), high density lipoprotein cholesterol (n=14), body 
mass index (n=21), diabetes (n=40), coronary heart disease (n=30). 
 
 
Cross-sectional analyses 
Compared to euthyroid subjects, hyperthyroid participants had a higher eGFR, 
while participants with hypothyroidism had a lower eGFR at baseline (Figure 2). 
There was a significant p for trend across the different thyroid function categories 
for eGFR at baseline (p <0.001). Higher TSH levels were associated with a lower 
baseline eGFR (Beta [β] -1.75, 95% confidence interval [CI]; -2.17, -1.33, per one 
unit of log transformed TSH).The effect estimates for the TSH analyses were 
similar between primary and multivariable models (Table 2). 
Chapter 5.2 
344 
Figure 1 Participants inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Cross-sectional association of thyroid function markers with kidney function 
 RS I & II RS III Combined 
 eGFR 
 Beta(95% CI) 
N =2524 
Beta(95% CI) 
N = 2579 
Beta(95% CI) 
N =5103 
TSH    
Model I -2.10 (-2.64, -1.56) -1.48 (-2.14, -0.81) -1.83 (-2.25, -1.41) 
Model II -2.00 (-2.53, -1.46) -1.40 (-2.06, -0.73) -1.75 (-2.17, -1.33) 
FT4    
Model I 0.02 (-0.18, 0.22) -0.05 (-0.27, 0.17) -0.02 (-0.17, 0.13) 
Model II -0.01 (-0.21, 0.19) -0.06 (-0.28, 0.16) -0.04 (-0.19, 0.10) 
Model I: Adjusted for age, sex, and cohort effect. 
Model II: Additionally adjusted for systolic blood pressure, diastolic blood pressure, smoking, total 
cholesterol, high density lipoprotein cholesterol, diabetes mellitus, antihypertensive medications, history 
of coronary heart disease, and body mass index. 
Abbreviations: CI: confidence interval, eGFR: estimated glomerular filtration rate, TSH: thyroid 
stimulating hormone, FT4: free thyroxine 
 
 
 
11432 with informed 
consent 
9691 had both FT4 
and TSH 
measurement 
available 
11740 in 
original cohort 
308 had no informed consent 
1741 did not have both TSH and FT4 
measurements  
5103 included 
participants 
4588 had no repeated kidney 
function measurements 
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Figure 2 Mean values of eGFR in categories of thyroid function  
 
  
From 5013 participants, 4488 were euthyroid, 467 subclinical hypothyroid, 32 hypothyroid, 106 
subclinical hyperthyroid, and 10 were hyperthyroid. These analyses were adjusted for age, sex, systolic 
blood pressure, diastolic blood pressure, antihypertensive medication, smoking, total cholesterol, high 
density lipoprotein cholesterol, diabetes mellitus, history of coronary heart disease, and body mass 
index. 
 
 
Longitudinal analyses 
In contrast to the cross-sectional analyses, higher TSH levels were associated with 
less annual eGFR decline (β -0.06, 95% CI; -0.11, -0.01, Table 3). Also, higher 
TSH levels were associated with lower incidence of CKD (OR 0.85, 95% CI; (0.75, 
0.96, Table 3) There was no association between TSH in the normal range of 
thyroid function and decline in eGFR or incident CKD (Table 4). When excluding 
subjects with clinically known thyroid disease or thyroid medication use (Table 4) 
the estimates were similar, but lost significance. Overall, FT4 values were not 
associated with eGFR decline or incident CKD (Table 3). There was no differential 
risk by age or sex (p for interaction > 0.15). Additionally adjusting for BMI change 
over time, did not change risk estimates (data not shown).
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Table 4 Sensitivity analyses for the longitudinal association of thyroid function markers with 
future decline in kidney function and incidence of CKD 
  eGFR decline  CKD incidence 
 N Beta (95% CI) N(cases) OR (95% CI) 
In subjects with normal range of TSH and FT4   
TSH     
            Model I  4459 -0.09 (-0.18, 0.01) 4265 (513) 1.01 (0.80, 1.27) 
            Model II  -0.09 (-0.19, 0.00)  0.99 (0.77, 1.26) 
FT4     
            Model I  0.00 (-0.02, 0.02)  1.00 (0.95, 1.06) 
            Model II  0.00 (-0.02, 0.02)  1.00 (0.95, 1.06) 
In individuals without thyroid function altering medication or thyroid disease 
TSH     
            Model I  4896 -0.04 (-0.10, 0.01) 4662 (566) 0.88 (0.77, 1.01) 
            Model II  -0.05 (-0.10, 0.01)  0.87 (0.76, 1.00) 
FT4     
            Model I  0.01 (-0.01, 0.03)  1.01 (0.97, 1.06) 
            Model II  0.01 (-0.01, 0.03)  1.01 (0.96, 1.06) 
Model I: Adjusted for age, sex, and cohort effect. 
Model II: Additionally adjusted for baseline eGFR, follow-up time, systolic blood pressure, diastolic 
blood pressure, antihypertensive medication, smoking, total cholesterol, high density lipoprotein 
cholesterol, diabetes mellitus, history of coronary heart disease, and body mass index. 
All analyses with CKD incidence as outcome are adjusted for follow up time. We determined the cut-off 
values for normal range of TSH as 0.4-4.0 mIU/L and FT4 as 11-25 pmol/L (0.86-1.94 ng/dL). Thyroid-
altering medication includes levothyroxine, anti-thyroid drugs, amiodarone and corticosteroids 
Abbreviations: CI: confidence interval, eGFR: estimated glomerular filtration rate, CKD: chronic kidney 
disease, OR: odds ratio, TSH: thyroid stimulating hormone, FT4: free thyroxine 
 
 
Participants with subclinical hyperthyroidism had more eGFR decline and 
hypothyroid participants had less decline in eGFR (Figure 3). For the CKD 
analyses, the hyperthyroidism category was excluded due to small number of 
events and therefore infinite estimates. Participants with hypothyroidism had a 
decreased risk of incident CKD while participants with subclinical hyperthyroidism 
had an increased risk of CKD. The p for trend was a significant across the different 
categories of thyroid function for incident CKD (p = 0.04) and for mean eGFR 
decline (p = 0.05). 
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Figure 3 Mean values of eGFR decline and odds ratios of CKD incident in categories of 
thyroid function 
 
 
From 5103 participants 4488 were euthyroid, 467 subclinical hypothyroid, 32 hypothyroid, 106 
subclinical hyperthyroid, and 10 were hyperthyroid. These analyses were adjusted for age, sex, systolic 
blood pressure, diastolic blood pressure, antihypertensive medication, smoking, total cholesterol, high 
density lipoprotein cholesterol, diabetes mellitus, history of coronary heart disease, and body mass 
index.NA = not available, due to small number of events in this strata. 
 
DISCUSSION 
To our knowledge, this is the first prospective population-based study to report an 
association between high thyroid function and kidney function decline in the 
general population. We report an increased risk of CKD and eGFR decline in 
subjects with lower TSH levels or hyperthyroid state, while hypothyroidism seems 
protective. This is irrespective of age, sex and several cardiovascular risk factors 
including blood pressure, smoking and cholesterol. 
A large study in over 460,000 veterans reports an inverse association between 
eGFR and the risk of hypothyroidism.
16
 This study is however not comparable to 
ours as it only participants with CKD defined as an eGFR of <60 mL/min/1.73 m2, 
while our population reflects the general population. Only two previous studies 
have longitudinally investigated the association between thyroid function and 
kidney function. However, these studies focused on specific study populations with 
small sample size, investigated specific thyroid states, instead of the continuous 
range of thyroid function, and their results were conflicting. While Zhang et al.
4
 
found a modestly increased risk of CKD with high-normal TSH levels in >100,000 
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euthyroid subjects, Meuwese et al.
12
 found no relation between thyroid function 
and kidney function in 555 subjects of 85 years old in the longitudinal analyses. 
The differences between our data and these studies may be explained by various 
factors. 
The Kangbuk Samsung Health (KSH) Study looked specifically in euthyroid 
subjects, while our results concern the continuous and full spectrum of thyroid 
function.
4
 When we restrict our analyses to subjects with thyroid function within the 
reference range, we find no association of thyroid function with kidney function 
decline or CKD. The CKD-EPI equation, which was used in KSH, has shown to 
introduce inaccuracy among certain racial-ethnic groups such as Asians.
17
 In 
addition, the mean age of the populations and follow-up times differ, since our 
population is substantially older (mean age of 38 vs 63.6 years), and had a longer 
follow-up (3.5 vs 8.2 years of follow-up). Finally, selection bias cannot be excluded 
from the KSH Study due to its design: screening health service of employees. The 
Leiden 85-plus Study, which focussed on older adults, included a relatively small 
number of participants (n = 555) and does not report information on CKD at 
baseline and during follow-up. The mean annual change presented for 
hyperthyroidism (eGFR -1 ml/min/1.73m
2
) and hypothyroidism (eGFR +0.5 
ml/min/1.73m
2
) compared to euthyroidism are in line with our results, but did not 
reach statistical significance in that study, possibly due to the lower numbers. 
Furthermore, in the current study we also conducted analyses with TSH as a 
continuous variable, where again we observed a protective effect of higher TSH 
values (i.e. lower thyroid function). 
Most, predominantly cross-sectional, studies to date have focused on the 
hypothesis that hypothyroidism gives rise to several cardiovascular risk factors and 
circulatory changes through which kidney function could be affected.
4,12,18,19
 In our 
study we confirm the cross-sectional association between (subclinical) 
hypothyroidism and lower eGFR. However, cross-sectional studies cannot provide 
information on the temporal relationship between thyroid function and kidney 
function and are prone to reverse causation. 
Therefore, the major aim of this study was to address the issue of temporality by 
conducting longitudinal analyses. In our study, participants with hypothyroidism 
had a decreased risk of incident CKD and less eGFR decline while participants 
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with subclinical hyperthyroidism had an increased risk of CKD and more eGFR 
decline. No studies to date had focussed on the possible association between a 
high thyroid function state and renal dysfunction even though both low and high 
state of thyroid function are associated with cardiovascular risk factors and 
disease. Effects of subclinical hyperthyroidism include atrial fibrillation, increase in 
left ventricular mass index, reduced exercise tolerance, reduced heart rate 
variability and an increase in markers of coagulation.
20-22
 Furthermore, thyroid 
hormone is known to activate the renin–angiotensin system
2
, which may cause 
efferent arteriolar vasoconstriction and lead to glomerular hypertension and 
hyperfiltration.
23
 The opposite relationship on eGFR in our cross-sectional and 
longitudinal analysis is similar to what has been described for diabetic 
nephropathy, which is also characterized by a higher eGFR initially (due to 
hyperfiltration), but by eGFR-loss and CKD in the long run.
24
  
The seemingly discrepant findings between cross-sectional and prospective 
analyses on thyroid function and kidney decline could be explained by distinctly 
different mechanisms. With cross-sectional data we may detect the bi-directional 
association of kidney and thyroid function, while with longitudinal data we could 
measure the deleterious effect of long-term exposure to high thyroid function state 
on kidney function. More research is needed to explore the difference between 
these two mechanisms to further characterize the long-term effects of variations of 
thyroid function on kidney function and disease. This is especially important when 
considering thyroid hormone replacement therapy in subclinical hypothyroidism.  
Strengths of our study include the large number of participants, detailed 
information on a wide variety of confounders and long follow-up period. Study 
limitations include the relatively small number of participants with hyperthyroidism 
and measuring thyroid function only once at baseline. In addition, information 
regarding the etiology of CKD cases is not present in the Rotterdam Study. 
Albuminuria is a strong predictor of kidney function decline, but unfortunately was 
not available in our cohort at baseline; adjusting our results for albumin-creatinine 
ratio at follow-up in a subset of participants did not change our findings (data not 
shown). Also, we were limited by the number of eGFR measurements and were 
only able to use 2 measurements to define a slope. Furthermore, the Rotterdam 
Study is constituted of a mainly white population of 45 years and older and might 
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therefore not be generalizable to other populations. Finally, because we primarily 
used creatinine-based estimating equations for GFR, we cannot exclude effects of 
thyroid hormone on the muscle metabolism of creatinine or its tubular secretion. 
In conclusion, high thyroid function is associated with an increased risk of incident 
CKD while hypothyroidism is associated with a decreased CKD risk. Further 
research should focus on the association between high thyroid function and kidney 
function and possible pathophysiological mechanisms. 
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ABSTRACT 
BACKGROUND Gait is an important health indicator and poor gait is strongly 
associated with disability and risk of falls. Thyroid dysfunction is suggested as a 
potential determinant of gait deterioration, but this has not been explored in a 
population-based study.  
 
METHODS We therefore investigated the association of thyroid function with gait 
patterns in 2645 participants from the Rotterdam Study with data available on TSH 
(thyroid-stimulating hormone), FT4 (free thyroxine) and gait, without known thyroid 
disease or dementia. The primary outcome was Global gait (standardized Z-score), 
while secondary outcomes included gait domains (Rhythm, Variability, Phases, 
Pace, Base of support, Tandem, Turning) and velocity. Gait was assessed by 
electronic walkway.  
 
RESULTS Multivariable regression models revealed an inverted U-shaped 
association of TSH (p<0.001), but no association of FT4 concentrations with Global 
gait (p=0.2). TSH levels were positively associated with Base of support (p=0.01) 
and followed an inverted U-shaped curve with Tandem (p=0.002) and velocity 
(p=0.02). Clinical and subclinical hypothyroidism were associated with worse 
Global gait than euthyroidism (β=-0.61;CI=-1.03,-0.18; p=0.004 and β=-0.13;CI=-
0.26,-0.00; p=0.04, respectively). In euthyroid participants, higher thyroid function 
was associated with worse gait patterns.  
 
CONCLUSIONS Both low and high thyroid function are associated with alterations 
in Global gait, Tandem, Base of support and velocity.  
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INTRODUCTION 
Gait is an important marker of general health. Disturbances in gait gradually 
increase with advancing age and affect approximately one third of community-
dwelling individuals older than 60 years
1
. Gait impairment has a substantial impact 
on quality of life and is strongly associated with increased risk of falls, which can in 
turn cause soft-tissue injuries, fractures and death
2,3
. Quantitative gait assessment 
comprises many parameters that can be summarized into seven independent 
domains, namely Rhythm, Variability, Phases, Pace, Base of support, Tandem and 
Turning (Figure 1)
4,5
. These gait domains reflect distinct functional abilities and 
their investigation is crucial to identify novel modifiable contributors to gait 
deterioration
5
.  
Thyroid hormones regulate metabolism in most tissues, including neurological and 
musculoskeletal systems, whose integrated functioning is reflected in gait
6-8
. 
Similar to gait disturbances, thyroid dysfunction becomes more prevalent with 
advancing age. However, the clinical manifestations of thyroid dysfunction are less 
pronounced among older adults
9
 and this may result in a diagnostic delay and 
increased risk of systemic complications. Research to date has suggested a 
possible role of thyroid dysfunction in gait impairment. Adult mice lacking the 
thyroid-hormone activating enzyme type 2 deiodinase have shown progressive gait 
impairment in the late stages of life
10
. In humans, several case series
11,12
 and case 
reports
13-15
 have shown a restoration of gait disturbances after treatment of thyroid 
disease.  
Thyroid function in the general population has been linked to gait velocity, which 
constitutes one of the parameters in the Pace domain 
16,17
. However, the link of 
thyroid function with gait and its spatiotemporal aspects remains unknown. 
Therefore, we aimed to investigate the association of thyroid function with Global 
gait and its separate domains, in a large population-based cohort of middle-aged 
and elderly subjects.  
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METHODS 
Study Population  
The Rotterdam Study (RS) is an ongoing prospective population-based cohort 
study that investigates chronic diseases in the middle-aged and elderly. The 
objectives and study design of RS have been described in detail elsewhere
18
. RS 
was initiated in 1990, including 7983 participants aged 55 years or older (RS I). In 
2000, the cohort was expanded with 3011 participants aged 55 or older (RS II). In 
2006, a third cohort of 3932 participants aged 45 years and over was added (RS 
III). As of now, RS comprises a total of 14926 participants, who undergo extensive 
follow-up medical examinations every 2 to 4 years. From 2009 onwards, 
quantitative gait assessment was included in the study protocol. Between March 
2009 and March 2012, 3651 participants of the RS were invited for gait 
assessment. An overview on the selection of study participants can be found in the 
flowchart (Supplementary Figure 1). 
The Medical Ethics Committee of the Erasmus University and the Ministry of 
Health, Welfare and Sport of the Netherlands have approved the study protocols, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study)”. The methods were performed in accordance with the approved 
guidelines. All included participants provided written informed consent in 
accordance with the Declaration of Helsinki.  
Population for analysis 
A total of 2857 subjects had complete information on thyroid function and gait. Of 
these, we excluded 212 subjects with at least one out of several conditions: 1) 
dementia diagnosis (n=14); 2) thyroid medication usage (n=79); 3) history of 
thyroid disease (n= 192) and 4) previous thyroid surgery (n=33) (Supplementary 
Figure 1). The remaining 2645 eligible participants were enrolled in the study. 
Assessment of thyroid function 
Thyroid function tests were performed in study cohorts RS I visit 3 (RS I-3), RS II 
visit 1 (RS II-1) and RS III visit 1 (RS III-1) using the same method and assay. 
Concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4) and 
thyroid peroxidase antibodies (TPOAb) were measured on baseline serum 
samples stored at -80°C using the electrochemiluminescence immunoassay, 
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“ECLIA”, Roche. We determined the reference range of serum TSH as 0.40–4.0 
mIU/L and serum FT4 as 11–25 pmol/L (alternatively 0.86–1.94 ng/dL), according 
to national guidelines and our previous studies
19,20
. Euthyroidism was defined as 
serum TSH within the reference range. Subclinical hypothyroidism was defined as 
serum TSH >4.0 mIU/L and FT4 levels within the reference range. Overt 
hypothyroidism was defined as serum TSH >4.0 mIU/L and FT4 levels <11 pmol/L. 
Subclinical hyperthyroidism was defined as serum TSH <0.40 mIU/L and FT4 
levels within the reference range. Overt hyperthyroidism was defined as serum 
TSH <0.40 mIU/L and FT4 levels >25 pmol/L. TPOAb positivity (reflecting thyroid 
autoimmunity) was defined as TPOAb levels above the cut-off of 35 kU/ml, in 
accordance with the recommendations of the assay manufacturer
19,20
.  
Assessment of gait 
Quantitative gait assessment was performed in study cohorts RS I visit 5 (RS I-5), 
RS II visit 3 (RS II-3) and RS III visit I (RS III.1). Gait was evaluated using a 5.79-m 
long walkway (GAITRite Platinum; CIR systems, Sparta, NJ: 4.88-m active area; 
120-Hz sampling rate). The reliability and validity of this device have been 
previously established
4,21-23
. The standardized gait protocol comprises three 
walking conditions: normal walk, turning and tandem walk (Figure 1). In the normal 
walk, participants walked at their usual pace across the walkway. This walk was 
repeated eight times, of which the first recording was considered a practice walk 
and excluded from the analyses. In turning, participants walked at their usual pace, 
turned halfway, and returned to the starting position. In the tandem walk, 
participants walked heel-to-toe on a line across the walkway. Based on the 
recorded footfalls, the walkway software calculated thirty gait parameters, including 
twenty five from the normal walk, two from turning and three from the tandem walk. 
Subsequently, principal component analysis (PCA) was performed to avoid 
multiple testing and collinearity across the variables. While capturing the largest 
amount of variance, PCA summarizes gait parameters into seven independent gait 
domains: Rhythm, Variability, Phases, Pace, Base of Support, Tandem and 
Turning
5
. Rhythm reflects cadence and stride time; Variability reflects variations in 
length and time among strides; Phases reflects double support time and double 
support as a percentage of the gait cycle; Pace reflects stride length and gait 
velocity; Base of Support reflects stride width and stride width variability; Tandem 
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reflects errors in tandem walking; Turning reflects turning time and the number of 
turn steps 
5
. When necessary, gait domains were inverted so that lower values 
represent “worse” gait. Global gait was calculated by averaging gait domains into a 
standardized Z-score
5
. Gait velocity was additionally included in our analysis in 
order to compare our findings with previous studies investigating the association 
between thyroid function and gait velocity
16,17
.  
 
Figure 1 The three walking conditions, including five gait domains for normal walk (Rhythm, 
Variability, Phases, Pace, Base of support), one for turn (Turning) and one for tandem walk 
(Tandem). 
 
 
 
Assessment of covariates 
The baseline home interview provided information on medical history, tobacco 
smoking, alcohol consumption, education level, medication, knee and hip pain or 
stiffness. Participants were categorized based on their smoking status (current, 
past and never smokers) and education level (low, intermediate and high). Height 
and weight were measured during the examinations at the research center. Stroke 
cases were reviewed and verified by an experienced vascular neurologist using 
hospital letters, information from practitioners and nursing home physicians. 
Depressive disorders were evaluated based on the Centre for Epidemiological 
Studies Depression Scale (CESD) questionnaire. A score above 16 was 
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considered indicative of a depressive disorder 
24
. Cerebellar cortical volume and 
intracranial volume were examined by standardized magnetic resonance imaging 
(MRI) scanning of the brain
18
.  
Statistical analysis 
We investigated the association of thyroid parameters (TSH, FT4 and TPOAb 
positivity) with Global gait and spatiotemporal gait components, by performing 
ordinary least-squares linear regression. The primary outcome was Global gait, 
while secondary outcomes included gait domains (i.e. Rhythm, Variability, Phases, 
Pace, Base of support, Tandem and Turning) and gait velocity. We fitted restricted 
cubic splines to allow for potential nonlinearity. Moreover, we evaluated Global gait 
and gait velocity throughout thyroid function categories, with euthyroid subjects as 
reference group. Next, we examined the association of thyroid function with gait in 
euthyroid participants. In addition, we performed a sensitivity analysis excluding 
participants with prevalent stroke (n=66) and Parkinson’s disease (n=3). 
All analyses were adjusted for potential confounding by age, sex, cohort, smoking 
status, alcohol intake (Model 1). As thyroid function measurement preceded the 
gait assessment, we also adjusted for the time interval between measurements. In 
Model 2, we additionally adjusted for covariates that could be either confounders or 
mediators, including education level, height, weight, knee pain or stiffness, hip pain 
or stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, 
intracranial volume, TPOAb concentrations. Step count and mean step size can 
affect the score of Tandem walk. Therefore, all models including Tandem walk 
were further adjusted for step count and mean step size. 
TSH values were logarithmically transformed, because of its skewed distribution. 
The assumption of normally distributed residuals was checked and met. All models 
were tested for effect modification by separately adding product interaction terms 
of the exposure (TSH or FT4 or TPOAb) with covariates of the multivariable model, 
but none of the interaction terms were significant. Multiple imputations were 
performed for covariates with missing data (less than 4.6% for all covariates). A p-
value (two-tailed) <0.05 was considered statistically significant. Statistical analyses 
were conducted using R statistical software (rms-package, R-project, Institute for 
Statistics and Mathematics, R Core Team, Vienna, Austria, version 3.2.2) and IBM 
SPSS version 21 (IBM Corp).  
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RESULTS 
We included a total of 2645 eligible participants with data available on thyroid 
function and gait, without known thyroid disease or dementia (Supplementary 
Figure 1). The baseline characteristics of the study population are shown in Table 
1. The mean age was 59.6 years and 52.6% were females (Table 1).  
 
Table 1 Baseline characteristics of 2645 participants 
Characteristics
 
Mean (SD)* 
Age, years 59.6 (6.6) 
Female, n (%) 1392 (52.6) 
Smoking, n (%)  
   Current 561 (21.2) 
   Past 1242 (47.0) 
   Never 842 (31.8) 
Alcohol intake >14 drinks/week, n (%) 565 (21.4) 
Education level, n (%)  
   Low 195 (7.4) 
   Intermediate 1821 (68.8) 
   High 629 (23.7) 
Height, cm 170.0 (9.2) 
Weight, kg 78.4 (14.1) 
Knee pain or stiffness, n (%) 693 (26.2) 
Hip pain or stiffness, n (%) 401 (15.2) 
Past stroke, n (%) 66 (2.5) 
CESD depressive symptoms, n (%) 298 (11.3) 
Cerebellar cortical volume, ml 99.3 (10.6) 
Intracranial volume, ml 1479.6 (159.6) 
TSH, mIU/L, median (IQR) 1.9 (1.3-2.8) 
FT4, pmol/L 15.5 (2.1) 
TPOAb positive, n (%) 312 (11.8) 
*Data are mean and standard deviation, unless otherwise specified. 
Abbreviations: sd, standard deviation ; CESD, Centre for Epidemiological Studies Depression Scale; 
TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine; TPOAb, thyroid 
peroxidase antibodies (cutoff 35 kU/ml). 
 
The association of thyroid function with global gait 
Our results did not change after primary and additional adjustments for potential 
confounders; therefore we further report only the most adjusted model (Model 2). 
TSH concentrations within the full range followed an inverted U-shaped curve with 
respect to Global gait (p-value <0.001) (Figure 2 A). However, there was no 
association of FT4 concentrations with Global gait (p=0.2) (Figure 2 B). When we 
restricted the analysis to euthyroid participants, higher TSH concentrations were 
associated with a better Global gait (β, 0.08; 95% confidence interval [CI], 0.02 to 
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0.13 per 1 unit logTSH; p=0.006). Moreover, there was a borderline statistically 
significant association between FT4 levels within the normal range and Global gait 
(β=-0.05; CI=-0.10 to 0.00 per 1 pmol/L FT4; p=0.05) (Figure 2 and Supplementary 
Table S1).  
 
Figure 2 Association of thyroid function with Global gait/Velocity 
 
Adjusted for age, sex, cohort, smoking, alcohol intake, education level, height, weight, time interval 
between thyroid function measurement and gait assessment, knee pain or stiffness, hip pain or 
stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, intracranial volume, 
thyroid peroxidase antibodies. We utilized linear regression models with restricted cubic splines. 
TSH/FT4 concentrations are plotted against predicted means of Z-score Global gait/Velocity (black 
lines) with 95% CI (gray areas). Dashed lines indicate the limits of TSH or FT4 reference ranges. A 
higher value of Global gait represents better gait. 
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Clinical and subclinical hypothyroidism were associated with a worse Global gait 
than euthyroidism (β=-0.61; CI=-1.03 to -0.18; p=0.004 and β, -0.13; CI, -0.26 to -
0.00; p=0.04 respectively) (Figure 3 A). No association was observed between 
TPOAb and Global gait in the main analysis or after restricting to euthyroid 
participants (Supplementary Table S2). Results remained similar after excluding 
participants with prevalent stroke and Parkinson’s disease (Supplementary Figure 
2). 
 
Figure 3 Association of thyroid status categories with Global gait/Velocity  
 
 
 
Adjusted for age, sex, cohort, smoking, alcohol intake, education level, height, weight, time interval 
between thyroid function measurement and gait assessment, knee pain or stiffness, hip pain or 
stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, intracranial volume, 
thyroid peroxidase antibodies. Thyroid status categories are plotted against differences in Z score of 
Global gait/Velocity, with euthyroid subjects as reference. None of the participants had clinical 
hyperthyroidism. Error bars represent the 95% confidence intervals around the standardized β (black 
dots). Within brackets: Total number. A higher value of global gait represents better gait. 
 
The associations of thyroid function with gait domains and gait velocity  
TSH levels were positively linearly associated with Base of support (p=0.01) and 
followed an inverted U-shaped curve with respect to Tandem (p=0.002) (Figure 4) 
and gait velocity (p=0.02) (Figure 2 C). In euthyroid participants, higher TSH levels 
were associated with higher Base of support (β=0.07; CI=0.01 to 0.14; p=0.01) and 
Tandem (β=0.06; CI=0.01 to 0.12; p=0.04), whereas higher FT4 levels were 
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associated with lower gait velocity (β=-0.96; CI=-1.85 to -0.07; p=0.03) 
(Supplementary Table S1). Clinical and subclinical hypothyroidism were associated 
with lower gait velocity than euthyroidism, with borderline statistical significance 
(β=-7.11; CI=-14.69 to 0.49; p=0.06 and β=-2.22; CI=- 4.50 to 0.05; p=0.05, 
respectively). Gait velocity decreased gradually from euthyroidism to clinical 
hypothyroidism (p-trend 0.01) (Figure 3 B). 
 
Figure 4 Association of TSH with the seven gait domains  
 
 
Adjusted for age, sex, cohort, smoking, alcohol intake, education level, height, weight, time interval 
between thyroid function measurement and gait assessment, knee pain or stiffness, hip pain or 
stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, intracranial volume, 
thyroid peroxidase antibodies. The model including Tandem walk was additionally adjusted for step 
count and mean step size. Point estimates are reported as predicted means (black lines) of gait 
domains with 95% CI (gray areas). A higher value of gait domains represents better gait. 
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DISCUSSION 
In a large cohort of middle-aged and elderly subjects, we reported an inverted U-
shaped association between TSH concentrations and Global gait, indicating that 
both low and high thyroid function are associated with worse gait. TSH levels were 
positively associated with Base of support and followed an inverted U-shaped 
curve with Tandem and gait velocity. In euthyroid subjects, higher thyroid function 
was associated with worse gait patterns. 
The association between thyroid function and gait could be explained by different 
pathophysiological mechanisms, particularly involving the neurological and 
musculoskeletal systems. Low and high circulating TSH levels may increase the 
risk of stroke through different pathways such as atrial fibrillation, hypercoagulation 
or unfavorable cardiovascular risk profile
25,26
. In addition, hypothyroidism can 
induce immune-mediated cerebellar degeneration
14
. Furthermore, both low and 
high thyroid function can lead to a dysregulation of the neurotransmission systems 
and subsequent depressive symptoms
27
. Low and high thyroid function may also 
contribute to myopathy and fractures, by affecting muscle mass and bone mineral 
density
28,29
. In turn, stroke, cerebellar degeneration, depression, myopathy and 
fractures are all implicated in gait deterioration
14,25-29
. In our study, adjustments for 
stroke, cerebellar cortical volume, TPOAb, CESD depression score, hip and knee 
pain or stiffness (proxy for musculoskeletal dysfunction) did not change the results, 
suggesting that the association between thyroid function and gait patterns is 
independent of these factors. Alternative underlying pathways could explain the 
association. The most plausible can be peripheral neuropathy, since thyroid 
dysfunction has been commonly associated with axonal degeneration and nerve 
conduction abnormalities
28,30,31
. Both hypothyroid and hyperthyroid patients usually 
experience symmetric distal sensory disturbances that can resolve after treatment 
of thyroid dysfunction
28,32
. Also, genetic disorders affecting thyroid hormone 
transport and metabolism might play a role in gait impairment
33
. However, the 
exact mechanisms through which thyroid function could affect the gait patterns 
remain unexplored and further studies should be directed towards unravelling the 
underlying pathophysiology. 
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Although gait is a multidimensional concept, gait assessment in prior comparable 
studies has been limited to the measurement of velocity
16,17
. A relatively small 
study (n = 602) reported an association of high-normal FT4 levels with slower 
walk
17
. A second study reported a faster walk in individuals with mildly elevated 
TSH levels (4.5-7.0 mU/L) compared with euthyroid individuals
16
. Our conclusions 
are in line with the results of the first study, but do not support those of the second 
study. Most likely, the discrepancy between our results and those of the second 
study may be attributable to differences in TSH reference ranges and thyroid status 
definitions. In the second study, participants with TSH levels between 4.5 and 7.0 
mIU/L were considered to have mild subclinical hypothyroidism, though they lacked 
FT4 measurements. Instead, we used both TSH and FT4 measurements to define 
the thyroid status of our participants. Therefore, our conclusions may add valuable 
information to the ongoing debate on the effects of untreated or undetected 
subclinical hypothyroidism. Most importantly, our large population-based cohort 
study extends the previous literature by addressing for the first time the association 
of thyroid function with Global gait and gait domains. Our results indicate the 
importance of comprehensive gait evaluation, as we observe a stronger 
association of thyroid status with Global gait than with gait velocity.  
We were able to identify Tandem, Base of Support and gait velocity as 
spatiotemporal gait aspects related to thyroid function. Likewise, past case reports 
have described hypothyroid patients with a “wide-based gait” and tandem walking 
errors on neurological examination
12-15
. In addition, adult mice lacking type 2 
deiodinase walked slower and with wider base of support than the wild-type mice
10
. 
Our results confirm these findings in the setting of a general population cohort 
study. Of note, the identification of thyroid-related gait domains may provide 
valuable hints on the pathways linking thyroid function to gait. Tandem, Base of 
Support and gait velocity have been associated with distinct brain structures (i.e. 
prefrontal regions, parietal cortex, pallidum, putamen, and cerebellum), executive 
functioning and balance, that might be specific targets of thyroid hormone 
action
4,15,34-38
.  
A limitation of our study is its cross-sectional design, which does not enable us to 
draw conclusions on causality. Though it is more likely that thyroid function affects 
gait than vice-versa, one could also hypothesize that health problems underlying 
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gait abnormalities may alter thyroid parameters in the setting of non-thyroidal 
illness syndrome (NTIS). This condition is characterized by normal TSH and low 
thyroid hormone levels
39
. Instead, we reported a non-linear association between 
TSH levels and Global gait. Also, NTIS is typical in critically ill patients, whereas 
the RS consists of community-dwelling adults
39
. Therefore, NTIS is unlikely to be 
the explanation of our findings. Furthermore, turning and tandem walk lacked 
repeated measurements, which would have reduced the intra-individual variability. 
However, we did perform up to eight consecutive recordings of the normal walk 
and used a well validated instrument for an objective gait evaluation in three 
walking conditions. Also, the RS does not have data available on serum 
triiodothyronine levels, which is a limitation for most population-based studies. 
However, TSH and FT4 concentrations are considered as the most relevant 
measurements of thyroid function in clinical practice. Moreover, RS includes 
predominantly Caucasians over 45 years old, which limits the generalizability of our 
findings to other populations. Lastly, the possibility of residual confounding cannot 
be excluded, even though we controlled for multiple potential confounders. 
In summary, both low and high thyroid function are associated with worse gait 
patterns. There is an inverted U-shaped association of TSH levels with Global gait, 
Tandem and gait velocity, as well as a positive association of TSH levels with Base 
of support. Subjects with clinical and subclinical hypothyroidism have worse gait 
patterns than euthyroid individuals. These conclusions might have future 
implications regarding the prevention and treatment of thyroid and gait disorders. 
Further studies are needed to confirm our findings, determine the underlying 
mechanisms linking thyroid function to gait patterns and subsequently investigate 
the possible motor benefits of thyroid treatment. 
 
Online supplemental material 
https://www.nature.com/articles/srep38912 
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ABSTRACT 
BACKGROUND In animal models, lack of thyroid hormone is associated with cone 
photoreceptor preservation while administration of high doses of active thyroid 
hormone leads to deterioration. The association between thyroid function and age-
related macular degeneration (AMD) has not been investigated in the general 
population. 
METHODS Participants ≥55 years from the Rotterdam Study with thyroid-
stimulating hormone (TSH) and/or free thyroxine (FT4) measurements and AMD 
assessment were included. We conducted age- and sex-adjusted Cox-
proportional-hazards models to explore the association of TSH or FT4 with AMD, in 
the full range and in those with TSH (0.4-4.0 mIU/L) and/or FT4 in normal range 
(11-25 pmol/L). Cox models were performed for the association of TSH or FT4 with 
Retinal Pigment Alterations (RPA), as an early marker of retinal changes. 
Multivariable models additionally included cardiovascular risk factors and thyroid 
peroxidase antibodies positivity. We also performed stratification by age and sex. A 
bidirectional look-up in Genome-Wide Association Studies (GWAS) data for thyroid 
parameters and AMD was performed. Single Nucleotide Polymorphisms (SNPs) 
that are significantly associated with both phenotypes were identified. 
RESULTS We included 5573 participants with a median follow-up of 6.9 years 
(interquartile range 4.4-10.8 years). During follow-up 805 people developed AMD. 
TSH levels were not associated with increased risk of AMD. Within normal range of 
FT4, participants in the highest FT4 quintile had a 1.34-fold increased risk of 
developing AMD, compared to individuals in the middle group (95% confidence 
interval [CI] 1.07-1.66). Higher FT4 values in the full range were associated with a 
higher risk of AMD (Hazard Ratio 1.04, CI, 1.01-1.06 per 1 pmol/L increase). 
Higher FT4 levels were similarly associated with a higher risk of RPA. Restricting 
analyses to euthyroid individuals, additional multivariable models and stratification 
did not change estimates. We found a SNP (rs943080) in the VEGF-A gene, 
associated with AMD, to be significant in the TSH GWAS (p=1.2x10
-4
). Adding this 
SNP to multivariable models did not change estimates. 
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CONCLUSIONS Higher FT4 values are associated with increased risk of AMD -
even in euthyroid individuals- and increased risk of RPA. Our data suggest an 
important role of thyroid hormone in pathways leading to AMD. 
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INTRODUCTION 
Age-related macular degeneration (AMD) is a disease of the retina in the elderly 
which can lead to irreversible blindness and is characterized by drusen, pigmentary 
changes, choroidal neovascularization and geographic atrophy. While AMD is one 
of the leading causes of visual impairment worldwide and increasing in prevalence 
1-7
, the exact pathophysiology and pathways leading to AMD are not entirely 
understood.  
Thyroid hormones are known to regulate various visual functions in experimental 
and human studies 
8-10
. Human retinal pigment epithelial (RPE) cells express 
thyroid hormone receptors and seem to be a direct target for thyroid hormones 
11
.  
Recently it has been shown that suppression of thyroid hormone signaling resulted 
in preservation of cone photoreceptors in mouse models of retinal degeneration 
12
. 
In contrast, administration of active thyroid hormone leads to deterioration of 
cones. Thyroid dysfunction and subclinical thyroid dysfunction are common in the 
general population, with a prevalence up to 10% 
13-16
. These thyroid disorders are 
associated with various cardiovascular risk factors, including alterations in lipid 
levels, atherosclerosis and hypertension 
17-19
, which are known predisposing 
factors for development and progression of AMD 
20,21
. However, there are no 
studies in the general population assessing the association between thyroid 
function and the risk of AMD. Therefore, we aimed to assess the relation between 
thyroid-stimulation hormone (TSH), free thyroxine (FT4) and the risk of incident 
AMD in a prospective population-based cohort study and to study possible 
underlying genetic pathways through investigating an overlap in genome-wide 
significant hits (i.e. bidirectional genetic look-up). 
 
METHODS 
The Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study that 
addresses determinants and occurrence of cardiovascular, neurological, 
ophthalmologic, psychiatric, and endocrine diseases in the elderly living in 
Ommoord, a suburb of Rotterdam. The aims and design of the Rotterdam study 
Thyroid function and AMD 
377 
have been described elaborately elsewhere 
22
. For this analysis we included 
participants from two independent cohorts from the Rotterdam Study. The 
Rotterdam Study Cohort 1 (RSI) started in 1989 and included a total of 7,983 
participants (response rate 78 percent) aged 55 years and older. Baseline data 
were collected from 1990 until 1993 and four follow-up examinations were 
performed in 1993-1995, 1997-1999, 2002-2004 and 2009-2011. 
The second cohort is the Rotterdam Study Cohort II (RSII) and includes a total of 
3,011 participants (response rate 67 percent) aged 55 years and older. Baseline 
data were collected from 2000-2001 and follow-up examinations were performed in 
2004-2005 and 2011-2012. 
Study population  
Participants from baseline study cohorts RSI (RSI-1) and RSII (RSII-1) were 
eligible for these analyses if they had TSH and/or FT4 measurements and had 
gradable fundus photographs at baseline and at least one follow-up eye 
examination. Since not all participants from RSI had thyroid measurements at 
baseline, additional baseline samples were drawn from RSI visit 3 (RSI-3). 
Participants with AMD at baseline (N=567) were excluded from further analyses. In 
total 5573 participants from these two cohorts were eligible to be included in our 
analyses (Additional Figure 1). The Medical Ethics Committee of the Erasmus 
University had approved the study protocols, and participants had given a written 
informed consent in accordance with the Declaration of Helsinki. 
Assessment of thyroid function 
For RSI-1, serum TSH (TSH Lumitest; Henning, Berlin, Germany), anti-TPOAb 
(ELISA; Milenia; Diagnostic Products Corp, Los Angeles, CA, USA) and free T4 
levels (FT4; Vitros, ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, 
Amersham, UK) were determined in a random subset of the baseline serum 
samples (n=1855). Thyroid function assessment was also performed in baseline 
serum samples for TSH and FT4 (The electrochemiluminescence immunoassay for 
thyroxine and thyrotropine, “ECLIA”, Roche) for RSI-3 and RSII-1. The tests’ TSH 
reference ranges did not differ substantially and had a good Spearman correlation 
co-efficient (0.96 for TSH, p < 0.0001and 0.81 for FT4, p < 0.0001). We determined 
the cut-off values for normal range TSH as 0.4-4.0 mIU/L according to national 
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guidelines. The reference range for FT4 was 11-25 pmol/L and anti-TPOAb levels 
greater than 60 kU/mL were regarded as positive. 
Diagnosis of age-related macular degeneration 
All eligible participants underwent fundus photography after pharmacologic 
mydriasis. For visits RSI-1 to RSI-3 and RSII-1 a 35 film fundus camera was used 
(Topcon TRV-50VT, Topcon Optical Company, Tokyo, Japan) after which a 35 
digital color fundus camera (Topcon TRC-50EX, Topcon Optical Company, Tokyo, 
Japan with a Sony DXC-950P digital camera; 0.44 megapixel, Sony Corporation, 
Tokyo, Japan) followed for visits RSI-4, RSI-5, RSII-2 and RSII-3. Fundus 
transparencies were graded according to the Wisconsin Age-Related Maculopathy 
Grading 
23
 and the modified International Classification System 
24
 by trained 
graders under the supervision of senior retinal specialists ( J.R.V., C.C.W.K.). The 
eyes of each participant were graded and classified separately, and the eye with 
the more severe grade was used to classify the person. In the analyses incident 
early and late AMD combined was used as outcome variable. In the manuscript 
this is referred to as AMD. Besides AMD we also investigated AMD specific lesions 
as a separate outcome variable. These lesions included retinal pigmentary 
alterations, large drusen (≥125µm) and large drusen area (≥ 5331,820 µm2) 
25
. 
Baseline measurements 
Smoking was derived from computerized baseline questionnaires and categorized 
in current or non-current smokers. Blood pressure, systolic and diastolic, was 
calculated as the average of two consecutive measurements, using random-zero 
mercury sphygmomanometers. Hypertension was defined as having a systolic 
blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90mmHg or using anti-
hypertensive medication at baseline. Cholesterol was measured at baseline by the 
CKCL (Centra Clinical Chemical Laboratory) of the Erasmus University Medical 
Center. A subgroup of measurements was carried out in the laboratory of the 
Department of Epidemiology & Biostatistics (Erasmus University Medical School). 
History of diabetes was defined by a repeated impaired fasting glucose ≥ 7 or use 
of anti-glycemic medication at baseline. Body-mass index (BMI) was calculated as 
weight kilograms divided by height squared in meters.  
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Statistical analysis 
Participant baseline characteristics were compared using a χ
2
 or t-test. Due to a 
skewed distribution, TSH was log-transformed for the statistical analyses. We used 
cox-proportional hazards model to calculate the relationship between TSH and FT4 
at baseline and the risk of incident AMD, first including all participants and then 
including only those with normal range TSH and/or FT4 values. We performed a 
crude cox-model including only thyroid parameters after which we also included 
quadratic and cubic terms to explore possible non-linear relationships. We then 
performed additional models adjusting first for age and sex and second also adding 
smoking, hypertension, cholesterol, diabetes and BMI to the model. Hypertension, 
cholesterol, diabetes and BMI could act as confounders and possible mediators 
depending on the presumed pathway through which thyroid function is related to 
AMD. These variables were included in the multivariable model as possible 
confounders of non-vascular pathways. We looked at the association between 
AMD and TSH or FT4 both continuously and in quintiles, as well as overall and 
within the normal range of TSH. The middle quintile was used as reference group 
as biologically it is expected to represent the subgroup with the most normal 
thyroid function within the euthyroid group. We performed pre-defined stratification 
by sex and age categories, using a cutoff 65 years as this is the median of the 
current population and the treatment threshold for subclinical thyroid dysfunction 
according to the European guidelines 
26
. Further interaction terms were introduced 
to the model to explore possible differential risk patterns. We performed a 
sensitivity analysis excluding those using thyroid medication at baseline 
(levothyroxine and anti-thyroid drugs) and those with prior self-reported thyroid 
disease at baseline. We also performed FT4 and TSH analyses with specific AMD 
lesions defined as retinal pigment alteration, large drusen and large drusen area as 
separate outcome variable to examine possible early changes in underlying 
pathways. To address the issue of drop-out of individualsduring follow-up that 
could possibly be not completely at random, we adjusted the model for inverse 
probability weights (IPW”s). These were calculated using possible baseline 
explanatory variables for drop-out such as smoking, BMI and medication use. 
Proportional hazards assumption was checked statistically using the Schoenfeld 
test and assessing the Schoenfeld plot. All statistical analyses were performed 
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using SPSS version 21 (SPSS IBM, New York, U.S.A) except for the Schoenfeld 
tests and (Schoenfeld) plots which were performed in R (survival package, R-
project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, 
Austria, version 3.0.2). 
Bidirectional genetic look-up 
Genome-Wide Association Studies (GWAS) have been performed for AMD 
27
 and 
thyroid function (TSH and FT4) 
28,29
. These studies identified several single-
nucleotide polymorphisms (SNPs) associated to these two phenotypes. Some of 
the genome-wide significant SNPs in the AMD GWAS might also play a role in 
thyroid function and vice versa. Overlap between common genetic polymorphisms 
can provide insight into possible shared genetic pathways. It might also elucidate a 
mediation effect between the two phenotypes, i.e. identify and explicate the 
process that underlies a possible observed relationship between thyroid function 
and AMD. To evaluate these potential genetic pathways, we conducted a 
bidirectional genetic look-up using the results of the above mentioned GWA 
Studies for AMD and thyroid function. We first extracted SNPs that reached 
genome-wide significance from the AMD GWAS performed by the AMD Gene 
consortium 
27
. We then checked whether these were significantly associated with 
TSH or FT4 in the thyroid function GWAS performed by Porcu et al. 
28
. Hereafter 
we extracted the genome-wide significant SNPs for TSH or FT4 from the thyroid 
function GWAS and checked whether they were associated with AMD in the AMD 
GWAS. For the significance level, we applied a multiple testing correction 
(Bonferroni Correction), using a p-value threshold of 0.05 divided by the amount of 
significant SNPs per GWAS. In case of a significant finding, we added the SNP to 
the multivariable model to evaluate a possible mediation effect.  
 
RESULTS 
We included 5573 participants with TSH and/or FT4 measurements at baseline 
and incident AMD data, with a median follow-up of 6.9 years (interquartile range 
[IQR] range of 4.4-10.8 years). Of these, 5572 had TSH and 5504 had FT4 
baseline measurements. A total of 805 people developed AMD (Early AMD N=725, 
Late AMD N=80) during follow-up with an incidence rate of 18 per 1000 person-
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years. The baseline characteristics for those with and without incident AMD during 
follow-up were comparable, except for proportion of diabetes (Table 1).  
 
 
Table 1 Baseline characteristics of included participants from the Rotterdam Study 
evaluating the association between thyroid function and AMD* 
Variable No incident AMD Incident AMD  
  N=4768 N=805 P-value** 
Age, years 67.6 (7.6) 67.9 (7.1) 0.29 
Sex % female 57.6 57.8 0.94 
History of Diabetes % 10.8 8.4 0.04 
BMI kg/m
2
  26.9 (3.9) 26.6 (3.7) 0.07 
Cholesterol mmol/L 6.1 (1.2) 6.1 (1.1) 0.23 
Smoking % current 20.7 21.0 0.85 
Hypertension % 63.0 58.7 0.17 
TSH mIU/L median (IQR) 1.78 (1.15-2.69) 1.73 (1.17-2.67) 0.78 
FT4 pmol/L 15.8 (2.6) 16.0 (3.2) 0.13 
TPOAb kU/L 30.5 (95.1) 30.8 (96.2) 0.93 
*Values are means and SD unless otherwise specified. 
** For comparison a t-test was conducted, for TSH the log-transformed values were used. 
Abbreviations: AMD = Age-related Macular Degeneration; BMI = body-mass index; TSH = thyroid-
stimulating hormone, FT4 = free thyroxine; SD = Standard deviation; IQR = inter-quartile range; TPOAb 
= thyroid peroxidase antibodies. 
 
 
Association between thyroid function and AMD 
Although there was no association between TSH and AMD (hazard ratio [HR] 0.99; 
95% confidence interval [CI] 0.91-1.07, Table 2), the risk of AMD was significantly 
increased in those with higher FT4 levels (Table 2). When categorizing the FT4 
values within normal range quintiles, those in the highest FT4 quintile had an 
increased risk compared to the middle group with a HR of 1.34 (95% CI, 1.07-1.66) 
and a non-significant p for interaction (p=0.066) (Table 2). This association 
remained similar after additional adjustments for smoking, diabetes, hypertension, 
cholesterol, BMI, and TPOAb positivity (Figure 1). This association also remained 
similar after analyzing only those within the normal range of TSH and FT4 i.e. 
normal thyroid function. Excluding those with thyroid medication or thyroid disease 
at baseline as a sensitivity analysis, did not alter the association (Table 3). 
Stratifying for age and sex did not reveal any significant differential risk (Additional 
Table 1).  
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Figure 1 Quintiles of FT4 within the normal range and risk of AMD 
 
 
††
 The normal range of FT4 was defined as 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL). 
a
 Analyses were adjusted for sex, age, smoking, hypertension, cholesterol, diabetes, body-mass index 
and thyroid peroxidase antibodies positivity
 
Abbreviation: Age-related Macular Degeneration; FT4 free thyroxine; HR hazard ratio  
 
 
Table 3 Sensitivity analyses excluding participants with thyroid medication or thyroid 
disease at baseline 
Incident AMD 
vs no AMD 
AMD N/ 
Total N 
HR (95% CI), 
model 1 
HR (95% CI), 
model 2 
HR (95% CI), 
model 3 
Excluded medication thyroid
a
   
Free T4 752/5225 1.03 (1.01-1.06) 1.03 (1.01-1.06) 1.03 (1.01-1.06) 
TSH mIU/L 778/5417 0.99 (0.91-1.08) 1.00 (0.92-1.09) 1.00 (0.91-1.09) 
     
Excluding baseline thyroid disease
b
   
Free T4 751/5237 1.04 (1.01-1.08) 1.04 (1.01-1.07) 1.04 (1.01-1.08) 
TSH mIU/L 764/5300 0.98 (0.89-1.07) 0.98 (0.89-1.07) 0.97 (0.89-1.07) 
a
 155 participants had thyroid medication (ie. thyroid hormone use) at baseline 
b 
272 participants had self-reported thyroid disease at baseline 
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, 
BMI. Model 3: Model 2 + thyroid peroxidase antibodies positivity 
Abbreviations: BMI body-mass index; CI confidence interval; FT4 free thyroxine; HR hazard ratio; TSH 
thyroid-stimulating hormone 
 
 
The association between thyroid function and retinal pigment alterations for FT4 
showed similar significant hazard ratios, with the exception of the risk estimates 
when looking at FT4 only in the normal range of TSH (Table 4). TSH and FT4 were 
not associated with large drusen or large drusen area (data not shown). 
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Introducing quadratic and cubic terms for TSH and FT4 to the crude model, as an 
exploration of non-linearity, did not improve model performance. Taking possible 
non-random follow-up using IPW’s did not change risk estimates. The proportional 
hazards assumption was checked statistically with the Schoenfeld test and 
Schoenfeld plot and met for both the TSH (p = 0.232) and FT4 (p = 0.154) 
analyses. 
 
 
Table 4 Association between FT4 and TSH with retinal pigment alterations
a 
Incident pigment 
alterations vs no 
pigment alterations 
Cases N/ 
Total N 
HR (95% CI), 
model 1 
HR (95% CI), 
model 2 
HR (95% CI), 
model 3 
     
TSH mIU/L 729/5401 0.98 (0.90-1.06) 0.97 (0.90-1.06) 0.96 (0.88-1.04) 
 
    
Normal range TSH
b
 618/4591 1.02 (0.87-1.20) 1.05 (0.89-1.23) 1.04 (0.88-1.22) 
     
FT4 pmol/L 720/538 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07) 
     
Normal range FT4
c
 697/5226 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07) 
     
Normal range FT4
c
 in 
normal range TSH
b 
601/4500 1.03 (1.00-1.07) 1.03 (0.99-1.06) 1.03 (0.99-1.06) 
      
a 
participants with late AMD were excluded from this analysis 
b 
normal range of TSH defined as 0.4-4.0 mIU/L. 
c
 normal range of FT4 defined as 11-25 pmol/L.
 
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, 
BMI. Model 3: Model 2 + thyroid peroxidase antibodies positivity 
Abbreviations: BMI body-mass index; CI confidence interval; FT4 free thyroxine; HR hazard ratio; TSH 
thyroid-stimulating hormone 
 
 
Bidirectional genetic look-up 
In the thyroid function GWAS, 20 SNPs were associated with TSH and 6 with FT4 
28
. The AMD GWAS revealed 19 genome-wide significant SNPs related to the 
phenotype. None of the SNPs from the thyroid function GWAS were significant in 
the AMD GWAS. One SNP (rs943080) in the Vascular Endothelial Growth Factor A 
(VEGFA) gene that is related to AMD, was also significantly associated with TSH 
(p=1.2x10
-4
, significance threshold =0.0026) (Additional Table 2). Within our study 
population, GWAS data were available for a total 4646 participants. Additionally 
correcting for the rs943080 SNP in the most adjusted model in these participants, 
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resulted in similar risk estimates for the FT4 analysis (HR 1.04, CI 95% 1.01-1.07). 
Stratifying for this SNP did show risk differences between the different genotypes 
but not significantly (Additional Table 1).  
 
DISCUSSION 
In this prospective cohort study we investigated the association between thyroid 
function and incidence of AMD. Higher FT4 values were associated with an 
increased risk of developing AMD, even within the normal range of TSH and FT4 
(i.e. euthyroid subjects), while there was no association between TSH and AMD. 
The similar findings between higher FT4 levels and retinal pigment alterations 
might suggest that thyroid hormone plays a role in the development of AMD rather 
than just act as a promoter of disease. To our knowledge, this is the first 
prospective population-based cohort study to look at the association between 
thyroid function and AMD.  
A limited number of studies investigating thyroid disease and AMD have been 
published, all lacking laboratory assessment of thyroid function. Bromfield et al. 
reported an increased risk of AMD in subjects with self-reported hypothyroidism 
30
. 
A case-control study by Anand et al. reported an association between thyroid 
hormone use and a higher risk of AMD with geographic atrophy 
31
, but no data 
were reported on the number of patients that were over- or undertreated. Similarly, 
the Beaver Dam Eye study also reported an association between thyroid hormone 
use and early AMD 
32
, but this was not confirmed by Douglas et al. 
33
. As 
mentioned previously, none of these studies had laboratory assessment of thyroid 
function nor did they investigate the association in a time-to-event analysis. In our 
study, excluding all subjects using thyroid medication did not alter risk estimates, 
supporting a potential intrinsic effect of thyroid hormone. 
There are several pathophysiological explanations for the relationship between 
thyroid hormones and AMD. In a mouse model of retinal degeneration, 
suppression of thyroid hormone signaling resulted in preservation of cone 
photoreceptors 
12
. The same study found that stimulating thyroid hormone 
signaling, by administering the active thyroid hormone triiodothyronine, deteriorates 
cones in mouse models with a slow progressive and moderate degeneration 
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phenotype 
12
. In addition, mice lacking type 3 deiodinase, the enzyme responsible 
for the degradation of thyroid hormones, have decreased survival and disturbed 
maturation of cone photoreceptors 
34
. The findings of these studies suggest that 
thyroid hormone may lead to a higher turnover of photoreceptors and in retinal 
degeneration this leads to deterioration of photoreceptors. Beside photoreceptors, 
thyroid hormone might also have an influence on the retinal pigment epithelial cells 
11
. In the healthy retina the turnover of photoreceptors is extremely high. Every day 
the photoreceptors shed the ends of their outer segments resulting in full renewal 
every ten days. These shedded parts of the outer segments are fagocytosed by the 
retinal pigment epithelium (RPE) cell 
35
. Increase of the turnover of the 
photoreceptors by thyroid hormone may bring additional stress to the process. 
RPE cells at distress may change resulting in pigmentary alterations in the macular 
area. The RPE cells may also be targeted directly by the thyroid hormone resulting 
in these changes 
11
. These results may provide an explanation for the findings in 
our study. 
Thyroid dysfunction has been linked to cardiovascular risk factors and disease, 
including effects on the vascular function, lipids and atherosclerosis 
36
. As some of 
these risk factors are also linked to AMD 
20,21
, one could speculate about a joint 
vascular pathway leading to both thyroid dysfunction and AMD or perhaps that the 
relation between thyroid dysfunction and AMD could be mediated through this 
pathway. We were not able to confirm these hypotheses. First of all, these 
cardiovascular risk factors are mainly seen in hypothyroidism, (i.e. high TSH and 
low FT4), whereas our data show an association between high FT4 and AMD. 
Also, correcting for some of these risk factors (e.g. hypertension), that could act as 
confounders and possible mediators, did not change risk estimates suggesting that 
the effect of thyroid function is not through these pathways. Lastly, VEGFA gene 
was found to be significant in the look-up for the TSH GWAS and not the FT4 
GWAS. However, our results suggest a higher risk of AMD in higher levels of FT4 
and not in TSH. Furthermore, the association did not change by adding this SNP to 
the multivariable model.  
We find an effect with FT4 but not with TS, which seems to be in line with previous 
literature from cohort studies in elderly populations investigating the relation 
between thyroid function and several other endpoints 
37,38
. Regulation of serum 
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thyroid hormone levels is controlled by the hypothalamus-pituitary-thyroid axis. The 
set point of this feedback mechanism is defined individually, with thyroid hormone 
levels showing a much greater inter-individual than intra-individual variability 
39
. 
The individual set point can be modulated by several pathophysiological (e.g. 
critical illness) and physiological (e.g. aging) mechanisms
40
. This could be an 
explanation why in this elderly and aging population we do find an association with 
FT4 but not with TSH, especially in the euthyroid range. Furthermore, previous 
literature showed an increase in TSH with increasing age, suggesting higher TSH 
levels are needed to keep thyroid hormone levels within the desired range
38
. We 
only have thyroid function measures at baseline and are therefore not able to 
investigate whether changes in thyroid function over time is an explanation for the 
discordant association between TSH, FT4 and AMD. 
Important strengths of our study are the assessment of thyroid function at baseline 
through laboratory testing as well as the elaborate assessment of AMD at baseline 
and follow-up. Also, we were also able to investigate the association between 
thyroid function and specific AMD lesions like retinal pigment alterations to 
examine possible early changes in underlying pathways. The availability of genetic 
data gave us the opportunity to explore possible genetic pathways. The 
bidirectional genetic look-up, revealed one SNP in the VEGFA gene to be 
significant in the TSH GWAS but not for FT4. Adding this SNP to the multivariate 
model did not alter risk estimates. An explanation for the absence of overlapping 
genome-wide significant SNP’s could be that these GWA studies were 
underpowered for this association.  
A limitation of our study is that thyroid parameters were measured once at 
baseline. Therefore, the evolution of thyroid hormone levels could not be taken into 
account. Also, residual confounding cannot be excluded, even with the large 
number of covariates included in these analyses. Lastly, this study is conducted in 
a mainly Caucasian population of 55 years and older and may not be generalizable 
to other populations. 
Conclusions 
We find an increased risk of incident AMD in subjects with higher FT4 levels, even 
in those with a normal thyroid function and when excluding thyroid medication 
users. This implies an intrinsic (i.e. not exogenous) deleterious effect of thyroid 
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hormone on AMD. We also find an association between higher FT4 levels and 
retinal pigment alterations, suggesting that thyroid hormone could even play a role 
in the early stage of development of AMD. Functional and clinical studies could 
provide more evidence for a true causal relationship.  
 
Supplemental online material 
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0329-0   
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ABSTRACT 
BACKGROUND Information on determinants and change of thyroid function over 
time is sparse and conflicting but crucial for clinical interpretation and research. 
Therefore, our aim was to systematically investigate determinants of thyroid-
stimulating hormone (TSH), free thyroxine (FT4) (as markers of thyroid function), 
their mutual relation (as marker of thyroid function set point) and changes in thyroid 
function over time in the Rotterdam Study, a population-based cohort study. 
 
METHODS We included 9402 participants not taking thyroid medication and with 
available thyroid function measurements. Repeated measurements (6.5 year-
interval) were available for 1225 participants. The association of selected 
determinants with TSH, FT4 and their mutual relation (reflecting thyroid function 
setpoint) was estimated using linear regression models using restricted cubic 
splines with three knots. The factors investigated were age, gender, body-mass 
index (BMI), tobacco smoking, alcohol use, thyroperoxidase antibodies (TPOAb), 
and common genetic factors. 
 
RESULTS Most influential determinants of TSH were age, smoking, genetic 
determinants and TPOAb levels (p < 0.001). For FT4, most influential determinants 
were age, BMI, gender, genetic determinants and TPOAb levels (p < 0.001). Older 
age, female gender and increased TPOAb levels were associated with a stronger 
relation between TSH and FT4. TSH levels did not change over time, irrespective 
of age. FT4 levels increased over time, most prominently those older than 65 years 
of age (mean increase of 4.5 pmol/L). 
 
CONCLUSIONS The main factors that influence the relationship between thyroid 
hormone and molar concentrations of TSH in study are age, smoking, BMI and 
common genetic variants. The set point that determines TSH secretion as it relates 
to negative thyroid hormone feedback is modified by age, gender and TPOAb 
positivity. FT4 levels increase over time, with a more pronounced increase in the 
elderly, while TSH values seem stable over time. Our results question the current 
notion of a TSH increase with increasing age.   
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INTRODUCTION 
Thyroid function is determined by genetic and environmental factors, including life-
style related influences. Clinically, thyroid function is defined by laboratory 
measurement of thyroid-stimulating hormone (TSH) and free thyroxine (FT4). Twin 
studies have estimated a heritability of 49-65% for TSH and 40%-90% for FT4, 
suggesting a strong influence of genetic factors on thyroid function
1-4
. 
Nevertheless, genome-wide association studies (GWAS), designed to identify 
common single nucleotide polymorphisms (SNPs) relevant to thyroid function, have 
so far only explained a small proportion of thyroid function variability
5,6
. Genetic 
variants analyzed by a large multi-center GWAS in over 25,000 participants explain 
5.6% and 2.3% of total TSH and FT4 trait variance, respectively, leaving a large 
proportion of genetic determinants undiscovered
6
. In addition to genetic 
predisposition, several environmental and existential factors have been implied to 
influence thyroid function, including age, gender, body-mass index (BMI), tobacco 
smoking, alcohol use and thyroperoxidase antibodies (TPOAb), reflecting thyroid 
autoimmunity
7-14
. The association of thyroid function with age has been 
investigated in several studies with conflicting results, ranging from positive to 
negative associations for both TSH and FT4 values 
9,13-16
. The between-study 
differences can at least partially be explained by variability in iodine status between 
populations, but other determinants might also contribute to these discrepancies
13
. 
For other determinants (e.g. BMI and smoking), literature has been less 
controversial on the direction of association. However, to date, no study has 
investigated the effect of these different characteristics and genetics factors on the 
mutual relationship between FT4 and TSH (as a marker of thyroid function set 
point) 
4,17-22
. 
The identification of thyroid function determinants and the quantification of the 
extent of potential effects is important for clinical interpretation and research, yet 
the evidence on determinants of thyroid function is insufficient and conflicting. 
Therefore, we aimed to investigate if and to what extent age, gender, BMI, 
smoking, alcohol use, TPOAb and common genetic variants are could be 
determinants of TSH, FT4 and their mutual relationship in a large prospective 
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population-based study. Furthermore, we set out to describe changes in thyroid 
function over time using repeated measurements.  
 
METHODS 
The Rotterdam Study 
All analyses were performed in the Rotterdam Study (RS), a prospective 
population-based cohort study that investigates determinants and occurrence of 
cardiovascular, neurological, ophthalmologic, psychiatric, and endocrine diseases 
in the middle-aged and elderly population. The aims and design of the RS have 
been described in detail elsewhere
23
. We included participants from three 
independent cohorts of the RS. The RS Cohort 1 (RSI) includes participants aged 
55 years and older and baseline data were collected during 1990-1993. RS Cohort 
II (RSII) includes participants aged 55 years and older and baseline data were 
collected from 2000-2001. For the RS Cohort 3 (RSIII), all residents aged 45 years 
and over who had not been invited before were asked to participate and baseline 
data were collected from 2006 to 2008. The Medical Ethics Committee of the 
Erasmus University approved the study protocols and by the Ministry of Health, 
Welfare and Sport of the Netherlands, implementing the “Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All 
included participants provided a written informed consent in accordance with the 
Declaration of Helsinki to participate in the study and to obtain information from 
their family physicians. 
Study population 
Participants from study cohorts RSI visit 3 (RSI-3), RSII visit 1 (RSII-1) and RSIII 
visit 1 (RSIII-1) were eligible for the cross-sectional analyses if TSH or FT4 
measurements were available (Supplemental Figure 1A). For the longitudinal 
analyses we included participants from RSI that had two measurements of TSH 
and/or FT4 at different visits (RSI-1 and RSI-3, Supplemental Figure 1B). For all 
analyses, we excluded participants using any thyroid medication (i.e. levothyroxine, 
thiamazole, carbamazole or propylthiouracil) at baseline. 
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Thyroid function measurements 
TSH, FT4 and/or TPOAb assessment for the cross-sectional analyses (1997 -
2007, Supplemental Figure 1A, Assay 1) was performed at the same time in all 
three cohorts in serum sample stored at -80 degrees Celsius of 9,402 participants 
not using thyroid medication (The electrochemiluminescence immunoassay for 
thyroxine, thyrotropine and thyroid peroxidase antibodies, “ECLIA”, Roche, 
Mannheim, Germany). TPOAb levels greater than 35 kU/mL were regarded as 
positive, according to assay manufacturer recommendations. 
For the longitudinal analyses thyroid function measurements were performed in 
participants of RSI (not using thyroid medication) using a different assay (TSH 
Lumitest; Henning, Berlin, Germany, TPOAb with ELISA; Milenia; Diagnostic 
Products Corp, Los Angeles, CA, USA, FT4; Vitros, ECI Immunodiagnostic 
System; Ortho-Clinical Diagnostics, Amersham, UK) and were conducted at two 
different time points between 1990 and 2000 with this same assay (n= 1255, 
Supplemental Figure 1B, Assay 2). In the assay used for the longitudinal analyses, 
TPOAb levels greater than 60 kU/mL were regarded as positive, according to 
assay manufacturer recommendations. The measurements performed with the two 
different assays were highly correlated (Spearman correlation co-efficient (r) =0.96 
for TSH, p <0.0001, r=0.81 for FT4, p < 0.0001 and r=0.68 for TPOAb, p <0.0001).  
Other variables 
Based on previous studies, biological plausibility and data availability 
4,6-8,19,24
, we 
selected age, gender, tobacco smoking, alcohol intake, BMI, TPOAb and a genetic 
risk score (GRS) of TSH or FT4 as potential determinants for thyroid function. 
Information on smoking was derived from baseline questionnaires and categorized 
in current, previous and never smokers. Information on alcohol consumption was 
acquired from questionnaires where participants were asked for the average daily 
consumption of alcohol. Alcohol intake was recorded in grams per day and then 
divided in quintiles of daily intake. BMI was calculated as weight in kilograms 
divided by height in meters squared. 
Genotyping and Genetic Risk Score 
Genotyping was conducted, in self-reported white participants, using the Illumina 
550K and 610k arrays and details are described elsewhere 
23
. Participants were 
excluded if they had excess autosomal heterozygosity, mismatch between called 
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and phenotypic sex, or recognized as being outlier with identical-by-state clustering 
analysis. We used MACH to impute SNP dosages based on the phase I version 3 
reference panel from the 1000 Genomes Project 
25,26
. For this study, we selected 
common SNPs previously reported to have an association with TSH or FT4, from 
the largest multi-center GWAS of >25,000 individuals 
6
. A GRS was compiled using 
20 SNPs that have been associated with TSH and six SNPs that have been 
associated with FT4 (Supplemental Table 1). We calculated a weighted GRS by 
multiplying the number of risk alleles at each locus by the corresponding reported β 
coefficient from the abovementioned GWAS and then summing the products. The 
total score was then divided by twice the average effect size multiplied by 100 to 
rescale the scores to a range between 0 and 100. A GRS for TSH and FT4 was 
available for a total of 7125 participants. 
Statistical analysis 
We assessed the relation and explained variability (r
2
) of the environmental and 
common genetic determinants with TSH or FT4 and their mutual relation, in 
univariable and multivariable ordinary least squares linear regression models. Non-
linearity was assessed with restricted cubic splines using three knots at the 10th, 
50th and 90th percentile and we additionally adjusted the multivariable analyses for 
cohort. Effect estimates are reported as standardized β (β per SD of the 
determinant). As a sensitivity analysis, we repeated these models after exclusion of 
participants within the lowest and highest 2.5-percentile of TSH and FT4. To 
account for multiple testing we applied a Bonferroni correction, considering 0.05 
divided by the number of tested variables multiplied by the number of outcomes as 
significant (0.05/ (7*2) = 0.0036). Furthermore, we assessed changes in TSH or 
FT4 over time using ordinary least squares linear regression models. For these 
analyses, we added time between the two measurements and FT4 or TSH at 
baseline to the multivariable models. Also, we compared participant baseline 
characteristics for subjects with and subjects without follow-up measurements of 
TSH and FT4. As a sensitivity analysis, we repeated these models after exclusion 
of participants receiving thyroid medication during follow-up. Additional sensitivity 
analyses performed were: 1) excluding participants with TPOAb positivity, as 
defined by the assay manufacturer, and 2) excluding those with self-reported 
thyroid disease. TSH and TPOAb levels were log transformed (natural logarithm) 
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for the continuous analyses to approximate a normal distribution and denoted as 
lnTSH and lnTPO. Multiple imputations were performed in case of missing 
variables (less than 2% for all variables). Statistical analyses were conducted using 
R statistical software (rms, Himsc, visreg packages, R-project, Institute for 
Statistics and Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2) or 
SPSS version 21 (SPSS IBM, New York, U.S.A). 
 
RESULTS 
Environmental characteristics as determinants of TSH and FT4 
The final study population consisted of 9402 participants for the cross-sectional 
analyses with a mean age of 65.1 years of which 55.9% were female (Table 1). 
The associations of the potential determinants with TSH are shown in Figure 1 and 
Supplemental Table 2. For TSH levels the most influential non-genetic factors were 
age (β -0.07), smoking (β -0.07) and TPOAb levels (p < 0.001). For FT4, the 
environmental determinants with the largest influence were age (β 0.07), BMI (β -
0.10), gender (-0.09) and TPOAb levels (p < 0.001) (Figure 2, Supplemental Table 
2).  
 
Table 1 Baseline characteristics of included participants in the Rotterdam Study with TSH or 
FT4 measurements 
Variable Mean (SD)
a 
Number of participants
b
 9402 
Age, years 65.1 (9.9) 
Female (%) 5253 (55.9) 
BMI kg/m2 27.2 (4.2) 
Smoking, N (%) 
 
   current 1998 (21.2) 
   past 4474 (47.6) 
   never 2930 (31.2) 
TSH ImU/L median (IQR) 1.90 (1.29-2.75) 
Alcohol grams/day, median (IQR) 14.6 (1.4-20.0) 
FT4 pmol/L 15.6 (2.2) 
TSH ImU/L (2.5%-97.5%) 0.40-6.64 
FT4 ImU/ L (2.5%-97.5%) 11.6-20.2 
TPOAb positive
c
, N (%) 1136 (12.1 ) 
Natural logarithm of TPOAb 2.38 (1.07) 
a 
Values are means and SD unless otherwise specified. 
b
 Of which 9392 had both FT4 and TSH 
measurements. A total of 9391 participants had TPO measurements. 
c 
TPOAb positivity was defined as 
>35 kU/L. Abbreviations: BMI body-mass index; TSH thyroid-stimulating hormone, FT4 free thyroxine; 
SD Standard deviation; IQR inter-quartile range; TPOAb thyroperoxidase antibodies 
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Repeating the analyses after exclusion of participants in the highest and lowest 
2.5
th
 percentile did not change the associations meaningfully except for gender and 
age (Supplemental Table 3). In these analyses the association between gender 
and thyroid function remained significant in all models while the association 
between age and TSH lost statistical significance after correction for multiple 
testing.  
 
Figure 1 The association of environmental determinants with TSH levels 
 
 
 
 
The association of each determinant with TSH is depicted as the regression line using ordinary least 
square restricted cubic splines regression with 3 knots or logistic regression and the accompanying 
95% CI interval for the entire population. P-values are for the plotted association. These associations 
were evaluated adjusting each determinant for all other determinants. Alcohol categories represent 
quintiles of alcohol use (grams/day) in the population, where quintile one has an average use of 0.06 
grams of alcohol a day, quintile two 3.5, quintile three 11.8, quintile four 16.3 and quintile five 32.9.  
Abbreviation: CI confidence interval, TSH thyroid-stimulating hormone  
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Genetic risk score as determinant of TSH and FT4 
The GRS for TSH explained 4.3% of variance in TSH levels in the population 
(Supplemental Table 4). The GRS for FT4 explained 2.3% of population variance 
in FT4 levels. After exclusion of participants in the highest and lowest 2.5
th
 
percentile, the r
2
 of the GRS for TSH and FT4 was 5.6% and 2.5% respectively. 
Including both common the GRS and environmental determinants in the model, the 
r
2
 increased to 10.3% (+4.7%) for TSH and 5.1% (+2.6%) for FT4. 
 
Figure 2 The association of environmental determinants with FT4 levels 
 
 
The association of each determinant with TSH is depicted as the regression line using ordinary least 
square restricted cubic splines regression with 3 knots or logistic regression and the accompanying 
95% CI interval for the entire population. P-values are for the plotted association. These associations 
were evaluated adjusting each determinant for all other determinants. Alcohol categories represent 
quintiles of alcohol use (grams/day) in the population, where quintile one has an average use of 0.06 
grams of alcohol a day, quintile two 3.5, quintile three 11.8, quintile four 16.3 and quintile five 32.9.  
Abbreviation: FT4 free thyroxine 
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Determinants of the thyroid function set point 
There was a negative log-linear association between TSH and FT4 (Supplemental 
Figure 2). The association between TSH and FT4 differed according to age, 
gender and TPOAb levels (Figure 3). Subjects with higher age, women and 
subjects with higher TPOAb levels had a stronger log-linear relationship between 
TSH and FT4 (p for interaction <0.001). As a consequence, for women with TSH 
levels in the lower range, FT4 levels were higher than in men with the same level 
of TSH values, whereas in the higher range of TSH women had lower FT4 levels 
than men. The association of FT4 with TSH was not modified by BMI, smoking or 
alcohol (p for interaction > 0.50). The association and effect modification remained 
similar after the exclusion of participants in the highest and lowest 2.5
th
 percentile. 
 
Figure 3 The association of age, gender and TPOAb on the relation between TSH and FT4 
 
 
The relation of TSH with FT4 according to age, gender and TPOAb are depicted. The p-value for 
interaction are for the continuous variables of age and TPOAb levels and 95% CI per group is depicted. 
TThese analyses were adjusted for age, gender, BMI, smoking, TPOAb levels and alcohol use. The 
natural logarithm of TPOAb and TSH levels were used for these analyses. Abbreviations: BMI body 
mass index, TPOAb thyroperoxidase antibodies, TSH thyroid stimulating hormone 
 
 
TSH and FT4 changes over time 
We included 1225 participants for the longitudinal analyses of which all participants 
had two TSH measurements and 1002 participants also had two FT4 
measurements (Supplemental Table 5). The median time between measurements 
was 6.5 years (range 6.01- 9.71 years). The time between the two measurements 
was not associated with age of subjects at first measurements. Participants who 
had a second measurement were on average younger, had lower blood pressure, 
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and were less often diabetics or current smokers. Nevertheless, the TSH and FT4 
values were not significantly different between participants who did and those who 
did not have two measurements (Supplemental Table 5).  
Overall, there was no change in TSH levels over time, irrespective of age at first 
measurement (Figure 4A). However, changes of TSH in time did depend on the 
TSH levels at baseline. If TSH levels at baseline were higher than ~TSH 2.72 
mIU/L, TSH decreased over time (Figure 4B). FT4 levels increased over time 
where the increase was more prominent in the elderly ( increase of 4.5 pmol/L, 
Figure 4C) and those with lower FT4 levels ( increase of 4 pmol/L, Figure 4D). In 
participants with baseline FT4 values higher than ~22 pmol/L, FT4 levels 
decreased over time (Figure 4D). Excluding participants in the lowest or highest 
2.5
th
 percentile did not change the association of thyroid function and age. 
Sensitivity analyses excluding participants using thyroid medication during follow-
up, excluding participants with a self-reported history of thyroid disease or 
excluding participants with TPOAb positivity, did not change the associations 
meaningfully.  
 
DISCUSSION 
In the current study, the main determinants of thyroid function were age, smoking, 
BMI, TPOAb levels and common genetic determinants. The mutual relation 
between TSH and FT4 (i.e. thyroid function set point), was modified by age, gender 
and TPOAb positivity. TSH values were fairly stable over time, except in those with 
higher baseline levels of TSH, where a decrease over time is seen. FT4 levels 
increase over time, with a more pronounced increase in older subjects and in those 
with low to average FT4 levels at baseline. 
The heritability of thyroid function has been reported to be high, while the GRS for 
TSH and FT4 in our study only explained 5.6% and 2.5 % of the variance 
respectively. This highlights the need for identification of additional genetic 
determinants 
27
. However, the large variability that is left unexplained is not solely 
due to yet unknown genetic factors but also dependents on environmental 
determinants.  
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Figure 4. The change in TSH and FT4 levels over time 
 
Panel A. The association of change of TSH levels over time plotted against the age of participants at 
baseline. Panel B. The association of change of TSH levels over time plotted against the TSH levels of 
participants at baseline. Panel C. The association of change of FT4 levels over time plotted against the 
age of participants at baseline. Panel D. The association of change of FT4 levels over time plotted 
against the FT4 levels of participants at baseline. These analyses were adjusted for age, gender, BMI, 
smoking, TPOAb and time between measurements. The median time between measurements was 6.5 
years (range 6.01- 9.71 years). For all panels the regression line and accompanying 95% confidence 
intervals are depicted. Abbreviations: BMI body mass index, TPOAb thyroperoxidase antibodies, TSH 
thyroid stimulating hormone 
 
Most studies to date have focused on a specific determinant (e.g. smoking) in 
relation to thyroid function 
7
. In contrast, in the current study we assess several 
important environmental as well as genetic determinants in relation to thyroid 
function. Only two previous smaller cross-sectional studies have analyzed several 
determinants of thyroid function in the general population, but the direction and 
extent of the associations differed from ours 
3,4
. For example, Roef et al. 
4
 report 
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that a lower TSH as well as FT4 with higher BMI, while in our population we find a 
positive association of BMI with TSH and a negative association of BMI with FT4. 
Differences between our results and results from these studies could be due to 
several reasons including; the large sample size of our population compared to 
previous studies (>9,000 vs <1,000), differences in mean age, iodine status and 
ethnical backgrounds. Also, the number of genetic variants included in these 
previous analyses was smaller than in the current study. To our knowledge, no 
population-based study to date has reported on the association of environmental 
factors with the relation between TSH and FT4. We could therefore not compare 
our results with previous literature. 
Regarding the association of age with thyroid function, results from cross-sectional 
studies are conflicting. Data from the National Health and Nutrition Examination 
Survey (NHANES) show a shift of the TSH distribution toward higher levels with 
older age, but provided no information on FT4 concentrations in different age 
groups 
12
. A study from Scotland reports a significantly higher median and 97.5
th
 
centile TSH with higher age 
24
. However, in contrast to these studies and in line 
with our results, two studies report a lower TSH and higher FT4 with higher age, of 
which the degree is partially dependent on historical iodine intake 
13,28
. 
Nevertheless, these are all cross-sectional reports on the association of age with 
thyroid function. Cross-sectional analyses can provide information on differences in 
different age-groups but cannot provide insight on dynamic changes with aging.  
To date, only two prospective population-based cohort studies with longitudinal 
thyroid function measurements have studied the relation of thyroid function with 
aging. Although both studies had similar iodine status, their results on the relation 
of thyroid function with aging (i.e. over time) differ from ours. Whereas both Waring 
et al (Cardiovascular Health Study [CHS], USA) and Bremner et al (Busselton 
Health Survey, Australia) find an increase in TSH over time and with increasing 
age, TSH levels did not change over time in our study. The lack of change in TSH 
in our study was independent of age at baseline. In participants with the highest 
levels of TSH at baseline, TSH even decreased over time. This decrease in TSH in 
the opposite direction of previous reports from CHS and the Busselton Health 
Survey could reflect a regression to the mean (i.e. normalization). We do not 
observe this phenomenon in participants with TSH values below 2.72 mU/L; the 
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TSH levels in these participants remain stable over time. Our data show an 
increase in FT4 values with age, which is in line with the previous report from 
Waring et al. but in contrast to Bremner et al, who report no change in FT4 levels 
with age. 
There are different possible explanations for the differences between our results 
and results from the two before mentioned studies. Most importantly, the mean age 
of the studies differs notably, varying between 49 and 85 years for the Busselton 
and CHS cohorts respectively, whereas the mean age was 67 years for our 
longitudinal analyses. Furthermore, even though the current iodine status between 
the three cohorts of Busselton, CHS and RS is comparable and can be classified 
as sufficient on average, the intra-study variability could still be large. For example, 
the RS and Busselton cohorts include mainly white participants from one specific 
community, while CHS is a multicenter cohort study including multi-ethnic 
participants from several regions from the USA. This could lead to large variability 
in iodine intake and status between participants 
29-32
. In addition, historical iodine 
intake is different between all three cohorts. This has been shown to result in 
differences in age-related thyroid function changes, which is irrespective to current 
iodine status 
13,33
.  
The observed increase of FT4 with age in our study could represent an increase in 
autonomous thyroid hormone excretion. In elderly, hyperthyroidism is more 
prevalent 
15,34,35
, with Graves’ disease and toxic (multi)nodular struma as the 
leading cause of hyperthyroidism in elderly living in iodine sufficient regions 
34,36,37
. 
The increase of FT4 levels with aging would physiologically be expected to result in 
a concordant decrease in TSH levels. However, the observation that TSH levels 
remain stable over time in our study, irrespective of age at baseline, suggests a 
change in the physiological set point of the hypothalamic-pituitary-thyroid (HPT) 
axis.  
Several age-related changes in pituitary sensitivity to TRH as well as pituitary TSH 
secretion capacity have been described, which could lead to alterations in the 
relation between TSH and FT4 
38,39
. However, even though we observe effect 
modification of the TSH-FT4 relation by age, the association is opposite to what we 
would expect. With older age there seems to be a stronger relation between TSH 
and FT4 (effect modification) suggesting an increased “sensitivity” of the HPT-axis 
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set point. This is in line with studies demonstrating that lower doses of LT4 are 
needed to suppress TSH secretion in elderly subjects 
40-43
. Alternatively, and 
biologically more plausible, this effect modification by age could mainly reflect a 
marked increase in autonomous thyroid hormone secretion in the elderly, as 
previously mentioned, with a relative mild change in set point. Independent of the 
mechanisms that lead to these changes, the increase in FT4 without a concomitant 
change in TSH with increasing age could explain several study results from 
population-based cohorts, including the Rotterdam Study, reporting on the 
association of FT4 with different clinical outcomes, while there is no significant 
association with TSH 
44-51
. Lastly, another explanation for changes during aging is 
a change in TSH bioactivity 
52
, which was not measured in our study. To date, 
there are no studies specifically addressing changes in TSH bioactivity and aging 
in the general population and thus this topic merits further research. 
Strengths of our study include the large number of participants, providing adequate 
statistical power to investigate the relations of interest. Furthermore, through 
longitudinal assessment of TSH and FT4, we were able to investigate the changes 
of thyroid function over time. Also, by evaluating several of the determinants in one 
model, we were able to investigate the independent effect of each determinant. A 
limitation of our study is the lack of information on iodine status, TSH bioactivity 
and T3 measurements in our participants, which is a limitation in most population-
based cohort studies 
9,14
. Another limitation could be the use of immunoassays for 
FT4. Studies thus far have shown immunoassays of FT4 to sometimes correlate 
poorly and equilibrium dialysis or ultrafiltration LC-MS/MS seem to correlate better, 
especially in certain circumstances such as pregnancy and illness
53,54
. However, 
our population consists of community-dwelling elderly, the correlation of the two 
immunoassays used in our population was good and therefore we think this 
limitation is less applicable to our study. Lastly, the RS consists of a mainly white 
population of 45 years and older and results from this study may therefore not be 
well-generalizable to other populations.  
Conclusions 
Age, smoking, BMI, TPOAb and genetic influences have the largest impact on TSH 
and FT4, while age, gender and TPOAb had the greatest influence on the relation 
between TSH and FT4. With the included common genetic and environmental 
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factors we were able to explain 10.3 % of TSH and 5.1% of FT4 variability. Our 
data show that with age, TSH levels remain stable whereas FT4 increases 
substantially. This could explain why several studies report associations between 
clinical outcomes and FT4 but not TSH. Differences in findings with other 
populations could be due to differences in (historical) iodine status or other factors 
(e.g. ethnicity) and should be investigated. Further research should examine the 
influence of changes in thyroid function over time on health and disease. 
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MAIN FINDINGS AND INTERPRETATION 
 
THE HEART 
Thyroid hormone is important for development and growth in nearly all organs and 
tissues throughout life. The role of thyroid hormone on the cardiovascular system 
has been long recognized
1
 and the heart is by far the most rigorously studied 
target organ of thyroid hormone in basic, epidemiological and translational 
research.
2
 Previous epidemiological studies have focused mainly on the 
association of subclinical thyroid dysfunction and cardiovascular disease.
3-5
 Our 
work has shown that the association between thyroid function and diseases of the 
heart also extends within the currently defined reference range. In Chapters 2.1, 
2.2 and 2.4, we show that higher free thyroxine (FT4), and lower thyroid-
stimulating hormone (TSH) to a lesser extent, is associated with an increased risk 
of atrial fibrillation (AF), sudden cardiac death (SCD) and atherosclerotic disease 
and mortality. These associations extend both within as well as outside of the 
reference range, with most prominent increased risk within the reference range. 
Within the reference range of FT4, the absolute risk of atrial fibrillation in elderly 
(defined as participants 65 years and older) increased from 6% to almost 12% from 
low-normal to high-normal FT4. For sudden cardiac death the 10-year risk 
increases from 1% to 4% for euthyroid participants with higher FT4 levels. We 
describe a 3.64-fold increased risk of atherosclerotic cardiovascular mortality with 
higher FT4 levels within the reference range. This was more marked in but not 
restricted to participants with previous atherosclerotic disease (3.26-fold vs 4.84-
fold within the reference range). Also, we show a 2.42-fold increased risk of having 
high coronary artery calcifications scores, a marker of subclinical atherosclerosis, 
with higher FT4 levels, again, within the reference range. Interestingly, these 
associations were independent from cardiovascular risk factors such as 
dyslipidemia and hypertension, suggesting alternative mediating factors. In 
Chapter 2.5 we provide an alternative approach to defining reference ranges. We 
present a proof of principle of how to define ‘optimal health ranges’ for thyroid 
function based on cardiovascular risk and these results will be discussed further 
under gaps in knowledge and future directions. 
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THE BRAIN 
Stroke and other cardiovascular disease share many of the same risk factors 
including dyslipidemia and hypertension.
6
 In turn, these risk factors are affected by 
thyroid hormone action and thyroid dysfunction.
2
 Nevertheless, in contrast to an 
abundance of studies on ischemic heart disease and heart failure, we identified 
paucity in literature on the association of thyroid function with stroke (Chapter 3.1). 
In a published study meta-analysis we report no association of subclinical hypo-or 
hyperthyroidism on the risk of stroke, but we were able to identify no more than 6 
published studies. Therefore, we performed a large individual participant-based 
(IPD) meta-analysis, including 17 cohorts and over 45,000 participants, to 
investigate the association of subclinical hypothyroidism and variations of thyroid 
function within the reference range with stroke risk (Chapters 3.2 and 3.3). We 
report on an increased risk of stroke with subclinical hypothyroidism, but mainly in 
participants younger than 65 years of age (up to 4.22-fold). Furthermore, we 
conclude that within the reference range, high-normal thyroid function is associated 
with an increased risk of stroke (approximately 1.3-fold). Even though within the 
Rotterdam study we mainly find an association of high and high-normal thyroid 
function with stroke (absolute risk difference of ~ 3% with increasing levels of FT4), 
the findings of the IPD meta-analysis on subclinical hypothyroidism do elude to a 
possible non-linear association. However, this has to be investigated in several 
populations with different backgrounds, in order to explain the possible 
discrepancies.  
Neurocognitive and cerebrovascular disease have gained interest as important 
targets of thyroid hormone disturbances in recent years.
7
 We identified higher 
levels of FT4 and lower levels of TSH as a risk factor for dementia, both within as 
well as outside of the reference range (Chapter 3.4), independent of 
cardiovascular risk factors. This association was most pronounced in older women, 
with a risk difference of 4% for the 10-year absolute risk of dementia, perhaps 
partially due to the higher baseline risk in the Rotterdam Study as compared to 
men. There was no association of thyroid function parameters with subclinical 
vascular disease on MRI and we therefore concluded that cardiovascular risk 
factors and disease are unlikely a part of the underlying pathophysiology.  
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METABOLISM 
The recent findings of the association of thyroid function with diseases of older age 
show a deleterious effect of high thyroid function, most commonly high FT4. An 
exception to this rule seems to be metabolism-related disorders. In Chapter 4.1, 
we show an increased risk of type 2 diabetes with higher TSH and lower FT4 
levels, most prominently in those with prediabetes at baseline and thyroid function 
within the reference range. The drop of type 2 diabetes risk in this specific 
subgroup was dramatic, going from a risk of 35% of developing diabetes to less 
than 15% when going from low-normal to high-normal FT4 levels. This is not only 
etiologically interesting, but could also candidate people with prediabetes as a 
specific subgroup to target for diabetes prevention in the context of thyroid 
function. Screening efforts, mainly targeting people with prediabetes, could be one 
of the first steps for research concerning the association of thyroid function and 
diabetes.  
Non-alcoholic fatty liver disease (NAFLD) is the one of the most common chronic 
liver conditions worldwide and thyroid hormone affects numerous risk factors that 
can lead to NAFLD.
8
 In Chapter 4.2 we report an increased risk of NAFLD with 
lower FT4 levels (2.38-fold) and higher TSH levels. In line, higher TSH levels were 
associated with an increased risk of having clinically relevant fibrosis in NAFLD. A 
post-hoc analysis in a subgroup of participants from a randomized controlled trial 
(RCT) showed improvement of NAFLD with levothyroxine therapy in patients with 
subclinical hypothyroidism.
9
 However, these results need to be verified in a larger 
RCT and with special attention to possible overtreatment and adverse short-term 
and long-term effects. 
 
AGING 
Cancer is one of the leading causes of morbidity and mortality around the world 
and increasingly becoming the leading cause in the industrialized world (Table 1).
10
 
Literature findings on the association of thyroid function with cancer have been 
controversial ranging from an association of hypothyroidism or hyperthyroidism 
with cancer risk, to no association.
11-14
 Most studies to date have lacked a 
sufficiently large sample size or prospective study design. In Chapter 5.1 we 
identify higher FT4 levels to be significantly associated with an increased risk of 
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any solid (1.42-fold), lung (2.33-fold), and breast cancer (1.77-fold). The exact 
mechanisms that link thyroid hormone with cancer risk need to be investigated in 
greater depth, but could vary according to certain characteristics. Thyroid hormone 
might well have pro-oncogenic and antioncogenic activities depending on cancer 
type (e.g. breast cancer vs lung cancer or small cell vs non-small cell lung cancer), 
site and stage. Further epidemiological studies could give a first clue in this 
respect. 
In Chapter 5.2, we describe both the cross-sectional as well as longitudinal 
association of thyroid function with CKD. Interestingly, higher TSH levels were 
associated with lower eGFR cross-sectionally. However, longitudinally, higher TSH 
levels were associated with less annual eGFR decline and lower chronic kidney 
disease incidence. In the cross-sectional analysis, there is no distinction in 
temporality and because we know that poor kidney function also affects thyroid 
function, the cross-sectional results could also point towards reverse causation (i.e. 
poor kidney function leading to low thyroid function and not vice versa). However, 
in our prospective analysis temporality is assessed and we conclude that higher 
thyroid function is a risk factor for kidney function deterioration. Previous studies 
showing similar trends have been underpowered to report significant findings.
15
 
Future collaborative efforts could provide replication of our findings. 
Disturbances in gait gradually increase with advancing age and perceived as a 
marker of general health status.
16
 Previous studies have suggested an association 
of subclinical hypothyroidism with increased gait speed.
17
 However, information on 
the association of thyroid function in general with gait velocity and other domains of 
gait was lacking. In Chapter 5.3, we describe a non-linear association of FT4 with 
global gait, a general marker of gait incorporating several gait domains, and to a 
lesser extent gait velocity, where both high and low FT4 seem deleterious. Gait is 
perceived as multifactorial, including musculoskeletal and neurological components 
amongst others and the underlying mechanism linking thyroid function to gait still 
need to be determined. 
Vision impairment is one of the most burdensome diseases in elderly (Table 2).
10
 
Age-related macular degeneration (AMD) is the leading cause of loss of vision in 
people over 65 years of age.
18,19
 Animal models have shown cone photoreceptor 
preservation with lack of thyroid hormone, while administration of high doses of 
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active thyroid hormone leads to deterioration.
20
 In line, we report that high FT4 
levels are associated with a higher AMD risk in the general population (Chapter 
5.4), suggesting an important role of thyroid hormone in pathways leading to AMD, 
both within as outside of the reference range of thyroid function. 
The thyroid gland itself is also not resistant to external and existential factors such 
as aging. In Chapter 5.5 we investigated determinants of thyroid function and 
established the trajectory of TSH and FT4 over time. We conclude that most 
important factors influencing both TSH and FT4 include age, genetic determinants 
and thyroid peroxidase antibodies. For TSH we additionally identified smoking as 
an influential factor, while for FT4 we additionally identified BMI and gender. 
However, the explained variability of thyroid function including environmental, 
existential and genetic determinants remained low (11.2% for TSH and 7.1% for 
FT4). Older age, female gender and increased TPOAb levels were associated with 
a stronger relation between TSH and FT4 (i.e. set point). Unlike previous literature, 
we report that in our study TSH levels did not change over time, irrespective of 
age, while FT4 levels did increase over time, most prominently those older than 65 
years. Reasons for discrepancy could be differences in age groups studied and 
historical iodine status. Therefore, these factors should be taken into account when 
comparing future studies and results. 
 
MEDIATING FACTORS 
While establishing an association of thyroid function with hard clinical endpoints is 
a pivotal start, it is just that; a start. An important next step pertains to the 
identification of underlying pathways and mediators. Interestingly, the associations 
studied of thyroid function with clinical end points by our and other groups, ranging 
from SCD to dementia and from cancer to chronic kidney disease, appear to be 
independent of cardiovascular risk factors, such as lipids and hypertension. This 
implies that factors other than cardiovascular risk factors could play a role in the 
link between thyroid function and diseases of older age. In Chapter 2.3 we 
investigated a promising possible mediator of the association between thyroid 
function and sudden cardiac death; QT variability. We report on a U-shaped 
association of FT4 with QT variability, implying that QT variability could be a 
mediator of FT4 with SCD. This probably only holds true in the higher range of 
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thyroid function, because higher FT4 is linearly associated with SCD risk. 
Even though we initially speculated that the association of thyroid function with 
dementia could be through cardiovascular risk factors and possible subclinical 
vascular brain disease, our results did not provide evidence for this hypothesis. 
Thyroid hormone impacts different essential neuronal processes including 
neurogenesis, myelination, and neural differentiation throughout life.
21
 In Chapter 
3.5 we investigated the association of thyroid function with brain morphology and 
microstructural organization and report an age-dependent relation of FT4 with brain 
volumes and microstructural organization. Higher FT4 levels were associated with 
larger total brain (mainly white matter) in younger individuals, but with smaller total 
brain volume in older individuals. There was a similar pattern by age for the 
association of FT4 with mean diffusivity on diffusion tensor imaging. Our results 
need to be replicated, but can improve understanding of the role of thyroid function 
in neurodegenerative disorders. 
 
METHODOLOGICAL CONSIDERATIONS 
To answer the research questions in this thesis, we used several study designs 
and types of analyses. The strengths and limitations thereof are described in the 
respective chapters within this thesis. A few general considerations regarding 
systematic reviews and meta-analyses, including IPD meta-analyses, will be 
discussed here. In general, systematic reviews and meta-analyses are considered 
the highest form of evidence, whether the research question is etiological, 
diagnostic, prognostic, or therapeutic in nature.
22
 IPD meta-analyses in turn are 
described as the ‘gold standard’ of systematic reviews by the Cochrane 
collaboration.
23
 In an IPD meta-analysis, rather than extracting the published 
summary data from identified literature, researchers aim to collect all individual 
data available from the researchers of the individual studies. This provides the 
opportunity for a range of analyses that is usually not possible with so-called 
published data meta-analyses, such as specific sensitivity and stratified analyses. 
IPD meta-analyses can also help overcome possible publication bias, because 
unpublished data is obtained and incorporated in the analyses. Other advantages 
of IPD meta-analysis over published data meta-analyses include the use of 
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consistent inclusion and exclusion criteria of participants, possibility to account for 
missing data, use of the longest possible follow-up, adjustment of analyses for the 
same set of variables and use of identical statistical analytic approach in each 
study before aggregation of data amongst others. In this thesis, IPD-meta-analyses 
have proven to be especially useful in investigating the association of thyroid 
function with the risk of stroke (Chapters 3.1, 3.2 and 3.3).  
However, even the ‘gold standard’ of evidence synthesis had disadvantages. Most 
importantly, as compared to published studies meta-analysis, it takes time and 
efforts to identify, obtain and analyze the individual participant data from each 
study included.
24
 Also, in IPD meta-analyses more advanced statistical knowledge 
may be required when analyzing data from individual studies than when 
aggregating summary data from published results. Furthermore, even though often 
overlooked, IPD meta-analyses are prone to some of the same biases as 
published studies meta-analysis, including publication and selection bias.
25
 Lastly, 
even if all relevant data is rigorously sought, it might not always be found or 
shared, increasing concerns of possible availability bias. In our IPD meta-analyses, 
all but one small study agreed to participate and all participating studies eventually 
shared individual participant data, rendering the possibility of availability bias small.  
 
GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS 
Thyroid dysfunction is common in the general population and easily diagnosed 
through laboratory measurement of thyroid-stimulating hormone (TSH). 
Furthermore, especially in case of hypothyroidism, treatment is accessible, 
inexpensive and perceived as safe. All necessary conditions for screening 
therefore seem to be met; yet, screening is not applied in the general population. In 
2015, the U.S. Preventive Services Task Force identified “professional 
disagreement about the appropriate cut points for the lower and upper boundaries 
of normal TSH levels in the general population and in subgroups” as one of the 
issues hampering decision making on screening for thyroid dysfunction
26
. Why 
does this professional disagreement exist and more importantly, how to resolve 
this? 
General discussion 
421 
Many patients with overt thyroid dysfunction present with non-specific complaints 
such as fatigue and weight changes.
27
 Overt thyroid dysfunction is currently 
defined by TSH and free thyroxine (FT4) values outside of the reference range. In 
case of subclinical or mild thyroid dysfunction, the TSH, but not the FT4 value is 
outside the reference range. These reference ranges are statistically defined by the 
2.5
th
 and 97.5
th
 percentile and are usually determined in a seemingly healthy 
population without taking symptoms or long-term risk of disease into account. 
However, there is increasing evidence, including evidence from our research 
efforts, that mild thyroid dysfunction and even variations in thyroid function 
currently defined as ‘normal’ are associated with several serious adverse outcomes 
including cardiovascular disease (CVD) and cognitive decline.
3,4,28,29
 Since 
reference ranges not only define thyroid disease but also provide the basis for 
treatment decisions, a debate has emerged concerning the current definition of 
thyroid dysfunction, especially for subclinical hypothyroidism.
30,31
  
The definition of reference ranges by taking the 2.5
th
 and 97.5
th
 percentiles is not 
restricted to thyroid function but is commonly used for serum and clinical 
measurements, such as heart rate. Because these percentiles for laboratory 
measurements are calculated from normal or log-normal distribution, they are 
sometimes also referred to as ‘normal ranges’ - not to be confused with ‘optimal 
ranges’. The exceptions to this rule include cardiovascular risk factors such as 
cholesterol and body-mass index (BMI). The reference ranges for BMI and 
cholesterol do not depend on the distribution in the general population. Instead 
they are targeted towards prevention of CVD.
32
 Could a similar approach also be 
applied for TSH and FT4 values? 
Current American and European Thyroid Association guidelines already partially 
apply a threshold for treatment of mild hypothyroidism based on CVD risk. Based 
on individual participant data level meta-analyses showing a higher risk of CVD in 
people with TSH levels >10mIU/l 
4,29
, both guidelines recommend to consider 
treatment in patients with subclinical hypothyroidism if TSH levels are ≥10 mIU/L. 
In similar analyses, a higher risk of CVD was also shown for subclinical 
hyperthyroidism, especially in participants with TSH <0.1 mIU/L.
3,4
 Thyroid 
hormone action is however not restricted to the cardiovascular system, but has 
implications on nearly all tissues and organs. Numerous studies have shown 
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associations of mild thyroid dysfunction with cognitive and bone health amongst 
others. 
28,33,34
 Interestingly, studies also identified relevant associations of variation 
of thyroid function within the reference ranges with sudden cardiac death, diabetes 
and dementia, suggesting a continuum of risk as opposed to clear 
thresholds.
28,30,35
 
Another challenge includes the non-linear nature of thyroid function associations. 
In other words, both high and low thyroid function are associated with adverse 
clinical outcomes, even though this is not always the case for the same outcome. 
For example, a higher thyroid function within the reference range has been 
associated with dementia risk and sudden cardiac death, while lower thyroid 
function seems protective 
28,35
. In contrast, a lower instead of higher thyroid 
function within the reference range has been associated with the risk of incident 
diabetes 
36
. In case of CVD it is even more complex, since both high and low 
thyroid function increase the risk of coronary heart disease and heart failure 
3,4,29
. 
This means that when tailoring the thyroid function reference ranges to adverse 
clinical outcomes, the direction of association has to be taken into account. If not, 
treatment of subclinical hypothyroidism for prevention of a particular outcome (e.g. 
diabetes) may lead to an increased risk of another outcome (e.g. dementia). This is 
even more complex for outcomes showing a non-linear association with thyroid 
function, such as CVD. In that case, treatment of subclinical hypothyroidism 
without an accurate target range may easily result in overtreatment and as such 
increase the risk of CVD.  
Randomized trials give more definitive answers concerning treatment risks and 
benefits. However, they are resource exhaustive, take a long time to complete and 
are therefore not always able to answer the most pressing or even most relevant 
questions. For example, there are currently at least four interventional clinical trials 
being performed worldwide comparing treatment with levothyroxine versus placebo 
or other therapies for patients with subclinical hypothyroidism
37
. The target 
populations range from patients after head- and neck surgery to elderly with 
subclinical hypothyroidism and primary outcomes ranging from post-operative 
complications to quality of life. All of these trials apply the statistical definition of the 
reference ranges, none of these trials primarily address relevant hard end-points 
(e.g. CVD or dementia) and none address the issue of differences between 
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subgroups (e.g. different targets for women vs men). While the current trials might 
answer the research questions they have specifically been designed for, most 
overarching population-wide questions will remain unanswered. 
A recent example is the Thyroid hormone Replacement for Untreated older adults 
with Subclinical hypothyroidism (TRUST) trial, to date the largest randomized 
controlled trial (RCT) on subclinical hypothyroidism in elderly, showing no effect of 
levothyroxine use in elderly with subclinical hypothyroidism on thyroid function 
related quality of life.
38
 As previously mentioned, current American Thyroid 
Association and European Thyroid Association guidelines recommend treatment of 
subclinical hypothyroidism with TSH levels >10mIU/l but also particularly in 
patients at high cardiovascular risk and in patients with hypothyroidism-related 
complaints.
39,40
 It seems that those patients were not included in the trial by Stott et 
al. Due to the initial trial design, where patients were included if their healthcare 
provider did not start levothyroxine, patients with a high cardiovascular risk and 
more complaints were probably excluded, as evidenced by the low median thyroid-
stimulating hormone levels (~5.7 mIU/L) and lack of symptoms at inclusion. In 
addition, due to the change in primary outcome from cardiovascular events to 
quality of life because of difficulties in inclusion, although understandable, the trial 
was underpowered to show effects of treatment on cardiovascular disease 
incidence. Other outcomes than cardiovascular disease were not considered in the 
study design. Although this trial does provide evidence to refrain from treatment in 
elderly with mild subclinical hypothyroidism that are not being treated by their 
general practitioner, numerous gaps in knowledge, including treatment effects on 
risk of hard clinical end-points and appropriate treatment targets, remain 
unanswered. 
 
One of the challenges in defining the ‘optimal health ranges’ for thyroid function will 
be to reach a consensus on relevant clinical outcomes that define optimal thyroid 
function and determine which subgroups need specific reference ranges. But how 
do we take on these challenges as a scientific community without wasting 
resources? In this respect, epidemiological observational studies can provide a 
more tailored direction on thyroid function related outcomes and help to define at 
which threshold these risks increase. In Chapter 2.5, we describe the absolute 10-
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year risk of CVD ter mortality according to TSH and FT4 levels. We also propose a 
proof of principle to define ‘optimal health ranges’ that can be more meaningful 
than the current statistical definition based on these disease risks. We also suggest 
that the ‘optimal health ranges’ could be age- and sex-dependent; e.g. due to the 
inherent different risks of disease in different subgroups.  
Remarkably, FT4 and not TSH is the better predictor of the 10-year risk of CVD 
mortality (Chapter 2.5). This is not the first study from our and other groups to 
report an association with FT4 and not or to a lesser extent with TSH with certain 
outcomes (p could be several explanations for this phenomenon. It has been 
described that older age is associated with an altered set point of the 
hypothalamic-pituitary-thyroid axis associated with older age.
41
 This could mean 
that different levels of TSH are needed during aging to maintain the same FT4 
levels and might explain the lack of an association with TSH in elderly populations 
like in the Rotterdam Study. Another explanation could be that TSH predominantly 
reflects the hypothalamic-pituitary-thyroid axis set point itself rather than disease 
risk,
42
 while, independent of TSH, circulating FT4 (and subsequently 
triiodothyronine acting intracellular) represents the bioavailable thyroid hormone 
that can be taken up by cells, thereby leading to clinical consequences of thyroid 
hormones peripherally. Independent of the underlying mechanism, these findings 
prompt the question to whether FT4 independently of TSH, should be included in 
the definition of thyroid function and dysfunction. Our results need to be replicated 
with sufficient samples and representative populations, both in populations similar 
to our population as well as complementary populations such as younger 
participants. Furthermore, a similar approach of defining ‘optimal health ranges’ 
can be applied to other hard clinical endpoints deemed relevant and specific for 
thyroid function. It will be a challenge to decide which outcomes to include and will 
require international collaboration and discussion to come to a consensus within 
the clinical and scientific thyroid community. 
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Table 1 Burdensome chronic non-communicable disease categories in elderly
1 
 TSH FT4 Chapter(s) of this thesis in RS 
CVD = ↑/ U 2.1-2.5 
Cancer = ↑ 5.1 
Chronic respiratory diseases - - - 
Digestive diseases =/↑ ↓ 4.2 
MND* ↓ =/↑ 3.4; 3.5 
Sensory impairment = ↑ 5.4 
Musculoskeletal** U = 5.3 
Genitourinary diseases ↓ = 5.2 
CVD = cardiovascular and circulatory diseases, MND = Mental and behavioral, and neurological 
disorders, RS = Rotterdam Study, U = U-shaped or inverted U-shaped association.  
*Association is age-dependent for the brain morphology and microstructural analysis and depicted in 
this table for elderly. **Chapter 5.3 discusses gait disturbances associated with thyroid function. Gait 
disturbances are perceived as multifactorial, including musculoskeletal. 
1
Prince et al., “The burden of disease in older people and implications for health policy and practice” 
Lancet 2015; 385: 549–62 
 
 
Table 2 Burdensome chronic non-communicable diseases in elderly
1 
 TSH FT4 Chapter(s) of this thesis in RS 
Ischemic heart disease = =/↑ 2.1; 2.4; 2.5 
Cerebrovascular disease = ↑ 2.5 
Diabetes Mellitus ↑ ↓ 4.1 
COPD - - - 
Dementia ↓ =/↑ 3.4 
Vision impairment = ↑ 5.4 
Hearing impairment - - - 
COPD = Chronic obstructive pulmonary disease, RS = Rotterdam Study, U = U-shaped or inverted U-
shaped association.  
1
Prince et al., “The burden of disease in older people and implications for health policy and practice” 
Lancet 2015; 385: 549–62 
 
 
In practice, IPD meta-analyses, including a large number of participants and a 
variation in populations will be necessary to provide sufficiently robust evidence on 
‘optimal health ranges’. IPD-meta-analyses also provide a platform for 
communication concerning these concepts to reach a general agreement that can 
influence clinical guidelines globally. Information from these observational studies 
can then be used to design more comprehensive RCT’s that have the potential to 
answer questions regarding treatment risk-benefits beyond these ‘optimal health 
ranges’. Then, and only then, can the appropriateness of screening for thyroid 
dysfunction established with meaningful reference ranges be fully addressed.   
Chapter 6 
426 
CHAPTER REFERENCES 
1. Vanhaelst L, Neve P, Chailly P, 
Bastenie PA. Coronary-artery 
disease in hypothyroidism. 
Observations in clinical 
myxoedema. Lancet. 
1967;2(7520):800-802. 
2. Jabbar A, Pingitore A, Pearce SH, 
Zaman A, Iervasi G, Razvi S. 
Thyroid hormones and 
cardiovascular disease. Nat Rev 
Cardiol. 2017;14(1):39-55. 
3. Collet TH, Gussekloo J, Bauer DC, 
et al. Subclinical hyperthyroidism 
and the risk of coronary heart 
disease and mortality. Arch Intern 
Med. 2012;172(10):799-809. 
4. Gencer B, Collet TH, Virgini V, et al. 
Subclinical thyroid dysfunction and 
the risk of heart failure events: an 
individual participant data analysis 
from 6 prospective cohorts. 
Circulation. 2012;126(9):1040-1049. 
5. Rodondi N, Den Elzen WPJ, Bauer 
DC, et al. Subclinical 
hypothyroidism and the risk of 
coronary heart disease and 
mortality. JAMA - Journal of the 
American Medical Association. 
2010;304(12):1365-1374. 
6. Hankey GJ. Stroke. Lancet. 
2017;389(10069):641-654. 
7. Pasqualetti G, Pagano G, Rengo G, 
Ferrara N, Monzani F. Subclinical 
hypothyroidism and cognitive 
impairment: Systematic review and 
meta-analysis. Journal of Clinical 
Endocrinology and Metabolism. 
2015;100(11):4240-4248. 
8. Neuschwander-Tetri BA. Non-
alcoholic fatty liver disease. BMC 
Med. 2017;15(1):45. 
9. Liu L, Yu Y, Zhao M, et al. Benefits 
of Levothyroxine Replacement 
Therapy on Nonalcoholic Fatty Liver 
Disease in Subclinical 
Hypothyroidism Patients. Int J 
Endocrinol. 2017;2017:5753039. 
10. Prince MJ, Wu F, Guo Y, et al. The 
burden of disease in older people 
and implications for health policy 
and practice. Lancet. 
2015;385(9967):549-562. 
11. Mondul AM, Weinstein SJ, 
Bosworth T, Remaley AT, Virtamo 
J, Albanes D. Circulating Thyroxine, 
Thyroid-Stimulating Hormone, and 
Hypothyroid Status and the Risk of 
Prostate Cancer. PLoS ONE. 
2012;7(10). 
12. Søgaard M, Farkas DK, Ehrenstein 
V, Jørgensen JOL, Dekkers OM, 
Sørensen HT. Hypothyroidism and 
hyperthyroidism and breast cancer 
risk: A nationwide cohort study. 
European Journal of Endocrinology. 
2016;174(4):409-414. 
13. Tosovic A, Bondeson AG, 
Bondeson L, Ericsson UB, Malm J, 
Manjer J. Prospectively measured 
triiodothyronine levels are positively 
associated with breast cancer risk 
in postmenopausal women. Breast 
Cancer Res. 2010;12(3):R33. 
14. Hellevik AI, Asvold BO, Bjoro T, 
Romundstad PR, Nilsen TI, Vatten 
LJ. Thyroid function and cancer 
risk: a prospective population study. 
Cancer Epidemiol Biomarkers Prev. 
2009;18(2):570-574. 
15. Meuwese CL, Gussekloo J, de 
Craen AJ, Dekker FW, den Elzen 
WP. Thyroid status and renal 
function in older persons in the 
general population. J Clin 
Endocrinol Metab. 2014;99(8):2689-
2696. 
16. Verlinden VJ, van der Geest JN, 
Hoogendam YY, Hofman A, 
Breteler MM, Ikram MA. Gait 
patterns in a community-dwelling 
population aged 50 years and older. 
Gait Posture. 2013;37(4):500-505. 
17. Simonsick EM, Newman AB, 
Ferrucci L, et al. Subclinical 
hypothyroidism and functional 
mobility in older adults. Archives of 
Internal Medicine. 
2009;169(21):2011-2017. 
18. Mehta S. Age-Related Macular 
Degeneration. Prim Care. 
2015;42(3):377-391. 
19. Bourne RR, Jonas JB, Flaxman SR, 
et al. Prevalence and causes of 
vision loss in high-income countries 
General discussion 
427 
and in Eastern and Central Europe: 
1990-2010. Br J Ophthalmol. 
2014;98(5):629-638. 
20. Ma H, Thapa A, Morris L, Redmond 
TM, Baehr W, Ding XQ. 
Suppressing thyroid hormone 
signaling preserves cone 
photoreceptors in mouse models of 
retinal degeneration. Proc Natl 
Acad Sci U S A. 2014;111(9):3602-
3607. 
21. Bernal J. Thyroid Hormones in 
Brain Development and Function. 
In: De Groot LJ, Chrousos G, 
Dungan K, et al., eds. Endotext. 
South Dartmouth (MA)2000. 
22. Riley RD, Lambert PC, Abo-Zaid G. 
Meta-analysis of individual 
participant data: rationale, conduct, 
and reporting. BMJ. 2010;340:c221. 
23. Cochrane Methods Group IPD 
meta-analysis. About IPD meta-
analyses. 
http://methods.cochrane.org/ipdma/
about-ipd-meta-analyses. Accessed 
June 8th, 2017. 
24. Tudur Smith C, Marcucci M, Nolan 
SJ, et al. Individual participant data 
meta-analyses compared with 
meta-analyses based on aggregate 
data. Cochrane Database Syst Rev. 
2016;9:MR000007. 
25. Ahmed I, Sutton AJ, Riley RD. 
Assessment of publication bias, 
selection bias, and unavailable data 
in meta-analyses using individual 
participant data: a database survey. 
BMJ. 2012;344:d7762. 
26. LeFevre ML, Force USPST. 
Screening for thyroid dysfunction: 
U.S. Preventive Services Task 
Force recommendation statement. 
Ann Intern Med. 2015;162(9):641-
650. 
27. Carlé A, Pedersen IB, Knudsen N, 
Perrild H, Ovesen L, Laurberg P. 
Hypothyroid symptoms and the 
likelihood of overt thyroid failure: A 
population-based case - Control 
study. European Journal of 
Endocrinology. 2014;171(5):593-
602. 
28. Chaker L, Wolters FJ, Bos D, et al. 
Thyroid function and the risk of 
dementia: The Rotterdam Study. 
Neurology. 2016;87(16):1688-1695. 
29. Rodondi N, den Elzen WP, Bauer 
DC, et al. Subclinical 
hypothyroidism and the risk of 
coronary heart disease and 
mortality. JAMA. 
2010;304(12):1365-1374. 
30. Cappola AR, Arnold AM, Wulczyn 
K, Carlson M, Robbins J, Psaty BM. 
Thyroid function in the euthyroid 
range and adverse outcomes in 
older adults. J Clin Endocrinol 
Metab. 2015;100(3):1088-1096. 
31. Klubo-Gwiezdzinska J, Wartofsky L. 
Thyrotropin blood levels, subclinical 
hypothyroidism, and the elderly 
patient. Arch Intern Med. 
2009;169(21):1949-1951. 
32. Conroy RM, Pyorala K, Fitzgerald 
AP, et al. Estimation of ten-year risk 
of fatal cardiovascular disease in 
Europe: the SCORE project. Eur 
Heart J. 2003;24(11):987-1003. 
33. Blum MR, Bauer DC, Collet TH, et 
al. Subclinical thyroid dysfunction 
and fracture risk: a meta-analysis. 
JAMA. 2015;313(20):2055-2065. 
34. Aubert CE, Floriani C, Bauer DC, et 
al. Thyroid function tests in the 
reference range and fracture: 
individual participant analysis of 
prospective cohorts. J Clin 
Endocrinol Metab. 2017. 
35. Chaker L, van den Berg ME, 
Niemeijer MN, et al. Thyroid 
Function and Sudden Cardiac 
Death: A Prospective Population-
Based Cohort Study. Circulation. 
2016;134(10):713-722. 
36. Chaker L, Ligthart S, Korevaar TI, 
et al. Thyroid function and risk of 
type 2 diabetes: a population-based 
prospective cohort study. BMC 
Med. 2016;14(1):150. 
37. Aggarwal S, Modi S, Jose T. 
Laparoscopic sleeve gastrectomy 
leads to reduction in thyroxine 
requirement in morbidly obese 
patients with hypothyroidism. World 
journal of surgery. 
2014;38(10):2628-2631. 
38. Stott DJ, Rodondi N, Kearney PM, 
et al. Thyroid Hormone Therapy for 
Chapter 6 
428 
Older Adults with Subclinical 
Hypothyroidism. N Engl J Med. 
2017. 
39. Garber JR, Cobin RH, Gharib H, et 
al. Clinical practice guidelines for 
hypothyroidism in adults: 
Cosponsored by the American 
Association of clinical 
endocrinologists and the American 
Thyroid Association. Thyroid. 
2012;22(12):1200-1235. 
40. Pearce SH, Brabant G, Duntas LH, 
et al. 2013 ETA Guideline: 
Management of Subclinical 
Hypothyroidism. Eur Thyroid J. 
2013;2(4):215-228. 
41. Gesing A, Lewinski A, Karbownik-
Lewinska M. The thyroid gland and 
the process of aging; what is new? 
Thyroid Res. 2012;5(1):16. 
42. Werneck de Castro JP, Fonseca 
TL, Ueta CB, et al. Differences in 
hypothalamic type 2 deiodinase 
ubiquitination explain localized 
sensitivity to thyroxine. J Clin 
Invest. 2015;125(2):769-781. 
 
  
  
  
 
 
 
CHAPTER 7 
SUMMARY & SAMENVATTING 
 
  
Chapter 7 
432 
ENGLISH SUMMARY  
Chapter 1 of this thesis provides a general introduction and background 
information on thyroid function and dysfunction (Chapter 1.1). Hypothyroidism is 
more elaborately discussed in Chapter 1.2, with a focus on the current definition of 
thyroid function in general and hypothyroidism in particular.  
Chapter 2 is devoted to the association of thyroid function with diseases of the 
heart. In Chapter 2.1 we describe that higher free thyroxine (FT4) serum 
concentrations are associated with a higher 10-year risk of sudden cardiac death 
(SCD), even within the reference range. In Chapter 2.2 we conclude that FT4 and 
not thyroid-stimulating hormone (TSH) is a risk factor for atrial fibrillation. In 
Chapter 2.3 we report on a U-shaped association of FT4 with QT variability, a 
marker for cardiac repolarization, which could provide a link between thyroid 
function and cardiovascular disease (CVD) in general and SCD more specifically. 
In Chapter 2.4 we investigate atherosclerotic CVD (ACVD), subclinical and clinical, 
and report on an increased risk of ACVD with higher FT4 levels, more marked in 
people with prevalent ACVD. We also report that higher FT4 levels are associated 
with a high coronary artery calcification score, which is a marker for subclinical 
atherosclerosis. In Chapter 2.5 we propose to define ‘optimal health ranges’ of 
thyroid function as reference ranges, by defining the risk of disease associated with 
variations of thyroid function. We identify FT4 as the main predictor of the 10-year 
risk of CVD mortality. Furthermore, we show that for CVD outcomes these ranges 
are possibly sex and age-dependent. 
Chapter 3 we discuss the relation of thyroid function with the brain. In Chapters 
3.1 we identify a lack of literature on the association of thyroid function with the risk 
of stroke, one of the major causes of mortality and morbidity globally. In Chapter 
3.2, we conduct a large individual participant meta-analysis and show that 
subclinical hypothyroidism is associated with the risk of stroke, but only in younger 
participants. However, when we restrict our analyses to the reference range in 
Chapter 3.3 we identify high-normal thyroid function as a risk factor for stroke in all 
age-groups. One of the most burdensome diseases of older age is undoubtedly 
dementia. While hypothyroidism can clinically present with impaired memory, 
studies on the association of thyroid function and risk of dementia were sparse. In 
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Chapter 3.4, we identify high and high-normal thyroid function (mainly low TSH) as 
a risk factor of dementia. Additionally, there was a lack of association of thyroid 
function with any of the markers of subclinical vascular brain disease and we 
therefore conclude that this association is unlikely to be mediated through vascular 
risk factors. In Chapter 3.5 we explore brain volumes and microstructural 
organization measured on MRI as possible factors influenced by thyroid function. 
We report that the association of thyroid function with brain morphology and 
microstructural organization may be age-dependent. In elderly, high thyroid 
function seems deleterious (smaller brain volumes and indication of reduced matter 
microstructural integrity), while this was not the case in younger participants. 
Chapter 4 includes results from our studies on the possible role of thyroid function 
with diabetes and non-alcoholic fatty liver disease (NAFLD). In Chapter 4.1 we 
identify low and low-normal thyroid function as a risk factor for diabetes. This is 
especially the case in people with prediabetes. This finding can serve as a possible 
first step into identifying subgroups at risk of developing diabetes in the context of 
thyroid function. Most studies on the association of thyroid function and NAFLD 
have been cross-sectional. In Chapter 4.2 we show an increased risk of NAFLD 
and even fibrosis in participants with low and low-normal thyroid function in a 
longitudinal study design.  
Chapter 5 includes our studies on disorders and diseases of older age that are 
especially burdensome in elderly populations. Cancer contributes heavily to the 
global burden of disease, especially in the developed world, and the risk of cancer 
increases with aging. In Chapter 5.1 we show that higher FT4 levels are 
associated with a higher risk of all solid cancers but particularly lung cancer and 
breast cancer. It will be important to replicate these findings, but also to discover 
the underlying pathophysiological mechanisms. In Chapter 5.2 we describe the 
association both cross-sectionally as well as longitudinally of thyroid function with 
kidney function and kidney function decline. Our cross-sectional results are in line 
with previous studies, which have been mostly cross-sectional, in finding low 
thyroid function to be associated with lower kidney function. However, our 
longitudinal analyses, which are less sensitive to reverse causation, show that 
higher thyroid function is related to higher risk of chronic kidney disease. 
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Apart from cancer and kidney disease we also studied the association of thyroid 
function with gait. Gait can be defined as the pattern of limb motion of animals, 
including humans, when moving from one place to another and has proven an 
important general health marker. In Chapter 5.3, we identify that TSH is non-
linearly associated with global gait, a marker that combines several gait domains, 
where both high and low TSH seem deleterious. In elderly, age-related macular 
degeneration is the leading cause of vision loss. Previous animal studies have 
shown that exogenously administered thyroid hormone is deleterious for cone 
receptors in mice. In Chapter 5.4 we report a higher risk of age-related macular 
degeneration with higher FT4 values, which is in line with the findings of animal 
models. In Chapter 5.5 we discuss thyroid function not as a risk factor, but as an 
outcome. We suggest that genetic determinants, thyroid peroxidase antibodies and 
age are the main determinants for thyroid function, both FT4 and TSH. Unlike 
previous studies, we suggest that TSH is stable and FT4 increases with aging. We 
propose several mechanisms that could have led to discrepancies with previous 
literature, including the average age of the elderly population studied and historic 
iodine status.  
Finally, in Chapter 6 we combine results of this thesis in a comprehensive 
overview and suggest future research efforts that could be a continuation of the 
current results.  
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NEDERLANDSE SAMENVATTING  
In Hoofdstuk 1 van dit proefschrift geven wij een algemene introductie en 
achtergrond informatie over schildklierfunctie en –dysfunctie (Hoofdstuk 1.1).  
In Hoofdstuk 1.2 bespreken we het fenomeen hypothyreoïdie, waarbij we ingaan 
op de huidige definitie van schildklier(dys-)functie in het algemeen en 
hypothyreoïdie in het bijzonder. In Hoofdstuk 2 tonen we de associatie tussen 
schildklierfunctie en hart- en vaatziekten. In Hoofdstuk 2.1 laten we zien dat, zelfs 
binnen de referentiewaarden, hogere vrij T4 serumwaardes geassocieerd zijn met 
een hoger tienjaarsrisico op plotse hartdood. In Hoofdstuk 2.2 concluderen we dat 
vrij T4, en niet thyroid-stimulating hormone (TSH), een risicofactor vormt voor 
atriumfibrilleren. In Hoofdstuk 2.3 rapporteren we een U-vormige associatie 
tussen vrij T4 en QT variabiliteit, een marker van cardiale repolarisatie. Deze U-
vormige associatie verklaart mogelijk de gevonden associatie tussen 
schildklierfunctie enerzijds en cardiovasculaire ziekten (CVD) en plotse hartdood 
anderzijds. In Hoofdstuk 2.4 onderzoeken we klinische en subklinische 
atherosclerotische CVD (ASCVD). We beschrijven een relatie tussen hogere vrij 
T4 serumwaardes en een hoger risico op ASCVD. Deze relatie geldt name voor 
mensen met bestaande ASCVD. We tonen ook dat hogere vrij T4 serumwaardes 
geassocieerd zijn met een hogere coronary artery calcificatie score, een marker 
voor subklinische atherosclerose. In Hoofdstuk 2.5 stellen wij voor om de 
referentiewaarden voor schildklierfunctie te definiëren aan de hand van een 
‘optimal health range’, door ook het risico op ziekten mee te nemen in de definitie. 
Wij laten in dit hoofdstuk ook zien dat vrij T4 de belangrijkste voorspeller is van het 
tienjaarsrisico op CVD mortaliteit. Tevens laten wij zien dat deze ‘optimal health 
ranges’ hoogstwaarschijnlijk afhankelijk is van geslacht en leeftijd. 
In Hoofdstuk 3 onderzoeken we de relatie tussen schildklierfunctie en de 
hersenen. In Hoofdstuk 3.1 laten we zien dat er een gebrek aan literatuur is over 
het verband tussen schildklierdysfunctie en het risico op beroerte, een van de 
belangrijkste oorzaken van mortaliteit en morbiditeit wereldwijd. Hoofdstuk 3.2 
toont de individuele participanten data meta-analyse, uitgevoerd om dit hiaat op te 
vullen. Deze meta-analyse laat zien dat subklinische hypothyreoïdie met name bij 
jongere mensen geassocieerd is met een verhoogd risico op beroerte. Als we de 
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analyse beperken tot referentiewaardes van schildklierfunctie (Hoofdstuk 3.3), 
vinden we dat hoog-normale schildklierfunctie een risicofactor is voor beroertes in 
alle leeftijdsgroepen. Dementie is een vaak voorkomende aandoening onder 
ouderen en is zeer belastend voor de directe omgeving en de maatschappij. 
Hoewel hypothyreoïdie gepaard kan gaan met geheugenstoornissen, zijn 
onderzoeken naar de associatie tussen schildklierdysfunctie en het risico op 
dementie schaars. In Hoofdstuk 3.4 laten we zien dat hoge en hoog-normale 
schildklierfunctie (met name een laag TSH) risicofactoren zijn voor dementie. 
Opmerkelijk genoeg vonden wij geen associatie tussen schildklierfunctie en 
subklinische vasculaire brein markers. Dit maakt het minder waarschijnlijk dat de 
associatie tussen schildklierfunctie en dementie wordt gemedieerd door vasculaire 
risicofactoren. In Hoofdstuk 3.5 onderzoeken we de relatie tussen 
schildklierfunctie, hersenvolume en markers van microstructurele organisatie van 
het brein (op MRI). Wij vinden een leeftijdsafhankelijke relatie tussen 
schildklierfunctie enerzijds, en hersenvolume en –organisatie anderzijds. Met name 
bij ouderen lijkt een hoge schildklierfunctie samen te hangen met een kleiner 
hersenvolume en markers passend bij een slechtere microstructuur van de 
hersenen. 
In Hoofdstuk 4 onderzoeken we het mogelijke verband tussen schildklierfunctie en 
het risico op diabetes en non-alcoholic fatty liver disease (NAFLD). In Hoofdstuk 
4.1 laten we zien dat lage en laag-normale schildklierwaardes risicofactoren zijn 
voor diabetes, met name bij mensen met pre-diabetes. Deze bevinding kan een 
eerste stap zijn om, op basis van schildklierfunctie, subgroepen met een verhoogd 
diabetesrisico aan te wijzen zijn binnen de normale populatie. In Hoofdstuk 4.2 
laten wij in een longitudinale studie zien dat lage en laag-normale 
schildklierwaardes geassocieerd zijn met een hoger risico op NAFLD en zelfs een 
hogere kans op fibrose bij mensen met NAFLD. 
Hoofdstuk 5 beschrijft studies naar aandoeningen en ziekten die zich 
manifesteren op oudere leeftijd en een grote impact hebben in een ouder 
wordende populatie. Kanker heeft veel impact op de ‘global burden of disease’, 
met name in ontwikkelde landen, en het risico op maligniteiten neemt toe met de 
leeftijd. In Hoofdstuk 5.1 laten wij zien dat hogere vrij T4 waardes geassocieerd 
zijn met een hoger risico op solide tumoren, met name borst- en longkanker. Het is 
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belangrijk om deze bevindingen te repliceren en, minstens zo belangrijk, om de 
onderliggende mechanismen te ontrafelen. In Hoofdstuk 5.2 beschrijven wij de 
cross-sectionele en longitudinale onderzoeken naar de associatie tussen 
schildklier- en nierfunctie. Onze cross-sectionele bevindingen zijn in 
overeenstemming met resultaten van voorgaande (met name cross-sectionele) 
studies, die een relatie laten zien tussen lage schildklierfunctie en slechtere 
nierfunctie. In onze longitudinale analyses, die minder sensitief zijn voor ‘reverse 
causation’ of omgekeerde causaliteit, laten wij echter zien dat juist een hoge 
schildklierfunctie geassocieerd is met een hogere kans op chronische nierziekten. 
Naast voorgaande studies onderzochten wij het verband tussen schildklierfunctie 
en looppatroon. Een afwijkend looppatroon wordt gezien als een belangrijke 
algemene gezondheidsindicator. In Hoofdstuk 5.3 beschrijven wij een niet-lineare 
associatie tussen TSH en de ‘global gait score’, een score die verschillende 
domeinen van het looppatroon incorporeert. Dit betekent dat zowel hoge als lage 
TSH waardes zouden kunnen samenhangen met een afwijkend looppatroon.  
Eerdere studies hebben aangetoond dat het toedienen van schildklierhormoon bij 
muizen schadelijke gevolgen kan hebben voor de kegeltjes in het netvlies. In 
Hoofstuk 5.4 zien wij dat bij mensen een hogere schildklierfunctie geassocieerd is 
met macula degeneratie, wat de eerder genoemde dierstudies bevestigt. In 
Hoofdstuk 5.5 onderzoeken wij welke factoren bepalend zijn voor de 
schildklierfunctie. Genetische factoren, schildklier peroxidase antistoffen en leeftijd 
lijken de belangrijkste determinanten voor TSH en vrij T4 te zijn. In tegenstelling tot 
eerdere onderzoeken, vinden wij dat vrij T4, in tegenstelling tot TSH, stijgt met de 
leeftijd. Wij zetten een aantal mechanismen uiteen die deze discrepantie met de 
eerdere literatuur zouden kunnen verklaren, zoals de gemiddelde leeftijd van de 
bestudeerde populatie en de historische jodium status van de bevolking.  
Ten slotte combineren wij in Hoofdstuk 6 de resultaten van dit proefschrift in een 
uitgebreid overzicht en doen wij op basis van onze resultaten suggesties voor 
toekomstig onderzoek. 
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